<SEC-DOCUMENT>0001659617-18-000027.txt : 20180328
<SEC-HEADER>0001659617-18-000027.hdr.sgml : 20180328
<ACCEPTANCE-DATETIME>20180328081706
ACCESSION NUMBER:		0001659617-18-000027
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180328
DATE AS OF CHANGE:		20180328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		18717063

	BUSINESS ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a2017q410-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2F8E1C33CF23182B9C80A0B86781D1BB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C., 20549</font></div><div style="line-height:120%;text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;"><hr></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;"><hr></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;font-weight:bold;">&#253; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 001-37758</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><img src="pg1img1_10k.jpg" alt="pg1img1_10k.jpg" style="height:42px;width:200px;"></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2834</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47-4671997</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or Other Jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Primary Standard Industrial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Classification Code Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2575 West Bellfort, Suite 333</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Houston, Texas 77054</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(713) 300-5160</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock, par value $0.001 per share NASDAQ Capital Market</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act: None&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;NO&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;NO&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;NO&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;NO&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. (check one)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:24%;"></td><td style="width:20%;"></td><td style="width:22%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer&#160;                &#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer  &#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company    </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;NO&#160;&#160; </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The aggregate market value of the registrant&#8217;s voting equity held by non-affiliates of the registrant, computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $32,242,351. In determining the market value of the voting equity held by non-affiliates, securities of the registrant beneficially owned by directors, officers and 10% or greater shareholders of the registrant have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of shares of the registrant&#8217;s common stock outstanding as of March 16, 2018 was 25,768,861.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of this registrant&#8217;s definitive proxy statement for its 2018 Annual Meeting of Stockholders to be filed with the SEC no later than 120 days after the end of the registrant&#8217;s fiscal year are incorporated herein by reference in Part III of this Annual Report on Form 10-K.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sCCA08C6596FCA6D5D86CA0B867CF34BC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s008AE7505F2648E93F7CA0B868221BEB"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s008AE7505F2648E93F7CA0B868221BEB">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6D8B0D848C52F7F93E5CA0B86847F569"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. BUSINESS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6D8B0D848C52F7F93E5CA0B86847F569">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE0FBF3A53E13C8DA9A6CA0B86875851A"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A. RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE0FBF3A53E13C8DA9A6CA0B86875851A">22</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s956F7FDC33942AFE3876A0B8689A0FBE"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s956F7FDC33942AFE3876A0B8689A0FBE">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s889D8CE31C52B105B21EA0B868C81324"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. PROPERTIES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s889D8CE31C52B105B21EA0B868C81324">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0FF8E41283E86E614E9AA0B868E93F19"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. LEGAL PROCEEDINGS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0FF8E41283E86E614E9AA0B868E93F19">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE69328DC3CB8B6F39E13A0B8691D2C8D"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4. MINE SAFETY DISCLOSURE</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE69328DC3CB8B6F39E13A0B8691D2C8D">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s465214CC73D7C40680FAA0B8629EFC09"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s465214CC73D7C40680FAA0B8629EFC09">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6671F50495B07F884A52A0B869959739"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. SELECTED FINANCIAL DATA</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6671F50495B07F884A52A0B869959739">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s99CBAA72236C23232FFDA0B869C21FB1"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s99CBAA72236C23232FFDA0B869C21FB1">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s159E68AD68F8C7D9FFF6A0B86C30E46B"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s159E68AD68F8C7D9FFF6A0B86C30E46B">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sED3E12AF6840EAB3421BA0B86C5EBE5E"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sED3E12AF6840EAB3421BA0B86C5EBE5E">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s115C4590748174F41531A0B86C851E37"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s115C4590748174F41531A0B86C851E37">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE4E6070CE322E650FD60A0B86CB14355"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A. CONTROLS AND PROCEDURES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE4E6070CE322E650FD60A0B86CB14355">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD4AFC90177D7BBAA78A8A0B86D2DDA43"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sD4AFC90177D7BBAA78A8A0B86D2DDA43">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6073E440415A8C0E88ABA0B86D580956"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11. EXECUTIVE COMPENSATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6073E440415A8C0E88ABA0B86D580956">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC1B7C3D00CA35D532870A0B86D796F50"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC1B7C3D00CA35D532870A0B86D796F50">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4F52169C7E7F93D75737A0B86DABBF4E"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4F52169C7E7F93D75737A0B86DABBF4E">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s52685F02DE99812505CDA0B86DFEB544"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s52685F02DE99812505CDA0B86DFEB544">58</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s21F6CC83BFD1D2B107E3A0B86E25A7B8"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s21F6CC83BFD1D2B107E3A0B86E25A7B8">58</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s3C4A665D37B38837D859A0B867EF0B45"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Securities and Exchange Commission, referred to herein as the SEC, encourages companies to disclose forward-looking information so that investors can better understand a company&#8217;s future prospects and make informed investment decisions. Certain statements that we may make from time to time, including, without limitation, statements contained in this report constitute &#8220;forward- looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make forward-looking statements under the &#8220;Risk Factors,&#8221; &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in other sections of this report. In some cases, you can identify these statements by forward-looking words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under &#8220;Risk Factors.&#8221;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this report describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very highly regulated, competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this report to conform our prior statements to actual results or revised expectations, and we do not intend to do so.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain additional funding to develop our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to obtain regulatory approval of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success of our clinical trials through all phases of clinical development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to complete our clinical trials in a timely fashion and within our expected budget;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with obligations under intellectual property licenses with third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any delays in regulatory review and approval of product candidates in clinical development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">market acceptance of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition from existing products or new products that may emerge;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential product liability claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our dependency on third-party manufacturers to supply or manufacture our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish or maintain collaborations, licensing or other arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability and third parties&#8217; abilities to protect intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to adequately support future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain key personnel to manage our business effectively.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-K in the case of forward-looking statements contained in this Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s008AE7505F2648E93F7CA0B868221BEB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">References in this Annual Report on Form 10-K to &#8220;MBI&#8221; or &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; are used herein to refer to Moleculin Biotech, Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s6D8B0D848C52F7F93E5CA0B86847F569"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. BUSINESS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as &#8220;MD Anderson&#8221;. MBI has three core drug technologies: a uniquely designed anthracycline (Annamycin), a portfolio of STAT3 inhibitors (WP1066 Portfolio) and a collection of inhibitors of glycolysis (WP1122 Portfolio). Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors through the inhibition of glycolysis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin has been in clinical trials pursuant to an IND, that had been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. We have two other drug development projects: (i) one involving a library of small molecules, which we refer to as the WP1066 Portfolio, a collection of STAT3 inhibitors, some of which also have immuno-stimulating capability, targeting brain tumors, pancreatic cancer and AML, and (ii) the WP1122 Portfolio, a library of small molecules targeting the metabolic processes involved in cancer in general and glioblastoma (the most aggressive and most common form of brain tumor) and pancreatic cancer in particular through the inhibition of glycolysis. A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, we intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin for the treatment of AML, which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug Application (&#8220;NDA&#8221;) in the United States. We may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another Annamycin product for the same use. We also intend to apply for similar status in the European Union (&#8220;EU&#8221;) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (&#8220;MAA&#8221;). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With regard to additional potential clinical activity, we submitted in October 2017 a request for Clinical Trial Authorization (&#8220;CTA&#8221;) in Poland which, if allowed, will enable a Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland. This will be in addition to the previously announced allowance of our IND in the United States. In December 2017, the Ethics Committee in Poland approved our Phase I/II clinical trial of Annamycin. The CTA remains subject to final approval by the Polish National Office. Furthermore, in September 2017 we engaged a contract research organization (&#8220;CRO&#8221;) to prepare for a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the topical treatment of cutaneous T-cell lymphoma (&#8220;CTCL&#8221;).</font></div><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Our Drug Candidates</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annamycin</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead product candidate is Annamycin, for which FDA has allowed an IND for a Phase I/II trial for the treatment of relapsed or refractory AML and granted Orphan Drug designation for the treatment of AML. We intend to conduct Phase I/II clinical trials for Annamycin as a monotherapy for the treatment of relapsed or refractory AML in the United States and in Poland. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We took over the development of Annamycin from a prior drug development company that ceased development work on Annamycin because it believed the clinical data did not support further clinical evaluation of L-Annamycin as a single agent to treat relapsed or refractory adult acute leukemia patients, leading to the termination of its IND by the FDA. The basis for our decision to proceed notwithstanding the prior developer&#8217;s determination is that we believe the actual clinical data as reported by Dr. Robert Shepard, our Chief Medical Officer and who was the prior developer&#8217;s Chief Medical Officer at the time of the clinical trials, to the 2009 Annual Meeting of the American Society of Clinical Oncology, and as further reported by the Principal Investigators of the clinical trials in a peer-reviewed journal article (Clin Lymphoma Myeloma Leuk. 2013 August; 13(4): 430-434. doi:10.1016/j.clml.2013.03.015.), supports further clinical evaluation. In addition, the conclusion published in the 2013 Clinical Lymphoma, Myeloma &amp; Leukemia journal article was that &#8220;Single agent nanomolecular liposomal annamycin appears to be well-tolerated and [demonstrates] evidence of clinical activity as a single agent in refractory adult ALL.&#8221; As reported in both the ASCO presentation and the 2013 journal article referenced, the definition of efficacy is based on the following Response Criteria: &#8220;Response criteria were achievement of CR defined as &#8804;5% blasts, granulocyte count of &#8805;1&#215;109/L, and a platelet count of &#8805;100&#215;109/L. Partial remission was defined the same as CR, except for the presence of 6% to 25% blasts. Hematologic improvement was defined as for CR but platelet count &lt;100&#215;109/L.&#8221; The summary of patient response from the 2013 journal article reads: &#8220;After determining the MTD, a 10-patient phase IIA was conducted. Eight of the patients completed one cycle of the three days of treatment at the MTD. Of these, five (62%) demonstrated encouraging anti-leukemic activity with complete clearing of circulating peripheral blasts. Three of these subjects also cleared bone marrow blasts with one subsequently proceeding onto successful stem cell transplantation. The other two developed tumor lysis syndrome and unfortunately expired prior to response assessment.&#8221; In our review of these trials, we confirmed that the activity demonstrated in this summary corresponds with a &#8220;Partial remission&#8221; as described in the Response Criteria and that the three subjects who &#8220;cleared bone marrow blasts&#8221; correspond with &#8220;CR&#8221; (Complete Response).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market for Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leukemia is a cancer of the white blood cells and acute forms of leukemia can manifest quickly and leave patients with limited treatment options. AML is the most common type of acute leukemia in adults. It occurs when a clone of leukemic progenitor white blood cells proliferates in the bone marrow, suppressing the production of normal blood cells. Currently, the only viable option for acute leukemia patients is a bone marrow transplant, also known as a hematopoietic stem cell transplant or &#8220;HSCT&#8221;, which is successful in a significant number of patients. However, in order to qualify for a bone marrow transplant, the patient&#8217;s leukemia cells must be decreased to a sufficiently low level. This usually began with a therapy referred to as &#8220;7+3,&#8221; which consisted of combining seven injections of Cytarbine with 3 infusions of an anthracycline to induce remission (a complete response, or &#8220;CR&#8221;). This therapy had not improved since it was first used in the 1970s and we estimate that this induction therapy had a success rate of about 20% to 25%. A revision to this therapy was recently approved in the form of a drug called Vyxeos, which involves combining Cytarabine and an anthracycline (daunorubicin) into a single liposomal injection given 3 times. This improvement appears to have increased the level of CRs to 34% and the overall survival by 3.5 months. Unfortunately, the current clinically approved anthracyclines (including Vyxeos) are cardiotoxic (i.e., can damage the heart), which can limit the dosage amount that may be administered to patients. Additionally, the tumor cells often present de novo or develop resistance to the first line anthracycline, through what is called &#8220;multidrug resistance,&#8221; enabling the tumor cells to purge themselves of the available anthracyclines. Consequently, there remains no effective therapy for inducing remission in the majority of these patients sufficient to enable a curative bone marrow transplant and unfortunately most will succumb quickly to their leukemia. If a patient&#8217;s leukemia reappears before they can be prepared for a bone marrow transplant, they are considered to have &#8220;relapsed.&#8221; If a patient fails to achieve a sufficient response from the induction therapy to qualify for a bone marrow transplant, they are considered to be &#8220;refractory&#8221; (resistant to therapy). Together, this group of relapsed and refractory AML patients constitutes our primary focus for treatment with Annamycin and our intent is to pursue FDA approval for Annamycin as a second-line induction therapy for adult relapsed or refractory AML patients.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that pursuing approval as a second line induction therapy for adult relapsed or refractory AML patients is the shortest path to regulatory approval, but we also believe that one of the most important potential uses of Annamycin is in the treatment of children with either AML or ALL (acute lymphoblastic leukemia, which is more common in children). Accordingly, we also intend to pursue approval for pediatric use in these conditions when practicable. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Of the estimated 21,380 U.S. cases of acute myeloid leukemia diagnosed in 2017, an estimated 97% were adult and although exact numbers are not available, we estimate that 70% to 80% (approximately 14,000 to 16,000 patients) were expected to relapse or be resistant to first-line therapy.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prior Clinical Trials for Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annamycin is a liposome formulated anthracycline (also referred to in literature as &#8220;L-Annamycin&#8221;). It has been tested in 6 prior clinical trials and 114 patients with little to no reported cardiotoxicity and, in the two clinical trials focused on leukemia, with fewer dose-limiting toxicities than are normally expected with doxorubicin (one of the leading first-line anthracyclines used for induction therapy). Each of these trials was conducted by a prior developer of Annamycin, and not by our company. Annamycin demonstrated significant activity in 8 of 16 patients in a Phase I study in adult relapsed or refractory AML and ALL patients, with 6 of 14 patients completely clearing leukemic bone marrow blasts. The reason only 14 (rather than 16) patients were tested for leukemic bone marrow blasts is that 2 of the 16 patients succumbed to their disease before bone marrow testing could be completed. In a 30-patient dose-ranging Phase I/II study in ALL, 3 of 8 patients treated with the maximum tolerable dose cleared their leukemic blasts to a level sufficient to qualify for a bone marrow transplant. One of these patients went on to receive a successful curative bone marrow transplant. The other two of these three patients died of tumor lysis syndrome, a condition resulting from the overloading of their system with the debris from leukemic blast cells destroyed by the induction therapy. Armed with the knowledge of this potential, prophylactic pretreatment intended to protect patients from the effects of tumor lysis syndrome will be deployed where appropriate in future trials. Based on the results of the above clinical trials, we believe Annamycin may be different from currently approved induction therapy drugs in four key ways: (i) it has demonstrated clinical activity in a patient population for whom there are currently no effective therapies, (ii) it appears to be capable of avoiding the &#8220;multi-drug resistance&#8221; mechanisms that have been associated with limiting the effectiveness of currently approved anthracyclines; (iii) it has been shown to be non-cardiotoxic in animal models and little to no cardiotoxicity has been reported from the use of Annamycin in 114 patients; and (iv) in certain AML cell lines, it has been shown to be more potent than one of the leading approved anthracyclines.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on initial conversations with the FDA, because of the serious unmet medical need, we believe Annamycin may qualify for accelerated approval based on our planned clinical trials. In order to facilitate our communication with the FDA, we requested access to and reviewed in detail the available data supporting the dose-ranging Phase I/II clinical trial discussed above, which was conducted by a previous developer of Annamycin. In October 2016, we announced that we had identified some positive findings from this review, which gave rise to a modification of our own clinical development plan. We had indicated that our plan was to conduct a detailed review of the clinical results generated by that prior developer, and then to use those results to reestablish an IND in order to continue clinical trials of Annamycin. However, in the course of our review, we identified that Annamycin may have greater potential for efficacy than we originally believed, based on an unexpected potential opportunity to increase the drug&#8217;s Maximum Tolerable Dose (&#8220;MTD&#8221;).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In particular, the Dose Limiting Toxicities (&#8220;DLTs&#8221;) reported in the previous trial that led to the establishment of the current MTD of 150 mg/m2 were all from patients who had an unusually high number of induction therapy failures prior to being treated with Annamycin. Specifically, of the three patients in the last clinical trial who experienced these DLTs, one of them had failed nineteen prior induction therapy attempts, another had failed sixteen and the other had failed fifteen before being enrolled in the trial. We concluded from our review of this data that, if the heavily treated patients are excluded from the data set, the MTD may have been higher than the level that was actually set by this previous trial.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Planned Clinical Trials for Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the discovery that we may be able to increase our MTD, we adjusted our clinical strategy by adding in a Phase I arm to our trial, which will add expense to our development effort. We believe this change in strategy will add several months to the eventual final approval of the drug, if the drug is approved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the prior developer of Annamycin allowed their IND to lapse, we were required to submit a new IND for continued clinical trials with Annamycin. We filed our IND application for Annamycin, with the clinical strategy of increasing the MTD mentioned above, on February 10, 2017. In subsequent discussions with us, FDA requested certain revisions to the protocol, additional&#160;information, and additional data related to Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;). We made the requested revisions to the protocol,&#160;and included the CMC data in our re-submission of the IND in August 2017 and the FDA allowed this IND in September 2017. &#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, we met with the European Medicines Agency (&#8220;EMA&#8221;) to discuss a CTA in Europe for the study of Annamycin for the treatment of AML. As a result of that meeting, we decided to proceed with an application in October 2017 for a CTA for Annamycin in Poland. Unlike in the United States, the process for beginning a clinical trial in Poland requires a hospital contract before a request for CTA can be made. We obtained the required hospital contract, which allowed the formal request for Polish approval. In December 2017, the Ethics Committee in Poland approved our Phase I/II trial of Annamycin for the treatment of relapsed or refractory AML. A final approval is required by the Polish National Office.&#160; In March we received requests for and provided additional information to the Polish National Office.&#160; We expect a response from the Polish National Office in the first half of 2018 and at the earliest mid-April 2018. The start of clinical trials in Poland remains subject to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">confirmation and approval of the CTA by the Polish National Office. We can provide no assurance that we will receive such confirmation on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have appointed a CRO in both the United States and Poland. In addition, we continue to recruit and contract clinics both in the United States and Poland. In the US, we have one site - University Hospitals Cleveland Medical Center (&#8220;UHCMC&#8221;) - recruiting patients and active with drug ready to provide treatments.  A patient has been enrolled with anticipated treatment to occur in the near term.&#160; We can provide no assurance treatment will occur on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 21, 2017, we received notice that FDA had granted Orphan Drug designation for Annamycin for the treatment of AML, effective March 20, 2017.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Little to No Cardiotoxicity</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One of the key dose-limiting toxicities associated with currently available anthracyclines (including the anthracycline in Vyxeos) is their propensity to induce life-threatening heart damage. This is especially problematic for pediatric leukemia patients whose life spans can be severely shortened by the very induction therapy designed to cure them of acute leukemia. In the animal model relied upon by the FDA as an indicator of human cardiotoxicity, the non-liposomal (free) form of Annamycin has been shown to be significantly less likely than doxorubicin to create heart lesions in mice, and the liposomal formulation (L-Annamycin) has been shown in these same models to have reduced cardiotoxicity to the point where it is unlikely to cause harm to human patients. This possible lack of human cardiotoxicity means L-Annamycin may be able to be used more aggressively in helping patients achieve remission. This would be especially valuable in the case of pediatric acute leukemia (both AML and ALL) where long-term survival can be greatly impacted by cardiotoxicity. In our current Phase I/II trial for Annamycin, we will collect data to further validate the design intent of Annamycin to have little or no cardiotoxicity. Unless otherwise noted, all of our references to Annamycin refer to the liposomal form (L-Annamycin).</font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Circumventing Multidrug Resistance</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to cardiotoxicity, the effectiveness of currently approved anthracyclines is limited by their propensity for succumbing to &#8220;multidrug resistance,&#8221; whereby transmembrane proteins acting as transporters (one type of which is referred to as a &#8220;P-glycoprotein pump&#8221;) develop on the outer surface of cells to expel drugs like anthracyclines as a natural defense mechanism. The dosing of current therapies cannot be increased in an attempt to overcome multidrug resistance because of the likelihood of cardiotoxicity and other serious side effects. This limitation prevents adequate dosing of current anthracyclines to produce lasting remission in most patients. A laboratory study has suggested that Annamycin may resist being expelled by P-glycoprotein pumps and other similar tested multidrug resistance transporters, which may mean the drug circumvents multidrug resistance. This characteristic has been shown in pre-clinical testing to allow for higher drug uptake in diseased cells, which we believe could allow for more effective induction therapy with less risk to the patient.</font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order for anthracyclines to provide effective induction therapy, they must be allowed to accumulate in leukemic cells sufficiently to enter the cell&#8217;s nucleus, where they damage the cell&#8217;s DNA and induce apoptosis (cell death). As induction therapy progresses, however, the targeted cells can develop a natural defense mechanism to prevent the anthracycline activity. The graphic below provides a simplified depiction of the formation of a P-glycoprotein pump on the outer surface (membrane) of a leukemic cell. As typical anthracyclines enter the cell, they are attracted to such pumps and are expelled (referred to as &#8220;efflux&#8221;) before they can accumulate sufficiently to serve their purpose. In contrast, Annamycin appears to avoid such pumps, thereby being allowed to accumulate sufficiently to destroy the leukemia cell despite the presence of the multidrug resistance mechanisms.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="pg11img1_10k.jpg" alt="pg11img1_10k.jpg" style="height:241px;width:325px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a license agreement with MD Anderson pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related to our WP1066 Portfolio and its close analogs, molecules targeting the modulation of key oncogenic transcription factors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Testing of WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;testing has shown a high level of activity for WP1066 against a wide range of solid tumors, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;testing has shown significant activity against head and neck, pancreatic, stomach, and renal cancers, as well as metastatic melanoma and glioblastoma, among others. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that leads to the formation of blood vasculature needed for tumor growth) and increases survival.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to our WP1066 Portfolio, we collaborated with a clinician at MD Anderson who submitted an IND for WP1066 treatment of brain tumors to the FDA. In December 2017, the FDA allowed this application for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Phase I trial with WP1066 drug will receive $2 million in private grant funding at MD Anderson which is in addition to two Specialized Programs of Research Excellence or (SPORE) peer reviewed grants awarded by the National Cancer Institute. We believe the rigorous peer-review process applied to SPORE grant applications represents an important additional measure of independent assessment and validation of the research connected with our approach to using WP1066/STAT3 for the treatment of cancer. The grants described here do not flow through Moleculin's financial statements, but instead are applied to the cost of preclinical and clinical activities at and conducted by MD Anderson.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that this physician-sponsored Phase I trial will begin treating patients in the first half of 2018. However, as this is a physician-sponsored clinical trial, we have limited influence on the process in beginning clinical trials and, as such, any disruptions to this process may delay the treatment of patients with WP1066, which may delay the commencement of this trial beyond the first half of 2018.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An analog of WP1066, referred to as WP1220, was previously the subject of an IND (WP1220 was referred to as &#8220;MOL4239&#8221; for purposes of this IND) related to use of the molecule in the topical treatment of psoriasis. Clinical trials were commenced on WP1220 in the US, but were terminated early due to limited efficacy in the topical treatment of psoriatic plaques. Notwithstanding its limitations in treating psoriasis, our pre-clinical research in multiple cutaneous T-cell lymphoma (&#8220;CTCL&#8221;) cell lines has suggested that WP1220 may be effective in inhibiting CTCL. Based on this data, we are collaborating with a Polish drug development company, Dermin, which has received Polish government grant money to develop WP1220 in Poland for the topical treatment of early stage CTCL patients. CTCL is a potentially deadly form of skin cancer for which there are limited treatment options.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, we engaged a CRO to prepare a proof-of-concept clinical trial in Poland to study WP1220 for the topical treatment of CTCL.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also conducted a Phase II clinical trial for WP1066 for the topical treatment of psoriasis, using a longer treatment period as compared with the WP1220 psoriasis trial, however this trial was terminated early as a significant number of patients experienced a non-permanent worsening of their psoriatic plaques after extended use of the drug, suggesting that its use as a topical agent for non-life-threatening diseases such as psoriasis will require further study to optimize dosing and scheduling regimens.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Scientific Rationale for WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cellular biology depends upon signaling mechanisms to regulate functions such as cell growth, death and adaptation. Signal &#8220;transduction&#8221; is such a mechanism that converts an upstream stimulus to a cell into a specific cellular response. Signal transduction starts with a signal to a receptor or via a compound capable of passing through the cell membrane and ends with a change in cell function. The end result of this signal is often the activation of &#8220;transcription,&#8221; whereby genetic information is expressed and, in the case of oncogenic transcription, disease processes are initiated or maintained.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receptors span the cell membrane, with part of the receptor outside and part inside the cell. When a chemical signal represented by a specific protein binds to the outer portion of the receptor, it conveys another signal inside the cell. Often there is a cascade of signals within the cell, wherein an upstream inducer starts a chain of events that resembles a domino effect. Collectively, this sequence is referred to as a &#8220;signaling pathway.&#8221; Eventually, the signal creates a change in the cell function by changing the expression of specific genes and production of specific proteins within the cell, and again, in the case of tumor development, such expression results in unwanted oncogenic processes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Importantly, while normal healthy cell function relies on signaling mechanisms, diseases are capable of co-opting these mechanisms with negative consequences. Oncogenic processes (including inflammation and proliferation) depend upon signaling pathways that are responsible for coordinating functions such as cell growth, survival and cell differentiation. A particular class of proteins referred to as Signal Transducers and Activators of Transcription (such proteins are &#8220;STATs&#8221;) regulates the process of disease cell survival and proliferation, angiogenesis and immune system function and is persistently activated in a large number of human inflammatory processes and in hyper-proliferating diseases. Because certain of these proteins are known to be co-opted by tumor cells, we refer to them as &#8220;oncogenic transcription factors,&#8221; of which certain STATs are a subset.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some STATs, such as STAT3, can be activated by any one of many different upstream inducers, making them very difficult to target by blocking just one or more of these upstream inducers. We believe that blocking a targeted STAT directly rather than via its multiple upstream inducers should result in greater efficacy with lower toxicity.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the diagram shown below, any one of many different pathways (categorized as Growth Factor Receptors, Cytokine Receptors and Non-Receptor Tyrosine Kinases) triggers the activation of STAT3 proteins in a process called &#8220;phosphorylation&#8221;. In this process, phosphates attach to corresponding receptors on STAT3 and, eventually, two phosphorylated STAT3 proteins (&#8220;p-STAT3&#8221;) bind together in a pair referred to as a &#8220;dimer.&#8221; Once the dimer is formed, it enters the cell nucleus and triggers gene transcription. Conversely, if we reduce the presence of p-STAT3 before dimers can be formed, we can prevent the triggering of gene transcription and effectively inhibit the disease process.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="pg13img1_10k.jpg" alt="pg13img1_10k.jpg" style="height:294px;width:396px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upstream effectors shown in the above diagram (SRC, JAK and ABL) are just some of those capable of activating STAT3 once they themselves are activated by a variety of signal compounds. The complexity and diversity of pathways capable of activating STAT3 make it very difficult to develop effective drugs that attempt to target the upstream effectors. Furthermore, many of these upstream pathways are necessary for normal healthy cell function, so blocking them indiscriminately can lead to unwanted toxicities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Published research has identified STAT3 as a master regulator of a wide range of tumors and linked STAT3 activation with the progression of these tumors. For this reason, it is believed that direct inhibition of p-STAT3 may be an effective way to reduce or eliminate the progression of these diseases.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many research efforts have been directed toward development of specific methods to control activation of STAT3, but most have focused on targeting the upstream effectors of these pathways like growth factors, cytokines, and specific kinases including Janus kinases (&#8220;JAKs&#8221;). However, we believe that the multifactorial nature of the activation of STAT3 limits the effectiveness of such upstream approaches. Because the activity of p-STAT3 is a final and determinative step in triggering unwanted transcription, we believe it is preferable to inhibit p-STAT3 more directly and independently from upstream effectors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the WP1066 Portfolio represents a novel class of agents capable of hitting multiple targets, including p-STAT3, regardless of their upstream method of activation. Numerous preclinical tests involving a wide range of tumor cells suggest that by inhibiting the presence of p-STAT3, WP1066 directly attacks tumor cells. We believe the effectiveness of WP1066 is not only the result of attacking tumors directly, but also indirectly by stimulating the immune system, increasing the patient&#8217;s natural ability to fight off tumor development. STAT1 is believed to stimulate T-cell activity and thereby the immune system responsible for fighting tumors. WP1066 has been shown to increase the activity of STAT1 at the same time it inhibits the activity of p-STAT3. We believe this dual activity makes WP1066 a uniquely promising oncology drug candidate, although we recognize that substantial additional preclinical and clinical research remains to be done, and may not bear out these early results and our optimism.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe the combination of the direct and indirect effects of WP1066 may ultimately be shown to provide significant tumor suppression and increased survival in a number of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;cancer models. Below is one example of an animal model suggesting an increase in survival by treating mice with metastatic melanoma with WP1066.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="pg14img1_10k.jpg" alt="pg14img1_10k.jpg" style="height:252px;width:278px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Developments in the WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we announced that, pursuant to our continued collaboration with MD Anderson we had developed and licensed what we believe, based on preclinical testing, is a potential breakthrough - WP1732, a new molecule in the WP1066 portfolio - in our effort to develop a new cancer treatment that selectively kills highly resistant tumors.&#160;We believe this new discovery could improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer. Specifically, we have preclinical data to suggest this new molecule is capable of controlling a process known as 'ubiquitination' to block the activated form of STAT3, an important oncogenic transcription factor. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In developing our current lead STAT3 inhibitor, WP1066, for brain tumors, we have focused on its oral bioavailability and brain uptake but at the same time we have continued to expand this portfolio by creating alternative inhibitors with increased bioavailability and altered tissue and organ distribution that are not affected by first-pass metabolism. The lead molecule resulting from this new discovery - WP1732 - not only appears to share the same key mechanistic properties with WP1066, it has markedly different organ distribution and its dramatically increased solubility makes it ideal for administration via standard IV injection. In addition, preclinical testing has also shown that WP1732's properties make it a promising candidate for treating pancreatic cancer, one of the most resistant and deadly forms of cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have begun planning and performing the necessary pre-clinical work required to submit an IND for WP1732.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The WP1122 Portfolio</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a license agreement with MD Anderson pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related to our WP1122 Portfolio and similar molecules targeting the treatment of glioblastoma multiforme (&#8220;GBM&#8221;) and related central nervous system malignancies.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe this technology has the potential to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system malignancies and especially GBM. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the treatment options available to their physicians are among the most limited of any cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The American Cancer Society has estimated 23,770 new cases of brain and other nervous system cancers will occur in the United States in 2016, resulting in 16,050 deaths. Despite the severity and poor prognosis of these tumors, there are few FDA-approved drugs on the market.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have preliminary preclinical data for WP1122, including </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;activity against cancer cell lines, as well as data on survival of animals subjected to xenografts of human brain tumors, including data regarding biodistribution and pharmacokinetics. In non-optimal doses and treatment regimes, WP1122 performed equal to or better than the current market leader, temozolomide and provided for superior survival for animals treated in combination with temozolomide. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding these early results, we recognize that substantial additional preclinical and clinical research remains to be done, and may not support these initial findings or their translation into activity in humans.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Scientific Rationale for WP1122</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Science has recognized that many cancer cells have a unique metabolism, distinct from that of normal cells. Dubbed the &#8220;Warburg Effect&#8221; after its discoverer, tumors rely preferentially on glycolysis for the metabolism of glucose, even in the presence of abundant oxygen, for energy (adenosine triphosphate (&#8220;ATP&#8221;) production. This alternative form of energy production makes cancer cells as much as 17 times more dependent on glucose than normal cells.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fundamental mechanism for imaging actively growing tumors using positron emission tomography (&#8220;PET scans&#8221;) is the Warburg Effect. A radiolabeled glucose decoy called F18DG accumulates disproportionately in tumors because of their dramatically increased rate of glucose uptake and accumulation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Researchers have theorized that if a tumor&#8217;s access to glucose could be blocked, the tumor could be starved out of existence. Previous attempts at targeting the metabolism of tumor cells have failed due to the rapid metabolism and short half-life (minutes) of the drugs being investigated. Efforts to target tumor metabolism in the brain were further thwarted by the inability to get glycolytic inhibitors into the brain in sufficient/therapeutic amounts due to the presence of what is called the &#8220;blood brain barrier.&#8221;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe WP1122 has the potential for developing into a technology platform for enabling increased cellular uptake, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater uptake in the brain. Our approach was inspired by the same principle that distinguishes morphine from heroin. Heroin is chemically the diacetyl ester of morphine. While morphine has a limited ability to cross the blood brain barrier (making it a good candidate for pain killing without impairing mental function), its diacetyl form, heroin, has the ability to accumulate in the brain by 10 to 100 times more than morphine. Once across the blood brain barrier, the acetyl groups are cleaved off by natural enzyme esterases, leaving pure morphine to accumulate in the brain. Similarly, we believe, based on pre-clinical testing, that WP1122, the diacetyl form of a glucose analog and decoy known as &#8220;2-DG,&#8221; crosses the blood brain barrier where its acetyl groups are cleaved off, allowing the resulting 2-DG to accumulate in the brain at a much higher rate than free 2-DG can do by itself.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adding to the difficulty in getting free 2-DG in circulation (reaching a sufficient plasma level) and to cross the blood brain barrier in therapeutic quantities is the relatively short half-life of 2-DG. The free form of 2-DG is rapidly metabolized causing typically observed 2-DG plasma levels to be generally lower than desired to achieve sufficient therapeutic potential. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contrast, WP1122 -generated 2-DG has significantly increased half-life and observed levels of 2-DG in plasma are substantially higher, making it much more feasible to deliver 2-DG to tumors in quantities adequate to produce a therapeutic effect. In addition, based on preliminary data, we believe WP1122 may represent an improvement to current PET scan diagnostics techniques because of its unique ability to reach tumors protected by the blood brain barrier in greater amounts than the glucose decoys currently used for PET scans. Significant additional development is required to determine if these findings are valid and if they will translate into the desired activity in humans.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, we announced promising initial results of the preclinical toxicology work on WP1122, our unique inhibitor of glucose metabolism, an important driver of glycolytic brain tumor progression and survival. We view this as an important step toward future clinical trials for WP1122. We indicated that preliminary escalating single dose toxicity testing in mice (oral administration) was successfully completed and even at the highest possible dose, no toxic death was observed. In multiple therapeutic doses, WP1122 was well tolerated during intense twice-daily oral dosing.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. In pre-clinical testing, WP1234, a modification to WP1122, has shown improved in-vitro drug characteristics and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with WP1122. We know that pancreatic cancer thrives even in a reduced oxygen environment, and is highly dependent on glycolysis to proliferate and survive. We believe WP1234 may be a promising drug candidate to be studied for the treatment of pancreatic cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;"><img src="wp1122inmice.jpg" alt="wp1122inmice.jpg" style="height:242px;width:453px;"></div><div style="line-height:120%;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pancreatic cancer is still considered largely untreatable, so even modest gains in treating this disease could represent a significant clinical benefit. In pre-clinical testing, WP1234 improves on known inhibitors for glycolysis by increasing drug circulation time, which should increase the potential for drug uptake by and destruction of tumor cells. We intend to pursue development opportunities with WP1234 for the treatment of pancreatic cancer and compare its activity with our other inhibitors, including WP1122.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview of the market for our oncology drugs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is the second leading cause of death in the United States behind heart disease. In 2016, an estimated 15.5 million people in the United States were living with a past or current diagnosis of cancer and, in 2018, the National Institutes of Health estimated that nearly 1.7 million new cases will be diagnosed and over 600,000 Americans will die from cancer.</font></div><div style="line-height:120%;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:52px;"><img src="cancerindustrychart.jpg" alt="cancerindustrychart.jpg" style="height:332px;width:554px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Source: American Cancer Society - Cancer Facts &amp; Figures 2018</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Digestive, reproductive, breast and respiratory cancers comprise 65% of expected cancer diagnoses in 2018, while cancers like leukemia and brain tumors are considered &#8220;rare diseases.&#8221; Leukemia in particular, can be divided into acute, chronic and other, with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (&#8220;AML&#8221;) comprising 26,900 of the estimated 60,300 new cases expected in the United States in 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The worldwide cancer drug business has been estimated to represent approximately $100 billion in annual sales. Our lead drug candidate, Annamycin, is in a class of drugs referred to as anthracyclines, which are chemotherapy drugs designed to destroy the DNA of targeted cancer cells. The most common approved anthracyclines are daunorubicin and doxorubicin and, prior to the expansion of their generic equivalents, annual revenues generated from anthracyclines have been estimated in the range of $600 million. Acute leukemia is one of a number of cancers that are treated with anthracyclines. One industry report estimates that annual drug revenues generated from the demand for AML-related therapies in the United States, United Kingdom, France, Germany, Italy and Spain were in the range of $151 million in 2012, and we believe that this number may increase if and when improved AML treatments are available.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other two active development projects have applications (among others) in the treatment of brain tumors, another rare disease for which there are few available treatments. The leading brain tumor drug is temozolomide, a drug introduced under the brand name Temodar. In 2012, one industry source reported annual revenues of approximately $882 million for Temodar before the expiration of its patent protection, at which point generic versions of the drug began to enter the market and reduce prices.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Orphan Drug Act and other legislative initiatives provide incentives, including market exclusivity and accelerated approval pathways, for companies that pursue the development of treatments for rare diseases and serious diseases for which there are few or no acceptable available treatment alternatives. Over the last 10 years, an increasing number of companies have begun using these designations to obtain new drug approvals for drugs where patent coverage has expired and/or where accelerated approval appears possible. An IMS Health report estimated that, in 2013, the sale of drugs with full or partial Orphan Drug exclusivity represented approximately $29 billion in revenue. We consider obtaining Orphan Drug exclusivity and accelerated approval to be an important part of our development strategy for our drug candidates. Notwithstanding these potential opportunities, we can provide no assurance that our drugs will receive Orphan Drug designation (other than Annamycin, which recently received such designation) or, if approved, exclusivity or any other special designation that could, among other things, provide for accelerated approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our License Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sponsored Research Agreements with MD Anderson</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2017, we amended our Sponsored Laboratory Study Agreement with MD Anderson whereby we paid $302,500 in 2017, and the agreement was extended to October 31, 2018. On December 4, 2017, we extended this Agreement until October 31, 2019 for a total of payments of $346,687 spread over that period of time. Of this amount, $236,687 was paid in the first quarter of 2018. The final payment of $110,000 is due on July 31, 2018.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of August 2015, we obtained the rights and obligations of Annamed under a June 2012 Patent and Technology Development and License Agreement by and between Annamed and Dermin (the &#8220;Annamed Agreement&#8221;). Therefore, certain intellectual property rights, including rights, if any, covering the potential drug product, Annamycin have been licensed to Dermin and Dermin has been granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany (&#8220;Annamed licensed territories&#8221;). We are obligated to develop and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin will pay a royalty for the sale of any licensed product in the Annamed licensed territories and pay all out-of-pocket expenses incurred by us in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Dermin also agrees to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. The agreement includes a one-time license documentation fee of $40,000, annual maintenance fees of $25,000 until the first sale of drug and has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product - $125,000; (ii) submission of the first NDA within the United States - $175,000; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- $225,000.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#8220;Moleculin Agreement&#8221;) have been assigned to us. Therefore, we have obtained a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, we must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Annual maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. The agreement, as amended, has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- $600,000.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), pursuant to which we have granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#8220;HPI Out-Licensing Agreement&#8221;). Under the HPI Out-Licensing Agreement, we must make quarterly payments totaling $0.75 million for the first twelve quarters following the effective date of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of $1.0 million to HPI within three years of the effective date of the HPI Out-Licensing Agreement we will regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly payments. In the event that we do not exercise our right to regain our rights to the licensed subject matter within three years of the effective date of the HPI Out-Licensing Agreement, the license granted to HPI shall convert to an exclusive license upon HPI&#8217;s written notice and we shall be obligated to transfer all existing data relating to licensed subject matter including any development data and any IND to HPI.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into a license agreement covering a new group of molecules recently discovered in connection with research we have been sponsoring at MD Anderson Cancer Center called WP1732, a part of the WP1066 Portfolio. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are $10,000 on the effective date of the agreement and increase by $5,000 per year up to a maximum of $50,000 per year. Under the agreement, we are required to make royalty payments ranging from 3% to 5% of Net Sales, depending on the intended use, each quarter upon the commencement of sales, with a minimum of $200,000 per year. Additional payments are due upon the commencement of a Phase II study ($150,000), submission of an New Drug Application ($500,000), and the receipt of marketing approval of a licensed product ($600,000).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1122 Portfolio</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#8220;IntertechBio Agreement&#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are $10,000 on the first anniversary of the effective date of the agreement, $20,000 on the second anniversary of the effective date of the agreement, $40,000 on the third anniversary of the effective date of the agreement, $60,000 on the fourth anniversary of the effective date of the agreement, $80,000 on the fifth anniversary of the effective date of the agreement and $100,000 on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the assignment, we agreed to make a minimum annual royalty payment in the amount of $200,000 for the first anniversary following the first sale of a licensed product, $400,000 for the second anniversary following the first sale of a licensed product, and $600,000 for the third year following the first sale of a licensed product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One-time milestone payments are due as follows: 1) Upon commencement of a Phase II study for a licensed product - $200,000; 2) Upon commencement of a Phase III study for a licensed product - $250,000; 3) Upon filing of a New Drug Application (&#8220;NDA&#8221;) for a licensed product - $400,000; and 4) Upon receipt of market approval for sale of a licensed product - $500,000. The rights we have obtained pursuant to the assignment of the IntertechBio Agreement are made subject to the rights </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate History </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 2015 by Walter Klemp (our chairman and CEO), Dr. Don Picker (our Chief Science Officer) and Dr. Waldemar Priebe of MD Anderson (Chairman of our Scientific Advisory Board) in order to combine and consolidate development efforts that include several MD Anderson  oncology technologies. Dr. Priebe is a Professor of Medicinal Chemistry in the Department of Experimental Therapeutics, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center. This effort began with the acquisition of the Annamycin development project from AnnaMed, Inc., or AnnaMed, followed by the acquisition of the license rights to the WP1122 Portfolio from IntertechBio Corporation, or IntertechBio. Further, we undertook an effort to gain control of the WP1066 Portfolio, which culminated with the merger of Moleculin, LLC and MBI and the establishment of a co-development agreement with Houston Pharmaceuticals, Inc., or HPI, coincident with our IPO.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnnaMed, a company controlled by Mr. Klemp, was formed in 2012 to take over the development of Annamycin from a prior drug development company. In 2012, AnnaMed out-licensed development rights in a limited territory to a Polish special purpose drug development company called Dermin in exchange for Dermin&#8217;s development work based on its successful effort to obtain Polish government grant funding to assist in the development of Annamycin. In August 2015, we entered into a rights transfer agreement with AnnaMed pursuant to which, in exchange for our common stock, AnnaMed agreed to transfer any and all data it had regarding the development of Annamycin and the Annamycin IND, including all trade secrets, know-how, confidential information and other intellectual property rights held by AnnaMed.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IntertechBio was formed in 2009 to license and begin development on the WP1122 Portfolio. The WP1122 Portfolio was also out-licensed to Dermin, which was awarded a Polish government grant to assist in drug development efforts. In August 2015, IntertechBio agreed to assign all license rights to us in exchange for our common stock. Drs. Priebe and Picker are shareholders of IntertechBio and control the voting and dispositive power over the shares of our common stock held by IntertechBio.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moleculin, LLC was formed in 2006 and had been working to develop the WP1066 Portfolio it licensed from MD Anderson. As a part of the formation of Moleculin, LLC, an agreement was reached with HPI to limit Moleculin, LLC&#8217;s development efforts to uses in dermatology only, leaving non-dermatology indications to HPI. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to our IPO, Moleculin, LLC was merged with and into our company. Dr. Priebe, Mr. Klemp and Dr. Picker were members of Moleculin, LLC and received shares of our common stock as a result of the merger. In addition, Mr. Klemp and Dr. Picker were members of the board of Moleculin, LLC. The merger agreement contains mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of six years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof and Moleculin, LLC made representations to this effect in the merger agreement as of the date of such agreement. As additional consideration payable to the Moleculin, LLC unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us (or our successors) using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a 2.5% royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &#8220;Existing IP Assets&#8221; to mean all intellectual property, licensed by us and Moleculin, LLC as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated June 21, 2010, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein are for drugs developed only for dermatology indications, and do not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to our IPO, we entered into a co-development agreement with HPI whereby HPI is continuing its grant-funded research and making all resulting data available for our use in exchange for a development fee. We may buy HPI out of its co-development rights in the WP1066 Portfolio at our option. Please see the section &#8220;Business - License Agreements&#8221; for a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">description of our agreement with HPI. Drs. Priebe and Picker are shareholders of HPI, and Dr. Priebe has the voting and dispositive power over the shares of our common stock held by HPI.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly competitive segment of the pharmaceutical market, which market is highly competitive as a whole. We face competition from numerous sources including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Many of our competitors may have significantly greater financial, product development, manufacturing and marketing resources. Additionally, many universities and private and public research institutes are active in cancer research, and some may be in direct competition with us. We may also compete with these organizations to recruit scientists and clinical development personnel. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unmet medical need for more effective cancer therapies is such that oncology drugs are, by far, the leading class of drugs in development. These include a wide array of products against cancer targeting many of the same indications as our drug candidates. While the introduction of newer targeted agents may result in extended overall survival, induction therapy regimens are likely to remain a cornerstone of cancer treatment in the foreseeable future.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of established therapies that may be considered competitive for the cancer indications for which we intend to develop our lead product, Annamycin. A key consideration when treating AML patients is whether the patient is suitable for intensive therapy. The standard of care for the treatment of newly diagnosed AML patients who can tolerate intensive therapy is cytarabine in combination with an anthracycline (e.g., doxorubicin or daunorubicin), typically referred to as a &#8220;7+3&#8221; regimen. For some patients, primarily those less than 60 years of age, a stem cell transplant could also be considered if the induction regimen is effective in attaining a CR (Complete Response). The 7+3 regimen of cytarabine in combination with an anthracycline has been the standard of care for decades. A patient not suitable for intensive therapy may be offered the option for low-intensity therapy such as low-dose cytarabine, azacitidine or decitabine. It should be noted that, in the United States, these are not approved by the FDA for the treatment of AML patients and there remains no effective therapy for these patients or for relapsed or refractory AML, with the exception of some recently approved targeted therapies that have demonstrated a low level of activity for limited subgroups of AML patients. The initial focus for Annamycin development is in patients for whom the standard induction regimen has failed. Also, several major pharmaceutical companies and biotechnology companies are aggressively pursuing new cancer development programs for the treatment of AML.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of attempts have been made or are under way to provide an improved treatment for AML. Celator Pharmaceuticals reported Phase III clinical trial results for a new combined formulation of cytarabine and daunorubicin (commonly used induction therapy drugs) they call Vyxeos. This new liposome formulation provides a 5:1 ratio of cytarabine and daunorubicin in each of three injections. When compared with patients receiving 7 injections of cytarabine and 3 injections of daunorubicin (traditional 7+3 induction therapy), patients receiving Vyxeos achieved an average increase in overall survival of approximately 3.5 months (9.5 months compared with 6 months). Despite this extension of overall survival, Vyxeos did not reduce the toxic side effects of daunorubicin (including cardiotoxicity) and it failed to qualify a significant majority of patients for curative bone marrow transplant. With these results, Jazz Pharmaceuticals acquired Celator in 2016 and recently obtained FDA approval, making Vyxeos the new first line standard of care for the treatment of AML</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Drugs attempting to target a subset of AML patients who present with specific gene mutations, such as one referred to as FLT3, have recently received FDA approval, but by definition serve only subsets of the AML population. Other targeted therapies are currently in clinical trials, as well as other approaches that include immunotherapy relying on other biomarkers, other attempts at improved chemotherapy and alternative approaches to radiation therapy. Other approaches to improve the effectiveness of induction therapy are in early stage clinical trials and, although they do not appear to address the underlying problems with anthracyclines, we can provide no assurance that such improvements, if achieved, would not adversely impact the need for improved anthracyclines. A modified version of doxorubicin designed to reduce cardiotoxicity is in clinical trials for the treatment of sarcoma and, although this drug does not appear to address multidrug resistance and is not currently intended for the treatment of acute leukemia, we can provide no assurance that it will not become a competitive alternative to Annamycin. Although we are not aware of any other single agent therapies in clinical trials that would directly compete against Annamycin in the treatment of relapsed and refractory AML, we can provide no assurance that such therapies are not in development, will not receive regulatory approval and will reach market before our drug candidate Annamycin. In addition, any such competing therapy may be more effective and/or cost-effective than ours.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities in the US, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical drug product candidates that we develop must be approved by the FDA before they may be marketed and distributed.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act, and implementing regulations. Pharmaceutical products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA and related enforcement activity could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a pharmaceutical product may be marketed in the US generally involves the following:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical studies may begin;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Performance of adequate and well-controlled human clinical studies according to the FDA&#8217;s current good clinical practices (&#8220;GCP&#8221;), to establish the safety and efficacy of the proposed pharmaceutical product for its intended use;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Submission to the FDA of an NDA for a new pharmaceutical product;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical product is produced, to assess compliance with current good manufacturing practices (&#8220;cGMP&#8221;), to assure that the facilities, methods and controls are adequate to preserve the pharmaceutical product&#8217;s identity, strength, quality and purity;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Potential FDA audit of the preclinical and clinical study sites that generated the data in support of the NDA; and</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">FDA review and approval of the NDA.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources and approvals, and continued compliance are inherently uncertain.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before testing any compounds with potential therapeutic value in humans, the pharmaceutical product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the pharmaceutical product candidate. These early proof-of-principle studies are done using sound scientific procedures and thorough documentation. The conduct of the single and repeat dose toxicology and toxicokinetic studies in animals must comply with federal regulations and requirements including good laboratory practices. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA has concerns and notifies the sponsor. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. If resolution cannot be reached within the 30-day review period, either the FDA places the IND on clinical hold or the sponsor withdraws the application. The FDA may also impose clinical holds on a pharmaceutical product candidate at any time before or during clinical studies for various reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such clinical study.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical studies involve the administration of the pharmaceutical product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the clinical study sponsor&#8217;s control. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">procedures, subject selection and exclusion criteria, how the results will be analyzed and presented and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical studies must be conducted in accordance with GCP. Further, each clinical study must be reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;) at, or servicing, each institution at which the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until completed.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human clinical studies are typically conducted in three sequential phases that may overlap or be combined:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Phase 1: The pharmaceutical product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients, with a goal of characterizing the safety profile of the drug and establishing a maximum tolerable dose (&#8220;MTD&#8221;). Our pharmaceutical products fall into this latter category because its products are intended to treat cancer and contain cytotoxic agents. Hence, our Phase 1 studies are conducted in late-stage cancer patients whose disease has progressed after treatment with other agents.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Phase 2: With the maximum tolerable dose established in a Phase 1 trial, the pharmaceutical product is evaluated in a limited patient population at the MTD to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, to determine dosage tolerance, optimal dosage and dosing schedule and to identify patient populations with specific characteristics where the pharmaceutical product may be more effective.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Phase 3: Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. The studies must be well controlled and usually include a control arm for comparison. One or two Phase 3 studies are usually required by the FDA for an NDA approval, depending on the disease severity and other available treatment options. In some instances, an NDA approval may be obtained based on Phase 2 clinical data with the understanding that the approved drug can be sold subject to a confirmatory trial to be conducted post-approval.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Post-approval studies, or Phase 4 clinical studies, may be conducted after initial marketing approval. These studies are often used to gain additional experience from the treatment of patients in the intended therapeutic indication. The FDA also may require Phase 4 studies, Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) and post-marketing surveillance, among other things, to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the pharmaceutical product has been associated with unexpected serious harm to patients.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrent with clinical studies, companies may complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the pharmaceutical product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the pharmaceutical product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final pharmaceutical product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the pharmaceutical product candidate does not undergo unacceptable deterioration over its shelf life.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of product development, preclinical studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the pharmaceutical product, proposed labeling and other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees. A waiver of such fees may be obtained under certain limited circumstances.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA has 10 months after the 60-day filing date in which to complete its initial review of a standard review NDA and respond to the applicant, and six months after the 60-day filing date for a priority review NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the NDA submission is accepted for filing, the FDA reviews the NDA application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel pharmaceutical products or pharmaceutical products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the pharmaceutical product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the pharmaceutical product. If the FDA concludes that a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites as well as the site where the pharmaceutical product is manufactured to assure compliance with GCP and cGMP. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. In addition, the FDA will require the review and approval of product labeling.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NDA review and approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA. The complete response letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical studies designed to further assess pharmaceutical product safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expedited Development and Review Programs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new pharmaceutical products that meet certain criteria. Specifically, new pharmaceutical products are eligible for Fast Track designation if they are intended to treat a serious condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, if the FDA determines that the schedule is acceptable and if the sponsor pays any required user fees upon submission of the first section of the NDA.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any product submitted to the FDA for market, including a Fast Track program, may also be eligible for other FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it is intended to treat a serious condition and it offers a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new pharmaceutical product designated for priority review in an effort to facilitate the review. Additionally, accelerated approval may be available for a product intended to treat a serious condition that provides meaningful therapeutic benefit over existing treatments, which means the product may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint. As a condition of accelerated approval, the FDA may require the sponsor to perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires pre-approval of promotional materials for products receiving accelerated approval, which could impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Post-Approval Requirements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any pharmaceutical products for which the Company receives FDA approvals are subject to continuing regulation by the FDA, including, among other things, cGMP compliance, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, prohibitions on promoting pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, actions by the U.S. Department of Justice and/or U.S. Department of Health and Human Services&#8217; Office of Inspector General, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available pharmaceutical products for off-label uses, manufacturers may not directly or indirectly market or promote such off-label uses.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely and expect to continue to rely on third parties for the production of clinical and commercial quantities of our products. Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Term Restoration and Marketing Exclusivity</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending upon the timing, duration and specifics of the FDA approval of the use of our pharmaceutical product candidates, some of our products covered by U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process for a product the approval of which is the first permitted commercial marketing of the active pharmaceutical ingredient. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved pharmaceutical product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent unless an extension is obtained. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and renders a decision on the application for any patent term extension or restoration. In the future, we may be able to apply for extension of patent term for one or more of our currently licensed patents or any future owned patents to add patent life beyond its current expiration date, depending upon the expected length of the clinical studies and other factors involved in the filing of the relevant NDA.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market exclusivity provisions under the U.S. Food, Drug, and Cosmetic Act can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA or seeking approval for a similar product. Pediatric exclusivity adds six months to existing exclusivity periods and patent terms and may be granted based on the completion of a pediatric clinical study that &#8220;fairly responds&#8221; to an FDA-issued &#8220;Written Request&#8221; for such a clinical study.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical product candidates for which we may obtain regulatory approval. In the United States and in markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part upon the availability of reimbursement from third-party payers. Third-party payers include government payers such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a pharmaceutical product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the pharmaceutical product. Third-party payers may limit coverage to specific pharmaceutical products on an approved list, or formulary, which might not, and frequently does not, include all of the FDA-approved pharmaceutical products for a particular indication. Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. A payer&#8217;s decision to provide coverage for a pharmaceutical product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, in the United States there is a growing emphasis on comparative effectiveness research, both by private payers and by government agencies. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our pharmaceutical product candidates may not be considered medically necessary or cost-effective. To the extent other drugs or therapies are found to be more effective than our products, payers may elect to cover such therapies in lieu of our products and/or reimburse our products at a lower rate.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan Drug exclusivity prevents for seven years the approval of another product with the same active moiety for the same rare disease. If a product is a new chemical entity (i.e., generally that the moiety has not previously been approved), it may receive five years of exclusivity, during which period FDA may not accept for review certain NDAs for another product with the same moiety. If approval of a product required new clinical data, it may convey three years of exclusivity against approval of certain NDAs for similar products.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Different pricing and reimbursement schemes exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical studies that compare the cost-effectiveness of a particular pharmaceutical product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The marketability of any pharmaceutical product candidates for which we may receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect this will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we may receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Regulation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future drugs. Whether or not we obtain FDA approval for a drug, we must obtain approval of a drug by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country&#160;to country, and the time may be longer or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">shorter than that&#160;required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The mutual recognition procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">In addition to regulations in Europe and the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of our future drugs</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of 2,333 rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of 66 months, which may be renewed for an additional 5 years. We are required to remit base monthly rent of approximately $4,300 which will increase at an average approximate rate of 3% each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Investors&#8221;) for the sale of 4,290,000 shares of our common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the shares, pursuant to the Purchase Agreement, we also sold warrants to purchase 2,145,000 shares of common stock (the &#8220;Warrants&#8221;). We sold the shares and Warrants for aggregate gross proceeds of approximately $9.0 million. Subject to certain beneficial ownership limitations, the Warrants will be initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.80 per share, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the offering, we entered into a placement agent agreement (the &#8220;Placement Agency Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the shares and Warrants. We paid Roth an aggregate fee equal to 6.5% of the gross proceeds received from the sale of the securities in the transactions. Pursuant to the Placement Agency Agreement, we also agreed to grant to Roth or its designees warrants to purchase up to 3% of the aggregate number of shares sold in the transactions (the &#8220;Roth Warrants&#8221;). The Roth Warrants have substantially the same terms as the Warrants, except that the Roth Warrants will expire on February 15, 2023. We also reimbursed Roth for its expenses of $75,000.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We agreed to give Roth a nine-month right of first refusal to act as our lead underwriter or exclusive placement agent for any further capital raising transactions. With certain exceptions, we also granted Roth a six-month tail fee equal to the cash and warrant compensation in the offering, if any investor with which Roth had substantive discussions with respect to the offering, provides us with further capital during such six-month period following termination of our engagement of Roth.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, we had four full-time employees and four part-time employees, and accordingly, a high percentage of the work performed for our development projects is outsourced to qualified independent contractors. In early 2018, an additional four employees, three full time and one part-time, joined the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to any litigation.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="sE0FBF3A53E13C8DA9A6CA0B86875851A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following risks and uncertainties should be carefully considered. If any of the following occurs, our business, financial condition or operating results could be materially harmed. An investment in our securities is speculative in nature, involves a high degree of risk and should not be made by an investor who cannot bear the economic risk of its investment for an indefinite period of time and who cannot afford the loss of its entire investment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are developing our drugs to treat patients who are extremely or terminally ill, and patient deaths that occur in our clinical trials could negatively impact our business even if such deaths are not shown to be related to our drugs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our intention to further develop Annamycin and WP1066 with clinical trials in the near future for the treatment of AML and glioblastoma, respectively. Patients suffering from these diseases are extremely sick and have a high likelihood of experiencing adverse outcomes, including death, as a result of their disease or due to other significant risks including relapse of their underlying malignancies. Many patients have already received high-dose chemotherapy and/or radiation therapy, which are associated with their own inherent risks, prior to treatment with our drugs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result, it is likely that we will observe severe adverse outcomes during our clinical trials for our drugs, including patient death. If a significant number of study subject deaths were to occur, regardless of whether such deaths are attributable to one of our drugs, our ability to obtain regulatory approval and/or achieve commercial acceptance for the related drug may be adversely impacted and our business could be materially harmed.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to use the proceeds from our previous offerings, as well as the proceeds from any possible future offerings, to, among other uses, advance Annamycin through clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional future capital in order to complete clinical development and commercialize Annamycin. If the FDA requires that we perform additional nonclinical studies or clinical trials, or if we determine, as we did in October 2016, that additional clinical trials are required for Annamycin, our expenses would further increase beyond what we currently expect and the anticipated timing of any potential approval of Annamycin would likely be delayed. Further, there can be no assurance that the costs we will need to incur to obtain regulatory approval of Annamycin will not increase.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to require substantial additional capital to continue our clinical development and commercialization activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize our products under development.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount and timing of our future funding requirements will depend on many factors, including but not limited to:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">whether our updated plan for clinical trials will be completed on a timely basis and, if completed, whether we will be able to publicly announce results from our phase I/II clinical trials in accordance with our announced milestones;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">whether we are successful in obtaining the benefits of FDA&#8217;s expedited development and review programs related to Annamycin or our other drug candidates;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">&#160;the progress, costs, results of and timing of our clinical trials;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">&#160;the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the costs associated with securing and establishing commercialization and manufacturing capabilities;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">market acceptance of our product candidates;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to maintain, expand and enforce the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our need and ability to hire additional management and scientific and medical personnel;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the effect of competing drug candidates and new product approvals;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of these factors are outside of our control. Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operational plan into 2019, assuming not a significant amount of the warrants in our recent public offering are exercised for cash. This period could be shortened if there are any significant increases in planned spending on development programs or more rapid progress of development programs than anticipated. We do not believe that our existing capital resources are sufficient to enable us to complete the development and commercialization of Annamycin, if approved, or to initiate any clinical trials or additional development work needed for any other drug candidates. Accordingly, we expect that we will need to raise additional funds in the future.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or development programs. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have recently commenced clinical trials,</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical stage pharmaceutical company with a limited operating history. Our operations to date have been limited to acquiring our technology portfolio and preparing several drugs for authorization to conduct clinical trials. We have only recently commenced clinical trials with Annamycin and have yet to commence clinical trials for any other drug candidates in our pipeline and have yet to receive regulatory approvals for any of our drug candidates. With regard to Annamycin, the FDA has taken a more risk adverse view than European regulatory authorities, placing greater restrictions on our ability to increase dosing for AML patients, which could cause development in the US to lag behind development in Europe. Additionally, we have a limited amount of drug supply and the amount of drug required may depend upon patient response and the need for additional, unplanned treatments, making it difficult to predict the total amount of drug required.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Our operating results are expected to significantly fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">any delays in regulatory review and approval of our product candidates in clinical development, including our ability to receive approval from the FDA or the Polish authorities for Annamycin;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">delays in the commencement, enrollment and timing of clinical trials;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">difficulties in identifying patients suffering from our target indications;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the success of our clinical trials through all phases of clinical development;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">potential side effects of our product candidate that could delay or prevent approval or cause an approved drug to be taken off the market;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to obtain additional funding to develop drug candidates;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to identify and develop additional drug candidates beyond Annamycin and our WP1066 and WP1122 Portfolios;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">competition from existing products or new products that continue to emerge;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to adhere to clinical trial requirements directly or with third parties such as contract research organizations (CROs);</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our dependency on third-party manufacturers to manufacture our products and key ingredients;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to establish or maintain collaborations, licensing or other arrangements, particularly with MD Anderson;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to defend against any challenges to our intellectual property including, claims of patent infringement;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to enforce our intellectual property rights against potential competitors;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to secure additional intellectual property protection for our developing drug candidates and associated technologies;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain key personnel to manage our business effectively; and</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">potential product liability claims.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, the results of any historical quarterly or annual periods should not be relied upon as indications of future operating performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks associated with conducting research and clinical trials abroad could materially adversely affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have submitted a request for Clinical Trial Authorization in Poland which, if allowed, will enable a clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland.&#160;Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">differing regulatory requirements in foreign countries;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected changes in price and exchange controls and other regulatory requirements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased difficulties in managing the logistics and transportation of collecting and shipping patient material;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">import and export requirements and restrictions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign taxes, including withholding of payroll taxes;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses, and other obligations incident to doing business in another country;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties staffing and managing foreign operations;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business interruptions resulting from geo-political actions, including war and terrorism.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have in the past completed related party transactions that were not conducted on an arm&#8217;s length basis.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We acquired the rights to the license agreement with MD Anderson covering our WP1122 Portfolio held by IntertechBio Corporation, a company affiliated with certain members of our management and board of directors. We acquired the rights to all data related to the development of Annamycin held by AnnaMed, Inc., a company affiliated with certain members of our management and board of directors. Prior to our IPO, Moleculin, LLC merged with and into our company. Moleculin, LLC was affiliated with certain members of our management and board of directors. Prior to our IPO, we, on Moleculin, LLC&#8217;s behalf, entered into an agreement with HPI whereby HPI agreed to terminate its option to sublicense certain rights to the WP1066 Portfolio and entered into a co-development agreement with us. Our largest shareholder and a member of our management are shareholders of HPI. None of the foregoing transactions were conducted on an arm&#8217;s length basis. As such, it is possible that the terms were less favorable to us than in an arm&#8217;s length transaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to retain the development rights to the WP1066 Portfolio will require us to make up to a total of $1.75 million in payments to HPI, in addition to payments of shares of our common stock and cash made in connection with our IPO, pursuant to the development agreement we entered into with HPI.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our acquisition of Moleculin, LLC prior to our IPO provided us with the rights to the license agreement Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC previously granted HPI an option to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Prior to our IPO, we, on Moleculin, LLC&#8217;s behalf, entered into two agreements with HPI. The first agreement terminated HPI&#8217;s option to obtain the aforementioned exclusive sublicense in exchange for a payment of $100,000 and the issuance of 629,000 shares of our common stock. The second agreement, the HPI Out-Licensing Agreement is a technology rights and development license agreement that provided HPI with a non-exclusive sublicense to develop the WP1066 Portfolio. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI of $750,000 over a three-year period commencing after our IPO in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI, which payments will be expensed when incurred. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within three years of the date we entered into the agreement, which occurred in May 2016, to buy-out from HPI all rights granted to HPI under the agreement for a payment of $1.0 million. If we do not exercise the foregoing buy-out right within three years, the license granted to HPI shall convert into an exclusive license even as to our company. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-dermatology uses of the WP1066 Portfolio and all amounts paid to HPI prior to such date will have value only to the extent that the data, information and know-how may be applicable to dermatology applications of the WP1066 Portfolio. We do not expect to maintain a reserve of $1.0 million to exercise the buy-out payment and, as such, we will need to raise additional funds to make the buy-out payment. We cannot assure you that such additional funding, if required, will be available on satisfactory terms, or at all.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never been profitable and do not expect to be profitable in the foreseeable future. We have not yet submitted any drug candidates for approval by regulatory authorities in the United States or elsewhere. For the year ended December 31, 2017, we incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">. We had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, 2017.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have devoted most of our financial resources to research and development, including our drug discovery research, preclinical development activities and clinical trial preparation, as well as corporate overhead. We have not generated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any revenues from product sales. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for Annamycin and our other drug candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support our continuing product development efforts. We anticipate that any such losses could be significant for the next several years. If Annamycin or any of our other drug candidates fail in clinical trials or do not gain regulatory approval, or if our drug candidates do not achieve market acceptance, we may never become profitable. As a result of the foregoing, we expect to continue to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders' equity and working capital.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our financial condition would be adversely impacted if our intangible assets become impaired.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the accounting for our acquisition of Moleculin, LLC and the agreement we, on Moleculin, LLC&#8217;s behalf, entered into with Houston Pharmaceuticals, Inc., we have carried on our balance sheet within intangible assets in-process research and development (&#8220;IPR&amp;D&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, 2017. Intangibles are evaluated quarterly and are tested for impairment at least annually or when events or changes in circumstances indicate the carrying value of each segment, and collectively our company taken as a whole, might exceed its fair value.&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets related to IPR&amp;D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statement of operations. For those compounds that reach commercialization, if any, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we determine that the value of our intangible assets is less than the amounts reflected on our balance sheet, we will be required to reflect an impairment of our intangible assets in the period in which such determination is made. An impairment of our intangible assets would result in our recognizing an expense in the amount of the impairment in the relevant period, which would also result in the reduction of our intangible assets and a corresponding reduction in our stockholders&#8217; equity in the relevant period. As the transactions discussed above were related party transactions and were not conducted on an arm&#8217;s length basis, it is possible that the terms were less favorable to us than what we would have received in an arm&#8217;s length transaction.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are limited suppliers for active pharmaceutical ingredients (&#8220;API&#8221;) used in Annamycin. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Problems with the third parties that manufacture the API used in Annamycin may delay our clinical trials or subject us to liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not currently own or operate manufacturing facilities for clinical or commercial production of the API used in Annamycin or any of our product candidates. We have no experience in API manufacturing, and we lack the resources and the capability to manufacture any of the APIs used in Annamycin and our product candidates, on either a clinical or commercial scale. As a result, we rely on third parties to supply the API used in Annamycin and each of our product candidates. We expect to continue to depend on third parties to supply the API for Annamycin and our current and future product candidates and to supply the API for Annamycin in commercial quantities. We are ultimately responsible for confirming that the APIs used in Annamycin and our product candidates are manufactured in accordance with applicable regulations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third-party suppliers may not carry out their contractual obligations or meet our deadlines. In addition, the API they supply to us may not meet our specifications and quality policies and procedures or they may not be able to supply the API in commercial quantities. If we need to find alternative suppliers of the API used in Annamycin or any of our product candidates, we may not be able to contract for such supplies on acceptable terms, if at all. Any such failure to supply or delay caused by such contract manufacturers would have an adverse effect on our ability to continue clinical development of our product candidates or commercialize Annamycin.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our third-party drug suppliers fail to achieve and maintain high manufacturing standards in compliance with cGMP regulations, we could be subject to certain product liability claims in the event such failure to comply resulted in defective products that caused injury or harm.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We cannot be certain that Annamycin will receive regulatory approval, and without regulatory approval we will not be able to market Annamycin.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business currently depends largely on the successful development and commercialization of Annamycin. Our ability to generate revenue related to product sales, if ever, will depend on the successful development and regulatory approval of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia, or AML.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we receive approval of a NDA from the FDA. We have not submitted any marketing applications for any of our product candidates.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NDAs must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. NDAs must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of a NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take years to complete and approval is never guaranteed. If we submit a NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators in other jurisdictions have their own procedures for approval of product candidates. Even if a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and Europe also have requirements for approval of drug candidates with which we must comply with prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States, Europe or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of product development and the emergence of new information regarding our product candidates or other products. Also, regulatory approval for any of our product candidates may be withdrawn.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to obtain approval from the FDA, or other regulatory agencies, for Annamycin and our other product candidates, or if, subsequent to approval, we are unable to successfully commercialize Annamycin or our other product candidates, we will not be able to generate sufficient revenue to become profitable or to continue our operations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any statements in this report indicating that Annamycin has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA&#8217;s or any other comparable governmental agency&#8217;s assessment of Annamycin and do not indicate that Annamycin will achieve favorable efficacy results in any later stage trials or that the FDA or any comparable agency will ultimately determine that Annamycin is effective for purposes of granting marketing approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for Annamycin and our other product candidates.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delays in the commencement, enrollment and completion of clinical trials could increase our product development costs or limit the regulatory approval of our product candidates. We do not know whether any future trials or studies of our other product candidates will begin on time or will be completed on schedule, if at all. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, including delays or shortages in available drug product, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, that include the age and condition of the patients and the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments and/or availability of investigational treatment options for the relevant disease.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including, but not limited to, a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. We may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">inability to obtain sufficient funds required for a clinical trial;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">serious and unexpected drug-related side effects experienced by subjects in our clinical trials or by individuals using drugs similar to our product candidates;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">delays in enrolling research subjects in clinical trials;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">high drop-out rates and high fail rates of research subjects;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">greater than anticipated clinical trial costs;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">poor effectiveness of our product candidates during clinical trials; or</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or vendor.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have only recently commenced clinical trials and have never submitted an NDA, and any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical failure can occur at any stage of our clinical development. Clinical trials may produce negative or inconclusive results, and our collaborators or we may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure that subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier clinical trials. The commencement and completion of future clinical studies could be substantially delayed or prevented by several factors, including, but not limited to:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a limited number of, and competition for, suitable patients with particular types of cancer for enrollment in our clinical studies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays or failures in reaching acceptable clinical study agreement terms;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of patients to complete the clinical study; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If Annamycin is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be harmed.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we or any of our potential future collaborators may conduct will demonstrate the consistent or adequate efficacy and safety that would be required to obtain regulatory approval and market any products. If we are unable to bring Annamycin to market, or to acquire other products that are on the market or can be developed, our ability to create long-term stockholder value will be limited.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unforeseen side effects from any of our product candidates could arise either during clinical development or, if any product candidates are approved, after the approved product has been marketed. For example, in the most recent Phase I/II dose-ranging clinical trial of Annamycin, conducted by a prior developer, two patients succumbed to tumor lysis syndrome (&#8220;TLS&#8221;) resulting from the debris created by Annamycin killing the targeted leukemic blasts more rapidly than their body&#8217;s ability to cope. Now that this potential has been identified, prophylactic measures intended to protect patients from TLS will be deployed in future clinical trials, but there can be no assurance that such measures will be effective or that other adverse events may not emerge related to our drug. As another example, we intend to attempt to increase the maximum tolerable dose (&#8220;MTD&#8221;) for Annamycin by conducting another Phase I dose-ranging trial, however, unforeseen side effects could prevent us from increasing the MTD from the one established in the prior Phase I/II trial. Additional or unforeseen side effects from Annamycin or any of our other product candidates could arise either during clinical development or, if approved, after the approved product has been marketed.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The range and potential severity of possible side effects from therapies such as Annamycin are significant. If Annamycin causes undesirable or unacceptable side effects in the future, this could interrupt, delay or halt clinical trials and result in the failure to obtain or suspension or termination of marketing approval from the FDA and other regulatory authorities or result in marketing approval from the FDA and other regulatory authorities only with restrictive label warnings or other limitations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">we may be required to change instructions regarding the way the product is administered, conduct additional clinical trials or change the labeling of the product;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">we may be subject to limitations on how we may promote the product;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">sales of the product may decrease significantly;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to take our approved product off the market;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">we may be subject to litigation or product liability claims; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the FDA does not find the manufacturing facilities of our future contract manufacturers acceptable for commercial production, we may not be able to commercialize any of our product candidates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not intend to manufacture the pharmaceutical products that we plan to sell. We are currently utilizing contract manufacturers for the production of the active pharmaceutical ingredients and the formulation of drug product for our trials of Annamycin that we will need to conduct prior to seeking regulatory approval. However, we do not have agreements for supplies of Annamycin or any of our other product candidates and we may not be able to reach agreements with these or other contract manufacturers for sufficient supplies to commercialize Annamycin if it is approved. Additionally, the facilities used by any contract manufacturer to manufacture Annamycin or any of our other product candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate manufactured at that facility. We are completely dependent on these third-party manufacturers for compliance with the requirements of U.S. and non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conform to our specifications and the FDA&#8217;s current good manufacturing practice standards, or cGMP, and other requirements of any governmental agency whose jurisdiction to which we are subject, our product candidates will not be approved or, if already approved, may be subject to recalls or other negative actions. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates, including:&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the possibility that we are unable to enter into a manufacturing agreement with a third party to manufacture our product candidates;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the government agencies that regulate our products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing arrangements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no sales, marketing or distribution experience. To develop sales, distribution and marketing capabilities, we will have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation that Annamycin or any of our other product candidates will be approved by the FDA. For product candidates where we decide to perform sales, marketing and distribution functions ourselves or through third parties, we could face a number of additional risks, including that we or our third-party sales collaborators may not be able to build and maintain an effective marketing or sales force. If we use third parties to market and sell our products, we may have limited or no control over their sales, marketing and distribution activities on which our future revenues may depend.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products are expensive, we may seek to enter into collaborations with companies that have more experience. Additionally, if any of our product candidates receives marketing approval, we may enter into sales and marketing arrangements with third parties with respect to our unlicensed territories. If we are unable to enter into arrangements on acceptable terms, if at all, we may be unable to effectively market and sell our products in our target markets. We expect to face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements for the development of our product candidates.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. For example, we have formed a collaboration with a Polish drug development company called Dermin, where we have provided them with sub-license rights to our technologies for use in limited territories in exchange for their use of Polish government grant funding to pay for development costs we would otherwise have to fund ourselves. With the exception of Annamycin, Dermin&#8217;s territories are primarily Poland and lesser surrounding countries, but not including any of the major European markets (UK, Germany, France, Spain and Italy). In the case of Annamycin, Dermin&#8217;s territories also include Germany, but we retain the right to repurchase that territory for $500,000 at any time in the future.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One or more of our collaboration partners may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we establish may contain provisions that are not favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization of our product candidates. In some cases, we may be responsible for continuing preclinical and initial clinical development of a product candidate or research program under a collaboration arrangement, and the payment we receive from our collaboration partner may be insufficient to cover the cost of this development. If we are unable to reach agreements with suitable collaborators for our product candidates, we would face increased costs, we may be forced to limit the number of our product candidates we can commercially develop or the territories in which we commercialize them. As a result, we might fail to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations, our operating results and financial condition could be materially and adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our success depends greatly on the success of Annamycin&#8217;s development for the treatment of relapsed or refractory AML, and our pipeline of product candidates beyond this lead indication is extremely early stage and limited.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than Annamycin, our other two drug candidates, our WP1066 Portfolio and our WP1122 Portfolio, are each in the early stages of development. In addition, our current plan is to use a significant portion of our available funds to support our clinical plan for Annamycin, although this cash utilization may change in the future. As such, we are dependent on the success of Annamycin in the near term. We cannot provide you any assurance that we will be able to successfully advance any of these indications through the development process.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States, Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing drugs for the diseases that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target disease areas. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products that are more effective or less costly than any of our product candidates that we are currently developing or that we may develop, which could render our products obsolete or noncompetitive.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of attempts have been made or are under way to provide an improved treatment for AML. Drugs attempting to target a subset of AML patients who present with particular anomalies involving a gene referred to as FLT3 are currently in clinical trials. Other approaches to improve the effectiveness of induction therapy are in early stage clinical trials and, although </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">they do not appear to address the underlying problems with anthracyclines, we can provide no assurance that such improvements, if achieved, would not adversely impact the need for improved anthracyclines. A modified version of doxorubicin designed to reduce cardiotoxicity is in clinical trials for the treatment of sarcoma and, although this drug does not appear to address multidrug resistance and is not currently intended for the treatment of acute leukemia, we can provide no assurance that it will not become a competitive alternative to Annamycin. Although we are not aware of any other single agent therapies in clinical trials that would directly compete against Annamycin in the treatment of relapsed and refractory AML, we can provide no assurance that such therapies are not in development, will not receive regulatory approval and will reach market before our drug candidate Annamycin. In addition, any such competing therapy may be more effective and / or cost-effective than ours.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our competitors market products that are more effective, safer or less expensive or that reach the market sooner than our future products, if any, we may not achieve commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not receive Orphan Drug exclusivity for Annamycin, and if we do, it may not effectively prevent approval of a competing product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 21, 2017, we received notice that the FDA granted Orphan Drug designation for Annamycin for the treatment of AML.  Although we would anticipate Orphan Drug exclusivity being awarded with the approval of Annamycin for that use, we cannot be sure that will occur.  Moreover, even if Orphan Drug exclusivity is granted, we cannot know that it will prevent approval of another product containing Annamycin and intended to treat AML, because any such subsequent product could be demonstrated to be clinically superior to Annamycin.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The composition of matter patent for Annamycin has expired, and other patents have not yet issued, and may not issue.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to pursue patents with claims directed to Annamycin drug product formulations and the methods of use of Annamycin to treat relapsed or refractory AML and other conditions, and methods for its synthesis, as the composition of matter patent protection for Annamycin has expired. As a result, competitors may be able to offer and sell products so long as these competitors do not infringe any other patents that third parties or we hold, including formulation, synthesis and method of use patents. However, particularly with regard to products approved for more than one indication, method of use patents may not provide significant protection, because a competitor could obtain approval for only a non-protected use and thus come to market, where the product may legally be prescribed for the protected use, thus undermining the protection provided by the patent.  Although off-label prescriptions may infringe our method of use patents, the practice is common across medical specialties and such infringement is difficult to prevent or prosecute. Off-label sales would limit our ability to generate revenue from the sale of Annamycin, if approved for commercial sale</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;The intellectual property rights we have licensed from MD Anderson are subject to the rights of the U.S. government.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to our WP1066 Portfolio and WP1122 Portfolio drug product candidates from MD Anderson. Some of our licensed intellectual property rights from MD Anderson have been developed in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee to such inventions, to grant licenses to any of these inventions to a third party if they determine that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; (iii) government action is necessary to meet requirements for public use under federal regulations; or (iv) the right to use or sell such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the U.S. government&#8217;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing substantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title in any country in which a patent application is not filed within specified time limits. Additionally, certain inventions are subject to transfer restrictions during the term of these agreements and for a period thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair the value of our intellectual property and could adversely affect our business.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may from time to time seek to enforce our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against a party, then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post grant proceedings such as inter-partes review and post grant review is filed within the statutorily applicable time with the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;). These lawsuits and proceedings are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party's activities do not infringe our intellectual property rights. In addition, in recent years the U.S. Supreme Court modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of a challenge of any patents we obtain or license.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, we had four full-time and four part-time employees. As we advance our product candidates through preclinical studies and clinical trials, we will need to increase our product development, scientific and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we may need to increase our general and administrative capabilities. Our management, personnel and systems currently in place may not be adequate to support this future growth. If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent on the development, regulatory, commercialization and business development expertise of our management team, key employees and consultants. If we lose one or more of our executive officers or key employees or consultants, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers or key employees or consultants may terminate their employment at any time. Replacing executive officers, key employees and consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our business.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have scientific and clinical advisors and consultants who assist us in formulating our research, development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our chief executive officer is currently working for another company.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter Klemp, our chairman and chief executive officer is also the chief executive officer of Soliton, Inc., a medical device development company whose business operations we do not believe conflict with those of our company. As we progress, if more of his time as CEO is required and the current officer cannot provide that level of commitment, we will need to identify a suitable CEO who can dedicate such time to our company. We can provide no assurance that we will be able to successfully identify and retain a qualified candidate for this position.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not expect that our insurance policies will cover all of our business exposures thus leaving us exposed to significant uninsured liabilities.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not carry insurance for all categories of risk that our business may encounter. Although we intend to obtain product insurance before we commence any clinical trials, there can be no assurance that we will secure adequate insurance coverage or that any such insurance coverage will be sufficient to protect our operations to significant potential liability in the future. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly. We do not carry specific hazardous waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may incur penalties if we fail to comply with healthcare regulations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical and medical device industries in recent years, as well as consulting or other service agreements with physicians or other potential referral sources. These laws include anti-kickback statutes and false claims statutes that prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or, in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally-financed healthcare programs, and knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services, reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:10pt;">payer. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and any practices we adopt may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#8217;s products from reimbursement under government programs, criminal fines and imprisonment. Any challenge to our business practices under these laws could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to recover from any catastrophic event affecting our suppliers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our suppliers may not have adequate measures in place to minimize and recover from catastrophic events that may substantially destroy their capability to meet customer needs, and any measures they may in place may not be adequate to recover production processes quickly enough to support critical timelines or market demands. These catastrophic events may include weather events such as tornadoes, earthquakes, floods or fires. In addition, these catastrophic events may render some or all of the products at the affected facilities unusable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be materially adversely affected in the event of cyber-based attacks, network security breaches, service interruptions, or data corruption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on information technology to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities. We use technology systems to record, process, and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. Our information technology systems, some of which are managed by third-parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. Although we have developed systems and processes that are designed to protect proprietary or confidential information and prevent data loss and other security breaches, such measures cannot provide absolute security. If our systems are breached or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may significantly suffer and we may be subject to litigation, government enforcement actions or potential liability. Security breaches could also cause us to incur significant remediation costs, result in product development delays, disrupt key business operations, including development of our product candidates, and divert attention of management and key information technology resources.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Risks Relating to Our Common Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price has been and may continue to be volatile, which could result in substantial losses for investors.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our IPO in June 2016, our stock price has ranged from a high of $9.58 to a low of $0.71, and the market price of our common stock is likely to continue to be highly volatile and could fluctuate widely in response to various factors, many of which are beyond our control. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also significantly affect the market price of our common stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to seek to raise additional funds, finance acquisitions or develop strategic relationships by issuing equity or convertible debt securities, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority, without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common or preferred stock. Our certificate of incorporation authorizes us to issue up to 75,000,000 shares of common stock and 5,000,000 shares of preferred stock. Future issuances of common or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive to earnings per share. In addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of the common stock. Those rights, preferences and privileges could include, among other things, the establishment of dividends that must be paid prior to declaring or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation rights. These rights, preferences and privileges could negatively affect the rights of holders of our common stock, and the right to convert such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares of our common stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shares issuable upon the conversion of warrants or the exercise of outstanding options may substantially increase the number of shares available for sale in the public market and depress the price of our common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;We issued the underwriters in our IPO warrants to purchase 107,802 shares of common stock exercisable at a price of $7.50 per share and these warrants remain outstanding as of March 1, 2018. From the February 2017 Offering, we had as of March 1, 2018, outstanding warrants exercisable for an aggregate of 419,772 shares of our common stock at a weighted average exercise price of approximately $1.41 per share. On July 29, 2017, the Company entered into a consulting agreement for its investor relations operations and in exchange for the consulting services, we agreed to issue two warrants (to purchase 100,000 and 50,000 shares of common stock at exercise prices of $2.41 and $3.00 per share). These warrants were outstanding </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as of March 1, 2018. Additionally from the February 2018 Offering, we had as of March 1, 2018, outstanding warrants exercisable for an aggregate of 2,145,000 shares of common stock, at an exercisable price of $2.80 per share. As of December 31, 2017, we had 1,345,000 options to purchase shares of common stock at a weighted average price of $3.50 per share. To the extent any of these warrants or options are exercised and any additional options are granted and exercised, there will be further dilution to stockholders and investors. Until the options and warrants expire, these holders will have an opportunity to profit from any increase in the market price of our common stock without assuming the risks of ownership. Holders of options and warrants may convert or exercise these securities at a time when we could obtain additional capital on terms more favorable than those provided by the options or warrants. The exercise of the options and warrants will dilute the voting interest of the owners of presently outstanding shares by adding a substantial number of additional shares of our common stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The concentration of our common stock ownership by our current management will limit your ability to influence corporate matters.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our founders, directors and executive officers beneficially own and are able to vote in the aggregate 34% of our outstanding common stock. As such, our founders, directors and executive officers, as stockholders, will continue to have the ability to exert significant influence over all corporate activities, including the election or removal of directors and the outcome of tender offers, mergers, proxy contests or other purchases of common stock that could give our stockholders the opportunity to realize a premium over the then-prevailing market price for their shares of common stock. This concentrated control will limit your ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. In addition, such concentrated control could discourage others from initiating changes of control. In such cases, the perception of our prospects in the market may be adversely affected and the market price of our common stock may decline.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain provisions in our organizational documents could enable our board of directors to prevent or delay a change of control.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our organizational documents contain provisions that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals, that a stockholder might consider favorable. These include provisions:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">prohibiting the stockholders from acting by written consent;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">requiring advance notice of director nominations and of business to be brought before a meeting of stockholders;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">requiring a majority vote of the outstanding shares of common stock to amend the bylaws; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">limiting the persons who may call special stockholders&#8217; meetings.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, our board of directors has the authority to issue shares of preferred stock in one or more series and to fix the rights and preferences of these shares without stockholder approval. Any series of preferred stock is likely to be senior to our common stock with respect to dividends, liquidation rights and, possibly, voting rights. The ability of our board of directors to issue preferred stock also could have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, Delaware law makes it difficult for stockholders that recently have acquired a large interest in a corporation to cause the merger or acquisition of the corporation against the directors&#8217; wishes. Under Section&#160;203 of the Delaware General Corporation Law, a Delaware corporation may not engage in any merger or other business combination with an interested stockholder for a period of three years following the date that the stockholder became an interested stockholder except in limited circumstances, including by approval of the corporation&#8217;s board of directors.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As a biotechnology company, we are at increased risk of securities class action litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biotechnology companies have experienced greater than average stock price volatility in recent years, and our common stock price has been particularly volatile ranging from a high of $9.58 to a low of $0.71. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of management would be diverted from the operation of our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no intention of declaring dividends in the foreseeable future.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decision to pay cash dividends on our common stock rests with our board of directors and will depend on our earnings, unencumbered cash, capital requirements and financial condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund our operations. Investors in our common stock should not expect to receive dividend income on their investment, and investors will be dependent on the appreciation of our common stock to earn a return on their investment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, to maintain internal control over financial reporting and to assess and report on the effectiveness of those controls. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Our management concluded that our internal controls over financial reporting were, and continue to be ineffective, and as of the year ended December 31, 2017, identified a material weakness in our internal controls due to the lack of segregation of duties. While management is working to remediate the material weakness, there is no assurance that such changes, when economically feasible and sustainable, will remediate the identified material weaknesses or that the controls will prevent or detect future material weaknesses. If we are not able to maintain effective internal control over financial reporting, our financial statements, including related disclosures, may be inaccurate, which could have a material adverse effect on our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to continue improving our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations of the SEC. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management performed an annual assessment as of December 31, 2017 of the effectiveness of our internal control over financial reporting for its annual report. Our management concluded that our internal control over financial reporting was, and continues to be, ineffective and as of the year ended December 31, 2017, due to a material weakness in our internal controls due to the lack of segregation of duties. For as long as we remain an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we have and intend to consider to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We may continue to take advantage of these reporting exemptions until we are no longer an &#8220;emerging growth company.&#8221; During 2016, we were required to restate certain financial periods due to an error in the accounting for our business combination of Moleculin, LLC. To remediate this material weakness, we engaged an outside firm to assist management with such accounting and will continue to use outside firms as a resource to deal with other non-recurring or unusual transactions. However, notwithstanding our remediation efforts, there is no assurance we will not encounter future accounting errors in the future. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose confidence in our reported financial information.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As an &#8220;emerging growth company&#8221; under the Jumpstart Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an &#8220;emerging growth company&#8221; under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. We are an emerging growth company until the earliest of:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the last day of the fiscal year during which we have total annual gross revenues of $1 billion or more;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the last day of the fiscal year following the fifth anniversary of our IPO, or December 31, 2021;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt; or</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the date on which we are deemed a &#8220;large accelerated issuer&#8221; as defined under the federal securities laws.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For so long as we remain an emerging growth company, we will not be required to:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">have an auditor report on our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis);</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">submit certain executive compensation matters to shareholders advisory votes pursuant to the &#8220;say on frequency&#8221; and &#8220;say on pay&#8221; provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the &#8220;say on golden parachute&#8221; provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">include detailed compensation discussion and analysis in our filings under the Securities Exchange Act of 1934, as amended, and instead may provide a reduced level of disclosure concerning executive compensation; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">may present only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to take advantage of all of these reduced reporting requirements and exemptions. Certain of these reduced reporting requirements and exemptions were already available to us due to the fact that we also qualify as a &#8220;smaller reporting company&#8221; under SEC rules. For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding management&#8217;s assessment of internal control over financial reporting; are not required to provide a compensation discussion and analysis; are not required to provide a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related MD&amp;A disclosure.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions until December 31, 2021, or such earlier time that we no longer meet the definition of an emerging growth company.&#160;In this regard, the JOBS Act provides that we would cease to be an &#8220;emerging growth company&#8221; if we have more than $1.0 billion in annual revenues, have more than $700 million in market value of our common stock held by non-affiliates, or issue more than $1.0 billion in principal amount of non-convertible debt over a three-year period.&#160;Further, under current SEC rules, we will continue to qualify as a &#8220;smaller reporting company&#8221; for so long as we have a public float (i.e., the market value of common equity held by non-affiliates) of less than $75 million as of the last business day of our most recently completed second fiscal quarter.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict if investors will find our securities less attractive due to our reliance on these exemptions.&#160;If investors were to find our common stock less attractive as a result of our election, we may have difficulty raising capital.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to maintain compliance with the listing requirements of The Nasdaq Capital Market, our common stock may be delisted from The Nasdaq Capital Market which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on The Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholder's equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from The Nasdaq Capital Market.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we received a notice that we were not in compliance with the $1.00 minimum closing bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). On July 6, 2017, we received a letter from NASDAQ notifying us that we had regained compliance with the rule as a result of the closing bid price of our common stock being at $1.00 per share or greater for the 10 consecutive business days from June 21, 2017 through July 5, 2017. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the future, we may again fail to comply with the continued listing requirements of the Nasdaq Capital Market, which would subject our common stock to being delisted. Delisting from The Nasdaq Capital Market would adversely affect </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s956F7FDC33942AFE3876A0B8689A0FBE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B. UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s889D8CE31C52B105B21EA0B868C81324"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. PROPERTIES</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate, executive offices and laboratory are in located in a leased facility in Houston, Texas. The current lease is month-to-month. On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of 2,333 rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of 66 months, which may be renewed for an additional 5 years. We are required to remit base monthly rent of approximately $4,300 which will increase at an average approximate rate of 3% each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas. We believe our facilities, as expanded, will be sufficient to meet our current needs and that suitable space will be available as and when needed. We do not own any real property.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s0FF8E41283E86E614E9AA0B868E93F19"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not at this time involved in any legal proceedings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sE69328DC3CB8B6F39E13A0B8691D2C8D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4. MINE SAFETY DISCLOSURE</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="sA80DDD1473DDC8977AF5A0B869416350"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s465214CC73D7C40680FAA0B8629EFC09"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock has been listed on the NASDAQ Capital Market since June 1, 2016, the date of our initial public offering, under the symbol &#8220;MBRX&#8221;. On March 18, 2018, the closing price reported on the NASDAQ Capital Market for our common stock was $2.05. The following tables set forth, for the calendar quarter indicated, the quarterly high and low sales price of our common stock, respectively, as reported on the NASDAQ Capital Market.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price Range</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Year-Ended December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter (commencing June 1, 2016)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Year-Ended December 31, 2017 </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Holders</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 16, 2018, there were approximately 170 holders of record of our common stock. In addition, we believe that a significant number of beneficial owners of our common stock hold their shares in nominee or in &#8220;street name&#8221; accounts through brokers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never paid any dividends on our common stock. The payment of dividends in the future will be contingent upon our revenues and earnings, if any, capital requirements and general financial condition. It is the present intention of our Board of Directors to retain all earnings, if any, for use in our business operations and, accordingly, our Board of Directors does not anticipate declaring any dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Forgone to Satisfy Minimum Statutory Withholdings</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of our stock plans, at the election of each employee, we can authorize a net settlement of distributable shares to employees after satisfaction of an individual employees&#8217; tax withholding obligations. For the years ended December&#160;31, 2017 and 2016, respectively, we received no shares from employees for tax withholding obligations.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Securities Authorized for Issuance under Equity Compensation Plans</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information regarding our equity compensation plans at December 31, 2017:</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of securities to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">be issued upon exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">of outstanding options,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">warrants and rights</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">exercise price of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">outstanding options,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">warrants and rights</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of securities (by</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">class) remaining available</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">for future issuance under</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">equity compensation</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">plans (excluding</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">securities reflected in</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">column (a))</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(c)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans approved by security holders (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,155,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans not approved by security holders (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,802</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans not approved by security holders (3)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,602,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,155,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Represents shares of common stock issuable upon exercise of outstanding stock options under our 2015 Stock Plan, as amended. Our 2015 Stock Plan has been approved by our stockholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of a five-year warrant issued to the underwriters in our initial public offering.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consists of warrants issued to a consultant for services.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors for the sale by us of 4,290,000 shares of our common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold to the investors warrants to purchase 2,145,000 shares of common stock. We sold the common shares and warrants for aggregate gross proceeds of approximately $9.0 million. Subject to certain beneficial ownership limitations, the warrants will be initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.80 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for five years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement closed on February 21, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net proceeds from the transactions was approximately $8.27 million after deducting certain fees due to the placement agent and transaction expenses. The net proceeds will be used for planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common shares were offered and sold by us pursuant to an effective shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on July 24, 2017 and subsequently declared effective on August 21, 2017 (File No. 333-219434), and the base prospectus contained therein. We filed a prospectus supplement with the SEC on February 16, 2018 in connection with the sale of the common shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants and the shares issuable upon exercise of the warrants were sold without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering to accredited investors, and in reliance on similar exemptions under applicable state laws.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a placement agent agreement (the &#8220;Placement Agency Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the common shares and warrants. We paid Roth an aggregate fee equal to 6.5% of the gross proceeds received by us from the sale of the securities in the transactions. Pursuant to the Placement Agency Agreement, we also agreed to grant to Roth or its designees warrants to purchase up to 3% of the aggregate number of shares of common stock sold in the transactions (the &#8220;Roth Warrants&#8221;). The Roth Warrants have substantially the same terms as the warrants, except that the Roth Warrants will expire on February 15, 2023. The Roth Warrants and the shares issuable upon exercise of the Roth Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. We also reimbursed Roth for its expenses of $75,000.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not repurchase any of our equity securities during the years ended December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6671F50495B07F884A52A0B869959739"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s99CBAA72236C23232FFDA0B869C21FB1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion should be read in conjunction with the Financial Statements and Notes thereto included in this Form 10-K. The forward-looking statements included in this discussion and elsewhere in this Form 10-K involve risks and uncertainties, including those set forth under &#8220;Cautionary Statement About Forward-Looking Statements.&#8221; Actual results and experience could differ materially from the anticipated results and other expectations expressed in our forward-looking statements as a result of a number of factors, including but not limited to those discussed in this Item and in Item&#160;1A - &#8220;Risk Factors.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sE1B12AA4CDDCEE52373FA0B869E91298"></a></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in July 2015 to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as &#8220;MD Anderson&#8221;. MBI has three core drug technologies: a uniquely designed anthracycline (Annamycin), a portfolio of STAT3 inhibitors (WP1066 Portfolio) and a collection of inhibitors of glycolysis (WP1122 Portfolio). Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors through the inhibition of glycolysis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin has been in clinical trials pursuant to an IND, that had been filed with the FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. We have two other drug development projects: (i) one involving a library of small molecules, which we refer to as the WP1066 Portfolio, a collection of STAT3 inhibitors, some of which also have immuno-stimulating capability, targeting brain tumors, pancreatic cancer and AML, and (ii) the WP1122 Portfolio, a library of small molecules targeting the metabolic processes involved in cancer in general and glioblastoma (the most aggressive and most common form of brain tumor) and pancreatic cancer in particular through the inhibition of glycolysis. A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, we intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin for the treatment of AML, which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug Application (&#8220;NDA&#8221;) in the United States. We may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another Annamycin product for the same use. We also intend to apply for similar status in the European Union (&#8220;EU&#8221;) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (&#8220;MAA&#8221;). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With regard to additional potential clinical activity, we submitted in October 2017 a request for Clinical Trial Authorization (&#8220;CTA&#8221;) in Poland which, if allowed, will enable a Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland. This will be in addition to the previously announced allowance of our IND in the United States. In December 2017, the Ethics Committee in Poland approved our Phase I/II clinical trial of Annamycin. The CTA remains subject to final approval by the Polish National Office. Furthermore, in September 2017 we engaged a contract research organization (&#8220;CRO&#8221;) to prepare for a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the treatment of cutaneous T-cell lymphoma (&#8220;CTCL&#8221;).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s32B19064B59F9C00E8BDA0B86A169F0F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Drug Candidates</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annamycin</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead product candidate is Annamycin, for which FDA has allowed an IND for a Phase I/II trial for the treatment of relapsed or refractory AML and granted Orphan Drug designation for the treatment of AML. We intend to conduct Phase I/II clinical trials for Annamycin as a monotherapy for the treatment of relapsed or refractory AML in the United States and in Poland.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Planned Clinical Trials for Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, we adjusted our clinical strategy for Annamycin by adding in a Phase I arm to our trial, which will add expense to our development effort. We believe this change in strategy will add several months to the eventual final approval of the drug, if the drug is approved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the prior developer of Annamycin allowed their IND to lapse, we were required to submit a new IND for continued clinical trials with Annamycin. We filed our IND application for Annamycin, with the clinical strategy of increasing the MTD mentioned above, on February 10, 2017. In subsequent discussions with us, FDA requested certain revisions to the protocol, additional&#160;information, and additional data related to Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;). We made the requested revisions to the protocol and included the CMC data in our re-submission of the IND in August 2017 and the FDA allowed this IND in September 2017.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, we met with the European Medicines Agency (&#8220;EMA&#8221;) to discuss a CTA in Europe for the study of Annamycin for the treatment of AML. As a result of that meeting, we decided to proceed with an application in October 2017 for a CTA for Annamycin in Poland. Unlike in the United States, the process for beginning a clinical trial in Poland requires a hospital contract before a request for CTA can be made. We obtained the required hospital contract, which allowed the formal request for Polish approval. In December 2017, the Ethics Committee in Poland approved our Phase I/II trial of Annamycin for the treatment of relapsed or refractory AML. A final approval is required by the Polish National Office.  In March we received requests for and provided additional information to the Polish National Office.  We expect a response from the Polish National Office in the first half of 2018 and at the earliest mid-April 2018. The start of clinical trials in Poland remains subject to confirmation and approval of the CTA by the Polish National Office. We can provide no assurance that we will receive such confirmation on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have appointed a CRO in both the United States and Poland. In addition, we continue to recruit and contract clinics both in the United States and Poland. In the US, we have one site - University Hospitals Cleveland Medical Center (&#8220;UHCMC&#8221;) - recruiting patients and active with drug ready to provide treatments.  A patient has been enrolled with anticipated treatment to occur in the near term.&#160; We can provide no assurance treatment will occur on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One of the key dose-limiting toxicities associated with currently available anthracyclines is their propensity to induce life-threatening heart damage. In our current Phase I/II trial for Annamycin, we will collect data to further validate the design intent of Annamycin to have little or no cardiotoxicity. Unless otherwise noted, all of our references to Annamycin refer to the liposomal form (L-Annamycin).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 21, 2017, we received notice that FDA had granted Orphan Drug designation for Annamycin for the treatment of AML, effective March 20, 2017.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF0C5EB8096F208727A42A0B86A39A9D0"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a license agreement with MD Anderson pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related to our WP1066 Portfolio and its close analogs, molecules targeting the modulation of key oncogenic transcription factors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Planned Clinical Testing of WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;testing has shown a high level of activity for WP1066 against a wide range of solid tumors, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;testing has shown significant activity against head and neck, pancreatic, stomach, and renal cancers, as well as metastatic melanoma and glioblastoma, among others. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;testing in mouse tumor models has shown that WP1066 inhibits tumor growth, blocks angiogenesis (a process that leads to the formation of blood vasculature needed for tumor growth) and increases survival.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to our WP1066 Portfolio, we collaborated with a clinician at MD Anderson who submitted an IND for WP1066 treatment of brain tumors to the FDA. In December 2017, the FDA allowed this application for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Phase I trial with WP1066 drug will receive $2 million in private grant funding at MD Anderson which is in addition to two Specialized Programs of Research Excellence (SPORE) peer reviewed grants awarded by the National Cancer Institute.  We believe the rigorous peer-review process applied to SPORE grant applications represents an important additional measure of independent assessment and validation of the research connected with our approach to using WP1066/STAT3 for the treatment of cancer. The grants described here do not flow through Moleculin's financial statements, but instead are applied to the cost of preclinical and clinical activities at and conducted by MD Anderson.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that this physician-sponsored Phase I trial will begin treating patients in the first half of 2018. However, as this is a physician-sponsored clinical trial, we have limited influence on the process in beginning clinical trials and, as such, any disruptions to this process may delay the treatment of patients with WP1066, which may delay the commencement of this trial beyond the first half of 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An analog of WP1066, referred to as WP1220, was previously the subject of an IND (WP1220 was referred to as &#8220;MOL4239&#8221; for purposes of this IND) related to use of the molecule in the topical treatment of psoriasis. Clinical trials were commenced on WP1220 in the US, but were terminated early due to limited efficacy in the topical treatment of psoriatic plaques. Notwithstanding its limitations in treating psoriasis, our pre-clinical research in multiple cutaneous T-cell lymphoma (&#8220;CTCL&#8221;) cell lines has suggested that WP1220 may be effective in inhibiting CTCL. Based on this data, we are collaborating with a Polish drug development company, Dermin, which has received Polish government grant money to develop WP1220 in Poland for the topical treatment of early stage CTCL patients. CTCL is a potentially deadly form of skin cancer for which there are limited treatment options.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, we engaged a CRO to prepare a proof-of-concept clinical trial in Poland to study WP1220 for the topical treatment of CTCL.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also conducted a Phase II clinical trial for WP1066 for the topical treatment of psoriasis using a longer treatment period as compared with the WP1220 psoriasis trial, however this trial was terminated early as a significant number of patients experienced a non-permanent worsening of their psoriatic plaques after extended use of the drug, suggesting that its use as a topical agent for non-life-threatening diseases such as psoriasis will require further study to optimize dosing and scheduling regimens.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The WP1122 Portfolio</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a license agreement with MD Anderson pursuant to which we have been granted a royalty-bearing, worldwide, exclusive license for the patent and technology rights related to our WP1122 Portfolio and similar molecules targeting the treatment of glioblastoma multiforme (&#8220;GBM&#8221;) and related central nervous system malignancies.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe this technology has the potential to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system malignancies and especially GBM. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the treatment options available to their physicians are among the most limited of any cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have preliminary preclinical data for WP1122, including </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;activity against cancer cell lines, as well as data on survival of animals subjected to xenografts of human brain tumors, including data regarding biodistribution and pharmacokinetics. In non-optimal doses and treatment regimes, WP1122 performed equal to or better than the current market leader, temozolomide and provided for superior survival for animals treated in combination with temozolomide. Notwithstanding these early results, we recognize that substantial additional preclinical and clinical research remains to be done and may not support these initial findings or their translation into activity in humans.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have begun planning and performing the necessary pre-clinical work required to submit an IND for WP1122.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s878E542E796189DEF15BA0B86A6A69F9"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">$9 million Registered Direct Offering</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors for the sale by us of 4,290,000 shares of our common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold warrants to purchase </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,145,000 shares of common stock. We sold the common shares and warrants for aggregate gross proceeds of approximately $9.0 million with net proceed approximating $8.3 million. Subject to certain beneficial ownership limitations, the warrants will be initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $2.80 per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for five years from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement closed on February 21, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Announcement of STAT3 Inhibitors and WP1732</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we announced that, pursuant to our continued collaboration with MD Anderson we had developed and licensed what we believe, based on preclinical testing, is a potential breakthrough - WP1732, a new molecule in the WP1066 portfolio - in our effort to develop a new cancer treatment that selectively kills highly resistant tumors.&#160;We believe this new discovery could improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer. Specifically, we have preclinical evidence to suggest this new molecule is capable of controlling a process known as 'ubiquitination' to block the activated form of STAT3, an important oncogenic transcription factor.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have begun planning and performing the necessary pre-clinical work required to submit an IND for WP1732</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of 2,333 rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of 66 months, which may be renewed for an additional 5 years. We are required to remit base monthly rent of approximately $4,300 which will increase at an average approximate rate of 3% each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA059484306B34444A90BA0B8624C885E"></a></div><div style="line-height:174%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc. Results of Operations for the Year Ended December 31, 2017 Compared to the Year Ended December 31, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table is data derived from the Statement of Operations (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:635px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:434px;"></td><td style="width:8px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,090</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Loss from change in fair value of warrant liability </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Gain from settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Gain from expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Other income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expense.</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development (&#8220;R&amp;D&#8221;) expense was $4.5 million and $1.5 million for the years ended December 31, 2017 and 2016, respectively. The increase in R&amp;D of approximately $3.0 million mainly represents an increase of approximately: $2.0 million associated with developing and testing drug product as we prepared for clinical trials; $0.4 million related to an increase in R&amp;D headcount and associated payroll costs; $0.3 million for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sponsored research and related expenses; and $0.3 million associated with license fees. The increase in R&amp;D headcount mainly represents the associated costs of increasing the commitments of our part-time employees and the addition of a second Chief Medical Officer - New Molecules. These all are a reflection of the increased clinical and pre-clinical activity for our drug portfolio as compared to 2016. </font></div><div style="line-height:120%;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General and Administrative Expense.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative (&#8220;G&amp;A&#8221;) expense was $4.1 million and $2.4 million for the years ended December 31, 2017 and 2016, respectively. The increase in G&amp;A of approximately $1.7 million was mainly attributable to: (a) the increase in headcount and associated payroll costs including additional stock-based compensation expense of $1.0 million; (b) approximately $0.4 million in legal, accounting, consulting, and other professional expenses; (c) $0.2 million in insurance expense; and (d) approximately $0.1 million in occupancy, office and other costs. These increases reflect the increase in support of our clinical activity described above as compared to 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize outside consultants, both in R&amp;D and G&amp;A, to a large extent to leverage the work of our employees. Total wages paid to our employees, including our CEO, CFO, COO, CMOs plus three other employees, were approximately $1.5 million.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in fair value of warrant liability. </font><font style="font-family:inherit;font-size:10pt;">Loss from change in fair value of warrant liability was $2.5 million for the twelve months ended December 31, 2017. The non-cash loss in 2017 was associated with an increased fair value calculation. We record the change (income or expense) in fair value on revaluation of our warrant liability associated with the warrants we issued in conjunction with our stock offering in February 2017 (the &#8220;February 2017 Offering&#8221;). We are required to revalue certain of our 2017 warrants at the time of each warrant exercise and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculate the fair value of the warrants outstanding using the Black-Scholes and Monte Carlo Simulation models. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain from settlement of liability. </font><font style="font-family:inherit;font-size:10pt;">During the period, we settled a previously incurred expense utilizing shares of our common stock with an attributed value of $3.00 per share. The gain of roughly $0.1 million reflects the difference in our share price in the open market as of the settlement date and the $3.00 per share; which was recorded in the first quarter of 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain from expiration of warrants. </font><font style="font-family:inherit;font-size:10pt;">Gain from expiration of warrants was $1.2 million for the twelve months ended December 31, 2017, due to the termination during the period of short-term warrants, issued as part of our February 2017 stock offering.</font></div><div style="line-height:120%;text-align:left;text-indent:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">. Interest expense in 2016 included expense accrued on our convertible promissory notes issued in prior years bearing interest at the rate of 8% per annum. During the period and, lastly, on June 22, 2017, pursuant to the conversion feature of the notes, we issued common shares, which effectively converted all remaining outstanding convertible debt and accrued interests outstanding on the notes as of that date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss</font><font style="font-family:inherit;font-size:10pt;">. The net loss for the twelve months ended December 31, 2017 was $9.8 million which included non-cash expenses of approximately $0.7 million, which was comprised almost completely of stock-based compensation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s12F7A778742744BA33E3A0B8624B7E82"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, we had </font><font style="font-family:inherit;font-size:10pt;">$7.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash. During 2017, via the February 2017 Offering, our at-the- market issuance agreement (&#8220;ATM&#8221;), and the exercise of warrants associated with the February 2017 Offering, we issued 7.2 million shares of common stock and received $10.1 million in net proceeds. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As mentioned above, subsequent to year-end in February 2018 we entered into the Purchase Agreement with certain investors for the sale of 4,290,000 shares of our common stock, at a purchase price of $2.10 per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold warrants to purchase 2,145,000 shares of common stock, which have an exercise price of $2.80 per share. We sold the common shares and warrants for aggregate gross proceeds of approximately $9.0 million with net proceeds approximating $8.3 million (the &#8220;February 2018 Offering&#8221;). </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our existing cash and cash equivalents as of December 31, 2017 along with the cash generated by the February 2018 Offering, will be sufficient to fund our planned operations into the first quarter of 2019. Such plans are subject to change depending on clinical enrollment and regulatory progress and the use and supply of drug product.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will not generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly, we will need to raise additional capital to fund our future operations. Until such time that we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings and debt financings and we may seek to raise additional capital through strategic collaborations. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations, which may cause dilution to our existing stockholders.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period from January 1, 2016 through May&#160;2, 2016, we sold 234,296 of common stock for $702,894. On May 31, 2016, we completed our initial public offering, pursuant to which we sold 1,540,026 shares of our common stock at $6.00 per share for net proceeds of $8,464,183 after deducting underwriting discounts and commissions and direct offering expenses payable by us. In the February 2017 Offering, we completed a public offering of our common stock and warrants, pursuant to which we received approximately $4.4 million in net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the primary sources and uses of cash for the years indicated (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,865</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,979</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash used in operating activities</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2017 compared to </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2016. This increase in use of cash for operations was due to the increase in R&amp;D associated with: 1) developing and testing drug product as we prepared for clinical trials; 2) an increase in R&amp;D headcount and associated payroll costs; 3) an increase in sponsored research and related expenses; and 4) an increase in license fees. These all are a reflection of the increased clinical and pre-clinical activity, and the associated G&amp;A support, for our drug portfolio as compared to 2016. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash used in investing activities</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was $0.03 million for the twelve months ended December 31, 2017 compared to $0.1 million for the twelve months ended December 31, 2016. The decrease in cash used in investing is primarily related to the cash outflow of funds in 2016 related to the acquisition of Moleculin, LLC. The only cash used for investing purposes in 2017 was related to the purchase of fixed assets.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash provided by financing activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was $10.1 million for the year ended December 31, 2017 compared to the prior period of $8.9 million. Net cash provided by financing in 2017 consisted of $4.0 million net proceeds from exercise of warrants, and $6.1 million net proceeds from issuance of common stock in the February 2017 Offering, as well as the use of our at-the-market agreement. The prior period financing activities consisted of $8.5 million net proceeds from our IPO stock issuance, $0.7 million from issuance of common stock at $3.00 per share, and $0.2 million from issuance of convertible notes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sEF99FBBBDE23C3E26CF5A0B86ADDA94A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Transactions</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not engage in off-balance sheet transactions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sB0009A81C3F1D5638476A0B86B113CC7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">JOBS Act and Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recently enacted JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have implemented all new accounting pronouncements that are in effect and may impact our financial statements and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sA04EB6347658A8104DA8A0B86B336ABB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We acquired Moleculin, LLC on May 2, 2016, and, going forward our financial statements will include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. We obtained input from third-parties regarding our tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Conversion Feature</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. We estimate the fair value of our common stock using the most recent selling price available. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record accrued expenses for estimated costs of our research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and preparation for clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and we include these costs in accrued liabilities in the balance sheets and within research and development expense in the statement of operations. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets &#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sA003AFCCB6841ACA7FC6A0B86B660AEA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of our Results of Operations and Financial Condition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating expenses</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We classify our operating expenses into three categories: research and development, general and administrative and depreciation.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</font><font style="font-family:inherit;font-size:10pt;">. Research and development expenses consist primarily of:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">costs incurred to conduct research, such as the discovery and development of our product candidates;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">costs related to production of clinical supplies, including fees paid to contract manufacturers;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">fees paid to clinical consultants, clinical trial sites and vendors, including clinical research organizations, in preparation for clinical trials and our IND and Orphan Drug applications with the FDA; and</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:48px;"><font style="font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">costs related to compliance with drug development regulatory requirements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize all research and development costs as they are incurred. Pre-clinical costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our research and development expenses to increase in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates in the United States and Europe. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the quality of our product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent, if any, we will generate revenue from the commercialization and sale of our product candidates.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense consists of personnel related costs, which include salaries, as well as the costs of professional services, such as accounting and legal, facilities, information technology and other administrative expenses. We expect our general and administrative expense to increase due to the anticipated growth of our business and related infrastructure as well as accounting, insurance, investor relations and other costs associated with becoming a public company.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Depreciation.</font><font style="font-family:inherit;font-size:10pt;">&#32;Depreciation expense consists of depreciation on our property and equipment. We depreciate our assets over their estimated useful life. We estimate leasehold improvements to have a 1-year life; computer equipment to have a 2-year life; machinery and equipment to have a 5-year life and furniture and office equipment to have a 7-year life. Property and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">equipment assets acquired as a result of the acquisition of Moleculin, LLC were given a 2-year life given the assessment at acquisition of their age and condition and expected useful remaining life.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (expense), net</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net consists of interest expense associated with our notes payable and interest income.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7AC2728E87275ADD5F2EA0B86B84DE4B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting for warrants</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued warrants to purchase shares of common stock related to equity transactions in 2016. We account for our warrants issued in accordance with Accounting Standards Codification (ASC) Topic 815, Derivatives and Hedging, guidance applicable to derivative instruments, which requires every derivative instrument within its scope to be recorded on the balance sheet as either an asset or liability measured at its fair value, with changes in fair value recognized in earnings for liability classified warrants. Based on this guidance, we determined that our warrants meet the criteria for classification as equity. Accordingly, the warrants were classified as equity and are not subject to remeasurement at each balance sheet date. The fair value was estimated using the Black-Scholes option pricing model, based on the market value of the underlying common stock at the measurement date, the contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants issued in the February 2017 Offering generated a warrant liability. Our financial instruments consist primarily of account payables, accrued expenses, and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Unadjusted quoted prices in active markets of identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs for the asset or liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&#160;liability discussed below. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.  </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basis of value is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. We estimated the fair value of the warrants issued in the February 2017 Offering under ASC 820 as of February&#160;14, 2017 for financial reporting purposes. We used the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of the Series A and Series B Warrants and a Monte Carlo simulation (&#8220;MCM&#8221;) with regard to the Series C Warrants in consideration of path dependent vesting terms of the contract. Both the BSM and MCM models are acceptable in accordance with GAAP. The BSM requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The MCM simulates our common stock price from the valuation date through the Series B Warrant and the unvested Series C Warrant expiration dates using Geometric Browman Motion on a risk-neutral basis - thereby impacting the likelihood that the Series B Warrants would have been exercised and, subsequently, the Series C Warrants would then vest. As disclosed, all Series B and unvested Series C warrants expired on May&#160;15, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the warrants. Where appropriate, we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2016-2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the fair value during the accounting period are shown as other income or expense.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s3355F4BD3C9F1BEB3D09A0B86BB6E27D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation transactions are recognized as compensation expense in the statement of operations based on their fair values on the date of the grant, with the compensation expense recognized over the period in which a grantee is required to provide service in exchange for the award. We estimate the fair value of options granted using the Black-Scholes option valuation model. This estimate uses assumptions regarding a number of inputs that require us to make significant estimates and judgments. Because we are a relatively new publicly traded common stock the expected volatility assumption was based on industry peer information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s09BE8FE94DF69E0A94C7A0B86BD7E991"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for income taxes using ASC 740 Income Taxes. ASC 740 Income Taxes is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, ASC 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized. Valuation allowances are provided if, considering available evidence, it is more likely than not that the deferred tax assets will not be realized. ASC 740 clarifies the criteria that must be met prior to recognition of the financial statement benefit of a position taken in a tax return. ASC 740 provides a benefit recognition model with a two-step approach consisting of &#8220;more-likely-than-not&#8221; recognition criteria, and a measurement attribute that measures a given tax position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. ASC 740 also requires the recognition of liabilities created by differences between tax positions taken in a tax return and amounts recognized in the financial statements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Tax Reform</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing, and the company has maintained the full valuation allowance. As a result we have recorded no income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The amount related to the remeasurement of deferred tax assets and liabilities, based on the rates at which they are expected to reverse in the future, was an expense of $1.56 million. Since the Company maintains a full valuation allowance against its deferred tax assets, there is not net impact to the Company's earnings on this revaluation of its gross deferred tax assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, we have determined that the deferred tax expense of $1.56 million recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available. As discussed above, this deferred tax expense is fully offset by a valuation allowance and, thus, there is not net impact on the Company's earnings from this remeasurement. The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions we have made, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act. Additional work is necessary for a more detailed analysis of our deferred tax assets and liabilities. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete. The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0666BDECAE5473E636F4A0B86C0A4789"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&#160;31, 2017. See also policy note disclosure on Going Concern in Note 2 to the Financial Statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-1&#8221;).&#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-1 is effective for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. We assumed no forfeiture since we have limited history. ASU 2016-9 is effective for annual periods beginning after December&#160;15, 2016, with early adoption permitted. The adoption of this standard on January&#160;1, 2017, did not have a significant impact on our financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">&#32;specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s159E68AD68F8C7D9FFF6A0B86C30E46B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moleculin is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide information required under this item.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sED3E12AF6840EAB3421BA0B86C5EBE5E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements required by this item are set forth beginning in Item 15 of this report and are incorporated herein by reference.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s115C4590748174F41531A0B86C851E37"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no disagreements with our independent registered public accountants on accounting or financial disclosure matters during our two most recent fiscal years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE4E6070CE322E650FD60A0B86CB14355"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Form 10-K. Based on this evaluation, our Chief Executive Officer (&#8220;CEO&#8221;) and our Chief Financial Officer (&#8220;CFO&#8221;), concluded that as a result of the material weakness in our internal controls over financial reporting discussed below, our disclosure controls and procedures were not effective at ensuring that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding disclosure.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal controls over financial reporting for as long as we are an &#8220;emerging growth company&#8221; pursuant to the provisions of the Jumpstart Our Business Startups Act.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive officer and our principal accounting and financial officer, are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017. In making this assessment, management used the criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management concluded that our internal controls over financial reporting were, and continue to be ineffective, as of December 31, 2017 due to a material weakness in our internal controls due to the lack of segregation of duties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of the material weakness described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the last quarter of fiscal 2016, and as our operational activities increased, management determined and continues to determine that it does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and has concluded that the control deficiency represents a material weakness. Management added a full-time controller during the quarter ended September 30, 2017 and a Senior Accountant - Reporting in early 2018. Management intends to further increase its accounting staff and enhance its system of financial accounting and reporting, as soon as economically feasible and sustainable, to remediate this material weakness.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s244130A6F0A129A47460A0B86CD386C3"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B. OTHER INFORMATION.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;">On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of 2,333 rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of 66 months, which may be renewed for an additional 5 years. We are required to remit base monthly rent of approximately $4,300 which will increase at an average approximate rate of 3% each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><a name="s289E9E4871E46CFA60CAA0B86D048EDD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sD4AFC90177D7BBAA78A8A0B86D2DDA43"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2017.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board of Directors has adopted a written Code of Business Conduct and Ethics applicable to all officers, directors and employees, which is available on our website (www.moleculin.com) under &#8220;Governance Documents&#8221; within the &#8220;Corporate Governance&#8221; section. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s6073E440415A8C0E88ABA0B86D580956"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11. EXECUTIVE COMPENSATION</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sC1B7C3D00CA35D532870A0B86D796F50"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s4F52169C7E7F93D75737A0B86DABBF4E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="sF9017A61221B661AE14BA0B86DD3246F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div><a name="s52685F02DE99812505CDA0B86DFEB544"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated by reference to our Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2017.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s21F6CC83BFD1D2B107E3A0B86E25A7B8"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-11px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Documents filed as part of this Report</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements and notes thereto which are attached hereto beginning on page F-1 have been included by reference into Item 8 of this part of the annual report on Form 10-K. See the Index to Financial Statements on page </font><a style="font-family:inherit;font-size:10pt;" href="#s58B33A425459C32FD736A0B86E530BB0"><font style="font-family:inherit;font-size:10pt;">F-1</font></a><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All schedules are omitted because they are inapplicable or not required or the required information is shown in the financial statements or notes thereto.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is set forth in the Exhibit Index that follows the signature page of this Annual Report.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="s58B33A425459C32FD736A0B86E530BB0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Index to Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PAGE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCA7F8C1BE97E66D28EAA0B86E75B9D1"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCA7F8C1BE97E66D28EAA0B86E75B9D1">F-2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24592AA29D887A3A530AA0B85F6EF18D"><font style="font-family:inherit;font-size:10pt;">Balance Sheets as of December 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24592AA29D887A3A530AA0B85F6EF18D">F-3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60308616DA971A1082EAA0B85FB8D5BD"><font style="font-family:inherit;font-size:10pt;">Statements of Operations for the years ended December 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60308616DA971A1082EAA0B85FB8D5BD">F-4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAA67885D1B3FED03D9C5A0B86001060B"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows for the years ended December 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE090DD9AB90E48103995A0B8600BCBE2">F-5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAA67885D1B3FED03D9C5A0B86001060B"><font style="font-family:inherit;font-size:10pt;">Statements of Stockholders&#8217; Equity for the years ended December 31, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAA67885D1B3FED03D9C5A0B86001060B">F-6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1CAA0F40BDF89326F3DBA0B86F9ECEE4"><font style="font-family:inherit;font-size:10pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1CAA0F40BDF89326F3DBA0B86F9ECEE4">F-7</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="sFCA7F8C1BE97E66D28EAA0B86E75B9D1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial Narrow;font-size:11pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Board of Directors and Stockholders</font></div><div style="line-height:120%;padding-bottom:18px;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Opinion on the financial statements </font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">We have audited the accompanying balance sheets of Moleculin Biotech, Inc. (a Delaware corporation) (the &#8220;Company&#8221;) as of December 31, 2017 and 2016 and the related statements of operations, changes in stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2017, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.</font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Going Concern </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred an accumulated deficit </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:10pt;">of </font><font style="font-family:Garamond,serif;font-size:10pt;">$14.5 million</font><font style="font-family:Garamond,serif;font-size:10pt;">&#32;since inception </font><font style="font-family:Garamond,serif;font-size:11pt;">and has not generated any revenue from operations. These conditions, along with other matters as set forth in Note 2, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Basis for opinion </font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">/s/ GRANT THORNTON LLP</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">We have served as the Company&#8217;s auditor since 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Houston, Texas</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">March 28, 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s24592AA29D887A3A530AA0B85F6EF18D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except for share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and equipment, net of accumulated depreciation</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of $21 and $6, respectively</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities and Stockholders' Equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term deferred compensation &#8211; related party</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 9)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' Equity:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 75,000,000 authorized, 21,469,109 issued and outstanding at December 31, 2017 and 12,164,852 shares issued and outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,480</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,960</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities and Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s60308616DA971A1082EAA0B85FB8D5BD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements of Operations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,090</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Operating Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,653</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,883</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense):</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Loss from change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Gain from settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Gain from expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share - basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,569,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,827,510</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sE090DD9AB90E48103995A0B8600BCBE2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Flows from Operating Activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,805</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,926</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Deferred compensation - related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Gain in settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(149</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Gain from expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Changes in operating assets and liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Cash Used in Operating Activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Flows from Investing Activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Purchase of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Acquisition of Moleculin, LLC, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Cash Used in Investing Activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash Flows from Financing Activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Proceeds from notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Payments on notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Proceeds from exercise of warrants </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Proceeds from sale of common stock, net of cash stock issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Cash Provided by Financing Activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,865</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,979</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,007</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosures of cash flow information:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Cash paid for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Common stock issued for the Acquisition of Moleculin, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Common stock issued for conversion of debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Warrants issued for services provided</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Common stock issued for services provided</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="sAA67885D1B3FED03D9C5A0B86001060B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands except for shares and per unit)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Par Value Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Paid-In-Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscriptions Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,661,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Private issuance @ $3.00 / share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234,297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for Moleculin acquisition</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">999,931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">629,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,773</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for cash - IPO, net of stock issuance costs of $1,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,540,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrants issued for services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock granted for services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for convertible debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,076,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Subscription agreement settled for cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,164,852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for cash - sale of units at $1.35 per unit, net of stock issuance costs </font><font style="font-family:inherit;font-size:9pt;background-color:#cceeff;">of $550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrants exercised, net of issuance costs of $73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,728,434</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for cash - sale of common stock in ATM offering, net of issuance costs of </font><font style="font-family:inherit;font-size:9pt;background-color:#cceeff;">$166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">776,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for convertible debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,010,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued for settlement of service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,469,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,480</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s1CAA0F40BDF89326F3DBA0B86F9ECEE4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to the Financial Statements</font></div><div><a name="sDFC5C4B6C9BE30E2884FA0B85FCC872A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Nature of Business and Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms &#8220;MBI&#8221; or &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;drug technologies. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin had been in clinical trials pursuant to an investigative new drug application or IND that had been filed with the U.S. Food and Drug Administration, or FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;other drug development projects, one involving a collection of small molecules, which we refer to as the WP1066 Portfolio, a collection of STAT3 inhibitors, some of which also have immuno-stimulating capability, targeting brain tumors, pancreatic cancer and AML, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (the most common form of brain tumor) and pancreatic cancer in particular. A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, we intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin for the treatment of AML, which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug Application (NDA) in the United States. We may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another Annamycin product for the same use. We also intend to apply for similar status in the European Union (EU) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (MAA). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With regard to additional potential clinical activity, we submitted in October 2017 a request for Clinical Trial Authorization ("CTA") in Poland which, if allowed, will enable a Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland. This will be in addition to the previously announced allowance of our IND in the United States. In December 2017, the Ethics Committee in Poland approved our Phase I/II clinical trial of Annamycin. In March we received requests for and provided additional information to the Polish National Office.  We expect a response from the Polish National Office in the first half of 2018 and at the earliest mid-April 2018. The start of clinical trials in Poland remains subject to confirmation and approval of the CTA by the Polish National Office. We can provide no assurance that we will receive such confirmation on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we continue to recruit and contract clinics both in the United States and Poland. In the US, we have one site - University Hospitals Cleveland Medical Center (&#8220;UHCMC&#8221;) - recruiting patients and active with drug ready to provide treatments.  A patient was enrolled in March 2018 with anticipated treatment to occur in the near term.&#160; We can provide no assurance treatment will occur on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, in September 2017 we engaged a contract research organization ("CRO") to prepare for a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the treatment of cutaneous T-cell lymphoma ("CTCL").</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment. As a result, the financial information disclosed herein represents all of the material financial information related to our principal operating segment.&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company filed a registration statement on Form S-1 (which was declared effective on May&#160;2, 2016) with respect to the Company&#8217;s initial public offering of shares of its common stock (&#8220;IPO&#8221;) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors. &#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s25DC272B9E7FA1619E15A0B85F972B33"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation - </font><font style="font-family:inherit;font-size:10pt;">The accompanying audited financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;">&#32;The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;We acquired Moleculin, LLC (&#8220;Moleculin&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Going Concern -</font><font style="font-family:inherit;font-size:10pt;">&#32;These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents -</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company considers all highly liquid accounts with original maturities of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;months or less at the date of acquisition to be cash equivalents.&#160;Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the insured limits of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">. The amount in excess of the applicable insurance coverage at December 31, 2017 was not material. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and equipment -</font><font style="font-family:inherit;font-size:10pt;">&#32;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:40%;"></td><td style="width:60%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of estimated useful lives or the term of the lease&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 years*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years*</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a </font><font style="font-family:inherit;font-size:10pt;">2 years</font><font style="font-family:inherit;font-size:10pt;">&#32;useful life due to their age and condition and expected remaining life assessed at merger date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets -</font><font style="font-family:inherit;font-size:10pt;">&#32;Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments - </font><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist primarily of account payables,  accrued expenses and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Unobservable inputs for the asset or liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&#160;liability discussed in Note 6. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December 31, 2017 (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Measured at Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrant liability:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December&#160;31, 2017 (in thousands): </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of period December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuances of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclass of liability from long-term to current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,846</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value - net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers in and out (exercise of warrants)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The above table of Level 3 liabilities begins with the initial valuation given the warrant issuances that occurred in the first quarter of 2017 and adjusts the balances for changes that occurred during the year. The ending balance of the Level 3 financial instrument presented above represent our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized "through an" immediate settlement of the instruments.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beneficial Conversion Feature</font><font style="font-family:inherit;font-size:10pt;">&#32;- From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes -</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation -</font><font style="font-family:inherit;font-size:10pt;">&#32;Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Common Share</font><font style="font-family:inherit;font-size:10pt;">&#32;- Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December&#160;31, 2017, the Company&#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included options to purchase </font><font style="font-family:inherit;font-size:10pt;">1,345,000</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">677,576</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares. As of December 31, 2016, the Company's potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to </font><font style="font-family:inherit;font-size:10pt;">1,821,013</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, options to purchase </font><font style="font-family:inherit;font-size:10pt;">510,000</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">107,802</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;">&#32;- A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Costs -</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development costs are expensed as incurred.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events -</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company&#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 10.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&#160;31, 2017. See also policy note disclosure mentioned above on Going Concern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-1&#8221;).&#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-1 is effective for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. MBI assumes no forfeiture since it has limited history. ASU 2016-9 is effective for annual periods beginning after December&#160;15, 2016, with early adoption permitted. The adoption of this standard on January&#160;1, 2017, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">&#32;specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="sAD701FA5EF524FE528B1A0B85F78B403"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Intangible Assets</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Acquisition of Moleculin, LLC</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of </font><font style="font-family:inherit;font-size:10pt;">999,931</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$5,999,586</font><font style="font-family:inherit;font-size:10pt;">, based on the estimated acquisition-date fair value of our common stock of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, equal to the IPO price announced in our prospectus filed on that date. Prior to the Company&#8217;s acquisition of Moleculin, the Company had loaned </font><font style="font-family:inherit;font-size:10pt;">$57,822</font><font style="font-family:inherit;font-size:10pt;">&#32;to Moleculin which was treated as part of the consideration paid to acquire Moleculin.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As additional consideration payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &#8220;Existing IP Assets&#8221; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated </font><font style="font-family:inherit;font-size:10pt;">June&#160;21, 2010</font><font style="font-family:inherit;font-size:10pt;">, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein is limited to&#160;drugs developed only for dermatology indications and does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), a related party, an option, which could be exercised at any time, to obtain an exclusive </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis, however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range of tumors, Moleculin, LLC&#8217;s focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin, LLC.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the merger agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;agreements with HPI. Under the first agreement, HPI&#8217;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and the issuance of </font><font style="font-family:inherit;font-size:10pt;">629,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, valued at </font><font style="font-family:inherit;font-size:10pt;">$6</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period, of which </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid as of December 31, 2017. The Company expenses such costs as incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;obligation discussed above. If we do not exercise the foregoing buy-out right within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years, the license granted to HPI shall convert into an exclusive license. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend to set aside and designate cash and cash equivalents in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to make the buy-out payment. If we ultimately decide to exercise the buy-out right from HPI, we will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The agreements with HPI were executed on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&#8217;s ability to complete the IPO by </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. They became effective on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The termination of the HPI option was completed on behalf of Moleculin, LLC, which was required to enable the sale of Moleculin, LLC by materializing the value of its most significant asset and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the acquisition on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The HPI option termination price amounted to </font><font style="font-family:inherit;font-size:10pt;">$3,874,000</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">629,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock valued at the IPO price of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, and </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;paid in cash in </font><font style="font-family:inherit;font-size:10pt;">July 2016</font><font style="font-family:inherit;font-size:10pt;">, and was included in acquisition-date liabilities assumed.</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase Price Allocation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability assumed (HPI)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities assumed, including $470 of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired/total consideration transferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or most of the intangible assets are IPR&amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles acquired from Moleculin, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Pro Forma Results of Operations</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following comparative table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future (amounts in thousands except share data).</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro Forma For the Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,963</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average outstanding common shares &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,401,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was adjusted on a pro forma basis to exclude </font><font style="font-family:inherit;font-size:10pt;">$145,078</font><font style="font-family:inherit;font-size:10pt;">&#32;in net interest expense related to the amortization of deferred financing costs and debt discount amortization for Moleculin, LLC&#8217;s convertible notes. The holders of the convertible notes were issued the Company&#8217;s common shares upon the Company&#8217;s acquisition of Moleculin, LLC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="s4be6a926ced242419c23afefe42e3911"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Accrued Expenses and other accrued liabilities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities consist of the following components (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued license fees and SRA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal and professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued board expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA500F63BE9608C8B241DA0B85F4E692E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Convertible Notes Payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On various dates from </font><font style="font-family:inherit;font-size:10pt;">August&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">January&#160;19, 2016</font><font style="font-family:inherit;font-size:10pt;">, each as amended on </font><font style="font-family:inherit;font-size:10pt;">March&#160;10, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#32;unsecured promissory notes with </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;separate third-party investors. Each note bore interest at </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum and was to mature on the earlier of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;or the completion of an IPO of the Company&#8217;s securities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the completion of the IPO occurred prior to </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, these notes were to be automatically converted according to their terms into shares of the Company&#8217;s common stock at applicable conversion price upon the Company&#8217;s IPO to the extent and provided that no holder of these notes was permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our common stock after such conversion. Due to this </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;limitation, a portion of these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes remained outstanding and were converted into shares of our common stock at such time as the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;limitation was met. Until such time as the notes were converted into shares of common stock, the maturity date of the notes was automatically extended, and we were not required to repay the notes or the accrued interest relating to the notes in cash.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IPO was completed on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, pursuant to the conversion feature of the foregoing notes and with restriction of the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;beneficially owned condition limitation, discussed above, the Company issued </font><font style="font-family:inherit;font-size:10pt;">1,166,503</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares in total, reducing the convertible debt principal by </font><font style="font-family:inherit;font-size:10pt;">$183,356</font><font style="font-family:inherit;font-size:10pt;">&#32;and accrued interest by </font><font style="font-family:inherit;font-size:10pt;">$17,699</font><font style="font-family:inherit;font-size:10pt;">. Subsequent to these transactions and through December&#160;31, 2016, an additional </font><font style="font-family:inherit;font-size:10pt;">910,095</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;beneficially owned condition limitation. This reduced the convertible debt principal by </font><font style="font-family:inherit;font-size:10pt;">$155,565</font><font style="font-family:inherit;font-size:10pt;">&#32;and accrued interest by </font><font style="font-family:inherit;font-size:10pt;">$7,172</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist. On June 22, 2017, pursuant to the conversion feature of the foregoing notes and with restriction of the beneficially owned condition limitation discussed above, the Company issued common shares which effectively converted all remaining outstanding convertible debt and accrued interest outstanding as of that date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below represents the shares that are convertible at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:</font></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Amounts and shares in whole values)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares Convertible at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 31, 2015(a)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 3, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 6, 2015(a)(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 19, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,821,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Debt partially converted on May&#160;31, 2016 and on August&#160;19, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Debt partially converted on September&#160;1, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Excluded from the </font><font style="font-family:inherit;font-size:10pt;">$276,079</font><font style="font-family:inherit;font-size:10pt;">&#32;is </font><font style="font-family:inherit;font-size:10pt;">$20,333</font><font style="font-family:inherit;font-size:10pt;">&#32;in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common shares relating to the above mentioned convertible notes payable contained the following trading restrictions: (a) beginning </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days after the initial closing of our IPO and until the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the daily volume; (b) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days then the holder of the note can sell up to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the daily volume; (c) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days then the holder of the note can sell up to an additional </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the daily volume; and (d) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$14.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below </font><font style="font-family:inherit;font-size:10pt;">$14.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share; and (b) thereafter, until the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">-year </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">anniversary of the initial closing of IPO, the holder of the note can sell on any trading day </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the daily volume; provided that if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div><a name="see481fc59c35445599a5a4f361618534"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Warrant Liability</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;9, 2017, the Company entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Roth Capital Partners, LLC, as representative of the several underwriters identified therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which we sold in a registered public offering (the &#8220;Offering&#8221;), </font><font style="font-family:inherit;font-size:10pt;">3,710,000</font><font style="font-family:inherit;font-size:10pt;">&#32;units, priced at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit (the closing price that day was </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">), with each unit consisting of: (i) </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock, (ii) a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year Series A warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;of a share of common stock, (iii) a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day Series B warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock, and (iv) a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year Series C warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;of a share of common stock. The Series C warrants in a unit could only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock. The Series B warrant had an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and/or an additional </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;">&#32;warrant combination (comprised of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">278,250</font><font style="font-family:inherit;font-size:10pt;">&#32;Series A warrants, </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;">&#32;Series B warrants and </font><font style="font-family:inherit;font-size:10pt;">278,250</font><font style="font-family:inherit;font-size:10pt;">&#32;Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per share of </font><font style="font-family:inherit;font-size:10pt;">$1.349</font><font style="font-family:inherit;font-size:10pt;">&#32;and public offering price per warrant combination of </font><font style="font-family:inherit;font-size:10pt;">$.001</font><font style="font-family:inherit;font-size:10pt;">, respectively, less the underwriting discounts and commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to </font><font style="font-family:inherit;font-size:10pt;">$278,100</font><font style="font-family:inherit;font-size:10pt;">&#32;warrant combinations. We received approximately </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basis of value is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. The Company estimated the fair value of the Warrants under ASC 820 as of February&#160;14, 2017 for financial reporting purposes. We used the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of the Series A and Series B Warrants and a Monte Carlo simulation (&#8220;MCM&#8221;) with regard to the Series C Warrants in consideration of path dependent vesting terms of the contract. Both the BSM and MCM models are acceptable in accordance with GAAP. The BSM requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The MCM simulates the Company&#8217;s common stock price from the valuation date through the Series B Warrant and the unvested Series C Warrant expiration dates using Geometric Browman Motion on a risk-neutral basis - thereby impacting the likelihood that the Series B Warrants would have been exercised and, subsequently, the Series C Warrants would then vest. All Series B and unvested Series C warrants expired on May&#160;15, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the Warrants. Where appropriate, we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2016-2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in the BSM and MCM models for the Warrants are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68%-1.86%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.00%-160.11%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5-5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of our Warrant activity and related information follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Under</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Price</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise&#160; Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual&#160;Life (Years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,235,923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,728,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,087,717</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Activity During 2017:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;14, 2017, </font><font style="font-family:inherit;font-size:10pt;">8,235,923</font><font style="font-family:inherit;font-size:10pt;">&#32;Warrants were granted, as discussed above. During the year, </font><font style="font-family:inherit;font-size:10pt;">1,833,984</font><font style="font-family:inherit;font-size:10pt;">&#32;Series A warrants were exercised, </font><font style="font-family:inherit;font-size:10pt;">596,300</font><font style="font-family:inherit;font-size:10pt;">&#32;Series B warrants were exercised - thereby vesting </font><font style="font-family:inherit;font-size:10pt;">298,150</font><font style="font-family:inherit;font-size:10pt;">&#32;Series C warrants - and all of the vested </font><font style="font-family:inherit;font-size:10pt;">298,150</font><font style="font-family:inherit;font-size:10pt;">&#32;Series C warrants were exercised. Of the remaining Series B and C warrants, </font><font style="font-family:inherit;font-size:10pt;">5,087,717</font><font style="font-family:inherit;font-size:10pt;">&#32;expired on May&#160;15, 2017. Therefore, the associated warranty liability of </font><font style="font-family:inherit;font-size:10pt;">$1.24 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was extinguished on that date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA9BF3B1887CB8E859C5BA0B85F5C9FEF"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company amended and restated its certificate of incorporation to increase the number of shares authorized to </font><font style="font-family:inherit;font-size:10pt;">80,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of which </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock are authorized and </font><font style="font-family:inherit;font-size:10pt;">75,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock are authorized.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;issued preferred stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Settlement of a Liability</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company issued </font><font style="font-family:inherit;font-size:10pt;">79,167</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to a consultant in full settlement for prior services rendered to the Company. Settlement occurred February 21, 2017 with the issuance of the shares, resulting in a gain on settlement of </font><font style="font-family:inherit;font-size:10pt;">$0.15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded in gain in settlement of liability on the Statements of Operations. The obligation of </font><font style="font-family:inherit;font-size:10pt;">$0.24 million</font><font style="font-family:inherit;font-size:10pt;">&#32;had been recorded by the Company in accounts payable and accrued expenses as of December 31, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Follow-On Public Offering</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the Company completed a public offering and sold </font><font style="font-family:inherit;font-size:10pt;">3,710,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock. The offering price per unit was </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;">. The Company received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after deducting underwriting discounts, commissions and direct offering expenses payable by us. See Note 6 above regarding Warrant issuances related to our February 2017 public offering.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">At Market Issuance Sales Agreement (ATM)</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 15, 2017, the Company entered into an At Market Issuance Sales Agreement (the &#8220;Agreement&#8221; or &#8220;ATM&#8221;) with Roth Capital Partners, LLC and National Securities Corporation (collectively, the &#8220;Agents&#8221;). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company's common stock with an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any sales of Shares pursuant to the Agreement will be made under the Company's effective shelf registration statement on Form S-3 (File No. 333-219434) which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September 15, 2017. Under the Agreement, the Company may sell Shares through an Agent by any method that is deemed an at the market offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of the Shares may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company's Board of Directors or a duly authorized committee thereof. The Company or the Agents, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">, or sooner if either the Company or the Agents terminate the Agreement pursuant to its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to pay a commission to the Agents of </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds of the sale of the Shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company has also provided the Agents with customary indemnification rights. The Company is not obligated to make any sales of Common Stock under the Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 2017, the Company had sold </font><font style="font-family:inherit;font-size:10pt;">776,016</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock from </font><font style="font-family:inherit;font-size:10pt;">$2.05</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$2.71</font><font style="font-family:inherit;font-size:10pt;">&#32;per share with gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company completed its IPO and sold </font><font style="font-family:inherit;font-size:10pt;">1,540,026</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock. The IPO price per share was </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;">. The Company received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$8,464,183</font><font style="font-family:inherit;font-size:10pt;">&#32;after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">107,802</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock exercisable for a period of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;years from date of issuance at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The relative fair value of these warrants was </font><font style="font-family:inherit;font-size:10pt;">$374,763</font><font style="font-family:inherit;font-size:10pt;">&#32;and is included in stock issuance costs calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of </font><font style="font-family:inherit;font-size:10pt;">1.39%</font><font style="font-family:inherit;font-size:10pt;">&#32;(2) expected life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;years, (3) expected volatility of </font><font style="font-family:inherit;font-size:10pt;">80.61%</font><font style="font-family:inherit;font-size:10pt;">, and (4) </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;expected dividends.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period from January&#160;1, 2016 through May&#160;2, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;">234,297</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for </font><font style="font-family:inherit;font-size:10pt;">$702,894</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;20, 2016, the Company agreed to issue </font><font style="font-family:inherit;font-size:10pt;">24,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to PCG Advisory Group, the Company&#8217;s investor relations firm, for services provided. The fair value of these shares was </font><font style="font-family:inherit;font-size:10pt;">$157,680</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the market price on the grant date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160; GSK Consulting Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2017, the Company entered into a consulting agreement with GSK Strategies, LLC (&#8220;GSK&#8221;), for its investor relations operations. The consulting agreement covers for a period of </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;">&#32;months from the date of July 29, 2017. In exchange for the consulting services, the Company agreed to issue </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants (collectively, the &#8220;Warrants&#8221;) to purchase </font><font style="font-family:inherit;font-size:10pt;">100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">50,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at exercise prices of </font><font style="font-family:inherit;font-size:10pt;">$2.41</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively, subject to approval by Nasdaq of a listing of additional shares application, which was received in August 2017. Each of the Warrants vests over a </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;">-month period in equal monthly installments starting July 29, 2017, provided that GSK is providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017, and expire </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the initial exercise date. The Company recorded stock compensation expense for the non-employee consulting agreement of </font><font style="font-family:inherit;font-size:10pt;">$104,000</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended December 31, 2017 based on the fair value of the warrants vested as of December 31, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of 2015 Stock Plan</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On December&#160;5, 2015, the Board of Directors of the Company approved the Company&#8217;s 2015 Stock Plan, which was amended on April&#160;22,&#160;2016. The expiration date of the plan is </font><font style="font-family:inherit;font-size:10pt;">December&#160;5, 2025</font><font style="font-family:inherit;font-size:10pt;">&#32;and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants under the plan is </font><font style="font-family:inherit;font-size:10pt;">2,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards or stock unit awards. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of option activities for the years ended December&#160;31, 2016 and 2017:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option grants has been estimated, with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.44%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for the years ended December 31, 2017 and 2016, are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted during 2017 have an aggregated fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that was calculated using the Black-Scholes option-pricing model. At December 31, 2017, total compensation cost not yet recognized was </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the weighted average period over which this amount is expected to be recognized is </font><font style="font-family:inherit;font-size:10pt;">8.7 years</font><font style="font-family:inherit;font-size:10pt;">. The aggregate fair value of options vesting in the years ended December 31, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;options were exercised in 2017 or 2016. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the &#8220;plain vanilla&#8221; method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because we do not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase </font><font style="font-family:inherit;font-size:10pt;">50,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><a name="sF2848C515FBBA0FE7BEFA0B85F663E82"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Income Taxes </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes consists of the following components (in thousands):&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes activity related to the Company&#8217;s valuation allowance (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at Beginning of Period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Tax Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Release of Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at End of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands): </font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(amounts in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Tax Benefit at Statutory Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,335</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Benefit Net of Federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPO Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Warrant Costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Permanent Differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in Deferred Tax Rate due to Tax Reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Tax (Expense) / Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a deferred tax expense of </font><font style="font-family:inherit;font-size:10pt;">$1.56 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2017 that is still fully valued against as of December 31, 2017.  This expense is attributable to the Company being in a net deferred tax asset position at the time of remeasurement.  As the company maintains fully valuation allowance, this amount can be seen on the rate reconciliation as an adjustment to deferred tax asset and corresponding valuation allowance. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Start Up Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Net Operating Loss Carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Loss Carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred net operating losses since inception. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had total federal operating loss carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.07 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which expire commencing in 2037. The value of these carryforwards depends on the Company&#8217;s ability to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally, the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses and the lack of utilization of the net operating losses during tax years open under statute.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple state jurisdictions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had state operating losses of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.81 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which expire commencing in 2037. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred tax asset at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$2.56 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.40 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been established at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in the valuation allowance for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research and development tax credits in the future, but has not conducted a study to date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;unrecognized tax benefits from any federal, state or foreign jurisdictions. The only tax years open under statute for the Company are December 31, 2017 and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;interest or penalties have been accrued at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, as the Company has not recorded any uncertain tax positions. The Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is inherently uncertain; therefore, the Company&#8217;s assessments can involve both a series of complex judgments about future events and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its assessments are reasonable, the final determination of tax audit settlements and any related litigation </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">could be materially different from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of limitations prior to&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance. As a result have recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The deferred tax expense recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act.   Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.  The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sA285D6ABED8972847879A0B85F60B623"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Commitments and Contingencies </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sponsored Research Agreements with MD Anderson</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2017, we amended our Sponsored Laboratory Study Agreement with MD Anderson whereby we paid </font><font style="font-family:inherit;font-size:10pt;">$302,500</font><font style="font-family:inherit;font-size:10pt;">&#32;in 2017, and the agreement was extended to October 31, 2018. On December 4, 2017, we extended this Agreement until October 31, 2019 for total payment amount of </font><font style="font-family:inherit;font-size:10pt;">$346,687</font><font style="font-family:inherit;font-size:10pt;">&#32;spread over that period of time. Of this amount, </font><font style="font-family:inherit;font-size:10pt;">$236,687</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid in the first quarter of 2018. The final payment of </font><font style="font-family:inherit;font-size:10pt;">$110,000</font><font style="font-family:inherit;font-size:10pt;">&#32;is due on July 31, 2018. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were </font><font style="font-family:inherit;font-size:10pt;">$291,687</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$33,000</font><font style="font-family:inherit;font-size:10pt;">, for the year ended December 31, 2017 and 2016, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of August 2015, we obtained the rights and obligations of Annamed under a June 2012 Patent and Technology Development and License Agreement by and between Annamed and Dermin (the &#8220;Annamed Agreement&#8221;). Therefore, certain intellectual property rights, including rights, if any, covering the potential drug product, Annamycin have been licensed to Dermin and Dermin has been granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany (&#8220;Annamed licensed territories&#8221;). We are obligated to develop and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin will pay a royalty for the sale of any licensed product in the Annamed licensed territories and pay all out-of-pocket expenses incurred by us in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Dermin also agrees to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. The agreement includes a one-time license documentation fee of </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">, annual maintenance fees of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">&#32;until the first sale of drug and has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product - </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">; (ii) submission of the first NDA within the United States - </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;">; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- </font><font style="font-family:inherit;font-size:10pt;">$225,000</font><font style="font-family:inherit;font-size:10pt;">. The expenses recognized under this agreement were </font><font style="font-family:inherit;font-size:10pt;">$52,500</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December 31, 2017 or 2016, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1066 Portfolio</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#8220;Moleculin Agreement&#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, we must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Annual maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. The agreement, as amended, has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">; (ii) submission of the first NDA within the United States - </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">. License fees expensed related to MD Anderson were </font><font style="font-family:inherit;font-size:10pt;">$85,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$77,500</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the year ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), pursuant to which we have granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#8220;HPI Out-Licensing Agreement&#8221;). Under the HPI Out-Licensing Agreement we must make quarterly payments totaling </font><font style="font-family:inherit;font-size:10pt;">$0.75 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first twelve quarters following the effective date of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to HPI within </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#32;of the effective date of the HPI Out-Licensing Agreement we will regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly payments. In the event that we do not exercise our right to regain our rights to the licensed subject matter within </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#32;of the effective date of the HPI Out-Licensing Agreement, the license granted to HPI shall convert to an exclusive license upon HPI&#8217;s written notice and we shall be obligated to transfer all existing data relating to licensed subject matter including any development data and any IND to HPI. License fees expensed related to HPI were </font><font style="font-family:inherit;font-size:10pt;">$225,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">&#32;respectively, for the year ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into a license agreement covering a new group of molecules recently discovered in connection with research we have been sponsoring at MD Anderson Cancer Center called WP1732, a part of the WP1066 Portfolio. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the effective date of the agreement and increase by </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year. Under the agreement, we are required to make royalty payments ranging from </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of Net Sales, depending on the intended use, each quarter upon the commencement of sales, with a minimum of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year. Additional payments are due upon the commencement of a Phase II study </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">, submission of a New Drug Application </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">, and the receipt of marketing approval of a licensed product, </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1122 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#8220;IntertechBio Agreement&#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the first anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the second anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the third anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$60,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the fourth anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$80,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the fifth anniversary of the effective date of the agreement and </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the assignment, we agreed to make a minimum annual royalty payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the first anniversary following the first sale of a licensed product, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second anniversary following the first sale of a licensed product, and </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the third year following the first sale of a licensed product. License fees expensed related to MD Anderson were </font><font style="font-family:inherit;font-size:10pt;">$95,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the year ended December 31, 2017 and 2016.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One-time milestone payments are due as follows: 1) Upon commencement of a Phase II study for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">; 2) Upon commencement of a Phase III study for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">; 3) Upon filing of a New Drug Application (&#8220;NDA&#8221;) for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">; and 4) Upon receipt of market approval for sale of a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">. The rights we have obtained pursuant to the assignment of the IntertechBio Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with&#160;</font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;using the rate of compensation in effect at December 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9FBC0F96D507DD873347A0B85F821925"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Appointment of Science Advisory Board Member</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January&#160;11, 2018, the Company issued to a Science Advisory Board (&#8220;SAB&#8221;) member </font><font style="font-family:inherit;font-size:10pt;">10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;options with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.89</font><font style="font-family:inherit;font-size:10pt;">&#32;with </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">-year annual vesting.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$9 million Registered Direct Offering</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors for the sale by us of </font><font style="font-family:inherit;font-size:10pt;">4,290,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$2.10</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,145,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. We sold the common shares and warrants for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">. Subject to certain beneficial ownership limitations, the warrants will be initially exercisable on the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month anniversary of the issuance date at an exercise price equal to </font><font style="font-family:inherit;font-size:10pt;">$2.80</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net proceeds from the transactions was approximately </font><font style="font-family:inherit;font-size:10pt;">$8.27 million</font><font style="font-family:inherit;font-size:10pt;">&#32;after deducting certain fees due to the placement agent and transaction expenses. The net proceeds will be used for planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common shares were offered and sold by us pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on July 24, 2017 and subsequently declared effective on August 21, 2017 (File No. 333-219434), and the base prospectus contained therein. We filed a prospectus supplement with the SEC on February 16, 2018 in connection with the sale of the common shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants and the shares issuable upon exercise of the warrants were sold without registration under the Securities Act of 1933 in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a placement agent agreement (the &#8220;Placement Agency Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the common shares and warrants. We have agreed to pay Roth an aggregate fee equal to </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds received by us from the sale of the securities in the transactions. Pursuant to the Placement Agency Agreement, we also agreed to grant to Roth or its designees warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of the aggregate number of shares of common stock sold in the transactions (the &#8220;Roth Warrants&#8221;). The Roth Warrants have substantially the same terms as the warrants, except that the Roth Warrants will expire on February 15, 2023. The Roth Warrants and the shares issuable upon exercise of the Roth Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. We also reimbursed Roth for its expenses of </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the consummation of the offering, we agreed to give Roth a </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month right of first refusal to act as our lead underwriter or exclusive placement agent for any further capital raising transactions undertaken by the us. With certain exceptions, the we also granted Roth a </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month tail fee equal to the cash and warrant compensation in the offering, if any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">investor with which Roth had substantive discussions with respect to the offering, provides us with further capital during such </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month period following termination of our engagement of Roth.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Agreement</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of </font><font style="font-family:inherit;font-size:10pt;">2,333</font><font style="font-family:inherit;font-size:10pt;">&#32;rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of </font><font style="font-family:inherit;font-size:10pt;">66 months</font><font style="font-family:inherit;font-size:10pt;">, which may be renewed for an additional </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;">. We are required to remit base monthly rent of approximately </font><font style="font-family:inherit;font-size:10pt;">$4,300</font><font style="font-family:inherit;font-size:10pt;">&#32;which will increase at an average approximate rate of </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><a name="sD6217D04C7A49F5351BFA0B872093547"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex3-1.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.1 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex3-2.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.2 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420417007063/v458901_ex4-1.htm"><font style="font-family:inherit;font-size:10pt;">Form of Series A/B/C Warrant Agreement issued in February 2017 offering (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 9, 2017)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1 **</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-1.htm"><font style="font-family:inherit;font-size:10pt;">Moleculin Biotech, Inc. 2015 Incentive Plan (incorporated by reference to exhibit 10.1 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-2.htm"><font style="font-family:inherit;font-size:10pt;">Rights Transfer Agreement between Moleculin Biotech, Inc. and AnnaMed, Inc. (incorporated by reference to exhibit 10.2 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-3.htm"><font style="font-family:inherit;font-size:10pt;">Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.3 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-4.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and Moleculin, LLC (incorporated by reference to exhibit 10.4 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-5.htm"><font style="font-family:inherit;font-size:10pt;">Patent and Technology License Agreement dated April 2, 2012 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.5 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-6.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1 to the Patent and Technology License Agreement dated June 21, 2010 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.6 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416094685/v436948_ex10-7.htm"><font style="font-family:inherit;font-size:10pt;">Patent and Technology Development and License Agreement June 28, 2012 by and between Annamed, Inc. and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.7 of the Form S-1/A filed April 15, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-8.htm"><font style="font-family:inherit;font-size:10pt;">Patent and Technology Development and License Agreement dated April 15, 2011 by and between IntertechBio Corporation and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.8 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-9.htm"><font style="font-family:inherit;font-size:10pt;">Patent and Technology Development and License Agreement dated October 27, 2010 by and between Moleculin, LLC and Dermin Sp. z.o.o (incorporated by reference to exhibit 10.9 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-10.htm"><font style="font-family:inherit;font-size:10pt;">Rights Transfer Agreement dated between Moleculin Biotech, Inc. and IntertechBio Corporation dated August 11, 2015 (incorporated by reference to exhibit 10.10 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex10-11.htm"><font style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger between Moleculin Biotech, Inc. and Moleculin, LLC (incorporated by reference to exhibit 10.11 of the Form S-1/A filed March 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416094685/v436948_ex10-13.htm"><font style="font-family:inherit;font-size:10pt;">Technology Rights and Development License Agreement to be entered into by Moleculin Biotech, Inc. and Houston Pharmaceuticals, Inc. (incorporated by reference to exhibit 10.13 of the Form S-1/A filed April 15, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13 **</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416121101/v447670_ex10-1.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between Moleculin Biotech, Inc. and Jonathan P. Foster dated August 19, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed August 25, 2016)</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14 **</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416128033/v450493_ex10-1.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement between Moleculin Biotech, Inc. and Walter Klemp dated October 13, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed October 13, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15 **</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416128033/v450493_ex10-2.htm"><font style="font-family:inherit;font-size:10pt;">General Release and Separation Agreement between Moleculin Biotech, Inc. and Louis Ploth dated October 7, 2016 (incorporated by reference to Exhibit 10.2 of the Form 8-K filed October 13, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416135472/v451792_ex10-4.htm"><font style="font-family:inherit;font-size:10pt;">Development Collaboration Agreement between Moleculin Biotech, Inc. and Dermin Sp. Z o. o. dated September 30, 2016 (incorporated by reference to Exhibit 10.4 of the Form 10-Q filed November 21, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1659617/000114420416094685/v436948_ex21.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of the Registrant (incorporated by reference to exhibit 21 of the Form S-1/A filed April 15, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2017q410-kexhibit231.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Grant Thornton, LLP</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2017q410-kexhibit311.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes- Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2017q410-kexhibit312.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2017q410-kexhibit321.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2017q410-kexhibit322.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE *</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13px;"></td><td style="width:44px;"></td><td style="width:625px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13px;"></td><td style="width:44px;"></td><td style="width:625px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denotes a management contract or compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5E04814E99838210CFE7A0B871E68F89"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:53%;"></td><td style="width:6%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MOLECULIN BIOTECH, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Walter V. Klemp</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter V. Klemp,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Chairman</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 28, 2018</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:35%;"></td><td style="width:4%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Walter V. Klemp</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and&#160;Chairman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter Klemp</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jonathan P. Foster</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President Officer and</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jonathan P. Foster</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Robert George</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert George</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael Cannon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Cannon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John Climaco</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John Climaco</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>a2017q410-kexhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEF64D1A486759968FDBFA0B872B4D07C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Garamond,serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">We have issued our report dated March 28, 2018, with respect to the financial statements included in the Annual Report of Moleculin Biotech, Inc. on Form 10-K for the year ended December 31, 2017.  We consent to the incorporation by reference of said reports in the Registration Statements of Moleculin Biotech, Inc. on Form S-1 (File No. 333-214898), Form S-3 (File No. 333-219434) and Form S-8 (File No. 333-212619).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">/s/GRANT THORNTON LLP</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">Houston, Texas</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;">March&#160;28, 2018</font><font style="font-family:Garamond,serif;font-size:11pt;">&#32;</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Garamond,serif;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2017q410-kexhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s01347B39B8478BC6C30AA0B87355B206"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000033;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Walter Klemp, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Annual Report on Form 10-K of Moleculin Biotech, Inc.;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">By: /s/ Walter Klemp&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter Klemp</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2017q410-kexhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8256D64EB5B7193CF1B0A0B873FB2A96"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000033;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Jonathan Foster, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Annual Report on Form 10-K of Moleculin Biotech, Inc.;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">By: /s/ Jonathan Foster&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jonathan Foster</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer and Principal Accounting Officer)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2017q410-kexhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3D9FE9854E628DF7196FA0B874A2AF57"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Walter Klemp, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">By: /s/ Walter Klemp &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter Klemp</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a2017q410-kexhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s06D993D17E59E8EF86AFA0B875480C10"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 of Moleculin Biotech, Inc. (the &#8220;Company&#8221;) as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jonathan Foster, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-10px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">By: /s/ Jonathan Foster&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jonathan Foster</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer and Principal Accounting Officer)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>mbrx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:e3745d60571a407d9453a6a79eb5b7be,x:ac48e94c7e3c40748ec6a5438e7d1ac3-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mbrx="http://www.moleculin.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="mbrx-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbrx:SubscriptionsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabiltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityLongtermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabiltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabilityCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mbrx:WarrantLiabiltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May2-May2_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-02</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May2-May2_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-02</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May2-May2_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:LicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-02</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May2-May2_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-02</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul1-Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May02_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:LicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_mbrx_PeriodTypeAxis_mbrx_AcquisitionDateOneMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:PeriodTypeAxis">mbrx:AcquisitionDateOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May02_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:OutlincenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May2-May2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-02</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mbrx:MoleculinLlcMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mbrx:LicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateJanuary192016Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorGMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateOctober062015OneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateSeptember032015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:InvestorBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:IssueDateAugust312015Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFiveMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Jun01-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermTwoMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFourMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-31</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermThreeMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:DebtTradingTermsAxis">mbrx:DebtInstrumentTradingTermThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Mar10-Mar10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-10</xbrli:startDate>
			<xbrli:endDate>2016-03-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_UnsecuredPromissoryNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbrx:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesCWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2017_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-09</xbrli:startDate>
			<xbrli:endDate>2017-02-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-09</xbrli:startDate>
			<xbrli:endDate>2017-02-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesCWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesCWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-09</xbrli:startDate>
			<xbrli:endDate>2017-02-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-09</xbrli:startDate>
			<xbrli:endDate>2017-02-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbrx:UnderwritingAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2014_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-14</xbrli:startDate>
			<xbrli:endDate>2017-02-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May2017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-15</xbrli:startDate>
			<xbrli:endDate>2017-05-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesAndSeriesCWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesAndSeriesCWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-15</xbrli:startDate>
			<xbrli:endDate>2017-05-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-09</xbrli:startDate>
			<xbrli:endDate>2017-02-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb09_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesCWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:SeriesBWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sep15_us-gaap_CounterpartyNameAxis_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:RothCapitalPartnersLLCandNationalSecuritiesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-31</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sep15-Sep15_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-15</xbrli:startDate>
			<xbrli:endDate>2017-09-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-31</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jan1-May2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul29-Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:TheWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-29</xbrli:startDate>
			<xbrli:endDate>2017-07-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jun20-Jun20_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbrx_PcgAdvisoryGroupMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbrx:PcgAdvisoryGroupMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-20</xbrli:startDate>
			<xbrli:endDate>2016-06-20</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:GSKConsultingAgreementWarrantOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1-Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ChiefFinancialOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:TheWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:AtMarketIssuanceSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:FormerScienceAdvisoryBoardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-21</xbrli:startDate>
			<xbrli:endDate>2017-02-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mbrx:GSKConsultingAgreementWarrantTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:FormerScienceAdvisoryBoardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Apr22_us-gaap_AwardTypeAxis_mbrx_StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mbrx:StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan01-Jan31_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mbrx:FormerScienceAdvisoryBoardMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_mbrx_FederalStateandForeignJurisdictionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mbrx:FederalStateandForeignJurisdictionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:MoleculinAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiiStudyForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:SubmissionOfFirstNDAWithinUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:ReceiptOfMarketApprovalForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:ServicingFeePayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_HoustonPharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiiStudyForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec04-Dec04_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-04</xbrli:startDate>
			<xbrli:endDate>2017-12-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:MoleculinAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_HoustonPharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:HoustonPharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiStudyForLicensedProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:ReceiptOfMarketApprovalForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfANewDrugApplicationMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:SubmissionOfANewDrugApplicationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1SD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-09</xbrli:startDate>
			<xbrli:endDate>2017-01-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiStudyForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:AnnamedAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_FilingOfNewDrugApplicationForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:FilingOfNewDrugApplicationForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_MinimumAnnualRoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">mbrx:MinimumAnnualRoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:MoleculinAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:SubmissionOfFirstNDAWithinUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:MoleculinAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:ReceiptOfMarketApprovalForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:MoleculinAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:ReceiptOfMarketApprovalForLicensedProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:MdAndersonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="mbrx:AgreementAxis">mbrx:IntertechBioAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mbrx:CommencementOfPhaseIiiStudyForLicensedProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar22-Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbrx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-22</xbrli:startDate>
			<xbrli:endDate>2018-03-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan11-Jan11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_mbrx_ScienceAdvisoryBoardMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-11</xbrli:startDate>
			<xbrli:endDate>2018-01-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-16</xbrli:startDate>
			<xbrli:endDate>2018-02-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mbrx:IPXMemorialDriveInvestorsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mbrx:LeaseAgreementForCorporateOfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_SecuritiesPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan11-Jan11_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_mbrx_ScienceAdvisoryBoardMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mbrx:ScienceAdvisoryBoardMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-11</xbrli:startDate>
			<xbrli:endDate>2018-01-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_PlacementAgencyAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:PlacementAgencyAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-16</xbrli:startDate>
			<xbrli:endDate>2018-02-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb16-Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_SecuritiesPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbrx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-16</xbrli:startDate>
			<xbrli:endDate>2018-02-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="project">
		<xbrli:measure>mbrx:project</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="note">
		<xbrli:measure>mbrx:note</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="investor">
		<xbrli:measure>mbrx:investor</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="technology">
		<xbrli:measure>mbrx:technology</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="employee">
		<xbrli:measure>mbrx:employee</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="agreement">
		<xbrli:measure>mbrx:agreement</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>mbrx:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="warrant">
		<xbrli:measure>mbrx:warrant</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-D59EE7C8525ABED9AB97555773980235">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-31AD95F21A516CFB2849555773957495">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-9397A073A05B379F658555577395A6AF">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-353295D71DD2ABD5D4F455577396FFE7">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-C10534035F6AE363E8D65557738F8639">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-14AB7D099DA261740434555773953A95">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-4246D6011ED1F3005FCC55577397B528">0001659617</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1Mar16" decimals="INF" id="Fact-90929102D629A9329FB255577395E805" unitRef="shares">25768861</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-BB488D232E8EDDA86AD35557738FA044">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-F165E950D461CBB58BED55577397161E">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="0" id="Fact-CEE767639C80DE286B4F5557738FBDDD" unitRef="usd">32242351</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-CD601350BCAB5FE2D20655577395ADF2">Moleculin Biotech, Inc.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-3B3985F2078D93DDC339555773A18A32">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-EA3F108BDD3EDBFCF493555773A0DC20">No</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="FD2017Q4YTD" id="Fact-A82C3EC2D348C2657CA55557739D3C1A">MBRX</dei:TradingSymbol>
	<mbrx:AccruedBoardExpensesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-02EBA78737D72DDD02692601A62F5E46" unitRef="usd">91000</mbrx:AccruedBoardExpensesCurrent>
	<mbrx:AccruedBoardExpensesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-56BB3C050CE7602FBA1E2601A6319B51" unitRef="usd">0</mbrx:AccruedBoardExpensesCurrent>
	<mbrx:AccruedClinicalTestingCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F1EBF761EAEB77E0E0F225FF9EC6A56F" unitRef="usd">238000</mbrx:AccruedClinicalTestingCurrent>
	<mbrx:AccruedClinicalTestingCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-A942709E2262330212B525FF9EC85700" unitRef="usd">320000</mbrx:AccruedClinicalTestingCurrent>
	<mbrx:AccruedLicenseAgreementPayment contextRef="I2016Q2May02_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember" decimals="INF" id="Fact-B09D2C55A52637F0D21E5557739EF827" unitRef="usd">100000</mbrx:AccruedLicenseAgreementPayment>
	<mbrx:AccruedLicenseAgreementPayment contextRef="I2016Q3Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="0" id="Fact-3F3FF433AA5E8C536DBB5557739F2C05" unitRef="usd">100000</mbrx:AccruedLicenseAgreementPayment>
	<mbrx:AccruedLicenseFeesAndSRACurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7B25DED4C9CF793C1C862600F44AC761" unitRef="usd">157000</mbrx:AccruedLicenseFeesAndSRACurrent>
	<mbrx:AccruedLicenseFeesAndSRACurrent contextRef="FI2017Q4" decimals="-3" id="Fact-5FFBCAD6BA9967F11F8A2600F4574A54" unitRef="usd">260000</mbrx:AccruedLicenseFeesAndSRACurrent>
	<mbrx:AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering contextRef="FD2017Q4YTD" decimals="-3" id="Fact-92E33AEF05BEF30A3F974A3BAF2AEE8A" unitRef="usd">166000</mbrx:AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering>
	<mbrx:AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-990F0961ACD80A0348404403DF5F1953" unitRef="usd">550000</mbrx:AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits>
	<mbrx:AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CE78653A779C31ED99A04A3BA3BF612D" unitRef="usd">73000</mbrx:AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts>
	<mbrx:BusinessAcquisitionIndemnificationAgreementTerm contextRef="D2016Q2May2-May2" id="Fact-01E55173D5207C7FE552555773A0C14F">P6Y</mbrx:BusinessAcquisitionIndemnificationAgreementTerm>
	<mbrx:BusinessAcquisitionNumberOfAgreements contextRef="D2016Q2May2-May2_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="INF" id="Fact-8CF52E94D950432A9DCC4A363A3550B1" unitRef="agreement">2</mbrx:BusinessAcquisitionNumberOfAgreements>
	<mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-FE65EBEDC83E6CC4ACF15557739DD15B" unitRef="usdPerShare">0.42</mbrx:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
	<mbrx:BusinessAcquisitionProFormaOperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-328BCD7346F9EC428FE45557739895CB" unitRef="usd">3979000</mbrx:BusinessAcquisitionProFormaOperatingExpenses>
	<mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-1C0A7A2ED553E12EFE255557739848D5" unitRef="shares">9401028</mbrx:BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
	<mbrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-A95055169C7A6481870655577398B631" unitRef="usd">470000</mbrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable>
	<mbrx:ClassOfWarrantOrRightInitialExercisePeriod contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-D533FB7C431402AA4D4B1B9104732483">P6M</mbrx:ClassOfWarrantOrRightInitialExercisePeriod>
	<mbrx:ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable contextRef="D2016Q2" id="Fact-62CB8F9BEC610EA1B0A45557739E35ED">P5Y</mbrx:ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable>
	<mbrx:ClassOfWarrantOrRightTerm contextRef="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember" id="Fact-064CDBA3410175FF16C124B9E6009F4E">P90D</mbrx:ClassOfWarrantOrRightTerm>
	<mbrx:ClassOfWarrantOrRightTerm contextRef="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember" id="Fact-282ABEFC7DB3ADBEF63224BA87220B97">P5Y</mbrx:ClassOfWarrantOrRightTerm>
	<mbrx:ClassOfWarrantOrRightTerm contextRef="D2017Q1Feb2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember" id="Fact-949226F2C3A67C233DC824B98EF0D475">P5Y</mbrx:ClassOfWarrantOrRightTerm>
	<mbrx:ClassOfWarrantOrRightTerm contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-8B6CF973A9215CCB38DA4523AB236D4F">P5Y</mbrx:ClassOfWarrantOrRightTerm>
	<mbrx:ClassOfWarrantOrRightsWarrantExercisedAmount contextRef="D2017Q1Feb2017_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember" decimals="0" id="Fact-43C98EF2CE15B8EA208724BCB78EC3C6" unitRef="usd">278100</mbrx:ClassOfWarrantOrRightsWarrantExercisedAmount>
	<mbrx:ClassofWarrantorRightAgreementPeriod contextRef="D2017Q3Jul29-Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember" id="Fact-E9BAA0C09E0E3F881A393F5B172CD64B">P12M</mbrx:ClassofWarrantorRightAgreementPeriod>
	<mbrx:ClassofWarrantorRightExpirationPeriod contextRef="D2017Q3Jul29-Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember" id="Fact-1740ADBAB034412D9C9D3F5C496921CC">P5Y</mbrx:ClassofWarrantorRightExpirationPeriod>
	<mbrx:ClassofWarrantorRightNumberofWarrantsIssued contextRef="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantOneMember" decimals="INF" id="Fact-305B23E24E50FDBB37B5544C27A060E6" unitRef="warrant">2</mbrx:ClassofWarrantorRightNumberofWarrantsIssued>
	<mbrx:ClassofWarrantorRightVestingPeriod contextRef="D2017Q3Jul29-Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember" id="Fact-B644FAF9613F67AD756A3F56AD8E95FF">P12M</mbrx:ClassofWarrantorRightVestingPeriod>
	<mbrx:ContractualObligationDueInNextFiscalYearAfterProductApproval contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_MinimumAnnualRoyaltyMember" decimals="-3" id="Fact-9B4C3CAC0D3782CC492F2A66CC267085" unitRef="usd">200000</mbrx:ContractualObligationDueInNextFiscalYearAfterProductApproval>
	<mbrx:ContractualObligationDueInSecondYearAfterProductApproval contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_MinimumAnnualRoyaltyMember" decimals="-3" id="Fact-529AF74C65EA8F7903FE2A66FC2C8B7D" unitRef="usd">400000</mbrx:ContractualObligationDueInSecondYearAfterProductApproval>
	<mbrx:ContractualObligationDueInThirdYearAfterProductApproval contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-B45CB3D41FA56658BF552A671BAD2417" unitRef="usd">600000</mbrx:ContractualObligationDueInThirdYearAfterProductApproval>
	<mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember" decimals="INF" id="Fact-690BB00B54C1BD7C16EB555773A08E47" unitRef="shares">294832</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>
	<mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember" decimals="INF" id="Fact-2AF6BE08E4CD3798FFE855577396412B" unitRef="shares">412500</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>
	<mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember" decimals="INF" id="Fact-DDA8458AFC568821368E5557738FB75B" unitRef="shares">151402</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>
	<mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember" decimals="INF" id="Fact-2A426E63E3B36C952E1D55577396898D" unitRef="shares">962279</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>
	<mbrx:DebtInstrumentConvertibleNumberOfCommonShares contextRef="FD2016Q4YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-4558584F17BE8CDBD69D55577395A1F8" unitRef="shares">1821013</mbrx:DebtInstrumentConvertibleNumberOfCommonShares>
	<mbrx:DebtInstrumentNumberOfUnsecuredNotesEntered contextRef="D2016Q1Mar10-Mar10" decimals="INF" id="Fact-F414714E07D9EC512339555773A125F6" unitRef="note">7</mbrx:DebtInstrumentNumberOfUnsecuredNotesEntered>
	<mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFiveMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-2EE454B302A3FA12B60E555773955669" unitRef="number">0.1</mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume>
	<mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-0C153F67109515D939265557738F596A" unitRef="number">0.04</mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume>
	<mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermThreeMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-00B152C027773909D533555773A7718D" unitRef="number">0.07</mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume>
	<mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermTwoMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-B1C4439C5F29E46D8021555773A6A402" unitRef="number">0.04</mbrx:DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume>
	<mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFiveMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-05FAFB0EFC77E6EF43B9555773A7143F" unitRef="usdPerShare">10.00</mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock>
	<mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFourMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-757AE44F3F05346D4929555773A6FFBA" unitRef="usdPerShare">14.00</mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock>
	<mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermThreeMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-A5F913B68D67F470A7A7555773A145D0" unitRef="usdPerShare">10.00</mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock>
	<mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermTwoMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-0D489B6CC850BD864ACD555773A1A936" unitRef="usdPerShare">7.00</mbrx:DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock>
	<mbrx:DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermThreeMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-2EABE64D3A7C7458043E555773A7859E">P5D</mbrx:DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold>
	<mbrx:DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermTwoMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-CB22ACC2B0A134EEA9495557739523A4">P5D</mbrx:DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold>
	<mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermThreeMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-9FC90667D0137C2E98FD555773A0A6BB" unitRef="number">0.05</mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument>
	<mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-0B6D8697FB5259788C37555773A1AC5B" unitRef="number">0.01</mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument>
	<mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermTwoMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-79F21A4E6B55752C9BA3555773955EA6" unitRef="number">0.03</mbrx:DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument>
	<mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermFiveMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-8639ECAA1D1F8DC68FF2555773A09A8B">P2Y</mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold>
	<mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-A39008C9E266CFFF50EE555773A629BD">P1Y</mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold>
	<mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold contextRef="FD2017Q4YTD_mbrx_DebtTradingTermsAxis_mbrx_DebtInstrumentTradingTermOneMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-12AB6CCE4ACE14AD0746555773A1714E">P90D</mbrx:DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold>
	<mbrx:DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors contextRef="D2016Q1Mar10-Mar10" decimals="INF" id="Fact-584AF58B160D70D8BE25555773A0678C" unitRef="investor">3</mbrx:DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors>
	<mbrx:DeferredTaxAssetsStartUpCosts contextRef="FI2016Q4" decimals="-3" id="Fact-6B3B2EB774676F003443555773980C30" unitRef="usd">735000</mbrx:DeferredTaxAssetsStartUpCosts>
	<mbrx:DeferredTaxAssetsStartUpCosts contextRef="FI2017Q4" decimals="-3" id="Fact-51BBC4523D3C5877B0345557739FC886" unitRef="usd">1105000</mbrx:DeferredTaxAssetsStartUpCosts>
	<mbrx:DeferredTaxAssetsValuationAllowanceReleases contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AD5F856948A59517F2ED55577396EC26" unitRef="usd">0</mbrx:DeferredTaxAssetsValuationAllowanceReleases>
	<mbrx:DeferredTaxAssetsValuationAllowanceReleases contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F47DBEEDF8C83946A10855577397BF89" unitRef="usd">0</mbrx:DeferredTaxAssetsValuationAllowanceReleases>
	<mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6F515B35B5837DD4608B43CC985A94CF" unitRef="usd">227000</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost>
	<mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F4822625E88C2681586E43CC99064602" unitRef="usd">76000</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost>
	<mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent contextRef="FD2016Q4YTD" decimals="4" id="Fact-308F6B1CDD7304B144E843CC9894E4CD" unitRef="number">0.0578</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent>
	<mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent contextRef="FD2017Q4YTD" decimals="4" id="Fact-9E87D598805F2DF9D60F43CC98B049CF" unitRef="number">0.0077</mbrx:EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent>
	<mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BF402860D09699FD375843CC98C22CFA" unitRef="usd">3000</mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
	<mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences contextRef="FD2017Q4YTD" decimals="-3" id="Fact-93DD86AC7DE820D0C42E43CC98EBC44F" unitRef="usd">9000</mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
	<mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent contextRef="FD2016Q4YTD" decimals="4" id="Fact-3BF73F6FCCE6C06C0D3C43CC98F7C3DA" unitRef="number">0.0008</mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent>
	<mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent contextRef="FD2017Q4YTD" decimals="4" id="Fact-773FF167DAAD6B7BEBC043CC9870B0C2" unitRef="number">0.0009</mbrx:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent>
	<mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6506A2BF519BDA5401404E1FF95BFE5E" unitRef="usd">0</mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCosts>
	<mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-113EF662A27323BE65FC4E1FF95444D6" unitRef="usd">395000</mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCosts>
	<mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent contextRef="FD2016Q4YTD" decimals="4" id="Fact-26BAB90476BB8D6125F24E1FF9448EF7" unitRef="number">0.0000</mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent>
	<mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent contextRef="FD2017Q4YTD" decimals="4" id="Fact-E59F965848023C83AC7F4E1FF95272A4" unitRef="number">0.0403</mbrx:EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent>
	<mbrx:EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees contextRef="FD2017Q4YTD" decimals="INF" id="Fact-53A518241D4E8400493F451974956A6C" unitRef="employee">4</mbrx:EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees>
	<mbrx:EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B11F9CFF8C253D01BDA54512BE6CB4E5" unitRef="usd">1000000</mbrx:EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-005B9ADADD4C4045032D2A4BD24C9286" unitRef="usd">1238000</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-58CB475F577F49532E022A4BD50D1EDD" unitRef="usd">0</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-799F7D7A593E7FFA350C2A4BD7520036" unitRef="usd">1238000</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-66488DDD0A62690D40032A4BBADE91A5" unitRef="usd">1846000</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-9D1FD00A2BA70C88288B2A4BBE431B36" unitRef="usd">-1846000</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
	<mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-84DDB3689CBB3E777EA62A4BC135B004" unitRef="usd">0</mbrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent>
	<mbrx:GainFromSettlementLiability contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8C495003464B085B5D9E5557739EFB4D" unitRef="usd">0</mbrx:GainFromSettlementLiability>
	<mbrx:GainFromSettlementLiability contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DD1416D4DE39F66DBA941B334C25232C" unitRef="usd">149000</mbrx:GainFromSettlementLiability>
	<mbrx:GainLossFromExpirationOfWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-53F92A0BE93E0DEA4B32555773970E7E" unitRef="usd">0</mbrx:GainLossFromExpirationOfWarrants>
	<mbrx:GainLossFromExpirationOfWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C74AA70BA8DEEEA084C61B334C241B92" unitRef="usd">1238000</mbrx:GainLossFromExpirationOfWarrants>
	<mbrx:GainLossOnNoncashSettlementOfLiability contextRef="D2017Q1_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember" decimals="-4" id="Fact-4D7CD3BF4A5EB1834C8E3EADC3E87C5F" unitRef="usd">150000</mbrx:GainLossOnNoncashSettlementOfLiability>
	<mbrx:LesseeOperatingLeaseAreaOfOfficeSpace contextRef="I2018Q1Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-BDE1D6626835A906E01048FE9DC804DC" unitRef="sqft">2333</mbrx:LesseeOperatingLeaseAreaOfOfficeSpace>
	<mbrx:LicenseAgreementDocumentationFee contextRef="D2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember" decimals="-3" id="Fact-64FA23584C3BEBF523463FEAB834CF6B" unitRef="usd">40000</mbrx:LicenseAgreementDocumentationFee>
	<mbrx:LicenseAgreementMaintenanceFee contextRef="D2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember" decimals="-3" id="Fact-422F52F2BDF3202DC7473FE79F84DD9E" unitRef="usd">25000</mbrx:LicenseAgreementMaintenanceFee>
	<mbrx:LicenseAgreementMaintenanceFee contextRef="D2018Q1Feb01-Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-086DAC57A71A53B4A1563FC1832011E0" unitRef="usd">10000</mbrx:LicenseAgreementMaintenanceFee>
	<mbrx:LicenseAgreementMaintenanceFeeAnnualIncrease contextRef="D2018Q1Feb01-Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-E7484BC9904430C35E403FBE40407A12" unitRef="usd">5000</mbrx:LicenseAgreementMaintenanceFeeAnnualIncrease>
	<mbrx:LicenseAgreementMaintenanceFeeMaximumPayablePerYear contextRef="D2018Q1Feb01-Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-24F7DB1D13C5E0EC3F953FBFFC8490A9" unitRef="usd">50000</mbrx:LicenseAgreementMaintenanceFeeMaximumPayablePerYear>
	<mbrx:LicensingAgreementTerm contextRef="D2016Q2May2-May2" id="Fact-2F6D987D4F278A9BB7D83FBA98E0A962">P3Y</mbrx:LicensingAgreementTerm>
	<mbrx:LicensingAgreementTerm contextRef="D2016Q2May2-May2_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember" id="Fact-709107C859E42E0D0657555773A0D425">P3Y</mbrx:LicensingAgreementTerm>
	<mbrx:LicensingArrangementsConsiderationPayable contextRef="FI2017Q4_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember" decimals="INF" id="Fact-784E2861F3007844FD4D5557739D1A6C" unitRef="usd">750000</mbrx:LicensingArrangementsConsiderationPayable>
	<mbrx:LicensingArrangementsConsiderationPayable contextRef="I2016Q2May02_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember" decimals="INF" id="Fact-8CFC6186C6A54465FCE35557739F5343" unitRef="usd">750000</mbrx:LicensingArrangementsConsiderationPayable>
	<mbrx:LicensingArrangementsReserve contextRef="FI2017Q4_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember" decimals="-5" id="Fact-49E68AE8403A04FF04EC555773A033FB" unitRef="usd">1000000</mbrx:LicensingArrangementsReserve>
	<mbrx:MilestonePaymentsLiabilities contextRef="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" decimals="-3" id="Fact-008B8D1A84E89E59775E3FB17746008B" unitRef="usd">150000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" decimals="-3" id="Fact-91586D9F5456C039EABC3FB177A011EA" unitRef="usd">600000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="FI2017Q4_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" decimals="-3" id="Fact-0FD321811833C80A62393FB178212BB4" unitRef="usd">500000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" decimals="-3" id="Fact-54A0468889EDC45097632A677F6252AB" unitRef="usd">200000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" decimals="-3" id="Fact-395DBC298E83CB165C122A67B60016DC" unitRef="usd">250000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_FilingOfNewDrugApplicationForLicensedProductMember" decimals="-3" id="Fact-17927F63B89987C2A2752A67EFF5851B" unitRef="usd">400000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" decimals="-3" id="Fact-C3F270292BA440D5C08B2A6812129F78" unitRef="usd">500000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" decimals="-3" id="Fact-C8AA572B78241045E0323FE5BB2025FF" unitRef="usd">125000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember" decimals="-3" id="Fact-BED9603B8FA50188FADD3FE5BAF786D4" unitRef="usd">225000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:MilestonePaymentsLiabilities contextRef="I2017Q2Jun29-Jun29_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" decimals="-3" id="Fact-BC53933B4B47DB3828D33FE5BB03318B" unitRef="usd">175000</mbrx:MilestonePaymentsLiabilities>
	<mbrx:NumberOfDrugTechnologies contextRef="FD2017Q4YTD" decimals="INF" id="Fact-305667F60A394DE3C16D4A2D82A2B2F6" unitRef="technology">3</mbrx:NumberOfDrugTechnologies>
	<mbrx:NumberOfOtherDrugDevelopmentProjects contextRef="FD2017Q4YTD" decimals="INF" id="Fact-6A779580CF1EF9908EE34A2E2ECD47FE" unitRef="project">2</mbrx:NumberOfOtherDrugDevelopmentProjects>
	<mbrx:NumberOfUnitsIssued contextRef="D2017Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-63465ACD47790651B1E23EAF41CEA881" unitRef="shares">3710000</mbrx:NumberOfUnitsIssued>
	<mbrx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent contextRef="D2018Q1Mar22-Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-0000DE7F85F8A3F8A27848F73269AC9F" unitRef="number">0.03</mbrx:OperatingLeaseRentExpenseAnnualIncreaseInRentPercent>
	<mbrx:OperatingLeasesMonthlyRentExpense contextRef="D2018Q1Mar22-Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-82340C845403CE16A91D48F5CACB09E7" unitRef="usd">4300</mbrx:OperatingLeasesMonthlyRentExpense>
	<mbrx:PaymentsForResearchAndDevelopmentAgreement contextRef="D2017Q1SD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-517D3738F837B67CD8F449146F0ABF50" unitRef="usd">302500</mbrx:PaymentsForResearchAndDevelopmentAgreement>
	<mbrx:PaymentsForResearchAndDevelopmentAgreement contextRef="D2017Q4Dec04-Dec04_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-A0F8CBAF035A949D0A21491619557C2E" unitRef="usd">346687</mbrx:PaymentsForResearchAndDevelopmentAgreement>
	<mbrx:PaymentsForResearchAndDevelopmentAgreement contextRef="FD2018Q1QTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-028D5568EB8258C6743F49162DE95D01" unitRef="usd">236687</mbrx:PaymentsForResearchAndDevelopmentAgreement>
	<mbrx:PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths contextRef="D2017Q4Dec04-Dec04_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="-3" id="Fact-2F19C7D307E8C1EB8DFA49164AFCB425" unitRef="usd">110000</mbrx:PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths>
	<mbrx:PaymentsForRoyaltiesMinimumPerYear contextRef="D2018Q1Feb01-Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-F96DB18E0A53459D374244FA78B99703" unitRef="usd">200000</mbrx:PaymentsForRoyaltiesMinimumPerYear>
	<mbrx:ResearchAndDevelopmentMilestonePaymentsDue contextRef="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-087DCCA2CA629432C2853FD8AA90D440" unitRef="usd">150000</mbrx:ResearchAndDevelopmentMilestonePaymentsDue>
	<mbrx:ResearchAndDevelopmentMilestonePaymentsDue contextRef="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-9B176B63327DB126E1FA3FD8AA8C8CC4" unitRef="usd">600000</mbrx:ResearchAndDevelopmentMilestonePaymentsDue>
	<mbrx:ResearchAndDevelopmentMilestonePaymentsDue contextRef="I2018Q1Feb28_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mbrx_SubmissionOfANewDrugApplicationMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-7863AD3FE448AC2902943FD8AA8D79B8" unitRef="usd">500000</mbrx:ResearchAndDevelopmentMilestonePaymentsDue>
	<mbrx:RoyaltyOnNetRevenuesPercentage contextRef="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="3" id="Fact-8919ABCB9CA7265103BA5557739F44A3" unitRef="number">0.025</mbrx:RoyaltyOnNetRevenuesPercentage>
	<mbrx:RoyaltyOnNetRevenuesPercentage contextRef="I2018Q1Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-0CA0F0DF87272C2C03F044F479B6864A" unitRef="number">0.05</mbrx:RoyaltyOnNetRevenuesPercentage>
	<mbrx:RoyaltyOnNetRevenuesPercentage contextRef="I2018Q1Feb28_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-5165698144A5E213B63244F3D2D3A90E" unitRef="number">0.03</mbrx:RoyaltyOnNetRevenuesPercentage>
	<mbrx:SaleOfStockCashAndWarrantCompensationTailFeePeriod contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-26BFBE94E80E576D53A062C357D792A9">P6M</mbrx:SaleOfStockCashAndWarrantCompensationTailFeePeriod>
	<mbrx:SaleOfStockFeesPaidPercentageOfGrossProceeds contextRef="D2017Q3Sep15-Sep15_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="INF" id="Fact-F99CD6BCA06B5F4C3E813EBE65983523" unitRef="number">0.03</mbrx:SaleOfStockFeesPaidPercentageOfGrossProceeds>
	<mbrx:SaleOfStockFeesPaidPercentageOfGrossProceeds contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_PlacementAgencyAgreementMember" decimals="INF" id="Fact-1CBF7A6FA98EEE2DAD7848E89A8FF2E7" unitRef="number">0.065</mbrx:SaleOfStockFeesPaidPercentageOfGrossProceeds>
	<mbrx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice contextRef="I2017Q3Sep15_us-gaap_CounterpartyNameAxis_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="-5" id="Fact-4D87C8EC5114620D6EFE3EB99477E7BE" unitRef="usd">13000000</mbrx:SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice>
	<mbrx:SaleOfStockReimbursementOfExpenses contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_PlacementAgencyAgreementMember" decimals="-3" id="Fact-FE823F9EAE388F787B2048ED302CFC94" unitRef="usd">75000</mbrx:SaleOfStockReimbursementOfExpenses>
	<mbrx:SaleOfStockRightOfFirstRefusalPeriod contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-4C7C30F6B88AD9634F2348D8AD779107">P9M</mbrx:SaleOfStockRightOfFirstRefusalPeriod>
	<mbrx:SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_PlacementAgencyAgreementMember" decimals="INF" id="Fact-3F80609DC866D0E608E748EB0BE13251" unitRef="number">0.03</mbrx:SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions>
	<mbrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-811F8010BAB94A200454254B3BBA1F6C">P0Y</mbrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms>
	<mbrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EED01CD227D5C9C908F74485D279FCA2" unitRef="usd">1400000</mbrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember" decimals="INF" id="Fact-CAC1C4423BD8017201D84380D004D20E" unitRef="shares">596300</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember" decimals="INF" id="Fact-41257285B35B32B6C858438FF970DC06" unitRef="shares">298150</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember" decimals="INF" id="Fact-63BCDD2DBF34E418EE72437FBFC6A075" unitRef="shares">1833984</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-21F909728FD45591123B4E288A1574E1" unitRef="shares">2728434</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-79EBDB53B790AD0E8545258AF27F9C29" unitRef="usdPerShare">1.50</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-C3A6ABEA368BFDF0CB13258AEDE58034" unitRef="usdPerShare">1.35</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-047163A1D51483D6F6424E288A0C7F5C" unitRef="shares">5087717</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-F1869A2D04B9A2F147055348DBE713E6">P0Y</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-690A4F20C3926C3593004E288A267CD1" unitRef="shares">419772</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-9F846E6BBD9B6FC2A7DC4AE87F7E7333">P4Y4M17D</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms>
	<mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue contextRef="FI2017Q4" decimals="2" id="Fact-AC22545C79C9C5415B7555577395F0DF" unitRef="usdPerShare">0.13</mbrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
	<mbrx:SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-B5EA1539E5837306FAAF4E288A173FDB" unitRef="usdPerShare">1.46</mbrx:SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-E05C47576111906E69C94E288A05BA78" unitRef="usdPerShare">1.46</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-6239679EFBFD8D3E4760254B3963E975">P0Y</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-8D9557179ECAADF653FE4E288A0DADCE" unitRef="usdPerShare">1.40</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-C972AD06B881D446C0194E288A2E11C2" unitRef="usdPerShare">1.43</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-F8907F22C579788DD5E44E288A276074" unitRef="usdPerShare">0.00</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice>
	<mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-DF9082F4A873064262904E2889FD6520" unitRef="usdPerShare">1.46</mbrx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice>
	<mbrx:SharesAuthorized contextRef="I2016Q2May02" decimals="INF" id="Fact-4E19FDE341B3D8845C2855577396AFDF" unitRef="shares">80000000</mbrx:SharesAuthorized>
	<mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="D2017Q1Feb2017" decimals="INF" id="Fact-2D5434FEB082E7CB799D24B8D1B968F0" unitRef="shares">3710000</mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts>
	<mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EB0D3CD1021FC2C6849F555773A18F67" unitRef="shares">1540026</mbrx:StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts>
	<mbrx:StockIssuedDuringPeriodSharesForTechnology contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-ED3657D53D0EE554DD2E555773A1292A" unitRef="shares">629000</mbrx:StockIssuedDuringPeriodSharesForTechnology>
	<mbrx:StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4910AD4D374AAB54E194555773A087C8" unitRef="shares">776016</mbrx:StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering>
	<mbrx:StockIssuedDuringPeriodSharesPrivateIssuances contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F5D1AB9FDEA385EDA3E2555773A035D7" unitRef="shares">234297</mbrx:StockIssuedDuringPeriodSharesPrivateIssuances>
	<mbrx:StockIssuedDuringPeriodSharesSaleOfUnits contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D450527D05B23FC188A1555773A1894F" unitRef="shares">3710000</mbrx:StockIssuedDuringPeriodSharesSaleOfUnits>
	<mbrx:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-25C4E4AA2822DE44BB8A555773A1BF50" unitRef="shares">2728434</mbrx:StockIssuedDuringPeriodSharesWarrantsExercised>
	<mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7AFDCDD235A953F1C9EF555773A70269" unitRef="usd">8089000</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>
	<mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F42909CF339F29219E01555773A0019A" unitRef="usd">8088000</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>
	<mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7B62C61939C1235154BE555773A794B7" unitRef="usd">1000</mbrx:StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts>
	<mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8CFF5CDFED75933219C655577395EB5B" unitRef="usd">3774000</mbrx:StockIssuedDuringPeriodValueForTechnology>
	<mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F0F9CFF85FECB64ADFAC5557739E2F02" unitRef="usd">3773000</mbrx:StockIssuedDuringPeriodValueForTechnology>
	<mbrx:StockIssuedDuringPeriodValueForTechnology contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C750A87306BCDEA5839E555773A6C277" unitRef="usd">1000</mbrx:StockIssuedDuringPeriodValueForTechnology>
	<mbrx:StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1024B08D36886C9A1F20555773A03625" unitRef="usd">1645000</mbrx:StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering>
	<mbrx:StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-639DDF841AA35610926C555773A7D206" unitRef="usd">1645000</mbrx:StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering>
	<mbrx:StockIssuedDuringPeriodValuePrivateIssuances contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A91129BAD17F433793AC555773A0B32F" unitRef="usd">703000</mbrx:StockIssuedDuringPeriodValuePrivateIssuances>
	<mbrx:StockIssuedDuringPeriodValuePrivateIssuances contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7061A0FEF839F0D47FEB555773955F8F" unitRef="usd">703000</mbrx:StockIssuedDuringPeriodValuePrivateIssuances>
	<mbrx:StockIssuedDuringPeriodValueSaleOfUnits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-17091F2985BBEB63724A5557738FA756" unitRef="usd">317000</mbrx:StockIssuedDuringPeriodValueSaleOfUnits>
	<mbrx:StockIssuedDuringPeriodValueSaleOfUnits contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3ABF25F95EE2AA092EDF555773A163E8" unitRef="usd">313000</mbrx:StockIssuedDuringPeriodValueSaleOfUnits>
	<mbrx:StockIssuedDuringPeriodValueSaleOfUnits contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-680CF4F63B9B4055C92F5557738FD806" unitRef="usd">4000</mbrx:StockIssuedDuringPeriodValueSaleOfUnits>
	<mbrx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1AB1F0B0E8F929DAD6055557739FFEC2" unitRef="usd">8903000</mbrx:StockIssuedDuringPeriodValueWarrantsExercised>
	<mbrx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D702C2B2391FF1DE9BDF555773A1438E" unitRef="usd">8900000</mbrx:StockIssuedDuringPeriodValueWarrantsExercised>
	<mbrx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F4030FD2A8AAB61A780B555773965397" unitRef="usd">3000</mbrx:StockIssuedDuringPeriodValueWarrantsExercised>
	<mbrx:StockholdersEquitySubscriptionsSettledForCash contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D02D82731F9E55BAC8755557739F0C6F" unitRef="usd">3000</mbrx:StockholdersEquitySubscriptionsSettledForCash>
	<mbrx:StockholdersEquitySubscriptionsSettledForCash contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember" decimals="-3" id="Fact-E5D162E63D4A165B0D744F1D41DB5CE2" unitRef="usd">3000</mbrx:StockholdersEquitySubscriptionsSettledForCash>
	<mbrx:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit contextRef="FD2017Q4QTD" decimals="INF" id="Fact-9210CDA756536F7635E162ED483738DB" unitRef="usd">0</mbrx:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit>
	<mbrx:WarrantsIssuedForServices contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5E7172CFE251312DC00E555773A176BE" unitRef="usd">375000</mbrx:WarrantsIssuedForServices>
	<mbrx:WarrantsIssuedForServices contextRef="FD2017Q4YTD" decimals="-3" id="Fact-91BBC56F7CE9581092F0555773A7AD48" unitRef="usd">104000</mbrx:WarrantsIssuedForServices>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2016Q4_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember" decimals="-4" id="Fact-784BF34CF943FA7BBB0F3EAE80FEEA25" unitRef="usd">240000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-52F3E1A7092DE567FDF55557739FF0F5" unitRef="usd">399000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-30EF095C0CEA8347DE345557739E57D0" unitRef="usd">810000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-58EF84238409D2212C5B1B342182A6BB" unitRef="usd">650000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-36000A0A2483642D89571B342176C1C3" unitRef="usd">902000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-FE51C669A8021C3C188225FBB12B434A" unitRef="usd">66000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BF172CD1435F3E0EA8FC25FBB128E6FF" unitRef="usd">50000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E1CDEE5F68CDF40C3EF325F28444CB5B" unitRef="usd">84000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
	<us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-199EC1B4240D338AA42425F2843F6888" unitRef="usd">250000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-702252AEFAF63AFA93C7555773A01028" unitRef="usd">6000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-68A8F23D75B6CBA29535555773A071A5" unitRef="usd">21000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-24BED4ACDAF19CB9439C555773A7B307" unitRef="usd">19623000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-0929E32FB44C01BFB014555773A15C10" unitRef="usd">31577000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EF73A6BDF62624BD0F605557739E85E6" unitRef="usd">166000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-69A8B09979D5E8CA3B0E555773A19BCE" unitRef="usd">166000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0A1DDA42D13098500696555773A16404" unitRef="usd">707000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FA3EAA9C844743A9B8F75557738F43E1" unitRef="usd">707000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-44E2EF3E9681C89B86BF4402C7199260" unitRef="usd">1150000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD" decimals="-3" id="Fact-41180E1CB58A3EE9B0F4555773A14D81" unitRef="usd">375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AD34C1FFEB30DE5D7EEB55577396EAF1" unitRef="usd">375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AE325B559D70D4B6F8BC3F7A3A7124FD" unitRef="usd">324000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-FC09DAFF00E2264ACF973F7A3A5F012F" unitRef="usd">321000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-2B8A18D97B96A142497A3F7A3A8AB5FC" unitRef="usd">3000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3A1BF42052276E6481C43F79DCD4F48E" unitRef="usd">707000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-F886D37CFD49FC9462793F79DCF37AED" unitRef="usd">684000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3618574BE9C0620F6B4E3F79DCC2D98E" unitRef="usd">23000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q4YTD_mbrx_PeriodTypeAxis_mbrx_AcquisitionDateOneMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="0" id="Fact-3906A15360BDE8275172555773A0BD1C" unitRef="usd">145078</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="0" id="Fact-F9F371E4E0FD02942B2D533D52F29100" unitRef="shares">107802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-042918F1C807A7938D42533EEDCB4B2D" unitRef="shares">1821013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-D25466974D614C37AE63533DAA77986B" unitRef="shares">510000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="0" id="Fact-AD1BDCF7B3CC3B42804E2648E30B480E" unitRef="shares">677576</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-CD6306AD862FA6A537D2264920E8EE69" unitRef="shares">1345000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-490E637E7241D9B9FFDE1B34216C40FB" unitRef="usd">16393000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-27FAA737A4275E495A861B34216611F6" unitRef="usd">19483000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C0256FB30A5CF3C235041B3421740BDF" unitRef="usd">5222000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-177582E1E4FFA38224CE1B342171146E" unitRef="usd">8302000</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-25672BB0647DE9536CC9555773A60EE4" unitRef="usd">5999586</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="D2016Q2May2-May2_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-53EE9A03F17ABCC0188C55577398B034" unitRef="shares">999931</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A0AEBAC17847CF32A4D35557739E8597" unitRef="usd">-3963000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="D2016Q2May2-May2" decimals="-4" id="Fact-6299D19F45E998EDF0AA3FB7DF9752FE" unitRef="usd">750000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-A6B6EE591E6696F83C41555773A7C7ED" unitRef="usd">11156000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-8B5ED81A88F4FF633E09555773A726A9" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-3A12DAE2BA989BD7B373555773A6584B" unitRef="usd">1224000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-DB02D86951E06CF234F2555773A77DCE" unitRef="usd">11148000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="FI2017Q4_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="-3" id="Fact-A0872099C5E8A8D41EE5555773A652ED" unitRef="usd">3874000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="I2016Q2May02" decimals="-5" id="Fact-F613F453385C3F2932763FB962A3EE60" unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="I2016Q3Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="INF" id="Fact-32120FD29F220F8A0BE2555773A0D151" unitRef="usd">3874000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-E8621BC51F7B4F08B78C555773A6DF3A" unitRef="usd">8000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="-3" id="Fact-28D4DBEE620802F74D63555773A7ED65" unitRef="usd">6057000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-70FE7DBBC0FB3E8E5B5C55577395D529" unitRef="usd">28000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-280FD4D22B2AD439532555577395BA73" unitRef="usd">5007000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-AAE087DCB7A66D645D20555773973B01" unitRef="usd">7714000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BF7E21A2C7FF1C730D6255577395090C" unitRef="usd">4979000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-098C37A8DFE68B06F76D5557739E6E8D" unitRef="usd">2707000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashFDICInsuredAmount contextRef="FI2017Q4" decimals="INF" id="Fact-21A19D48468058455FD65557739F1546" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2May31" decimals="INF" id="Fact-A0AE67E98CA1FA1EC213555773967DC4" unitRef="usdPerShare">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesAndSeriesCWarrantMember" decimals="INF" id="Fact-644AA9BBE3A3DEE568B924BAF8B64AE7" unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember" decimals="INF" id="Fact-630AE0239EAEA93A36E224BB183D3B6B" unitRef="usdPerShare">1.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q1Feb09_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember" decimals="INF" id="Fact-08A8E6BC3D6BBCE6293524BC82A1E642" unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantOneMember" decimals="INF" id="Fact-6729A3D646889458644C3F5548E0AE8C" unitRef="usdPerShare">2.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantTwoMember" decimals="INF" id="Fact-5A666171F5C19A29E0FF3F55DF074996" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q1Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-8FBD89E38EA09D09B1DA1B47C205ABFD" unitRef="usdPerShare">2.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9233BC891FBFE3F02E2B24BA628AB9FA" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E4687D0309A4385F358D24BAC43EB4D2" unitRef="shares">0.50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FA77BECBF8F8378EFBDC24B9B9446D17" unitRef="shares">0.50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2017Q1Feb09_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BCE045B75EE4AD0B769A24B9661DC7F7" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q2May31" decimals="INF" id="Fact-26FC8A9C809ECF1BD3F85557739E412F" unitRef="shares">107802</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember" decimals="INF" id="Fact-409E8B34F6C7259D753B24BBFE2BCB9F" unitRef="shares">556500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember" decimals="INF" id="Fact-00FE5284E9DC99B0903E24BC2422CF6D" unitRef="shares">278250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q1Feb09_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesWarrantMember" decimals="INF" id="Fact-978EDBA03D6D458147AE24BBB4502E34" unitRef="shares">278250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantOneMember" decimals="INF" id="Fact-64260C16639852E1DCBA3F52275780D3" unitRef="shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q3Jul29_us-gaap_ClassOfWarrantOrRightAxis_mbrx_GSKConsultingAgreementWarrantTwoMember" decimals="INF" id="Fact-53A2FEF44880AAE413323F54341D955F" unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-F2987A782F88BDB25F701B880146F3C5" unitRef="shares">2145000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-94E106E0EB2D3870C78255577398335A" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-906936A64A09A9A6948B55577395F4DB" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-D9DCA1E164387D558AC5555773A1489A" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-5F5C20553D5B8582ECC8555773A169FC" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-B05AC1DD11144917E7C0555773A757FD" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-B41A55BB1A9C2FEE1765555773A1E56A" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2016Q2May02" decimals="INF" id="Fact-CBB12515ACF0A0FE3BF55557739E6D35" unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-0790989E4713AB55C8AE555773A05E85" unitRef="shares">12164852</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-76665D1DF4209DEDBDA75557739F377F" unitRef="shares">21469109</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-2DD0F144F4E0A94BBFCF555773A189EE" unitRef="shares">12164852</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-D30F86AA14897A0F3996555773A17A20" unitRef="shares">21469109</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-9430E129614F14FC2206555773A0F4B6" unitRef="usd">12000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-8B3898C9E0047B927775555773A709DA" unitRef="usd">21000</us-gaap:CommonStockValue>
	<us-gaap:ContractualObligationDueAfterFifthYear contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-358F557BCF1E9460B51B2A66A0A43A41" unitRef="usd">100000</us-gaap:ContractualObligationDueAfterFifthYear>
	<us-gaap:ContractualObligationDueInFifthYear contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-8323D1DA3B63357457292A6676D896D3" unitRef="usd">80000</us-gaap:ContractualObligationDueInFifthYear>
	<us-gaap:ContractualObligationDueInFourthYear contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-96CB954DB2A6EA43B3622A664CFDA2F4" unitRef="usd">60000</us-gaap:ContractualObligationDueInFourthYear>
	<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-8527EA7A2EB394AA95E32A659EC742E4" unitRef="usd">10000</us-gaap:ContractualObligationDueInNextTwelveMonths>
	<us-gaap:ContractualObligationDueInSecondYear contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-6CDE6077635823C870732A65D2636E16" unitRef="usd">20000</us-gaap:ContractualObligationDueInSecondYear>
	<us-gaap:ContractualObligationDueInThirdYear contextRef="I2012Q2Apr30_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember_us-gaap_OtherCommitmentsAxis_mbrx_ServicingFeePayableMember" decimals="-3" id="Fact-B9BC0CABF6D1DD674E0B2A661935902D" unitRef="usd">40000</us-gaap:ContractualObligationDueInThirdYear>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AF11CC0433AADADABFD75557739719FC" unitRef="usd">296000</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember" decimals="0" id="Fact-C006302703075D756A1B555773A1D492" unitRef="usd">38299</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember" decimals="0" id="Fact-FA8F3F4F493AD69DCA465557738F39D1" unitRef="usd">82500</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember" decimals="0" id="Fact-6E36E4551F6ED73057815557739F49C7" unitRef="usd">30280</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember" decimals="0" id="Fact-5BB88CD14048DA5FC3E455577395AE1F" unitRef="usd">125000</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-3D83F63EFD8477347750555773956143" unitRef="usd">276079</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-98D8D7AAD40CD3452B405557739F4079" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember" decimals="0" id="Fact-CF6C57DCE25B7DEA0DB85557738FA1BA" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember" decimals="0" id="Fact-487AF5EAF880DD39936A555773A03C80" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember" decimals="0" id="Fact-20765827EC16D3C67C845557739566DB" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember" decimals="0" id="Fact-D4EE4A3306C3FC8372FB55577396338A" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:ConvertibleNotesPayableCurrent contextRef="FI2017Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-84BD53BCABAD9B5AF1FB5557739FD701" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-971C259F17AC181E7D54555773984BD1" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-36D6E8B2408B0F22545A5557739FEE85" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EC8C50FF9AD5B842BDFB55577398D45A" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DA1CFA4055A1BDC077F25557739EAEC2" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5113B82DDFC04D581D7855577398719D" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8747DB3B991ECBB1A7135557739864DC" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C9A480EAFBC5DF1F77DA5557739EF7C5" unitRef="usd">364000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-88ABAE1ADA86F0204175555773A0BE1F" unitRef="usd">302000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2016Q2" decimals="INF" id="Fact-C401DEC0892EE03BB152555773A0E181" unitRef="shares">1166503</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2016Q4Jun01-Dec31" decimals="INF" id="Fact-786D2191AF178EF1162F555773A12CF3" unitRef="shares">910095</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="D2016Q2" decimals="0" id="Fact-7B0DAF028EB2D1661CAF5557739E0244" unitRef="usd">183356</us-gaap:DebtConversionOriginalDebtAmount1>
	<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="FD2016Q4YTD" decimals="0" id="Fact-59A6243ECA609E50F3AA5557739F0EB6" unitRef="usd">155565</us-gaap:DebtConversionOriginalDebtAmount1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateAugust312015Member_us-gaap_RelatedPartyTransactionAxis_us-gaap_InvestorMember" decimals="4" id="Fact-CC7FE2AD5414BCA5165155577395DA04" unitRef="usdPerShare">0.1299</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateJanuary192016Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorGMember" decimals="2" id="Fact-0805614F115B853F0F155557739F28B5" unitRef="usdPerShare">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateOctober062015OneMember_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorCMember" decimals="2" id="Fact-7A4FFD94562646ACFDF3555773A125A6" unitRef="usdPerShare">0.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_IssueDateSeptember032015Member_us-gaap_RelatedPartyTransactionAxis_mbrx_InvestorBMember" decimals="4" id="Fact-5B733035C7EB22C9A53A555773966E90" unitRef="usdPerShare">0.1299</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_mbrx_UnsecuredPromissoryNotesMember" decimals="INF" id="Fact-4F498D5B31F852320B0C555773A78A73" unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A593B970F1647128D49355577398D9B2" unitRef="usd">87000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
	<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-11484FAF60DD45E21460555773984511" unitRef="usd">62000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AFD43B3F5CE06F67512E555773A0FC72" unitRef="usd">88000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-468B73B6641F0C314A49555773A1165A" unitRef="usd">150000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-69C02EFF314E8A9BE77D5557739895F6" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-804117C270E0CB7511315557739E6691" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D3AF827EB18E0CCF691B5557739E706C" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2B7B1D3EA82C1E56EFCD55577397E968" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-22B914E23422FD3F881C55577397DFDF" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F04E753AC94081866C1F55577395F644" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-116D0CF320D94D20BC615557739E4DA5" unitRef="usd">1401000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-221DC1B50281055F3C445557739EA34D" unitRef="usd">2565000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2016Q4" decimals="-3" id="Fact-8F755D9922E09DD1F1095557739FCA7E" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-CF0C40E00F4BC8CFF9815557739E5F68" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-BF72A0BD637DA379CE1B5557739F76D6" unitRef="usd">4000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-FC499ABECED8E88CCECE5557739D4862" unitRef="usd">4000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2016Q4" decimals="-3" id="Fact-07B93614C7ED6D0C1E765557739E1ED8" unitRef="usd">520000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2017Q4" decimals="-3" id="Fact-2FC1C0BA8148AE10F5735557739E5548" unitRef="usd">1275000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2016Q4" decimals="-3" id="Fact-96D818ABAA4BCF13D1645557739E131E" unitRef="usd">50000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2017Q4" decimals="-3" id="Fact-70E672259CB7737D6F925557739F02E6" unitRef="usd">9000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-3" id="Fact-12538C690D71782E981B5557739EDA17" unitRef="usd">96000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-C9776D92125D1B0D84035557739E24A5" unitRef="usd">176000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-F2E739678622928FB5AA5557739F3FD2" unitRef="usd">155000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-4" id="Fact-73F0FF5F6E52D9B34E45555773969922" unitRef="usd">1400000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-E38AC7929192F518782F555773950270" unitRef="usd">1397000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-4" id="Fact-C7E5D67F3EFE1B367D6855577396FB82" unitRef="usd">2560000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-24CBDB532B496E0BD93F5557739544DE" unitRef="usd">2561000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-C65B45043EBFEE77EDE85557739E1C65" unitRef="usd">4000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-72C1DEFA36028A39ACEC5557739E99A1" unitRef="usd">4000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-7BCDAF12ADEF8C51095C5557739DA4E7" unitRef="usd">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-895F9E4C682AB4AF452B555773A093B6" unitRef="usd">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4EA85E30FE11F36620F955577395367C" unitRef="usd">6000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F0ECF911B8D30F156EF855577395E15C" unitRef="usd">18000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CE7D8F1C4F29025DEC4D1A791BF4AB34" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4F06BCE106D9A03B52691A791C073ABE" unitRef="usd">503000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-749CABCCB6EEF257FAEB5557739521A8" unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-A77F54E2A12B6E8DA4B5555773985DA7" unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="4" id="Fact-A9105A715E72B3161D0243CC98E2AD12" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="4" id="Fact-959102FEE502220BC17E43CC98E41B0E" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-4089947F6320C0490D7543CC98352B39" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-91EEC9B6615C8F3B8A4E43CC986F73C0" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="4" id="Fact-B45A9A6FCAF4C9653DFD43CC98B93647" unitRef="number">0.3162</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="4" id="Fact-AB2858590C4EC7800F6E43CC9879E172" unitRef="number">0.1187</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="4" id="Fact-1CB2A1BD3B801C46F7D24E1FF95757D6" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="4" id="Fact-F49DA97316267975826B43D7B9839685" unitRef="number">0.1593</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="4" id="Fact-3AE8EBE8E93D1F04BA424E1FF95918EA" unitRef="number">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="4" id="Fact-185643DC4B6197B1779443D0AC291121" unitRef="number">0.0011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="4" id="Fact-BDA6AF55AACDD7AA731843CC98C07A71" unitRef="number">-0.0348</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="4" id="Fact-700F422D3C4E14FEF5F843CC98A9BFF7" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD" id="Fact-14C9DA97374B3D3A25ED3F8BB6E156EB">P8Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2017Q4" decimals="-5" id="Fact-CBCF201295730901F35A3F8AF7F44084" unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2017Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="4" id="Fact-71FC8E1CB31EEE3828CD555773A0CE87" unitRef="number">0.0499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2016Q2May31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="4" id="Fact-335FD1282DEFDDEF30A6555773A7502A" unitRef="number">0.0499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="D2017Q2May2017" decimals="-4" id="Fact-C49F8A07BC5CD537B5E9438358904EF2" unitRef="usd">1240000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-01EB1CA163EF61E00A3E55577395F0B5" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-63E1186677AA01117CDA1B334C2748DE" unitRef="usd">2548000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-44FA06633CD48638B9033F6E89842544" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-A788390EC1109CAC66314E2ADE945724" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-2533C3CE7A1302FDDDEE3F6E2F43550C" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-386B69947C662121BB9C2F56BE371EE2" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q2_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" id="Fact-6479EB1D1A170C60BE03555773A04BD5">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-AB842C364F7D0A2C4BE84B0DF5A339A5">P6Y3M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-91D48F6C144BFBF469FE4E3A0A0F7E6B">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-94A8B840A1C54637A42C4B0D71F97E5B">P6Y3M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-BAB0F22AB7A3228D9294254D00A4CF19">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-632F2A715BCABF99206F4B0D0CAB2C2F">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-B92C13B21B696CE29E50254CFD94D2CD">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q2_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="4" id="Fact-EEDBEC12107CC1DDB0F8555773960693" unitRef="number">0.8061</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-BE29158C19771ED390963F6BDE662BDB" unitRef="number">0.7044</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-EF4BD115EE16057ABC523F6B7FAAFFF5" unitRef="number">0.7018</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-D998192D9A48546242154E2A02DE5EB3" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD" decimals="2" id="Fact-AFFFAB64C8982D8BE7963F6A97B0ECE1" unitRef="number">0.80</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-ED20BF10D14DB4C2D4FD254CFB14539C" unitRef="number">1.6011</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-D9C5AEF1065AED5C1556254CF8A70B06" unitRef="number">0.8000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-C2D5ABDD32E5195A2EAB3F68F4548F9D" unitRef="number">0.013</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-20B06FB405BECEFF43444E2995085D89" unitRef="number">0.0000</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-734433A8F68A6CC65C323F68E87387FE" unitRef="number">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-C8B5B8C398AB325F2412254CF5A170A8" unitRef="number">0.0186</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-7CF7E7298E89B4772F093F65C2D12836" unitRef="number">0.0183</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-43BB43E4240EA6E839A8254CF164B23E" unitRef="number">0.0168</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2016Q2_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="4" id="Fact-C2DFD6119C86E8836C045557739F8F3F" unitRef="number">0.0139</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-DBC6479E53E603F5D5982A4BCAB7FD83" unitRef="usd">5201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-41EDC340CF774266EA2B2A4BCD5B7087" unitRef="usd">-251000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-1F2F4AFE949FD46F12D52A4BD0349482" unitRef="usd">4950000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-C8226154570B07D718B42A4BB2C36F3D" unitRef="usd">2453000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-BBE6C2ABC091395A51702A4BB57E92A6" unitRef="usd">1690000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-54AD58E95F222C8EF2892A4BB86BF3F3" unitRef="usd">4143000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-EE017D4F2DF8BD8840BD2A4BC34502EB" unitRef="usd">2643000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-3671D332C017232B108B2A4BC61241B9" unitRef="usd">-95000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-BE7A27C48C4E561468AA2A4BC9005F2A" unitRef="usd">2548000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-59BC06DC29DC011C1C4E2A4BAB83AAE1" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-09FA2B66A66B1A8D80BF2A4BAE51AAA4" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-01505899374C8176A9A42A4BB0996A7A" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityCurrentMember" decimals="-3" id="Fact-722C1642F4637AB52FAC2A4BD9A710C1" unitRef="usd">503000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabilityLongtermMember" decimals="-3" id="Fact-FCF136D93CDFA31A455C2A4BDC04EB68" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_mbrx_WarrantLiabiltyMember" decimals="-3" id="Fact-6AEDD5AEEFDFD8832DC62A4BDEFA199A" unitRef="usd">503000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="-3" id="Fact-B0D955701C60D672E92F555773A19D76" unitRef="usd">11148000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="-3" id="Fact-794E312E503C99AAFA31555773A69915" unitRef="usd">11148000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-507B4753E242D9AAD763555773960873" unitRef="usd">2381000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E9D0C26477AFB24704AB555773A16CAC" unitRef="usd">4090000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-66CA8967FB571885099F43CC9880075F" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CDE2CF98BA1EE698A8B243CC98D69A7D" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C5C82DD9A8702B2F2FE343CC98CF28CA" unitRef="usd">1242000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-161EE4F0E6F04385F7EC43CC98A240DB" unitRef="usd">1164000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-71F8A236F63A58725C1E43D773EC5219" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="-4" id="Fact-1AE29DB8EDAF414B5CE2632C867DFFB2" unitRef="usd">1560000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F8447084543AB305B03643D773FCB8C3" unitRef="usd">1562000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-23A45A50F0DA91AD1CC143CC989B254A" unitRef="usd">-1335000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-869B9ACFBA84088EDB8843CC98F9C7C1" unitRef="usd">-3334000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-84958E117B04F382A82B43D03D453205" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-42DAA143121604EF474F43D03D2B9318" unitRef="usd">11000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E3CBF59028E6DEE04F9B43CC98877ED5" unitRef="usd">-137000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="-3" id="Fact-899C5AA509CA91B5AB0943CC9862A1DA" unitRef="usd">117000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4ECA1EA07B150412C3D85557739815E4" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CF7F4F80E06876C7AA6B5557739E353F" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-41187DFBD326F5DDE1E05557739F4684" unitRef="usd">-41000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-00561F808DA67DD80F8A55577395BC1C" unitRef="usd">411000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-604946A583390C6C1D9126419ED0037E" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2687176DD10AE81469C626419ECEDBA7" unitRef="usd">495000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-055440AA5617875E3239555773988D91" unitRef="usd">215000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CBA0DBB5B5A84DB17D88555773A1C1BD" unitRef="usd">364000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2016Q4" decimals="-3" id="Fact-9E209BD396EE3B513149555773A0514C" unitRef="usd">11148000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2017Q4" decimals="-3" id="Fact-9F66FED86BCDBE729BF6555773988CB9" unitRef="usd">11148000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0C5FB8264427CE10472555577396DC11" unitRef="usd">43000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-164DF41BF9AA584A14B955577395D04D" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6C4EF810FB284F7197995557738F4D4D" unitRef="usd">5000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6C46E84D293183AA96BF5557739758CD" unitRef="usd">3000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4" decimals="0" id="Fact-49FF6DA74A01166AF627555773A79E03" unitRef="usd">7172</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-ACA3CB7D3940A103ED81555773A67FFE" unitRef="usd">20333</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="I2016Q2May31" decimals="0" id="Fact-BC6F4576B9FC480C44B1555773A16278" unitRef="usd">17699</us-gaap:InterestPayableCurrent>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_TheWarrantsMember" decimals="-3" id="Fact-F13499F53A8F622A24093F59606773A0" unitRef="usd">104000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="D2018Q1Mar22-Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-1291FB6CBAFC8B6829F948F4C97FDFE6">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="D2018Q1Mar22-Mar22_us-gaap_CounterpartyNameAxis_mbrx_IPXMemorialDriveInvestorsLLCMember_us-gaap_LeaseArrangementTypeAxis_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-DA3D0015F1544D01E74348F386BB5E47">P66M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-45A58203720238B3B86E1A77B14321BA" unitRef="usd">1433000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-FCF50ED4AB2FBB0D6C831A77B145E052" unitRef="usd">2365000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-76EA099C2CBE79FBA6AF1B342168D0AE" unitRef="usd">16393000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-7166917FF369ED5B343A1B34216A88A5" unitRef="usd">19483000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CC25D3B154C321ED2DD51A77B13CA13A" unitRef="usd">1345000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-17F24E494D92FF80D8C91A77B1470A81" unitRef="usd">2215000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2017Q4" decimals="-3" id="Fact-791A7E9B0C39648CC0C52A55F585EF58" unitRef="usd">503000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-5C5330684665CC6CE13C2A55F699AF6A" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-2A65CDC0A193FBF54CBF2A55F818E125" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-22E3C0F0485BE5C0FFCA2A55F9859F76" unitRef="usd">503000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LicenseCosts contextRef="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-CD3457E36237BEA1251344D0842E29BC" unitRef="usd">0</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="-3" id="Fact-5C03D928621259B4BB7A451D89C2D6C9" unitRef="usd">75000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2016Q4YTD_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-90E968A9B707E9AACD2D3FD71968F0F6" unitRef="usd">77500</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="-3" id="Fact-32AC0F25E942A9F4D5F63FD2EC7991F7" unitRef="usd">75000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_AnnamedAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-E9542889E415F9C2AE073FED60DB0CB1" unitRef="usd">52500</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_IntertechBioAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="-3" id="Fact-C6C1985F20FC2657085E451D5532A274" unitRef="usd">95000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2017Q4YTD_mbrx_AgreementAxis_mbrx_MoleculinAgreementMember_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="-3" id="Fact-FABFED9C18F45AE9C05B3FD68F938C1F" unitRef="usd">85000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="-3" id="Fact-2059E553913142F39BCF3FD2B7411F33" unitRef="usd">225000</us-gaap:LicenseCosts>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-070F51116333FDED58525557739812FA" unitRef="usd">8865000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F814C2909CDC448EE4E255577396F778" unitRef="usd">10059000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-89D55545CF5EA103CF2C555773A16C9D" unitRef="usd">-121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-46B55EF7AE0B307F1924555773A79ECF" unitRef="usd">-28000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D7AC88C470A7869A4984555773A6F846" unitRef="usd">-3765000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BECFEC196532E9E0B3E9555773A0C5F9" unitRef="usd">-7324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C1337BABD9CE7823635B5557739E781F" unitRef="usd">-3926000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-69CD838CD820760F5DF0555773A779D0" unitRef="usd">-3926000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0025DBC3A26702E2BE9C555773A166DF" unitRef="usd">-9805000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7FEFA4A717617B729FCA5557739526C2" unitRef="usd">-9805000</us-gaap:NetIncomeLoss>
	<us-gaap:NotesReceivableRelatedParties contextRef="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="0" id="Fact-9C062028B14BBA2403B85557739FA15D" unitRef="usd">57822</us-gaap:NotesReceivableRelatedParties>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2017Q4YTD" decimals="INF" id="Fact-E7A874482FB528628F5D555773A02279" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DEDB38D39DA1F76DDBA8555773A14D0C" unitRef="usd">3883000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AAC3788F9808A0C29674555773953208" unitRef="usd">8653000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EFFCEB75094EB252E68F555773958CD4" unitRef="usd">-3883000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-581C34657D67DDEA53CB555773A039B2" unitRef="usd">-8653000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4" decimals="-4" id="Fact-ABDC87DE7E606F62A783555773978019" unitRef="usd">6070000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-4" id="Fact-750F52B9867C9A0EA54A5557739FBB17" unitRef="usd">5810000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3A62B9229CB177D9B02925F9154F1A4C" unitRef="usd">14000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2137079B2883C59394CE25F902AA241A" unitRef="usd">22000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherIncome contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F9A6445A9DF8272307EA555773A03D60" unitRef="usd">0</us-gaap:OtherIncome>
	<us-gaap:OtherIncome contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2CA68F15898901EE6E0F1B334C2283A0" unitRef="usd">9000</us-gaap:OtherIncome>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-601DC332857747B113012B4B74F7DA3A" unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-880D2428A3F6CAAEC6542B4B74FC288A" unitRef="usd">9000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2016Q4YTD" decimals="-3" id="Fact-130129DDC4AF11B452AD5557739692FE" unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EA2BD35A0D77F8B92F1F555773A0718C" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q4YTD_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember" decimals="-3" id="Fact-C864731F31070722D95B67ADE17C43E7" unitRef="usd">300000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q4YTD_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_OutlincenseAgreementMember" decimals="-6" id="Fact-00D0294F021FBFAAA4E4555773A0AEC4" unitRef="usd">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A8B57C5D04C38320F9B5555773A18126" unitRef="usd">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2805571B9409C604E0A755577395AD70" unitRef="usd">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-D984121865E2FC77C696555773A0398F" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-272D89EDFB673B7A2D9F5557739523C4" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-32C8492EEA5E4A7ACCA15557739F9DA8" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-1B6E837A4ADB8B9AB72F555773A71D1A" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2016Q2May02" decimals="INF" id="Fact-8F0497482E262875FF125557739FC871" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-894238E318F01BFB49365557739F448C" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-BFCB7ADEB9C590D14831555773A19003" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-5B8988D4621A55E40C95555773A7D21F" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-547E406DEB366AB388F4555773A73215" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-BF8B45D7B7A381D4E250555773952418" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-4C5DF0E429A2EBE79EA9555773974CDA" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4406C5C89247AFF6808E555773A7C814" unitRef="usd">215000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FBC2DDA6E34A425244C2555773A033C2" unitRef="usd">588000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2016Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="0" id="Fact-27DA9131A63547A9A3D6555773985DCA" unitRef="usd">8464183</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2017Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-DA5E22B2D6652DF172A83EB10B5A32F1" unitRef="usd">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2017Q1Feb2017_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember" decimals="-5" id="Fact-BA68913EEB4A135AF28C24BCDBD4866C" unitRef="usd">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D127BBD167029FAB2D815557738F17CE" unitRef="usd">9170000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3173028181A6F15665E95557739766B1" unitRef="usd">6071000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="-5" id="Fact-220FD68F58B621F79D143EC150C93535" unitRef="usd">1600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-9552FD5E132AB528766A1B89AA4693D3" unitRef="usd">9000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AE103A7E8FC674ACA22C55577396FB37" unitRef="usd">165000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F244C53A420B0F4C97B65557739680D4" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2016Q4YTD" decimals="-3" id="Fact-27D619DE0E9F7B9191395557739F217E" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2017Q4YTD" decimals="-3" id="Fact-206C2D5DBD182F494A595557739E1DC0" unitRef="usd">3988000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-3ED7CA6493104006BAD65557739FB083" unitRef="usd">23000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-017F0F5E1099A726779455577398363E" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" id="Fact-EE3DE8EDC36E4D063C6D555773A78353">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-F6DCFDD1B32D674C82A8555773A68A87">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-67B6C767CFC02C1B51465557739EB5B6">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-67E7C074A114C54B9E59555773A11B0E">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CA3BECE5083BA81E2FE455577396FF5C" unitRef="usd">470000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D8539FDCDF71B9C2DAF1555773A7B6D7" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-85BF07F6BFBDF23AA8E155577395B76A" unitRef="usd">1496000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="-3" id="Fact-234E0214E1A5C09B326549166F07C47F" unitRef="usd">33000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9D82ABD3DB48618D7C255557739657E8" unitRef="usd">4545000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mbrx_MdAndersonMember" decimals="0" id="Fact-366C2B3BD550AB221837491662F42824" unitRef="usd">291687</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-A5ADBFAA844D076D83F755577396D39F" unitRef="usd">-4675000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-C888124EC7E4E96DA191555773A040F8" unitRef="usd">-14480000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-5" id="Fact-940B9DE951CD0753CAC34F340EC753EC" unitRef="usd">-14500000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q1Feb16-Feb16_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-4" id="Fact-C22AE4DE24EB47702F691B747515AC83" unitRef="usd">8270000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Feb16-Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_SecuritiesPurchaseAgreementMember" decimals="INF" id="Fact-36A612A711AF24882A111B790A1D78C1" unitRef="shares">4290000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="INF" id="Fact-586C2E466085824C80E1443ACFBC66F4" unitRef="shares">776016</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q1Feb16_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_SecuritiesPurchaseAgreementMember" decimals="INF" id="Fact-9D317B06024F77338C971B729EC08139" unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A8ABBE46280144CE75635557739510F8" unitRef="usd">0</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-60FBEE74AF6032DE2AFC55577395DC39" unitRef="usd">0</us-gaap:SalesRevenueNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9B24E27084F3FDC6504155577397A838" unitRef="usd">324000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1BBB4844B5DEDA8500EB55577397C449" unitRef="usd">707000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2018Q1Jan11-Jan11_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_mbrx_ScienceAdvisoryBoardMemberMember" id="Fact-90E2A8BC170F8B88ADE41ACAE2F04E06">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2017Q1Feb2014_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-0135C102CF1614A3CD2424BD49D5B83D" unitRef="shares">8235923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-CF7EB7C59175F99E389E4E288A24C2BA" unitRef="shares">8235923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-0459EAC32D0C4EC8A443258A7857CF86" unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-630DDA467A89F66D87D0258A73AB3887" unitRef="usdPerShare">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-EBA6CC86F5806CA88C244E288A1462C7" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-B4F2C0C00006FEA313C14E288A1E079A" unitRef="shares">419772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-47A20546089AD94928DF254B342E17FA">P0Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-C8E11B7A522FAF7DAB4A4AE813B861D0">P4Y4M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="D2016Q2_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-22E804269969133F363D555773972130" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="D2017Q2May2017_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesBWarrantMember" decimals="INF" id="Fact-83A2A7075BA4581485664386AD4CB3AD" unitRef="shares">5087717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2016Q2Apr22_us-gaap_AwardTypeAxis_mbrx_StockPlanMember" decimals="INF" id="Fact-45846AA8F7FEA96508A55557739FA7BC" unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q4" decimals="INF" id="Fact-B03FC0B824127C4A43C655577395B880" unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-5D2099D9580EAB17EE1D555773969DF9" unitRef="usdPerShare">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="0" id="Fact-D75AF6C6161B12F381965557739F8F45" unitRef="usd">83000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="D2016Q4Oct1-Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ChiefFinancialOfficerMember" decimals="INF" id="Fact-1A3BB4F91D72CCAD54C3448C1515FEB0" unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-370BADE43C1EEDE0EC985557739F03C5" unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-67010D98E957C8383EE92F5E769276A3" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q1Feb2017_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember" decimals="INF" id="Fact-9360BB602075B79B26AF24BB724B58C2" unitRef="shares">556500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q1Jan11-Jan11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_mbrx_ScienceAdvisoryBoardMemberMember" decimals="INF" id="Fact-418EB35B10D2ECB0300E4FABAC3B8294" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD" decimals="INF" id="Fact-27D7C2B57EBABC8468A85557739F36C4" unitRef="shares">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q4YTD" decimals="INF" id="Fact-A31E610A799A797A5AD02F5E769CEE42" unitRef="shares">835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-51CE904873CCC19461465557738F1D6F" unitRef="usdPerShare">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-28DA0BC0AE5F2BDA19343EC69818EC37" unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="0" id="Fact-0FCF5FD38262B42F5C7A555773969A52" unitRef="usd">275500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="0" id="Fact-FD3BF21814AD345A8CE03EC6F92AEB9A" unitRef="usd">83000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-43277F995D4C618F52635557739E1800" unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-D109344A51355E2D17B31AB2B2D73083" unitRef="shares">510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-DA1353B51028C3E28BE42F5E769D30CE" unitRef="shares">1345000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-0520E28C2258676201AB5557739F1887" unitRef="usdPerShare">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-6B961C59F2C422151DEA5557739DE70C" unitRef="usdPerShare">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-3C2D7DF4D419480F20C03EC6F63C5DE7" unitRef="usdPerShare">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-5627469889231BACFB1C5557739E32B0" unitRef="usdPerShare">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2018Q1Jan11-Jan11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TitleOfIndividualAxis_mbrx_ScienceAdvisoryBoardMemberMember" decimals="2" id="Fact-41FE2C1E423F79520C911AC9D82B8C1A" unitRef="usdPerShare">1.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-9A9E3DF39475E6DF99745557739E2543" unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-4AC46D6743A015C5267F3EC699C51B96" unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2016Q2May02_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember" decimals="2" id="Fact-5A72B17F5E85F268F5BA555773A02301" unitRef="usdPerShare">6.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q3Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="INF" id="Fact-8BC60F81B6A5213E83FD5557739FC2B8" unitRef="usdPerShare">6.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2017Q1Feb09_us-gaap_StatementClassOfStockAxis_mbrx_UnderwritingAgreementMember" decimals="INF" id="Fact-7EA8C84F9C741500589724BC5C51C6CB" unitRef="usdPerShare">1.349</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="D2016Q4Oct1-Oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TitleOfIndividualAxis_us-gaap_ChiefFinancialOfficerMember" decimals="INF" id="Fact-C1A616E5ABE6EE4DABE3448EE2535DFB" unitRef="shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD" id="Fact-35FBD9D8D4C2FE6B51DF55577396FBF0">P2Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-188C7AE17A9D55F66D0E5557739E7645" unitRef="usdPerShare">0.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4" decimals="2" id="Fact-C541F28FCC316FEB17485557739EE1DC" unitRef="usdPerShare">0.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4" decimals="2" id="Fact-6B8D4656580BE1310F0B55577395C098" unitRef="usdPerShare">3.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4" decimals="2" id="Fact-DB2CABF2D30645B716E63EC6F4980F2D" unitRef="usdPerShare">1.93</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-A44FAA0308D9FFC0B4FF55577396F666">P9Y3M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-2C24E0F136E3EE9FC9FA3EC6F7FA39A8">P9Y26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q4YTD" decimals="-5" id="Fact-929E07647D019E6F71203F8DB5DD1F19" unitRef="usd">1800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q4YTD" decimals="-5" id="Fact-CFF1AAED9DDF3F6BAF783F8DB6EF2CB3" unitRef="usd">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharesIssuedPricePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-1BAA16741372137926A7440299A80365" unitRef="usdPerShare">3.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-998BA608E94728D472B04403A935CF22" unitRef="usdPerShare">1.35</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="FI2017Q4_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="INF" id="Fact-7CA571E828C95E85031B3EC54CA66C1E" unitRef="usdPerShare">2.71</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="FI2017Q4_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mbrx_AtMarketIssuanceSalesAgreementMember" decimals="INF" id="Fact-36AD4DC18DB4BFAB49293EC4FE9B584C" unitRef="usdPerShare">2.05</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q2May02_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember" decimals="INF" id="Fact-68CD7B5B683B9AC027C45557739E7DE2" unitRef="usdPerShare">6</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q2May31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-4B59C20E3CF5A99498C0555773967BD1" unitRef="usdPerShare">6.00</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2017Q1Feb09_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-C51223BFE78BDE20D5A324B932BF665A" unitRef="usdPerShare">1.50</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2017Q1Feb09_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-81D9033BD88D3CBC4ED924B8FD4EEEFC" unitRef="usdPerShare">1.35</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2017Q1Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-14E7745BC8C001F093BE3EB3797C4FE8" unitRef="usdPerShare">1.35</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-23B0774ADC082F18186D555773A02E4E" unitRef="shares">6661000</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-433A6075202937F046FA5557739584BB" unitRef="shares">12164852</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3D149D0F4E5E3EE8E46F555773A034E3" unitRef="shares">21469109</us-gaap:SharesOutstanding>
	<us-gaap:StockIssued1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D096168ED3B9489CAE845557738FBA02" unitRef="usd">9774000</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-601A8698B6253FF7432255577395D2A8" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D42FC459E9F2A6DCE184555773940194" unitRef="shares">999931</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4865FC9F814F11598717555773A7DA36" unitRef="shares">2076598</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8C52F97EDBCE949C7AAB555773A013BF" unitRef="shares">2010640</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2017Q1Jan01-Jan31_us-gaap_RelatedPartyTransactionAxis_mbrx_FormerScienceAdvisoryBoardMember" decimals="INF" id="Fact-EE0BC46050632E6B1B513EA7DC8D5B94" unitRef="shares">79167</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FCA95BFBD64982A9C67B555773954348" unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-206F7C2F631EA9AD2EEB5557739423CA" unitRef="shares">79167</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q2Jan1-May2" decimals="INF" id="Fact-7D459B634846C7594E3255577398B61E" unitRef="shares">234297</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q2May2-May2_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember_us-gaap_BusinessAcquisitionAxis_mbrx_MoleculinLlcMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mbrx_LicenseAgreementMember" decimals="INF" id="Fact-4BF3A5479DABC821704E5557739E84E3" unitRef="shares">629000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-B80BBAE14A66BC4618B3555773988DCF" unitRef="shares">1540026</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q3Jul1-Jul31_dei_LegalEntityAxis_mbrx_HoustonPharmaceuticalsIncMember" decimals="INF" id="Fact-1ABC6B4DF5330C00B5C3555773A0367A" unitRef="shares">629000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q3Jun20-Jun20_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbrx_PcgAdvisoryGroupMember" decimals="INF" id="Fact-D9E02849F1E3885EBD7B555773A02D05" unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_mbrx_SeriesCWarrantMember" decimals="INF" id="Fact-8D562EFC216D6CB0CEDA438C6C411937" unitRef="shares">298150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-80AA2678D5622435BD054A2B1EC5EE65" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD" decimals="INF" id="Fact-D2DF1753D4A4F3CCC6053F8FE83CAC12" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5C19F9DC3525CC6CA909555773A03380" unitRef="usd">5999000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-518862DCF83543DF310155577396D5AE" unitRef="usd">5998000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D21B1EC25145A636DF02555773961B4B" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-799C9AE54770689C186E555773A10188" unitRef="usd">364000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DE8B98591CD01F2E1C9D555773A66DD4" unitRef="usd">362000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-978C266977D262AA0155555773A73546" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3886C97AE5BC5A1EB0AC55577395A7B2" unitRef="usd">302000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-89272FF8B9C6E2381151555773A6613E" unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5F786A7704FA173823F455577396050C" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F07F10B4791F073AD3F65557739F4E72" unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-06DBBA320FB6F2E187B8555773950498" unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A9F3D4679B546BCCD5D7555773968EA1" unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6562724CD4FC5485F7FE5557739F2855" unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2016Q2Jan1-May2" decimals="INF" id="Fact-39D7A0B41A40A0A9903C5557739FF081" unitRef="usd">702894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2016Q3Jun20-Jun20_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbrx_PcgAdvisoryGroupMember" decimals="INF" id="Fact-0B3990FEB604321559325557739F64E5" unitRef="usd">157680</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-02B54EF6D47EE7E243085557738F605B" unitRef="usd">-745000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember" decimals="-3" id="Fact-FA1C4C1D2F7B02B3F6E3555773959907" unitRef="usd">-3000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F51D93EBC57B63321A5C555773A72AEF" unitRef="usd">-749000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-444ABB6034C731EE7D595557738F4665" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-23809AE395F82A6480005557739EF328" unitRef="usd">7000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-BAFC18B8AA4782A42FB81B34216FC7B2" unitRef="usd">14960000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember" decimals="-3" id="Fact-A01552263286E2A39CA0555773A60C92" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C679C68981373DC5C642555773A7499C" unitRef="usd">-4675000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E820863D9D65B7A282CF555773A1195C" unitRef="usd">19623000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-16A2FAF43D3F2D2F3840555773A76C43" unitRef="usd">12000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-C36D322C86A7EDEF391E1B34217392BA" unitRef="usd">17118000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_mbrx_SubscriptionsReceivableMember" decimals="-3" id="Fact-77560D4EF30A0466FF6C5557738F1C06" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-BAB72E2C72169E6D374D555773A79229" unitRef="usd">-14480000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4178169E090AF6B1E823555773A736EB" unitRef="usd">31577000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C226487D41EC7598CEB15557739E84AC" unitRef="usd">21000</us-gaap:StockholdersEquity>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_mbrx_FederalStateandForeignJurisdictionsMember" decimals="INF" id="Fact-A8E24DC22AFC8546A609555773A0604B" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2016Q4" decimals="INF" id="Fact-C00498194DD2193852D34A25C756B898" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2017Q4" decimals="INF" id="Fact-2667F029000E8F22A55E4A247842036F" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6A78BF77DDDEF03A3FDE555773964E3F" unitRef="usd">1242000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B3D9825C3E4BDB5FEEF055577397A2C4" unitRef="usd">1164000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="I2016Q2May31_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" decimals="0" id="Fact-9A1D62558E3BC532B6EB555773A03537" unitRef="usd">374763</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-D6D0BC83EF24BE7CEB2255577398FC45" unitRef="shares">9827510</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-9D2095F4C958E92B980955577397CB59" unitRef="shares">18569193</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<mbrx:ComponentsofShareBasedCompensationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-8A03F43D3BD3F8B13E7544368ECCDE96">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense for the years ended December 31, 2017 and 2016, are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:ComponentsofShareBasedCompensationTableTextBlock>
	<mbrx:ConvertibleNotesPayableDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-2C1882B8B085F16C9FC5555773A06102">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Convertible Notes Payable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On various dates from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;August&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;19, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, each as amended on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;10, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unsecured promissory notes with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; separate third-party investors. Each note bore interest at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum and was to mature on the earlier of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or the completion of an IPO of the Company&amp;#8217;s securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Since the completion of the IPO occurred prior to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, these notes were to be automatically converted according to their terms into shares of the Company&amp;#8217;s common stock at applicable conversion price upon the Company&amp;#8217;s IPO to the extent and provided that no holder of these notes was permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our common stock after such conversion. Due to this &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; limitation, a portion of these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes remained outstanding and were converted into shares of our common stock at such time as the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; limitation was met. Until such time as the notes were converted into shares of common stock, the maturity date of the notes was automatically extended, and we were not required to repay the notes or the accrued interest relating to the notes in cash.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The IPO was completed on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, pursuant to the conversion feature of the foregoing notes and with restriction of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; beneficially owned condition limitation, discussed above, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,166,503&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares in total, reducing the convertible debt principal by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$183,356&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and accrued interest by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17,699&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Subsequent to these transactions and through December&amp;#160;31, 2016, an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;910,095&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; beneficially owned condition limitation. This reduced the convertible debt principal by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$155,565&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and accrued interest by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,172&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist. On June 22, 2017, pursuant to the conversion feature of the foregoing notes and with restriction of the beneficially owned condition limitation discussed above, the Company issued common shares which effectively converted all remaining outstanding convertible debt and accrued interest outstanding as of that date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below represents the shares that are convertible at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Amounts and shares in whole values)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016 (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares Convertible at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;August 31, 2015(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.1299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;294,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 3, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.1299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;962,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 6, 2015(a)(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 19, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,821,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Debt partially converted on May&amp;#160;31, 2016 and on August&amp;#160;19, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b) Debt partially converted on September&amp;#160;1, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c) Excluded from the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$276,079&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The common shares relating to the above mentioned convertible notes payable contained the following trading restrictions: (a) beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days after the initial closing of our IPO and until the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the daily volume; (b) if the common stock price is over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days then the holder of the note can sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the daily volume; (c) if the common stock price is over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days then the holder of the note can sell up to an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the daily volume; and (d) if the common stock price is over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share; and (b) thereafter, until the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the daily volume; provided that if the common stock price is over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:ConvertibleNotesPayableDisclosureTextBlock>
	<mbrx:DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-21D7E5FDB41F664CEBAE5557739E7B79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock>
	<mbrx:GoingConcernPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-2588340728811267CB6A555773A11A3E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Going Concern -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has incurred an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:GoingConcernPolicyPolicyTextBlock>
	<mbrx:NatureOfBusinessAndLiquidityTextBlock contextRef="FD2017Q4YTD" id="Fact-3BC175D02042C897637F555773A099A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nature of Business and Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The terms &amp;#8220;MBI&amp;#8221; or &amp;#8220;the Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221; and &amp;#8220;us&amp;#8221; are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; drug technologies. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin had been in clinical trials pursuant to an investigative new drug application or IND that had been filed with the U.S. Food and Drug Administration, or FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; other drug development projects, one involving a collection of small molecules, which we refer to as the WP1066 Portfolio, a collection of STAT3 inhibitors, some of which also have immuno-stimulating capability, targeting brain tumors, pancreatic cancer and AML, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (the most common form of brain tumor) and pancreatic cancer in particular. A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, we intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin for the treatment of AML, which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug Application (NDA) in the United States. We may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another Annamycin product for the same use. We also intend to apply for similar status in the European Union (EU) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (MAA). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;With regard to additional potential clinical activity, we submitted in October 2017 a request for Clinical Trial Authorization ("CTA") in Poland which, if allowed, will enable a Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland. This will be in addition to the previously announced allowance of our IND in the United States. In December 2017, the Ethics Committee in Poland approved our Phase I/II clinical trial of Annamycin. In March we received requests for and provided additional information to the Polish National Office.  We expect a response from the Polish National Office in the first half of 2018 and at the earliest mid-April 2018. The start of clinical trials in Poland remains subject to confirmation and approval of the CTA by the Polish National Office. We can provide no assurance that we will receive such confirmation on a timely basis, if at all.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, we continue to recruit and contract clinics both in the United States and Poland. In the US, we have one site - University Hospitals Cleveland Medical Center (&amp;#8220;UHCMC&amp;#8221;) - recruiting patients and active with drug ready to provide treatments.  A patient was enrolled in March 2018 with anticipated treatment to occur in the near term.&amp;#160; We can provide no assurance treatment will occur on a timely basis, if at all.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furthermore, in September 2017 we engaged a contract research organization ("CRO") to prepare for a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the treatment of cutaneous T-cell lymphoma ("CTCL").&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment. As a result, the financial information disclosed herein represents all of the material financial information related to our principal operating segment.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company filed a registration statement on Form S-1 (which was declared effective on May&amp;#160;2, 2016) with respect to the Company&amp;#8217;s initial public offering of shares of its common stock (&amp;#8220;IPO&amp;#8221;) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:NatureOfBusinessAndLiquidityTextBlock>
	<mbrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="FD2017Q4YTD" id="Fact-3F38B80AA0C9FD3E6D3E555773A68979">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of estimated useful lives or the term of the lease&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
	<mbrx:ScheduleOfWarrantActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-7FC02E23401902E5081224B4FF92D9DA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of our Warrant activity and related information follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares Under&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant Price&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&amp;#160; Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual&amp;#160;Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,235,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35-$1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,728,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,087,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Exercisable at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35-$1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:ScheduleOfWarrantActivityTableTextBlock>
	<mbrx:WarrantsLiabilityDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-73BA1763C1B567B32E5124AB94C62361">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February&amp;#160;9, 2017, the Company entered into an Underwriting Agreement (the &amp;#8220;Underwriting Agreement&amp;#8221;) with Roth Capital Partners, LLC, as representative of the several underwriters identified therein (collectively, the &amp;#8220;Underwriters&amp;#8221;), pursuant to which we sold in a registered public offering (the &amp;#8220;Offering&amp;#8221;), &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,710,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units, priced at a public offering price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit (the closing price that day was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), with each unit consisting of: (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock, (ii) a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year Series A warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of a share of common stock, (iii) a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day Series B warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock, and (iv) a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year Series C warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of a share of common stock. The Series C warrants in a unit could only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of common stock. The Series B warrant had an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;556,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and/or an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;556,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrant combination (comprised of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;278,250&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series A warrants, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;556,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series B warrants and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;278,250&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per share of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.349&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and public offering price per warrant combination of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$.001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, less the underwriting discounts and commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$278,100&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrant combinations. We received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The basis of value is fair value, which is defined pursuant to Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 820 to be &amp;#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&amp;#8221;. The Company estimated the fair value of the Warrants under ASC 820 as of February&amp;#160;14, 2017 for financial reporting purposes. We used the Black-Scholes option pricing model (&amp;#8220;BSM&amp;#8221;) to determine the fair value of the Series A and Series B Warrants and a Monte Carlo simulation (&amp;#8220;MCM&amp;#8221;) with regard to the Series C Warrants in consideration of path dependent vesting terms of the contract. Both the BSM and MCM models are acceptable in accordance with GAAP. The BSM requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The MCM simulates the Company&amp;#8217;s common stock price from the valuation date through the Series B Warrant and the unvested Series C Warrant expiration dates using Geometric Browman Motion on a risk-neutral basis - thereby impacting the likelihood that the Series B Warrants would have been exercised and, subsequently, the Series C Warrants would then vest. All Series B and unvested Series C warrants expired on May&amp;#160;15, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the Warrants. Where appropriate, we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2016-2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The assumptions used in the BSM and MCM models for the Warrants are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68%-1.86%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.00%-160.11%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5-5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of our Warrant activity and related information follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares Under&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant Price&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&amp;#160; Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual&amp;#160;Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,235,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35-$1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,728,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,087,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Exercisable at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35-$1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant Activity During 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February&amp;#160;14, 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,235,923&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Warrants were granted, as discussed above. During the year, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,833,984&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series A warrants were exercised, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596,300&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series B warrants were exercised - thereby vesting &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298,150&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series C warrants - and all of the vested &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298,150&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series C warrants were exercised. Of the remaining Series B and C warrants, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,087,717&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; expired on May&amp;#160;15, 2017. Therefore, the associated warranty liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.24 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was extinguished on that date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mbrx:WarrantsLiabilityDisclosureTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2017Q4YTD" id="Fact-2327017F5B268D763FC025A44FF2A5C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses and other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other liabilities consist of the following components (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical testing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued license fees and SRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal and professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued board expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-86F1B5C640F9D73C97DB5557739F6C02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future (amounts in thousands except share data).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro Forma For the Year Ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average outstanding common shares &amp;#8211; basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,401,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2017Q4YTD" id="Fact-C2A5B510F5F2BC887883555773A70876">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Acquisition &amp;#8211;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; We acquired Moleculin, LLC (&amp;#8220;Moleculin&amp;#8221;) on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-06DE671454987F815D8A555773A6B36A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company considers all highly liquid accounts with original maturities of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months or less at the date of acquisition to be cash equivalents.&amp;#160;Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the insured limits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The amount in excess of the applicable insurance coverage at December 31, 2017 was not material. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-EDB9B83BBCE9AA56E78A555773980FE2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Sponsored Research Agreements with MD Anderson&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 9, 2017, we amended our Sponsored Laboratory Study Agreement with MD Anderson whereby we paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$302,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in 2017, and the agreement was extended to October 31, 2018. On December 4, 2017, we extended this Agreement until October 31, 2019 for total payment amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$346,687&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; spread over that period of time. Of this amount, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$236,687&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was paid in the first quarter of 2018. The final payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$110,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is due on July 31, 2018. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$291,687&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, for the year ended December 31, 2017 and 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Annamycin&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of August 2015, we obtained the rights and obligations of Annamed under a June 2012 Patent and Technology Development and License Agreement by and between Annamed and Dermin (the &amp;#8220;Annamed Agreement&amp;#8221;). Therefore, certain intellectual property rights, including rights, if any, covering the potential drug product, Annamycin have been licensed to Dermin and Dermin has been granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany (&amp;#8220;Annamed licensed territories&amp;#8221;). We are obligated to develop and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin will pay a royalty for the sale of any licensed product in the Annamed licensed territories and pay all out-of-pocket expenses incurred by us in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Dermin also agrees to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. The agreement includes a one-time license documentation fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, annual maintenance fees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; until the first sale of drug and has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; (ii) submission of the first NDA within the United States - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$175,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; and (iii) receipt of first marketing approval for sale of a license product in the United States&amp;#160;- &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$225,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The expenses recognized under this agreement were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$52,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2017 or 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;WP1066 Portfolio&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &amp;#8220;Moleculin Agreement&amp;#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, we must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Annual maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. The agreement, as amended, has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; (ii) submission of the first NDA within the United States - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; and (iii) receipt of first marketing approval for sale of a license product in the United States&amp;#160;- &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. License fees expensed related to MD Anderson were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$85,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$77,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for the year ended December 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&amp;#8220;HPI&amp;#8221;), pursuant to which we have granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&amp;#8220;HPI Out-Licensing Agreement&amp;#8221;). Under the HPI Out-Licensing Agreement we must make quarterly payments totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.75 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the first twelve quarters following the effective date of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to HPI within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the effective date of the HPI Out-Licensing Agreement we will regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly payments. In the event that we do not exercise our right to regain our rights to the licensed subject matter within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the effective date of the HPI Out-Licensing Agreement, the license granted to HPI shall convert to an exclusive license upon HPI&amp;#8217;s written notice and we shall be obligated to transfer all existing data relating to licensed subject matter including any development data and any IND to HPI. License fees expensed related to HPI were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$225,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; respectively, for the year ended December 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, we entered into a license agreement covering a new group of molecules recently discovered in connection with research we have been sponsoring at MD Anderson Cancer Center called WP1732, a part of the WP1066 Portfolio. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the effective date of the agreement and increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year up to a maximum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. Under the agreement, we are required to make royalty payments ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Net Sales, depending on the intended use, each quarter upon the commencement of sales, with a minimum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. Additional payments are due upon the commencement of a Phase II study &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, submission of a New Drug Application &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the receipt of marketing approval of a licensed product, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;WP1122 Portfolio&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &amp;#8220;IntertechBio Agreement&amp;#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the first anniversary of the effective date of the agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the second anniversary of the effective date of the agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the third anniversary of the effective date of the agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$60,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the fourth anniversary of the effective date of the agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the fifth anniversary of the effective date of the agreement and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the assignment, we agreed to make a minimum annual royalty payment in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the first anniversary following the first sale of a licensed product, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the second anniversary following the first sale of a licensed product, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the third year following the first sale of a licensed product. License fees expensed related to MD Anderson were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$95,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for the year ended December 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One-time milestone payments are due as follows: 1) Upon commencement of a Phase II study for a licensed product - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2) Upon commencement of a Phase III study for a licensed product - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 3) Upon filing of a New Drug Application (&amp;#8220;NDA&amp;#8221;) for a licensed product - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; and 4) Upon receipt of market approval for sale of a licensed product - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The rights we have obtained pursuant to the assignment of the IntertechBio Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Employment Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has agreements with&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; using the rate of compensation in effect at December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConvertibleDebtTableTextBlock contextRef="FD2017Q4YTD" id="Fact-8DC4984F03ED66EBD5CA555773A6F2C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below represents the shares that are convertible at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Amounts and shares in whole values)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016 (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares Convertible at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;August 31, 2015(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.1299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;294,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 3, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.1299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;962,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 6, 2015(a)(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 19, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,821,013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Debt partially converted on May&amp;#160;31, 2016 and on August&amp;#160;19, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b) Debt partially converted on September&amp;#160;1, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c) Excluded from the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$276,079&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-46EE1A34359B05A83D6B555773A12B8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2017Q4YTD" id="Fact-82B59C1A70ECA66501A7265548E6F097">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December 31, 2017 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Measured at Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets (Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrant liability:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q4YTD" id="Fact-4137EFF7822F2A8482722A30CC0E998F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December&amp;#160;31, 2017 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of period December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuances of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclass of liability from long-term to current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value - net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transfers in and out (exercise of warrants)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expiration of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q4YTD" id="Fact-5A029E6C824195D978D244087D76B8E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value of Financial Instruments - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments consist primarily of account payables,  accrued expenses and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs for the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&amp;#160;liability discussed in Note 6. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-F0F3823DEE01A377E25B555773A065E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;The Acquisition of Moleculin, LLC&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;999,931&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,999,586&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, based on the estimated acquisition-date fair value of our common stock of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, equal to the IPO price announced in our prospectus filed on that date. Prior to the Company&amp;#8217;s acquisition of Moleculin, the Company had loaned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$57,822&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Moleculin which was treated as part of the consideration paid to acquire Moleculin.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As additional consideration payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &amp;#8220;Existing IP Assets&amp;#8221; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;21, 2010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein is limited to&amp;#160;drugs developed only for dermatology indications and does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&amp;#8220;HPI&amp;#8221;), a related party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis, however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range of tumors, Moleculin, LLC&amp;#8217;s focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin, LLC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additionally, the merger agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; agreements with HPI. Under the first agreement, HPI&amp;#8217;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the issuance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;629,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was paid as of December 31, 2017. The Company expenses such costs as incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; obligation discussed above. If we do not exercise the foregoing buy-out right within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, the license granted to HPI shall convert into an exclusive license. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend to set aside and designate cash and cash equivalents in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to make the buy-out payment. If we ultimately decide to exercise the buy-out right from HPI, we will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The agreements with HPI were executed on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&amp;#8217;s ability to complete the IPO by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. They became effective on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The termination of the HPI option was completed on behalf of Moleculin, LLC, which was required to enable the sale of Moleculin, LLC by materializing the value of its most significant asset and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the acquisition on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The HPI option termination price amounted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,874,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;629,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock valued at the IPO price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; paid in cash in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and was included in acquisition-date liabilities assumed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Purchase Price Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability assumed (HPI)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities assumed, including $470 of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired/total consideration transferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or most of the intangible assets are IPR&amp;amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets consisted of the following at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangibles acquired from Moleculin, LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unaudited Pro Forma Results of Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following comparative table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future (amounts in thousands except share data).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pro Forma For the Year Ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average outstanding common shares &amp;#8211; basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,401,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was adjusted on a pro forma basis to exclude &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$145,078&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net interest expense related to the amortization of deferred financing costs and debt discount amortization for Moleculin, LLC&amp;#8217;s convertible notes. The holders of the convertible notes were issued the Company&amp;#8217;s common shares upon the Company&amp;#8217;s acquisition of Moleculin, LLC.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2017Q4YTD" id="Fact-8C0B0F1E7F95B915C2FE5557739F95E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intangible assets -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-EA4216AFB6F1B62B06F55557739F4F5C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes consists of the following components (in thousands):&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current Expense (Benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Expense (Benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes activity related to the Company&amp;#8217;s valuation allowance (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation Allowance at Beginning of Period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income Tax Benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Release of Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation Allowance at End of Period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(amounts in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Percent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Percent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal Tax Benefit at Statutory Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State Tax Benefit Net of Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPO Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock Warrant Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other Permanent Differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in Deferred Tax Rate due to Tax Reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Tax (Expense) / Benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a deferred tax expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.56 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December 31, 2017 that is still fully valued against as of December 31, 2017.  This expense is attributable to the Company being in a net deferred tax asset position at the time of remeasurement.  As the company maintains fully valuation allowance, this amount can be seen on the rate reconciliation as an adjustment to deferred tax asset and corresponding valuation allowance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities consist of the following at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Tax Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Start Up Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal Net Operating Loss Carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State Tax Loss Carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Tax Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Deferred Tax Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has incurred net operating losses since inception. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had total federal operating loss carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.07 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which expire commencing in 2037. The value of these carryforwards depends on the Company&amp;#8217;s ability to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally, the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses and the lack of utilization of the net operating losses during tax years open under statute.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company conducts business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple state jurisdictions. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had state operating losses of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.81 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which expire commencing in 2037. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred tax asset at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.56 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.40 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been established at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The change in the valuation allowance for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research and development tax credits in the future, but has not conducted a study to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrecognized tax benefits from any federal, state or foreign jurisdictions. The only tax years open under statute for the Company are December 31, 2017 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; interest or penalties have been accrued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as the Company has not recorded any uncertain tax positions. The Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although the Company believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is inherently uncertain; therefore, the Company&amp;#8217;s assessments can involve both a series of complex judgments about future events and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its assessments are reasonable, the final determination of tax audit settlements and any related litigation could be materially different from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with U.S. GAAP&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;The Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of limitations prior to&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &amp;#8220;Tax Act&amp;#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance. As a result have recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The deferred tax expense recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act.   Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.  The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-D6F9881A8C9CDA8B1A80555773A78F1D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-D0F9B8BBFDD29E55A5DB555773A1F565">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&amp;#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&amp;#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&amp;#160;31, 2017. See also policy note disclosure mentioned above on Going Concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November&amp;#160;20, 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&amp;#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &amp;#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&amp;#8220;ASU 2016-1&amp;#8221;).&amp;#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&amp;#160;ASU 2016-1 is effective for fiscal years beginning after December&amp;#160;15, 2017, including interim periods within those fiscal years.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&amp;#8220;ASU 2016-2&amp;#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&amp;#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&amp;#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&amp;#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. MBI assumes no forfeiture since it has limited history. ASU 2016-9 is effective for annual periods beginning after December&amp;#160;15, 2016, with early adoption permitted. The adoption of this standard on January&amp;#160;1, 2017, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;eight&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&amp;#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&amp;#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2017Q4YTD" id="Fact-06FF3F285447C2C755753FFF604ACE79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-05AC0E2EEE7F73747488555773A6FBE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and equipment -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of estimated useful lives or the term of the lease&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q4YTD" id="Fact-89690F9EA79F6B41C9D7555773A0776A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Research and Development Costs -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-01F5741CDA082525761A25F1715C7C2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other liabilities consist of the following components (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical testing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued license fees and SRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;260&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal and professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued board expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-FFD141C9504D56B0EEAE24B43C747FB9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The assumptions used in the BSM and MCM models for the Warrants are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68%-1.86%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.00%-160.11%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5-5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the option grants has been estimated, with the following weighted-average assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.95%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.44%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2017Q4YTD" id="Fact-234E859135CB61C5046A555773975C87">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes consists of the following components (in thousands):&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current Expense (Benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Expense (Benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-CFAD297123A111A51CB755577396540A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The principal components of the Company&amp;#8217;s deferred tax assets and liabilities consist of the following at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Tax Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Start Up Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal Net Operating Loss Carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State Tax Loss Carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Tax Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Deferred Tax Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-9892D4704A07F37670B3555773963799">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(amounts in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Percent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Percent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal Tax Benefit at Statutory Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State Tax Benefit Net of Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPO Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock Warrant Costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other Permanent Differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in Deferred Tax Rate due to Tax Reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Tax (Expense) / Benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-EC6064C9F9AF8DEDE55C55577398F7ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets consisted of the following at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangibles acquired from Moleculin, LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-2BC695B95216251AFBCF555773A07D32">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability assumed (HPI)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities assumed, including $470 of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired/total consideration transferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-6E1BEBCB00CB00F4868A55577398673E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of option activities for the years ended December&amp;#160;31, 2016 and 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted - 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled - 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;510,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;275,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted - 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled - 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,345,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q4YTD" id="Fact-37607B05A1BD54D972D0555773A14CDC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-based Compensation -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-C10359535E56C0F07C68555773A0A145">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of Presentation - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying audited financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Use of Estimates in Financial Statement Presentation -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Acquisition &amp;#8211;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; We acquired Moleculin, LLC (&amp;#8220;Moleculin&amp;#8221;) on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Going Concern -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has incurred an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company considers all highly liquid accounts with original maturities of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months or less at the date of acquisition to be cash equivalents.&amp;#160;Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the insured limits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The amount in excess of the applicable insurance coverage at December 31, 2017 was not material. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and equipment -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of estimated useful lives or the term of the lease&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; useful life due to their age and condition and expected remaining life assessed at merger date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intangible assets -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp;amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value of Financial Instruments - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments consist primarily of account payables,  accrued expenses and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs for the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&amp;#160;liability discussed in Note 6. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December 31, 2017 (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Measured at Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets (Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrant liability:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December&amp;#160;31, 2017 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liability &amp;#8211;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of period December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuances of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclass of liability from long-term to current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value - net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transfers in and out (exercise of warrants)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expiration of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;The above table of Level 3 liabilities begins with the initial valuation given the warrant issuances that occurred in the first quarter of 2017 and adjusts the balances for changes that occurred during the year. The ending balance of the Level 3 financial instrument presented above represent our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized "through an" immediate settlement of the instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-based Compensation -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December&amp;#160;31, 2017, the Company&amp;#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,345,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares and warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;677,576&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares. As of December 31, 2016, the Company's potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,821,013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;510,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares and warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,802&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Research and Development Costs -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company&amp;#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 10.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&amp;#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&amp;#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&amp;#160;31, 2017. See also policy note disclosure mentioned above on Going Concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November&amp;#160;20, 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&amp;#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &amp;#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&amp;#8220;ASU 2016-1&amp;#8221;).&amp;#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&amp;#160;ASU 2016-1 is effective for fiscal years beginning after December&amp;#160;15, 2017, including interim periods within those fiscal years.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&amp;#8220;ASU 2016-2&amp;#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&amp;#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&amp;#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&amp;#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&amp;#160;The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. MBI assumes no forfeiture since it has limited history. ASU 2016-9 is effective for annual periods beginning after December&amp;#160;15, 2016, with early adoption permitted. The adoption of this standard on January&amp;#160;1, 2017, did not have a significant impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;eight&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&amp;#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&amp;#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-97CF18017EF5393FD376555773961B5F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;2, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company amended and restated its certificate of incorporation to increase the number of shares authorized to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock are authorized and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock are authorized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are authorized to issue up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; issued preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Settlement of a Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79,167&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to a consultant in full settlement for prior services rendered to the Company. Settlement occurred February 21, 2017 with the issuance of the shares, resulting in a gain on settlement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded in gain in settlement of liability on the Statements of Operations. The obligation of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.24 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had been recorded by the Company in accounts payable and accrued expenses as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Follow-On Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2017, the Company completed a public offering and sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,710,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock. The offering price per unit was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company received net cash proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after deducting underwriting discounts, commissions and direct offering expenses payable by us. See Note 6 above regarding Warrant issuances related to our February 2017 public offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;At Market Issuance Sales Agreement (ATM)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 15, 2017, the Company entered into an At Market Issuance Sales Agreement (the &amp;#8220;Agreement&amp;#8221; or &amp;#8220;ATM&amp;#8221;) with Roth Capital Partners, LLC and National Securities Corporation (collectively, the &amp;#8220;Agents&amp;#8221;). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company's common stock with an aggregate sales price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Any sales of Shares pursuant to the Agreement will be made under the Company's effective shelf registration statement on Form S-3 (File No. 333-219434) which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on September 15, 2017. Under the Agreement, the Company may sell Shares through an Agent by any method that is deemed an at the market offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales of the Shares may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company's Board of Directors or a duly authorized committee thereof. The Company or the Agents, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or sooner if either the Company or the Agents terminate the Agreement pursuant to its terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company agreed to pay a commission to the Agents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds of the sale of the Shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company has also provided the Agents with customary indemnification rights. The Company is not obligated to make any sales of Common Stock under the Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 2017, the Company had sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;776,016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.05&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.71&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share with gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under this Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Initial Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company completed its IPO and sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,540,026&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock. The IPO price per share was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company received net cash proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,464,183&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,802&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock exercisable for a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from date of issuance at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The relative fair value of these warrants was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$374,763&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and is included in stock issuance costs calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.39%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2) expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, (3) expected volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.61%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and (4) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; expected dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the period from January&amp;#160;1, 2016 through May&amp;#160;2, 2016, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;234,297&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$702,894&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June&amp;#160;20, 2016, the Company agreed to issue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to PCG Advisory Group, the Company&amp;#8217;s investor relations firm, for services provided. The fair value of these shares was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$157,680&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the market price on the grant date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;    &amp;#160;&amp;#160;&amp;#160;&amp;#160; GSK Consulting Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 29, 2017, the Company entered into a consulting agreement with GSK Strategies, LLC (&amp;#8220;GSK&amp;#8221;), for its investor relations operations. The consulting agreement covers for a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twelve&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months from the date of July 29, 2017. In exchange for the consulting services, the Company agreed to issue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants (collectively, the &amp;#8220;Warrants&amp;#8221;) to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at exercise prices of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.41&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively, subject to approval by Nasdaq of a listing of additional shares application, which was received in August 2017. Each of the Warrants vests over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period in equal monthly installments starting July 29, 2017, provided that GSK is providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017, and expire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the initial exercise date. The Company recorded stock compensation expense for the non-employee consulting agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$104,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended December 31, 2017 based on the fair value of the warrants vested as of December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Adoption of 2015 Stock Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;On December&amp;#160;5, 2015, the Board of Directors of the Company approved the Company&amp;#8217;s 2015 Stock Plan, which was amended on April&amp;#160;22,&amp;#160;2016. The expiration date of the plan is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;5, 2025&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the total number of underlying shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants under the plan is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards or stock unit awards. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of option activities for the years ended December&amp;#160;31, 2016 and 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted - 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled - 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;510,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;275,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted - 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;835,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled - 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,345,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:73px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the option grants has been estimated, with the following weighted-average assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.95%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70.44%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense for the years ended December 31, 2017 and 2016, are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted during 2017 have an aggregated fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that was calculated using the Black-Scholes option-pricing model. At December 31, 2017, total compensation cost not yet recognized was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the weighted average period over which this amount is expected to be recognized is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.7 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The aggregate fair value of options vesting in the years ended December 31, 2017 and 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options were exercised in 2017 or 2016. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the &amp;#8220;plain vanilla&amp;#8221; method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because we do not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-DBF2BDA21C2DCA1BBC1E555773951847">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company&amp;#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 10.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q4YTD" id="Fact-91E055B3C8D672CC50785557739EBE2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Appointment of Science Advisory Board Member&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January&amp;#160;11, 2018, the Company issued to a Science Advisory Board (&amp;#8220;SAB&amp;#8221;) member &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options with an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.89&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year annual vesting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$9 million Registered Direct Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 16, 2018, the Company entered into a Securities Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with certain institutional investors for the sale by us of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,290,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,145,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. We sold the common shares and warrants for aggregate gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Subject to certain beneficial ownership limitations, the warrants will be initially exercisable on the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month anniversary of the issuance date at an exercise price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.80&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The net proceeds from the transactions was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.27 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after deducting certain fees due to the placement agent and transaction expenses. The net proceeds will be used for planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The common shares were offered and sold by us pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on July 24, 2017 and subsequently declared effective on August 21, 2017 (File No. 333-219434), and the base prospectus contained therein. We filed a prospectus supplement with the SEC on February 16, 2018 in connection with the sale of the common shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The warrants and the shares issuable upon exercise of the warrants were sold without registration under the Securities Act of 1933 in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also entered into a placement agent agreement (the &amp;#8220;Placement Agency Agreement&amp;#8221;) with Roth Capital Partners, LLC (&amp;#8220;Roth&amp;#8221;), pursuant to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the common shares and warrants. We have agreed to pay Roth an aggregate fee equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds received by us from the sale of the securities in the transactions. Pursuant to the Placement Agency Agreement, we also agreed to grant to Roth or its designees warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the aggregate number of shares of common stock sold in the transactions (the &amp;#8220;Roth Warrants&amp;#8221;). The Roth Warrants have substantially the same terms as the warrants, except that the Roth Warrants will expire on February 15, 2023. The Roth Warrants and the shares issuable upon exercise of the Roth Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. We also reimbursed Roth for its expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subject to the consummation of the offering, we agreed to give Roth a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month right of first refusal to act as our lead underwriter or exclusive placement agent for any further capital raising transactions undertaken by the us. With certain exceptions, the we also granted Roth a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month tail fee equal to the cash and warrant compensation in the offering, if any investor with which Roth had substantive discussions with respect to the offering, provides us with further capital during such &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period following termination of our engagement of Roth.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lease Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 22, 2018, we entered into a Lease Agreement (the &amp;#8220;Lease&amp;#8221;) with IPX Memorial Drive Investors, LLC (the &amp;#8220;Landlord&amp;#8221;) for the lease of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; rentable square feet &amp;#8220;RSF&amp;#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which may be renewed for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We are required to remit base monthly rent of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,300&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which will increase at an average approximate rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="FD2017Q4YTD" id="Fact-A5B23747A28AB37719F7555773A0848F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes activity related to the Company&amp;#8217;s valuation allowance (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation Allowance at Beginning of Period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income Tax Benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Release of Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation Allowance at End of Period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,561&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-67EE78D850D08BA10FB1555773A03FCB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Use of Estimates in Financial Statement Presentation -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mbrx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.moleculin.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mbrx="http://www.moleculin.com/20171231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherAccruedLiabilities" roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities">
        <link:definition>2104100 - Disclosure - Accrued Expenses and other accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherAccruedLiabilitiesDetails" roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails">
        <link:definition>2404402 - Disclosure - Accrued Expenses and other accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherAccruedLiabilitiesTables" roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables">
        <link:definition>2304301 - Disclosure - Accrued Expenses and other accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.moleculin.com/role/BalanceSheets">
        <link:definition>1001000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2409401 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable">
        <link:definition>2105100 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableNarrativeDetails" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails">
        <link:definition>2405402 - Disclosure - Convertible Notes Payable  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails">
        <link:definition>2405403 - Disclosure - Convertible Notes Payable  - Schedule of Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableTables" roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables">
        <link:definition>2305301 - Disclosure - Convertible Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.moleculin.com/role/Equity">
        <link:definition>2107100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.moleculin.com/role/EquityNarrativeDetails">
        <link:definition>2407402 - Disclosure - Equity  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleOfAssumptionsDetails" roleURI="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails">
        <link:definition>2407404 - Disclosure - Equity  - Schedule of Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleOfStockBasedCompensationDetails" roleURI="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails">
        <link:definition>2407405 - Disclosure - Equity  - Schedule of Stock based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryOfOptionActivitiesDetails" roleURI="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails">
        <link:definition>2407403 - Disclosure - Equity  - Summary of Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.moleculin.com/role/EquityTables">
        <link:definition>2307301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.moleculin.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2408406 - Disclosure - Income Taxes  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>2408402 - Disclosure - Income Taxes  - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2408405 - Disclosure - Income Taxes  - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2408404 - Disclosure - Income Taxes  - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfValuationAllowanceDetails" roleURI="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails">
        <link:definition>2408403 - Disclosure - Income Taxes  - Summary of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.moleculin.com/role/IncomeTaxesTables">
        <link:definition>2308301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.moleculin.com/role/IntangibleAssets">
        <link:definition>2103100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2403402 - Disclosure - Intangible Assets  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>2403404 - Disclosure - Intangible Assets  - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails">
        <link:definition>2403405 - Disclosure - Intangible Assets  - Schedule of Pro Forma Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>2403403 - Disclosure - Intangible Assets  - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.moleculin.com/role/IntangibleAssetsTables">
        <link:definition>2303301 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessAndLiquidity" roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity">
        <link:definition>2101100 - Disclosure - Nature of Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessAndLiquidityDetails" roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails">
        <link:definition>2401401 - Disclosure - Nature of Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfCashFlows" roleURI="http://www.moleculin.com/role/StatementsOfCashFlows">
        <link:definition>1003000 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperations" roleURI="http://www.moleculin.com/role/StatementsOfOperations">
        <link:definition>1002000 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfStockholdersEquity" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfStockholdersEquityParenthetical" roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical">
        <link:definition>1004501 - Statement - Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.moleculin.com/role/SubsequentEvents">
        <link:definition>2110100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.moleculin.com/role/SubsequentEventsDetails">
        <link:definition>2410401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies  - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies  - Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiability" roleURI="http://www.moleculin.com/role/WarrantLiability">
        <link:definition>2106100 - Disclosure - Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityNarrativeDetails" roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails">
        <link:definition>2406402 - Disclosure - Warrant Liability  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityScheduleOfAssumptionsDetails" roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails">
        <link:definition>2406403 - Disclosure - Warrant Liability  - Schedule of Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityScheduleOfWarrantActivityDetails" roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails">
        <link:definition>2406404 - Disclosure - Warrant Liability  - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilityTables" roleURI="http://www.moleculin.com/role/WarrantLiabilityTables">
        <link:definition>2306301 - Disclosure - Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mbrx_AccruedBoardExpensesCurrent" name="AccruedBoardExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_AccruedClinicalTestingCurrent" name="AccruedClinicalTestingCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_AccruedLicenseAgreementPayment" name="AccruedLicenseAgreementPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_AccruedLicenseFeesAndSRACurrent" name="AccruedLicenseFeesAndSRACurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mbrx_AcquisitionDateOneMember" name="AcquisitionDateOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering" name="AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits" name="AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts" name="AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_AgreementAxis" name="AgreementAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_AgreementDomain" name="AgreementDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_AnnamedAgreementMember" name="AnnamedAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_AtMarketIssuanceSalesAgreementMember" name="AtMarketIssuanceSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessAcquisitionIndemnificationAgreementTerm" name="BusinessAcquisitionIndemnificationAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessAcquisitionNumberOfAgreements" name="BusinessAcquisitionNumberOfAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessAcquisitionProFormaOperatingExpenses" name="BusinessAcquisitionProFormaOperatingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_ClassOfWarrantOrRightInitialExercisePeriod" name="ClassOfWarrantOrRightInitialExercisePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount" name="ClassOfWarrantOrRightsWarrantExercisedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassofWarrantorRightAgreementPeriod" name="ClassofWarrantorRightAgreementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassofWarrantorRightExpirationPeriod" name="ClassofWarrantorRightExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ClassofWarrantorRightNumberofWarrantsIssued" name="ClassofWarrantorRightNumberofWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_ClassofWarrantorRightVestingPeriod" name="ClassofWarrantorRightVestingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" name="CommencementOfPhaseIiStudyForLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" name="CommencementOfPhaseIiiStudyForLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ComponentsofShareBasedCompensationTableTextBlock" name="ComponentsofShareBasedCompensationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" name="ContractualObligationDueInNextFiscalYearAfterProductApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_ContractualObligationDueInSecondYearAfterProductApproval" name="ContractualObligationDueInSecondYearAfterProductApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_ContractualObligationDueInThirdYearAfterProductApproval" name="ContractualObligationDueInThirdYearAfterProductApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_ConvertibleNotesPayableDisclosureTextBlock" name="ConvertibleNotesPayableDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtConversionTermsDomain" name="DebtConversionTermsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" name="DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentConvertibleNumberOfCommonShares" name="DebtInstrumentConvertibleNumberOfCommonShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered" name="DebtInstrumentNumberOfUnsecuredNotesEntered" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtInstrumentTradingTermFiveMember" name="DebtInstrumentTradingTermFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtInstrumentTradingTermFourMember" name="DebtInstrumentTradingTermFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtInstrumentTradingTermOneMember" name="DebtInstrumentTradingTermOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtInstrumentTradingTermThreeMember" name="DebtInstrumentTradingTermThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtInstrumentTradingTermTwoMember" name="DebtInstrumentTradingTermTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume" name="DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock" name="DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold" name="DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument" name="DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument" name="DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold" name="DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors" name="DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DebtTradingTermsAxis" name="DebtTradingTermsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_DeferredTaxAssetsStartUpCosts" name="DeferredTaxAssetsStartUpCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_DeferredTaxAssetsValuationAllowanceReleases" name="DeferredTaxAssetsValuationAllowanceReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" name="EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" name="EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts" name="EffectiveIncomeTaxRateReconciliationStockWarrantCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent" name="EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees" name="EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" name="EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_FederalStateandForeignJurisdictionsMember" name="FederalStateandForeignJurisdictionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_FilingOfNewDrugApplicationForLicensedProductMember" name="FilingOfNewDrugApplicationForLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_FormerScienceAdvisoryBoardMember" name="FormerScienceAdvisoryBoardMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_GSKConsultingAgreementWarrantOneMember" name="GSKConsultingAgreementWarrantOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_GSKConsultingAgreementWarrantTwoMember" name="GSKConsultingAgreementWarrantTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_GainFromSettlementLiability" name="GainFromSettlementLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_GainLossFromExpirationOfWarrants" name="GainLossFromExpirationOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_GainLossOnNoncashSettlementOfLiability" name="GainLossOnNoncashSettlementOfLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_HoustonPharmaceuticalsIncMember" name="HoustonPharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IPXMemorialDriveInvestorsLLCMember" name="IPXMemorialDriveInvestorsLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IntertechBioAgreementMember" name="IntertechBioAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_InvestorBMember" name="InvestorBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_InvestorCMember" name="InvestorCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_InvestorGMember" name="InvestorGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IssueDateAugust312015Member" name="IssueDateAugust312015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IssueDateJanuary192016Member" name="IssueDateJanuary192016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IssueDateOctober062015OneMember" name="IssueDateOctober062015OneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_IssueDateSeptember032015Member" name="IssueDateSeptember032015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_LeaseAgreementForCorporateOfficeSpaceMember" name="LeaseAgreementForCorporateOfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LesseeOperatingLeaseAreaOfOfficeSpace" name="LesseeOperatingLeaseAreaOfOfficeSpace" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_LicenseAgreementDocumentationFee" name="LicenseAgreementDocumentationFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LicenseAgreementMaintenanceFee" name="LicenseAgreementMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" name="LicenseAgreementMaintenanceFeeAnnualIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" name="LicenseAgreementMaintenanceFeeMaximumPayablePerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LicensingAgreementTerm" name="LicensingAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_LicensingArrangementsConsiderationPayable" name="LicensingArrangementsConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_LicensingArrangementsReserve" name="LicensingArrangementsReserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mbrx_MdAndersonMember" name="MdAndersonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_MilestonePaymentsLiabilities" name="MilestonePaymentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mbrx_MinimumAnnualRoyaltyMember" name="MinimumAnnualRoyaltyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_MoleculinAgreementMember" name="MoleculinAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_MoleculinLlcMember" name="MoleculinLlcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_NatureOfBusinessAndLiquidityTextBlock" name="NatureOfBusinessAndLiquidityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_NumberOfDrugTechnologies" name="NumberOfDrugTechnologies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_NumberOfOtherDrugDevelopmentProjects" name="NumberOfOtherDrugDevelopmentProjects" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_NumberOfUnitsIssued" name="NumberOfUnitsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" name="OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_OperatingLeasesMonthlyRentExpense" name="OperatingLeasesMonthlyRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_OutlincenseAgreementMember" name="OutlincenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_PaymentsForResearchAndDevelopmentAgreement" name="PaymentsForResearchAndDevelopmentAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths" name="PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_PaymentsForRoyaltiesMinimumPerYear" name="PaymentsForRoyaltiesMinimumPerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_PcgAdvisoryGroupMember" name="PcgAdvisoryGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_PeriodTypeAxis" name="PeriodTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_PeriodTypeDomain" name="PeriodTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_PlacementAgencyAgreementMember" name="PlacementAgencyAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_ReceiptOfMarketApprovalForLicensedProductMember" name="ReceiptOfMarketApprovalForLicensedProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ResearchAndDevelopmentMilestonePaymentsDue" name="ResearchAndDevelopmentMilestonePaymentsDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember" name="RothCapitalPartnersLLCandNationalSecuritiesCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_RoyaltyOnNetRevenuesPercentage" name="RoyaltyOnNetRevenuesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod" name="SaleOfStockCashAndWarrantCompensationTailFeePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" name="SaleOfStockFeesPaidPercentageOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" name="SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SaleOfStockReimbursementOfExpenses" name="SaleOfStockReimbursementOfExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SaleOfStockRightOfFirstRefusalPeriod" name="SaleOfStockRightOfFirstRefusalPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions" name="SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_ScienceAdvisoryBoardMemberMember" name="ScienceAdvisoryBoardMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SeriesAndSeriesCWarrantMember" name="SeriesAndSeriesCWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SeriesBWarrantMember" name="SeriesBWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SeriesCWarrantMember" name="SeriesCWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SeriesWarrantMember" name="SeriesWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_ServicingFeePayableMember" name="ServicingFeePayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" name="SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_SharesAuthorized" name="SharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" name="StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesForTechnology" name="StockIssuedDuringPeriodSharesForTechnology" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering" name="StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" name="StockIssuedDuringPeriodSharesPrivateIssuances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesSaleOfUnits" name="StockIssuedDuringPeriodSharesSaleOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" name="StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValueForTechnology" name="StockIssuedDuringPeriodValueForTechnology" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering" name="StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValuePrivateIssuances" name="StockIssuedDuringPeriodValuePrivateIssuances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValueSaleOfUnits" name="StockIssuedDuringPeriodValueSaleOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_StockPlanMember" name="StockPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_StockholdersEquitySubscriptionsSettledForCash" name="StockholdersEquitySubscriptionsSettledForCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SubmissionOfANewDrugApplicationMember" name="SubmissionOfANewDrugApplicationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" name="SubmissionOfFirstNDAWithinUnitedStatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_SubscriptionsReceivableMember" name="SubscriptionsReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_TheWarrantsMember" name="TheWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_UnsecuredPromissoryNotesMember" name="UnsecuredPromissoryNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_WarrantLiabilityCurrentMember" name="WarrantLiabilityCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_WarrantLiabilityLongtermMember" name="WarrantLiabilityLongtermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mbrx_WarrantLiabiltyMember" name="WarrantLiabiltyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mbrx_WarrantsIssuedForServices" name="WarrantsIssuedForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbrx_WarrantsLiabilityDisclosureTextBlock" name="WarrantsLiabilityDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mbrx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheets" xlink:href="mbrx-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:href="mbrx-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:href="mbrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:href="mbrx-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:href="mbrx-20171231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:href="mbrx-20171231.xsd#EquitySummaryOfOptionActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:href="mbrx-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:href="mbrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesTables" xlink:href="mbrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssets" xlink:href="mbrx-20171231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:href="mbrx-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:href="mbrx-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfOperations" xlink:href="mbrx-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:href="mbrx-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:href="mbrx-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:href="mbrx-20171231.xsd#WarrantLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:href="mbrx-20171231.xsd#WarrantLiabilityTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_8119e4ab-3ea0-6eb5-28e6-4b5b4d70a559" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_8119e4ab-3ea0-6eb5-28e6-4b5b4d70a559" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedClinicalTestingCurrent" xlink:label="loc_mbrx_AccruedClinicalTestingCurrent_DCCCE4BD7846D0A7D50B25FF92702DFE" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mbrx_AccruedClinicalTestingCurrent_DCCCE4BD7846D0A7D50B25FF92702DFE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseFeesAndSRACurrent" xlink:label="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EBF4941089DDD62E7A12600E99B7249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EBF4941089DDD62E7A12600E99B7249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedBoardExpensesCurrent" xlink:label="loc_mbrx_AccruedBoardExpensesCurrent_044CE427FE3D7FA8419526019BEC0546" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mbrx_AccruedBoardExpensesCurrent_044CE427FE3D7FA8419526019BEC0546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_6b7c7f79-cf9d-37d8-d915-1c342359d3aa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_6b7c7f79-cf9d-37d8-d915-1c342359d3aa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_02b1756e-a27a-df0b-cb87-4e42d7ab59c6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_02b1756e-a27a-df0b-cb87-4e42d7ab59c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_13bb68ff-220d-fc94-a876-04b8f3aef199" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_13bb68ff-220d-fc94-a876-04b8f3aef199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e844b255-713b-0357-7991-a8c78d02cb50" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e844b255-713b-0357-7991-a8c78d02cb50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c04dd71c-529e-62f9-136d-a0a478e6fbc1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c04dd71c-529e-62f9-136d-a0a478e6fbc1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts_b95a2133-6559-bc94-9bee-5557833c5749" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_mbrx_DeferredTaxAssetsStartUpCosts_b95a2133-6559-bc94-9bee-5557833c5749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_95b2e317-3338-2d68-dd44-b4b78f4246b8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_95b2e317-3338-2d68-dd44-b4b78f4246b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a9e69e90-362c-096d-424d-dfd51b492a2e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a9e69e90-362c-096d-424d-dfd51b492a2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dde5eeca-2b71-60e2-a05c-fb2f2f5703af" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dde5eeca-2b71-60e2-a05c-fb2f2f5703af" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_2c133e3f-c040-15a3-7a5e-555783416e5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_2c133e3f-c040-15a3-7a5e-555783416e5e" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_5C883296D541DEE914845435F7B92B69" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_5C883296D541DEE914845435F7B92B69" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_FCF659F8180C1136825154405C3693EC" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_FCF659F8180C1136825154405C3693EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0241d40c-718a-28d6-e497-9e09edfdc0b5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0241d40c-718a-28d6-e497-9e09edfdc0b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_a2059297-7eac-a454-cdd7-5557830410b6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_a2059297-7eac-a454-cdd7-5557830410b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_B589A6D2D68B305FBCF75436E508694D" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_B589A6D2D68B305FBCF75436E508694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_1964D05B216AFCB4E2FB5440E206544E" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_1964D05B216AFCB4E2FB5440E206544E" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_017de627-23c1-637c-52df-ee2eb736b728" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_920f422e-1374-af55-c08e-afb11056448e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_017de627-23c1-637c-52df-ee2eb736b728" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_920f422e-1374-af55-c08e-afb11056448e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5a23735a-10c2-64f7-3d5a-453792d1607d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_920f422e-1374-af55-c08e-afb11056448e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5a23735a-10c2-64f7-3d5a-453792d1607d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4e5d7007-764c-d3cb-5dbd-3a33b1b3941c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_920f422e-1374-af55-c08e-afb11056448e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4e5d7007-764c-d3cb-5dbd-3a33b1b3941c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ea5f0c55-82ec-3013-b10d-5cbd46212889" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_920f422e-1374-af55-c08e-afb11056448e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ea5f0c55-82ec-3013-b10d-5cbd46212889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_534c4147-6a9f-f763-f45b-0d025f929de9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_017de627-23c1-637c-52df-ee2eb736b728" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_534c4147-6a9f-f763-f45b-0d025f929de9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_833b6d2d-a622-8759-6212-2a8447c58ff7" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_017de627-23c1-637c-52df-ee2eb736b728" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_833b6d2d-a622-8759-6212-2a8447c58ff7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_03c804f2-45d1-f220-5c47-af04bcec94fa" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_03c804f2-45d1-f220-5c47-af04bcec94fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_776dceba-7cb4-b3a5-c60f-5d23c80d37ab" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_mbrx_GainFromSettlementLiability_776dceba-7cb4-b3a5-c60f-5d23c80d37ab" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_e6473c52-bc4b-1419-4b5c-5d23c80c9326" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_mbrx_GainLossFromExpirationOfWarrants_e6473c52-bc4b-1419-4b5c-5d23c80c9326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1050dc04-f8c2-03a3-34af-47f0ecaba5f4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_1050dc04-f8c2-03a3-34af-47f0ecaba5f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1828fb62-411d-fe29-53fa-005da2b99554" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1828fb62-411d-fe29-53fa-005da2b99554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_34cbd47b-5470-0c33-f0a4-e163dae7b15a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_34cbd47b-5470-0c33-f0a4-e163dae7b15a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7f9cc7d6-ff2c-26b4-0426-45c0dab4abe4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7f9cc7d6-ff2c-26b4-0426-45c0dab4abe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d35c912-5b2d-89f7-eeb3-812a0511db5e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_776dceba-7cb4-b3a5-c60f-5d23c80d37ab" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_mbrx_GainFromSettlementLiability_776dceba-7cb4-b3a5-c60f-5d23c80d37ab" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_e6473c52-bc4b-1419-4b5c-5d23c80c9326" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_mbrx_GainLossFromExpirationOfWarrants_e6473c52-bc4b-1419-4b5c-5d23c80c9326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_67402d53-bb55-2723-1295-126624c5472c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OtherIncome_67402d53-bb55-2723-1295-126624c5472c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mbrx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheets" xlink:href="mbrx-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:href="mbrx-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:href="mbrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:href="mbrx-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:href="mbrx-20171231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:href="mbrx-20171231.xsd#EquitySummaryOfOptionActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:href="mbrx-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:href="mbrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesTables" xlink:href="mbrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssets" xlink:href="mbrx-20171231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:href="mbrx-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:href="mbrx-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfOperations" xlink:href="mbrx-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:href="mbrx-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:href="mbrx-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:href="mbrx-20171231.xsd#WarrantLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:href="mbrx-20171231.xsd#WarrantLiabilityTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_D13D1B27A22A55C1796F67AE99752C80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_D13D1B27A22A55C1796F67AE99752C80" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:to="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DCCFD61F58FED786960967AE9974A6D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:to="loc_us-gaap_SubsequentEventMember_DCCFD61F58FED786960967AE9974A6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:to="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:to="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfANewDrugApplicationMember" xlink:label="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" xlink:label="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:to="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049_default" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:to="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AnnamedAgreementMember" xlink:label="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinAgreementMember" xlink:label="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IntertechBioAgreementMember" xlink:label="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:to="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:to="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:to="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:to="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7070C39FD4A8119EFCA567AE997672EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:to="loc_us-gaap_MinimumMember_7070C39FD4A8119EFCA567AE997672EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8C3131F8FD6825013F8467AE99763C6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:to="loc_us-gaap_MaximumMember_8C3131F8FD6825013F8467AE99763C6C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreement" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementDocumentationFee" xlink:label="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingAgreementTerm" xlink:label="loc_mbrx_LicensingAgreementTerm_BA37827DD89379A0D78267AE9977F1E8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicensingAgreementTerm_BA37827DD89379A0D78267AE9977F1E8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForRoyaltiesMinimumPerYear" xlink:label="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ResearchAndDevelopmentMilestonePaymentsDue" xlink:label="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RoyaltyOnNetRevenuesPercentage" xlink:label="loc_mbrx_RoyaltyOnNetRevenuesPercentage_4CBC3BF2D1D4CB2DF2E767AE997781FE" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_RoyaltyOnNetRevenuesPercentage_4CBC3BF2D1D4CB2DF2E767AE997781FE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees" xlink:label="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:label="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:to="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:to="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D30B8175F2DBBF2001CE67AE99F90636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:to="loc_us-gaap_MinimumMember_D30B8175F2DBBF2001CE67AE99F90636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B7A96678C44DA0ADC4EF67AE99F93563" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:to="loc_us-gaap_MaximumMember_B7A96678C44DA0ADC4EF67AE99F93563" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtTradingTermsAxis" xlink:label="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtConversionTermsDomain" xlink:label="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:to="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC_default" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtConversionTermsDomain" xlink:label="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:to="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermOneMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermTwoMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermThreeMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFourMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFiveMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:to="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:to="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered" xlink:label="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors" xlink:label="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3AA85C0728CF2F6D623A4E937EA14221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:to="loc_us-gaap_DebtInstrumentTable_3AA85C0728CF2F6D623A4E937EA14221" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3AA85C0728CF2F6D623A4E937EA14221" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:to="loc_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:to="loc_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:to="loc_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:to="loc_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5957AE19505192C4628E4E937EA1615A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3AA85C0728CF2F6D623A4E937EA14221" xlink:to="loc_us-gaap_DebtInstrumentAxis_5957AE19505192C4628E4E937EA1615A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5957AE19505192C4628E4E937EA1615A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5957AE19505192C4628E4E937EA1615A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:to="loc_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:to="loc_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:to="loc_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A187E3B4D07EC369D43F4E937EA13F45" xlink:to="loc_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1A20D7D1BAD0C52844A04E937EA22330" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3AA85C0728CF2F6D623A4E937EA14221" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1A20D7D1BAD0C52844A04E937EA22330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5446083E886B6E23619C4E937EA2028D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1A20D7D1BAD0C52844A04E937EA22330" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5446083E886B6E23619C4E937EA2028D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_5446083E886B6E23619C4E937EA2028D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1A20D7D1BAD0C52844A04E937EA22330" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_5446083E886B6E23619C4E937EA2028D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3E45EFAD9E23320D9C164E937EA27B1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_5446083E886B6E23619C4E937EA2028D" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3E45EFAD9E23320D9C164E937EA27B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:to="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_32A4773FBFDAB440D2F04E937EA2D090" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F11D96FE303BE59150A84E937EA23198" xlink:to="loc_us-gaap_InterestPayableCurrent_32A4773FBFDAB440D2F04E937EA2D090" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:to="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:to="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:to="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C29A5ED46CA7E0BE41C962B6751B28A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:to="loc_us-gaap_CommonStockMember_C29A5ED46CA7E0BE41C962B6751B28A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember" xlink:label="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:to="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:to="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_28794A29B9E260B6A89A62B6751B52E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:to="loc_us-gaap_IPOMember_28794A29B9E260B6A89A62B6751B52E5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AtMarketIssuanceSalesAgreementMember" xlink:label="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:to="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0C8A8A09202DEA6359C662B6751B7E65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_us-gaap_WarrantMember_0C8A8A09202DEA6359C662B6751B7E65" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantOneMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantTwoMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TheWarrantsMember" xlink:label="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:to="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:to="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:to="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:to="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:to="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0F8DE56410A69213968962B6751B4302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:to="loc_us-gaap_MaximumMember_0F8DE56410A69213968962B6751B4302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B97961F9E505F2DD684D62B6751B27AB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:to="loc_us-gaap_MinimumMember_B97961F9E505F2DD684D62B6751B27AB" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossOnNoncashSettlementOfLiability" xlink:label="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4AEC17E673980EBB7B1A62B6751BA9E9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4AEC17E673980EBB7B1A62B6751BA9E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_158442F6B71492DBC36F62B6751B4A2E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_158442F6B71492DBC36F62B6751B4A2E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:label="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:label="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_3BA3E6FACEC6CB7A591C62B6751BD0C6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_3BA3E6FACEC6CB7A591C62B6751BD0C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ECB30D39ACD055473B9D62B6751BF636" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ECB30D39ACD055473B9D62B6751BF636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E4855C232C0B567EF7FF62B6751B5B7E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E4855C232C0B567EF7FF62B6751B5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C9E8AEA1B93C14D209762B6751B9D51" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C9E8AEA1B93C14D209762B6751B9D51" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E5145658F8173703CEBC62B6751B6478" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E5145658F8173703CEBC62B6751B6478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_91C23C1BA4DF99922A8362B6751B6CCD" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_91C23C1BA4DF99922A8362B6751B6CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_26E0FB440F2D7D53DD2062B6751B410E" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_26E0FB440F2D7D53DD2062B6751B410E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightAgreementPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightVestingPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightExpirationPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:to="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:to="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:to="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_01C1E72E5526A2B83F5E4B0D120DA604" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:to="loc_us-gaap_MinimumMember_01C1E72E5526A2B83F5E4B0D120DA604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_87947B656C787F87A95D4B0D120D2AD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:to="loc_us-gaap_MaximumMember_87947B656C787F87A95D4B0D120D2AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E2C55756044C8723D824B0D120DF685" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E2C55756044C8723D824B0D120DF685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_80BEC589B5E7A67A0BB74B0D120D53BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_80BEC589B5E7A67A0BB74B0D120D53BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_F5A70EE2C2888255B3ED4B0D120D9DAC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_F5A70EE2C2888255B3ED4B0D120D9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FederalStateandForeignJurisdictionsMember" xlink:label="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:to="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:to="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:to="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_52A0374061418E2A84F16836202D989B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:to="loc_us-gaap_CommonStockMember_52A0374061418E2A84F16836202D989B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_210787ECE9DC508F52B56836202EAC57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:to="loc_mbrx_MoleculinLlcMember_210787ECE9DC508F52B56836202EAC57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:to="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:to="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:to="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:to="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_581A67A994ACCE00C0BA6836202E43C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_581A67A994ACCE00C0BA6836202E43C9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:to="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5_default" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:to="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:to="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_ABC2577DF352D032C1B56836202F58D8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_SharePrice_ABC2577DF352D032C1B56836202F58D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RoyaltyOnNetRevenuesPercentage" xlink:label="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionIndemnificationAgreementTerm" xlink:label="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionNumberOfAgreements" xlink:label="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_44B4359A7AD41C861EE46836202FE899" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_44B4359A7AD41C861EE46836202FE899" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingAgreementTerm" xlink:label="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsReserve" xlink:label="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_D0052E65BBA393691D7367F5640E2CB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:to="loc_mbrx_MoleculinLlcMember_D0052E65BBA393691D7367F5640E2CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:to="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:to="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:to="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/StatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:to="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:to="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3BEB215644659BDA67FC6416AF3964E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_CommonStockMember_3BEB215644659BDA67FC6416AF3964E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:to="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:to="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0CB52464896704E571D0641831508670" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:to="loc_us-gaap_CommonStockMember_0CB52464896704E571D0641831508670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6DF3141B4131F9F3653E64183150A37D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6DF3141B4131F9F3653E64183150A37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_97B25697A1FE181D155A6418F8BBD490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_97B25697A1FE181D155A6418F8BBD490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:to="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:to="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5E882E81851E8742B4F46418F8BB3196" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:to="loc_us-gaap_CommonStockMember_5E882E81851E8742B4F46418F8BB3196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:to="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PlacementAgencyAgreementMember" xlink:label="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:to="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IPXMemorialDriveInvestorsLLCMember" xlink:label="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:to="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:label="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:to="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScienceAdvisoryBoardMemberMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:to="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:to="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:label="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A6E23E9FB14040E0E5726418F8BDC8A6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A6E23E9FB14040E0E5726418F8BDC8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:label="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions" xlink:label="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockReimbursementOfExpenses" xlink:label="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockRightOfFirstRefusalPeriod" xlink:label="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod" xlink:label="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LesseeOperatingLeaseAreaOfOfficeSpace" xlink:label="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeasesMonthlyRentExpense" xlink:label="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:label="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityCurrentMember" xlink:label="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityLongtermMember" xlink:label="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabiltyMember" xlink:label="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16BDBB505E6525B6B8312A57737C3FA8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16BDBB505E6525B6B8312A57737C3FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:to="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_50898D70DB3264C67E1B62B67643FAB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:to="loc_us-gaap_WarrantMember_50898D70DB3264C67E1B62B67643FAB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:to="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:to="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:to="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:to="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesAndSeriesCWarrantMember" xlink:label="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:to="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:to="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:to="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:to="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:to="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:to="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:to="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:to="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:to="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:to="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A294C553CCDC25FAEDF94F201A96AF13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:to="loc_us-gaap_WarrantMember_A294C553CCDC25FAEDF94F201A96AF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:to="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:to="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:to="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_66CD5B5AECEA30F8CB914F201A9602A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:to="loc_us-gaap_MinimumMember_66CD5B5AECEA30F8CB914F201A9602A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2DAF3BAEE6629DB9DE314F201A963746" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:to="loc_us-gaap_MaximumMember_2DAF3BAEE6629DB9DE314F201A963746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:to="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:to="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:to="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4B05B00F025880BCCACA68361F6E5EE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:to="loc_us-gaap_MinimumMember_4B05B00F025880BCCACA68361F6E5EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9F95D4CF9B01BF77A2AD68361F6E5B9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:to="loc_us-gaap_MaximumMember_9F95D4CF9B01BF77A2AD68361F6E5B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:to="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:to="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0C9F22CBBECBFB42B77768361F73BD63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:to="loc_us-gaap_WarrantMember_0C9F22CBBECBFB42B77768361F73BD63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mbrx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:to="lab_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:to="lab_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:to="lab_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="arc" />
    <link:label id="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4_terseLabel_en-US" xlink:label="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting Agreement</link:label>
    <link:label id="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4_label_en-US" xlink:label="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:label id="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4_documentation_en-US" xlink:label="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:to="lab_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="arc" />
    <link:label id="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97_terseLabel_en-US" xlink:label="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Warrant</link:label>
    <link:label id="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97_label_en-US" xlink:label="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Warrant [Member]</link:label>
    <link:label id="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97_documentation_en-US" xlink:label="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:to="lab_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="arc" />
    <link:label id="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681_terseLabel_en-US" xlink:label="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Warrant</link:label>
    <link:label id="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681_label_en-US" xlink:label="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Warrant [Member]</link:label>
    <link:label id="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681_documentation_en-US" xlink:label="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:to="lab_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="arc" />
    <link:label id="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F_terseLabel_en-US" xlink:label="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Warrant</link:label>
    <link:label id="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F_label_en-US" xlink:label="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Warrant [Member]</link:label>
    <link:label id="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F_documentation_en-US" xlink:label="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:to="lab_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="arc" />
    <link:label id="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C_terseLabel_en-US" xlink:label="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A and Series C Warrants</link:label>
    <link:label id="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C_label_en-US" xlink:label="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A and Series C warrant [Member]</link:label>
    <link:label id="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C_documentation_en-US" xlink:label="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesAndSeriesCWarrantMember" xlink:label="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:to="lab_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:to="lab_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:to="lab_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD_label_en-US" xlink:label="lab_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:to="lab_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1_label_en-US" xlink:label="lab_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:to="lab_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743_label_en-US" xlink:label="lab_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:to="lab_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6_label_en-US" xlink:label="lab_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:to="lab_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1_label_en-US" xlink:label="lab_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:to="lab_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1_verboseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for cash, IPO</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares for Cash Initial Public offering Net of Stock Issuance Costs</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued for cash initial public offering net of stock issuance costs.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offered for each warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395_terseLabel_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395_label_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Term</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395_documentation_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Term</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:to="lab_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares available for purchase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrants aggregate amounts (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F_label_en-US" xlink:label="lab_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:to="lab_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86_verboseLabel_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86_label_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Rights Warrant Exercised, Amount</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86_documentation_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Rights Warrant Exercised, Amount</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:to="lab_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance, IPO</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares under warrant, exercised</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Series C warrants vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired Series B and Series C warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles acquired from Moleculin, LLC</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:type="arc" />
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD_terseLabel_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD_label_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD_documentation_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:to="lab_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:to="lab_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:to="lab_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:to="lab_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="arc" />
    <link:label id="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87_terseLabel_en-US" xlink:label="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moleculin LLC</link:label>
    <link:label id="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87_label_en-US" xlink:label="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moleculin LLC [Member]</link:label>
    <link:label id="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87_documentation_en-US" xlink:label="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:to="lab_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="arc" />
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1_terseLabel_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1_label_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1_documentation_en-US" xlink:label="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="lab_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, amount FDIC insured</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:to="lab_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment assets acquired, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive shares excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="lab_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:to="lab_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:to="lab_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:to="lab_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:to="lab_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss from change in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:type="arc" />
    <link:label id="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE_terseLabel_en-US" xlink:label="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from settlement of liability</link:label>
    <link:label id="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE_label_en-US" xlink:label="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain From Settlement Liability</link:label>
    <link:label id="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE_documentation_en-US" xlink:label="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gain from settlement liability associated with the issuance of common stock for service providers.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:to="lab_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:type="arc" />
    <link:label id="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538_terseLabel_en-US" xlink:label="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from expiration of warrants</link:label>
    <link:label id="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538_label_en-US" xlink:label="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss from Expiration of Warrants</link:label>
    <link:label id="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538_documentation_en-US" xlink:label="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of gain (loss) on expiration of warrants during the reporting period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:to="lab_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E_label_en-US" xlink:label="lab_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:to="lab_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325_label_en-US" xlink:label="lab_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:to="lab_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:to="lab_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:type="arc" />
    <link:label id="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8_terseLabel_en-US" xlink:label="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8_label_en-US" xlink:label="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Liability Disclosure [Text Block]</link:label>
    <link:label id="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8_documentation_en-US" xlink:label="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for warrants liability, including all tables.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantsLiabilityDisclosureTextBlock" xlink:label="loc_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:to="lab_mbrx_WarrantsLiabilityDisclosureTextBlock_214AD0A4F5593446ABA94ED4106B7FE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Option Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:type="arc" />
    <link:label id="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB_terseLabel_en-US" xlink:label="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Share-Based Compensation</link:label>
    <link:label id="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB_label_en-US" xlink:label="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Share-Based Compensation [Table Text Block]</link:label>
    <link:label id="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB_documentation_en-US" xlink:label="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Components of Share-Based Compensation [Table Text Block]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ComponentsofShareBasedCompensationTableTextBlock" xlink:label="loc_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:to="lab_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:type="arc" />
    <link:label id="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31_terseLabel_en-US" xlink:label="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical testing</link:label>
    <link:label id="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31_label_en-US" xlink:label="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Testing, Current</link:label>
    <link:label id="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31_documentation_en-US" xlink:label="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Testing, Current</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedClinicalTestingCurrent" xlink:label="loc_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:to="lab_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:type="arc" />
    <link:label id="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B_terseLabel_en-US" xlink:label="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued license fees and SRA</link:label>
    <link:label id="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B_label_en-US" xlink:label="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued License Fees And SRA, Current</link:label>
    <link:label id="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B_documentation_en-US" xlink:label="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued License Fees And SRA, Current</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseFeesAndSRACurrent" xlink:label="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:to="lab_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal and professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:type="arc" />
    <link:label id="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558_terseLabel_en-US" xlink:label="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued board expenses</link:label>
    <link:label id="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558_label_en-US" xlink:label="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Board Expenses, Current</link:label>
    <link:label id="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558_documentation_en-US" xlink:label="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Board Expenses, Current</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedBoardExpensesCurrent" xlink:label="loc_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:to="lab_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:to="lab_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="lab_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A_terseLabel_en-US" xlink:label="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Trading Terms [Axis]</link:label>
    <link:label id="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A_label_en-US" xlink:label="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Trading Terms [Axis]</link:label>
    <link:label id="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A_documentation_en-US" xlink:label="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Trading Terms [Axis]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtTradingTermsAxis" xlink:label="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:to="lab_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC_terseLabel_en-US" xlink:label="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Trading Terms [Domain]</link:label>
    <link:label id="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC_label_en-US" xlink:label="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms [Domain]</link:label>
    <link:label id="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC_documentation_en-US" xlink:label="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Conversion Terms [Axis]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtConversionTermsDomain" xlink:label="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="lab_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction A</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Term One [Member]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First term described within convertible notes payable trading restrictions</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermOneMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:to="lab_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction B</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Term Two [Member]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second term described within convertible notes payable trading restrictions</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermTwoMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:to="lab_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction C</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Term Three [Member]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third term described within convertible notes payable trading restrictions [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermThreeMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:to="lab_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction D</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Term Four [Member]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fourth term described within convertible notes payable trading restrictions [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFourMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:to="lab_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction E</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Term Five [Member]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifth term described within convertible notes payable trading restrictions [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFiveMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:to="lab_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="arc" />
    <link:label id="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0_terseLabel_en-US" xlink:label="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Promissory Notes</link:label>
    <link:label id="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0_label_en-US" xlink:label="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
    <link:label id="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0_documentation_en-US" xlink:label="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:to="lab_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8_label_en-US" xlink:label="lab_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:to="lab_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="lab_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of unsecured promissory notes entered into</link:label>
    <link:label id="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505_label_en-US" xlink:label="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Unsecured Notes Entered</link:label>
    <link:label id="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Unsecured Notes Entered</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered" xlink:label="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:to="lab_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of separate third party investors</link:label>
    <link:label id="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1_label_en-US" xlink:label="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unsecured Notes, Number Of Third Party Investors</link:label>
    <link:label id="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unsecured Notes, Number Of Third Party Investors</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors" xlink:label="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:to="lab_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on note (annual)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage, maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issued to settle accounts payable</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in convertible debt principle</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:to="lab_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days after initial closing of IPO</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Period Following Initial Public Offering Threshold</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Period Following Initial Public Offering Threshold</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:to="lab_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares underlying note available to sell on monthly basis</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Percentage Of Shares Underlying The Instrument</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Percentage Of Shares Underlying The Instrument</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:to="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum daily volume of trading activity (as a percent)</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Maximum Trading Day Sale, Percentage Of Daily Volume</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Maximum Trading Day Sale, Percentage Of Daily Volume</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:to="lab_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per common share of common stock (in dollars per share)</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Minimum Price Per Share of Common Stock</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Minimum Price Per Share of Common Stock</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:to="lab_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of consecutive trading days price per share is above threshold</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Consecutive Trading Day Threshold</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Consecutive Trading Day Threshold</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:to="lab_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares underlying note available to sell on monthly basis (as a percent)</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B_label_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Additional Percentage Of Shares Underlying The Instrument</link:label>
    <link:label id="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Additional Percentage Of Shares Underlying The Instrument</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:to="lab_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="arc" />
    <link:label id="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632_terseLabel_en-US" xlink:label="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal, State and Foreign Jurisdictions</link:label>
    <link:label id="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632_label_en-US" xlink:label="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal, State and Foreign Jurisdictions [Member]</link:label>
    <link:label id="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632_documentation_en-US" xlink:label="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal, State and Foreign Jurisdictions [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FederalStateandForeignJurisdictionsMember" xlink:label="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:to="lab_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:to="lab_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="arc" />
    <link:label id="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2_terseLabel_en-US" xlink:label="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Act, income tax expense</link:label>
    <link:label id="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2_label_en-US" xlink:label="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2_documentation_en-US" xlink:label="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:to="lab_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17_label_en-US" xlink:label="lab_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:to="lab_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373_label_en-US" xlink:label="lab_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:to="lab_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="arc" />
    <link:label id="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D_terseLabel_en-US" xlink:label="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Houston Pharmaceuticals, Inc</link:label>
    <link:label id="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D_label_en-US" xlink:label="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Houston Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D_documentation_en-US" xlink:label="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Houston Pharmaceuticals, Inc</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:to="lab_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Liability assumed (HPI)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other liabilities assumed, including $470 of notes payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired/total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113_terseLabel_en-US" xlink:label="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities assumed, notes payable</link:label>
    <link:label id="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113_label_en-US" xlink:label="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Notes Payable</link:label>
    <link:label id="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113_documentation_en-US" xlink:label="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of liabilities incurred related to notes payable, assumed at the acquisition date.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:to="lab_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:to="lab_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="lab_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:to="lab_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="arc" />
    <link:label id="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85_terseLabel_en-US" xlink:label="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85_label_en-US" xlink:label="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85_documentation_en-US" xlink:label="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:to="lab_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="arc" />
    <link:label id="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356_terseLabel_en-US" xlink:label="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement Agency Agreement</link:label>
    <link:label id="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356_label_en-US" xlink:label="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Agency Agreement [Member]</link:label>
    <link:label id="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356_documentation_en-US" xlink:label="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Placement Agency Agreement [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PlacementAgencyAgreementMember" xlink:label="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:to="lab_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:to="lab_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="arc" />
    <link:label id="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977_terseLabel_en-US" xlink:label="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPX Memorial Drive Investors, LLC</link:label>
    <link:label id="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977_label_en-US" xlink:label="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPX Memorial Drive Investors, LLC [Member]</link:label>
    <link:label id="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977_documentation_en-US" xlink:label="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPX Memorial Drive Investors, LLC [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IPXMemorialDriveInvestorsLLCMember" xlink:label="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:to="lab_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="arc" />
    <link:label id="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A_terseLabel_en-US" xlink:label="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Agreement For Corporate Office Space</link:label>
    <link:label id="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A_label_en-US" xlink:label="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Agreement For Corporate Office Space [Member]</link:label>
    <link:label id="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A_documentation_en-US" xlink:label="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Agreement For Corporate Office Space [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:label="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:to="lab_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:to="lab_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="arc" />
    <link:label id="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7_terseLabel_en-US" xlink:label="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Science Advisory Board Member</link:label>
    <link:label id="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7_label_en-US" xlink:label="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Science Advisory Board Member [Member]</link:label>
    <link:label id="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7_documentation_en-US" xlink:label="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Science Advisory Board Member</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScienceAdvisoryBoardMemberMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:to="lab_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:to="lab_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="lab_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares, granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options issued, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options issued, vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock sold</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds received from sale of shares and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336_terseLabel_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable period, subject to beneficial ownership limitations</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336_label_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Initial Exercise Period</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336_documentation_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Initial Exercise Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:label="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:to="lab_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF_verboseLabel_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:to="lab_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of shares and warrants</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission payment to agents (as a percent)</link:label>
    <link:label id="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1_label_en-US" xlink:label="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Fees Paid, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Fees Paid, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:label="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:to="lab_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted to purchase common stock, percentage</link:label>
    <link:label id="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1_label_en-US" xlink:label="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Warrants To Be Issued, Percentage Of Common Stock Sold In Transactions</link:label>
    <link:label id="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Warrants To Be Issued, Percentage Of Common Stock Sold In Transactions</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions" xlink:label="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:to="lab_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D_label_en-US" xlink:label="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Expenses</link:label>
    <link:label id="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Expenses</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockReimbursementOfExpenses" xlink:label="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:to="lab_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of first refusal period (in months)</link:label>
    <link:label id="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184_label_en-US" xlink:label="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Right Of First Refusal, Period</link:label>
    <link:label id="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Right Of First Refusal, Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockRightOfFirstRefusalPeriod" xlink:label="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:to="lab_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tail fee period (in months)</link:label>
    <link:label id="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F_label_en-US" xlink:label="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Cash And Warrant Compensation Tail Fee, Period</link:label>
    <link:label id="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Cash And Warrant Compensation Tail Fee, Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod" xlink:label="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:to="lab_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="arc" />
    <link:label id="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6_terseLabel_en-US" xlink:label="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rentable square feet</link:label>
    <link:label id="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6_label_en-US" xlink:label="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Office Space</link:label>
    <link:label id="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6_documentation_en-US" xlink:label="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Office Space</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LesseeOperatingLeaseAreaOfOfficeSpace" xlink:label="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:to="lab_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement, initial term</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement, renewal period (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="arc" />
    <link:label id="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065_terseLabel_en-US" xlink:label="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base monthly rent</link:label>
    <link:label id="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065_label_en-US" xlink:label="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Monthly Rent Expense</link:label>
    <link:label id="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065_documentation_en-US" xlink:label="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Monthly Rent Expense</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeasesMonthlyRentExpense" xlink:label="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:to="lab_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="arc" />
    <link:label id="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB_terseLabel_en-US" xlink:label="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in rent expense (as a percent)</link:label>
    <link:label id="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB_label_en-US" xlink:label="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Rent Expense, Annual Increase In Rent, Percent</link:label>
    <link:label id="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB_documentation_en-US" xlink:label="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Rent Expense, Annual Increase In Rent, Percent</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:label="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:to="lab_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:type="arc" />
    <link:label id="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF_terseLabel_en-US" xlink:label="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of drug technologies</link:label>
    <link:label id="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF_label_en-US" xlink:label="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Drug Technologies</link:label>
    <link:label id="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF_documentation_en-US" xlink:label="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Drug Technologies</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfDrugTechnologies" xlink:label="loc_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:to="lab_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:type="arc" />
    <link:label id="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86_terseLabel_en-US" xlink:label="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other drug development projects</link:label>
    <link:label id="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86_label_en-US" xlink:label="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Drug Development Projects</link:label>
    <link:label id="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86_documentation_en-US" xlink:label="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Other Drug Development Projects</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfOtherDrugDevelopmentProjects" xlink:label="loc_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:to="lab_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:to="lab_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pro Forma Results of Operations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:type="arc" />
    <link:label id="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D_terseLabel_en-US" xlink:label="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property Plant And Equipment Useful life</link:label>
    <link:label id="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D_label_en-US" xlink:label="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Property Plant And Equipment Useful life [Table Text Block]</link:label>
    <link:label id="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D_documentation_en-US" xlink:label="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of property plant and equipment useful life.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:to="lab_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:to="lab_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:type="arc" />
    <link:label id="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79_terseLabel_en-US" xlink:label="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79_label_en-US" xlink:label="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern, Policy [Policy Text Block]</link:label>
    <link:label id="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79_documentation_en-US" xlink:label="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for going concern.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GoingConcernPolicyPolicyTextBlock" xlink:label="loc_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:to="lab_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature</link:label>
    <link:label id="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C_label_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature Policy [Policy Text Block]</link:label>
    <link:label id="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for beneficial conversion feature of debt instrument.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xlink:label="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:to="lab_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2_label_en-US" xlink:label="lab_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:to="lab_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="lab_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="arc" />
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97_terseLabel_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs, sale of units</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97_label_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Sale Of Units</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97_documentation_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Sale Of Units</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:to="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="arc" />
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D_terseLabel_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrants exercised, issuance costs</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D_label_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Warrants Exercised During Period, Issuance Costs</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D_documentation_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Warrants Exercised During Period, Issuance Costs</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:to="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="arc" />
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415_terseLabel_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs, stock offering</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415_label_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, At-the-Market Offering</link:label>
    <link:label id="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415_documentation_en-US" xlink:label="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, At-the-Market Offering</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:to="lab_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_198C9CC6282BDED2A7D04E937EA1269D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_1D1B76224484913A7D1F4E937EA17166" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued August 31, 2015</link:label>
    <link:label id="lab_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3_label_en-US" xlink:label="lab_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:to="lab_us-gaap_InvestorMember_A8573CA96C95EADE39BF4E937EA1C9C3" xlink:type="arc" />
    <link:label id="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6_terseLabel_en-US" xlink:label="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued September 3, 2015</link:label>
    <link:label id="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6_label_en-US" xlink:label="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor B [Member]</link:label>
    <link:label id="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6_documentation_en-US" xlink:label="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:to="lab_mbrx_InvestorBMember_8E56BCA5FF35F951A1DD4E937EA10EC6" xlink:type="arc" />
    <link:label id="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3_terseLabel_en-US" xlink:label="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued October 6, 2015</link:label>
    <link:label id="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3_label_en-US" xlink:label="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor C [Member]</link:label>
    <link:label id="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3_documentation_en-US" xlink:label="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:to="lab_mbrx_InvestorCMember_07030A0CBCD95F6607344E937EA1F3E3" xlink:type="arc" />
    <link:label id="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7_terseLabel_en-US" xlink:label="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued January 19, 2016</link:label>
    <link:label id="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7_label_en-US" xlink:label="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor G [Member]</link:label>
    <link:label id="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7_documentation_en-US" xlink:label="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:to="lab_mbrx_InvestorGMember_966DCED23856E6E454D44E937EA183C7" xlink:type="arc" />
    <link:label id="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011_terseLabel_en-US" xlink:label="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue Date August 31 2015</link:label>
    <link:label id="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011_label_en-US" xlink:label="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Date August 31 2015 [Member]</link:label>
    <link:label id="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011_documentation_en-US" xlink:label="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:to="lab_mbrx_IssueDateAugust312015Member_C57975480D5034EF86D84E937EA17011" xlink:type="arc" />
    <link:label id="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090_terseLabel_en-US" xlink:label="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue Date September 03, 2015</link:label>
    <link:label id="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090_label_en-US" xlink:label="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Date September 03 2015 [Member]</link:label>
    <link:label id="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090_documentation_en-US" xlink:label="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:to="lab_mbrx_IssueDateSeptember032015Member_D7093A2267FB20A174594E937EA2F090" xlink:type="arc" />
    <link:label id="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697_terseLabel_en-US" xlink:label="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue Date October 06, 2015 One</link:label>
    <link:label id="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697_label_en-US" xlink:label="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Date October 06 2015 One [Member]</link:label>
    <link:label id="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697_documentation_en-US" xlink:label="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:to="lab_mbrx_IssueDateOctober062015OneMember_D3F08738D3F076D9D9C94E937EA2C697" xlink:type="arc" />
    <link:label id="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00_terseLabel_en-US" xlink:label="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue Date January 19, 2016</link:label>
    <link:label id="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00_label_en-US" xlink:label="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Date January 19 2016 [Member]</link:label>
    <link:label id="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00_documentation_en-US" xlink:label="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:to="lab_mbrx_IssueDateJanuary192016Member_CF6ACE4F036F5FB2C8964E937EA26E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent_CA6C577735AAA80426F44E937EA2C119" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90A28736C2F8AD09DA6D4E937EA28EE1" xlink:type="arc" />
    <link:label id="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871_terseLabel_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible number of common shares</link:label>
    <link:label id="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871_label_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number Of Common Shares</link:label>
    <link:label id="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871_documentation_en-US" xlink:label="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of common shares that the holder of the debt instrument would receive if the debt was converted to equity.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:to="lab_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_B946039CCE6D10EB6E244E937EA25871" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Under Warrant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17_negatedTerseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA_negatedTerseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares under warrant, vested and exercisable at December 31, 2017</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vest And Expected to Vest, Number</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of warrant price per share, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of warrant price per share, vested and exercisable at December 31, 2017 (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected and Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average fair value which vested and exercisable of nonvested awards on equity-based plans excluding option plans.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF_periodStartLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options , Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the weighted-average exercise price for outstanding equity instruments other than options.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options , Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of equity instruments other than options.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options , Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at exercised date to acquire shares of equity instruments other than options.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options , Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at expired date of equity instruments other than options.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22_periodEndLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share Payment Award, Equity Instruments Other than Options , Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">As of the balance sheet date, the weighted-average exercise price for outstanding equity instruments other than options.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term at grant date for equity-based awards excluding options,</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3_verboseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term at exercised date for equity-based awards excluding options,</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:to="lab_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="arc" />
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997_terseLabel_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997_label_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options expired In Period Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997_documentation_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term at expired date for equity-based awards excluding options,</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:to="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25_terseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Exercisable</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Exercisable, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options which vested and exercisable.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares exercisable, end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, outstanding, end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:type="arc" />
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7_verboseLabel_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, exercisable (in dollars per share)</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7_label_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7_documentation_en-US" xlink:label="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average grant-date fair value of options exercisable.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:to="lab_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43_negativeLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding, end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="arc" />
    <link:label id="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6_terseLabel_en-US" xlink:label="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscriptions Receivable</link:label>
    <link:label id="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6_label_en-US" xlink:label="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscriptions Receivable [Member]</link:label>
    <link:label id="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6_documentation_en-US" xlink:label="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:to="lab_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:to="lab_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:to="lab_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096_verboseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Private issuance @ $3.00 / share (in shares)</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During the Period, Shares, Private Issuances</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period in private issuances</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7_verboseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Private issuance @ $3.00 / share</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During the Period, Value, Private Issuances</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of private issuances during the period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:to="lab_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for Moleculin acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued for Moleculin acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for technology (in shares)</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares for Technology</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued for technology.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for technology</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value for Technology</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued for technology.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - IPO, net of stock issuance costs of $1,150 (in shares)</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - IPO, net of stock issuance costs of $1,150</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value for Cash Initial Public offering Net of Stock Issuance Costs</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued for Cash IPO Net of Stock Issuance Costs</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued for services</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock granted for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock granted for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued for convertible debt (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued for convertible debt</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="arc" />
    <link:label id="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8_verboseLabel_en-US" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subscription agreement settled for cash</link:label>
    <link:label id="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8_label_en-US" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Subscriptions Settled For Cash</link:label>
    <link:label id="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8_documentation_en-US" xlink:label="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents subscriptions receivable settled for cash during the period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:to="lab_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - sale of units at $1.35 per unit, net of stock issuance costs of $550 (in shares)</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Sale Of Units</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Sale Of Units</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - sale of units at $1.35 per unit, net of stock issuance costs of $550</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Sale Of Units</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Sale Of Units</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, net of issuance costs of $73 (in shares)</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7_verboseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, net of issuance costs of $73</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - sale of common stock in ATM offering, net of issuance costs of $166 (in shares)</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, At-the-Market Offering</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, At-the-Market Offering</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:to="lab_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="arc" />
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D_terseLabel_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued for cash - sale of common stock in ATM offering, net of issuance costs of $166</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D_label_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues, At-the-Market Offering</link:label>
    <link:label id="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D_documentation_en-US" xlink:label="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues, At-the-Market Offering</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:to="lab_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332_definitionGuidance_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:to="lab_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balances (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:to="lab_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:to="lab_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:type="arc" />
    <link:label id="lab_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B_label_en-US" xlink:label="lab_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B_documentation_en-US" xlink:label="lab_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DocumentAndEntityInformationAbstract" xlink:label="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="lab_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_A19E470631485CA7D7915557B69DFF13_terseLabel_en-US" xlink:label="lab_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_A19E470631485CA7D7915557B69DFF13_label_en-US" xlink:label="lab_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:to="lab_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66_label_en-US" xlink:label="lab_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:to="lab_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:to="lab_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:to="lab_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:to="lab_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5_label_en-US" xlink:label="lab_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:to="lab_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:to="lab_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:to="lab_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:to="lab_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:to="lab_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21_label_en-US" xlink:label="lab_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:to="lab_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40_label_en-US" xlink:label="lab_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:to="lab_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1_label_en-US" xlink:label="lab_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:to="lab_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Expenses and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="arc" />
    <link:label id="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059_terseLabel_en-US" xlink:label="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059_label_en-US" xlink:label="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059_documentation_en-US" xlink:label="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:to="lab_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="arc" />
    <link:label id="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704_terseLabel_en-US" xlink:label="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-Lincense Agreement</link:label>
    <link:label id="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704_label_en-US" xlink:label="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out-Lincense Agreement [Member]</link:label>
    <link:label id="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704_documentation_en-US" xlink:label="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-Lincense Agreement</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:to="lab_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="arc" />
    <link:label id="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F_terseLabel_en-US" xlink:label="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Type [Axis]</link:label>
    <link:label id="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F_label_en-US" xlink:label="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Type [Axis]</link:label>
    <link:label id="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F_documentation_en-US" xlink:label="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:to="lab_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="arc" />
    <link:label id="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5_terseLabel_en-US" xlink:label="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Type [Domain]</link:label>
    <link:label id="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5_label_en-US" xlink:label="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Type [Domain]</link:label>
    <link:label id="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5_documentation_en-US" xlink:label="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:to="lab_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="arc" />
    <link:label id="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2_terseLabel_en-US" xlink:label="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition Date One</link:label>
    <link:label id="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2_label_en-US" xlink:label="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Date One [Member]</link:label>
    <link:label id="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2_documentation_en-US" xlink:label="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:to="lab_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, equity interest issued (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, value of equity interest issued</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan to Moleculin</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:to="lab_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="arc" />
    <link:label id="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9_terseLabel_en-US" xlink:label="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty on net revenues (as a percent)</link:label>
    <link:label id="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9_label_en-US" xlink:label="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty On Net Revenues, Percentage</link:label>
    <link:label id="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9_documentation_en-US" xlink:label="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents the royalty percentage on net revenue.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RoyaltyOnNetRevenuesPercentage" xlink:label="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:to="lab_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF_terseLabel_en-US" xlink:label="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification period granted to former officers (in years)</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF_label_en-US" xlink:label="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Indemnification Agreement, Term</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF_documentation_en-US" xlink:label="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Indemnification Agreement, Term</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionIndemnificationAgreementTerm" xlink:label="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:to="lab_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA_terseLabel_en-US" xlink:label="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements with HPI</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA_label_en-US" xlink:label="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number Of Agreements</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA_documentation_en-US" xlink:label="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number Of Agreements</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionNumberOfAgreements" xlink:label="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:to="lab_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="arc" />
    <link:label id="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300_terseLabel_en-US" xlink:label="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued license agreement payment</link:label>
    <link:label id="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300_label_en-US" xlink:label="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued license agreement payment</link:label>
    <link:label id="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300_documentation_en-US" xlink:label="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount payable for license agreement payment.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:to="lab_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="arc" />
    <link:label id="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4_verboseLabel_en-US" xlink:label="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licensing arrangements consideration payable</link:label>
    <link:label id="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4_label_en-US" xlink:label="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangements Consideration Payable</link:label>
    <link:label id="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4_documentation_en-US" xlink:label="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount to be Paid for Technology Rights And Development of License under out license agreement</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:to="lab_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="arc" />
    <link:label id="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA_terseLabel_en-US" xlink:label="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing agreement term</link:label>
    <link:label id="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA_label_en-US" xlink:label="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Term</link:label>
    <link:label id="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA_documentation_en-US" xlink:label="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Term</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingAgreementTerm" xlink:label="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:to="lab_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="arc" />
    <link:label id="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558_verboseLabel_en-US" xlink:label="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licensing arrangements reserve</link:label>
    <link:label id="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558_label_en-US" xlink:label="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangements Reserve</link:label>
    <link:label id="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558_documentation_en-US" xlink:label="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of reserve maintained for the payments made against the licensing arrangements.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsReserve" xlink:label="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:to="lab_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">HPI option termination price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs and discounts excluded from pro forma</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="lab_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="arc" />
    <link:label id="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874_terseLabel_en-US" xlink:label="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MD Anderson</link:label>
    <link:label id="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874_label_en-US" xlink:label="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MD Anderson [Member]</link:label>
    <link:label id="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874_documentation_en-US" xlink:label="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:to="lab_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F_label_en-US" xlink:label="lab_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="lab_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="arc" />
    <link:label id="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643_terseLabel_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement Of Phase II Study For a Licensed Product</link:label>
    <link:label id="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643_label_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Of Phase II Study For a Licensed Product [Member]</link:label>
    <link:label id="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643_documentation_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:to="lab_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="arc" />
    <link:label id="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1_terseLabel_en-US" xlink:label="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Submission Of A New Drug Application</link:label>
    <link:label id="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1_label_en-US" xlink:label="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Submission Of A New Drug Application [Member]</link:label>
    <link:label id="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1_documentation_en-US" xlink:label="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Submission Of A New Drug Application [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfANewDrugApplicationMember" xlink:label="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:to="lab_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="arc" />
    <link:label id="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027_terseLabel_en-US" xlink:label="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt Of Market Approval For a Licensed Product</link:label>
    <link:label id="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027_label_en-US" xlink:label="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receipt Of Market Approval For a Licensed Product [Member]</link:label>
    <link:label id="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027_documentation_en-US" xlink:label="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:to="lab_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="arc" />
    <link:label id="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC_terseLabel_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement Of Phase III Study For a Licensed Product</link:label>
    <link:label id="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC_label_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Of Phase III Study For a Licensed Product [Member]</link:label>
    <link:label id="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC_documentation_en-US" xlink:label="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:to="lab_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="arc" />
    <link:label id="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B_terseLabel_en-US" xlink:label="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Submission Of First NDA Within United States</link:label>
    <link:label id="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B_label_en-US" xlink:label="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Submission Of First NDA Within United States [Member]</link:label>
    <link:label id="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B_documentation_en-US" xlink:label="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Submission Of First NDA Within United States [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" xlink:label="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:to="lab_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="arc" />
    <link:label id="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1_terseLabel_en-US" xlink:label="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Filing Of a New Drug Application For a Licensed Product</link:label>
    <link:label id="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1_label_en-US" xlink:label="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Filing Of a New Drug Application For a Licensed Product [Member]</link:label>
    <link:label id="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1_documentation_en-US" xlink:label="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:to="lab_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="arc" />
    <link:label id="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E_terseLabel_en-US" xlink:label="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E_label_en-US" xlink:label="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E_documentation_en-US" xlink:label="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:to="lab_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="arc" />
    <link:label id="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049_terseLabel_en-US" xlink:label="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049_label_en-US" xlink:label="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049_documentation_en-US" xlink:label="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="lab_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="arc" />
    <link:label id="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F_terseLabel_en-US" xlink:label="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annamed Agreement</link:label>
    <link:label id="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F_label_en-US" xlink:label="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annamed Agreement [Member]</link:label>
    <link:label id="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F_documentation_en-US" xlink:label="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annamed Agreement [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AnnamedAgreementMember" xlink:label="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:to="lab_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="arc" />
    <link:label id="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2_terseLabel_en-US" xlink:label="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moleculin Agreement</link:label>
    <link:label id="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2_label_en-US" xlink:label="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moleculin Agreement [Member]</link:label>
    <link:label id="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2_documentation_en-US" xlink:label="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Moleculin Agreement [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinAgreementMember" xlink:label="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:to="lab_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="arc" />
    <link:label id="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E_terseLabel_en-US" xlink:label="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IntertechBio Agreement</link:label>
    <link:label id="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E_label_en-US" xlink:label="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IntertechBio Agreement [Member]</link:label>
    <link:label id="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E_documentation_en-US" xlink:label="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IntertechBioAgreementMember" xlink:label="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:to="lab_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:to="lab_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:to="lab_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="arc" />
    <link:label id="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF_terseLabel_en-US" xlink:label="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servicing Fee payable</link:label>
    <link:label id="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF_label_en-US" xlink:label="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Fee payable [Member]</link:label>
    <link:label id="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF_documentation_en-US" xlink:label="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:to="lab_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="arc" />
    <link:label id="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57_terseLabel_en-US" xlink:label="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Annual Royalty</link:label>
    <link:label id="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57_label_en-US" xlink:label="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Annual Royalty [Member]</link:label>
    <link:label id="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57_documentation_en-US" xlink:label="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:to="lab_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="lab_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:type="arc" />
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853_terseLabel_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for research and development agreement</link:label>
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853_label_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Research And Development Agreement</link:label>
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853_documentation_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Research And Development Agreement</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreement" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:to="lab_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="arc" />
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128_terseLabel_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for research and development agreement, next twelve months</link:label>
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128_label_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Research And Development Agreement, Next Twelve Months</link:label>
    <link:label id="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128_documentation_en-US" xlink:label="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Research And Development Agreement, Next Twelve Months</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:to="lab_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="arc" />
    <link:label id="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F_terseLabel_en-US" xlink:label="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time license documentation fee</link:label>
    <link:label id="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F_label_en-US" xlink:label="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Documentation Fee</link:label>
    <link:label id="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F_documentation_en-US" xlink:label="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Documentation Fee</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementDocumentationFee" xlink:label="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:to="lab_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="arc" />
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E_terseLabel_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, annual maintenance fee</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E_label_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Maintenance Fee</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E_documentation_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The annual maintenance fee under the licensing agreement.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="arc" />
    <link:label id="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527_terseLabel_en-US" xlink:label="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments liabilities</link:label>
    <link:label id="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527_label_en-US" xlink:label="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Liabilities</link:label>
    <link:label id="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527_documentation_en-US" xlink:label="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount of expense payable towards milestone payments under Patent and Technology License Agreement.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:to="lab_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:to="lab_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to HPI over three-year period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buy-out option payment to HPI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="arc" />
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724_terseLabel_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, maintenance fee annual increase</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724_label_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Maintenance Fee Annual Increase</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724_documentation_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of increase annually on the annual maintenance fee under the licensing agreement.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="arc" />
    <link:label id="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1_terseLabel_en-US" xlink:label="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum royalty payment per year</link:label>
    <link:label id="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1_label_en-US" xlink:label="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Royalties, Minimum Per Year</link:label>
    <link:label id="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1_documentation_en-US" xlink:label="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Royalties, Minimum Per Year</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForRoyaltiesMinimumPerYear" xlink:label="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:to="lab_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="arc" />
    <link:label id="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2_terseLabel_en-US" xlink:label="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional payments due</link:label>
    <link:label id="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2_label_en-US" xlink:label="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payments Due</link:label>
    <link:label id="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2_documentation_en-US" xlink:label="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payments Due</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ResearchAndDevelopmentMilestonePaymentsDue" xlink:label="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:to="lab_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, first anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, second anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, third anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, fourth anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, fifth anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee, sixth anniversary</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="arc" />
    <link:label id="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5_terseLabel_en-US" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual royalty payment, first anniversary following first sale</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5_label_en-US" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year After Product Approval</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5_documentation_en-US" xlink:label="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contractual obligation due in the next fiscal year following the latest fiscal year after product approval.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:to="lab_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="arc" />
    <link:label id="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B_terseLabel_en-US" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual royalty payment, second anniversary following first sale</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B_label_en-US" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Second Year After Product Approval</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B_documentation_en-US" xlink:label="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contractual obligation due in the second fiscal year following the latest fiscal year after product approval.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:to="lab_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="arc" />
    <link:label id="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4_terseLabel_en-US" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual royalty payment, third anniversary following first sale</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4_label_en-US" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Third Year After Product Approval</link:label>
    <link:label id="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4_documentation_en-US" xlink:label="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contractual obligation due in the third fiscal year following the latest fiscal year after product approval.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:to="lab_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="arc" />
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836_terseLabel_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, maintenance fee - maximum payable per year</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836_label_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Maintenance Fee, Maximum Payable Per Year</link:label>
    <link:label id="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836_documentation_en-US" xlink:label="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum payable amount of annual maintenance fee under the licensing agreement.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:to="lab_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="arc" />
    <link:label id="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275_terseLabel_en-US" xlink:label="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee agreement, termination benefits, number of employees</link:label>
    <link:label id="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275_label_en-US" xlink:label="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Agreements, Special Termination Benefits, Number of Employees</link:label>
    <link:label id="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275_documentation_en-US" xlink:label="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Agreements, Special Termination Benefits, Number of Employees</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees" xlink:label="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:to="lab_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="arc" />
    <link:label id="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F_terseLabel_en-US" xlink:label="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits provided to key employees, aggregate amount</link:label>
    <link:label id="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F_label_en-US" xlink:label="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount</link:label>
    <link:label id="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F_documentation_en-US" xlink:label="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:label="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:to="lab_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:type="arc" />
    <link:label id="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97_verboseLabel_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Start Up Costs</link:label>
    <link:label id="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97_label_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Start Up Costs</link:label>
    <link:label id="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97_documentation_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, start up costs.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:to="lab_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State Tax Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:to="lab_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Deferred Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:to="lab_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:to="lab_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation - related party</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:type="arc" />
    <link:label id="lab_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546_negatedTerseLabel_en-US" xlink:label="lab_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain in settlement of liability</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:to="lab_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:type="arc" />
    <link:label id="lab_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57_negatedTerseLabel_en-US" xlink:label="lab_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain from expiration of warrants</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:to="lab_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Moleculin, LLC, net</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from notes payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock, net of cash stock issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D_label_en-US" xlink:label="lab_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:to="lab_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for the Acquisition of Moleculin, LLC</link:label>
    <link:label id="lab_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1_label_en-US" xlink:label="lab_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:to="lab_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for conversion of debt</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:type="arc" />
    <link:label id="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110_verboseLabel_en-US" xlink:label="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued for services provided</link:label>
    <link:label id="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110_label_en-US" xlink:label="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued For Services</link:label>
    <link:label id="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110_documentation_en-US" xlink:label="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of Warrants issued for services provided in non cash financing activities</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantsIssuedForServices" xlink:label="loc_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:to="lab_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for services provided</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="arc" />
    <link:label id="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C_terseLabel_en-US" xlink:label="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Science Advisory Board</link:label>
    <link:label id="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C_label_en-US" xlink:label="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Science Advisory Board [Member]</link:label>
    <link:label id="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C_documentation_en-US" xlink:label="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:to="lab_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="arc" />
    <link:label id="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25_terseLabel_en-US" xlink:label="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roth Capital Partners, LLC and National Securities Corporation</link:label>
    <link:label id="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25_label_en-US" xlink:label="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roth Capital Partners, LLC and National Securities Corporation [Member]</link:label>
    <link:label id="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25_documentation_en-US" xlink:label="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roth Capital Partners, LLC and National Securities Corporation [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember" xlink:label="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:to="lab_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270_label_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="arc" />
    <link:label id="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455_verboseLabel_en-US" xlink:label="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2015 Stock Plan</link:label>
    <link:label id="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455_label_en-US" xlink:label="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Plan [Member]</link:label>
    <link:label id="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455_documentation_en-US" xlink:label="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:to="lab_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="arc" />
    <link:label id="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D_terseLabel_en-US" xlink:label="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreement</link:label>
    <link:label id="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D_label_en-US" xlink:label="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreement [Member]</link:label>
    <link:label id="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D_documentation_en-US" xlink:label="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreement [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AtMarketIssuanceSalesAgreementMember" xlink:label="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:to="lab_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="arc" />
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE_terseLabel_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant One</link:label>
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE_label_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant One [Member]</link:label>
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE_documentation_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant One [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantOneMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:to="lab_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="arc" />
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1_terseLabel_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant Two</link:label>
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1_label_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant Two [Member]</link:label>
    <link:label id="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1_documentation_en-US" xlink:label="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK Consulting Agreement Warrant Two [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantTwoMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:to="lab_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="arc" />
    <link:label id="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F_terseLabel_en-US" xlink:label="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Warrants</link:label>
    <link:label id="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F_label_en-US" xlink:label="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Warrants [Member]</link:label>
    <link:label id="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F_documentation_en-US" xlink:label="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Warrants [Member]</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TheWarrantsMember" xlink:label="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:to="lab_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:to="lab_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="arc" />
    <link:label id="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25_terseLabel_en-US" xlink:label="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCG Advisory Group</link:label>
    <link:label id="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25_label_en-US" xlink:label="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PCG Advisory Group [Member]</link:label>
    <link:label id="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25_documentation_en-US" xlink:label="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:to="lab_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="lab_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:type="arc" />
    <link:label id="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970_terseLabel_en-US" xlink:label="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized</link:label>
    <link:label id="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970_label_en-US" xlink:label="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Authorized</link:label>
    <link:label id="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970_documentation_en-US" xlink:label="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:to="lab_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:to="lab_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued for services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="arc" />
    <link:label id="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C_terseLabel_en-US" xlink:label="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on settlement of liability</link:label>
    <link:label id="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C_label_en-US" xlink:label="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss on Noncash Settlement of Liability</link:label>
    <link:label id="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C_documentation_en-US" xlink:label="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the gain (loss) on liability settled by issuing stock or debt</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossOnNoncashSettlementOfLiability" xlink:label="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:to="lab_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation recorded from settlement of liability</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="arc" />
    <link:label id="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF_terseLabel_en-US" xlink:label="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of units issued</link:label>
    <link:label id="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF_label_en-US" xlink:label="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Units issued</link:label>
    <link:label id="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF_documentation_en-US" xlink:label="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of units issued during the period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:to="lab_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="arc" />
    <link:label id="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633_terseLabel_en-US" xlink:label="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate price of shares issued</link:label>
    <link:label id="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633_label_en-US" xlink:label="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Aggregate Price</link:label>
    <link:label id="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633_documentation_en-US" xlink:label="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Aggregate Price</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:label="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:to="lab_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285_terseLabel_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable period</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285_label_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights Exercisable</link:label>
    <link:label id="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285_documentation_en-US" xlink:label="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights Exercisable</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:to="lab_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of cash subscriptions to be received</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52_terseLabel_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement period</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52_label_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Agreement Period</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52_documentation_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Agreement Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightAgreementPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:to="lab_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580_terseLabel_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580_label_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Issued</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580_documentation_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Issued</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:to="lab_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22_terseLabel_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant vesting period (in months)</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22_label_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Vesting Period</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22_documentation_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Vesting Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightVestingPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:to="lab_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="arc" />
    <link:label id="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1_terseLabel_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period of warrants</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1_label_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Period</link:label>
    <link:label id="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1_documentation_en-US" xlink:label="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Period</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightExpirationPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:to="lab_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense for non-employee consulting agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of underlying shares under 2015 Stock Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="arc" />
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8_terseLabel_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of options granted</link:label>
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8_label_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Aggregate Fair Value</link:label>
    <link:label id="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8_documentation_en-US" xlink:label="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Aggregate Fair Value</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:to="lab_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost recognized, weighted average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares cancelled</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of remaining options accelerated for vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="arc" />
    <link:label id="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB_terseLabel_en-US" xlink:label="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability &#8211; Current</link:label>
    <link:label id="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB_label_en-US" xlink:label="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability Current [Member]</link:label>
    <link:label id="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB_documentation_en-US" xlink:label="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityCurrentMember" xlink:label="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:to="lab_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="arc" />
    <link:label id="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611_terseLabel_en-US" xlink:label="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability &#8211; Long-Term</link:label>
    <link:label id="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611_label_en-US" xlink:label="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability Long-Term [Member]</link:label>
    <link:label id="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611_documentation_en-US" xlink:label="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityLongtermMember" xlink:label="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:to="lab_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="arc" />
    <link:label id="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16_terseLabel_en-US" xlink:label="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability &#8211; Total</link:label>
    <link:label id="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16_label_en-US" xlink:label="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liabilty [Member]</link:label>
    <link:label id="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16_documentation_en-US" xlink:label="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabiltyMember" xlink:label="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:to="lab_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="arc" />
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710_terseLabel_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclass of liability from long-term to current</link:label>
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710_label_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis , Transfer of liability from long-term to current</link:label>
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710_documentation_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transfers of financial instrument from long term to current.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:to="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value - net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfer in and out (exercise of warrants)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="arc" />
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324_negatedTerseLabel_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expiration of warrants</link:label>
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324_label_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Expirations</link:label>
    <link:label id="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324_documentation_en-US" xlink:label="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of Expiration of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:to="lab_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:type="arc" />
    <link:label id="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0_terseLabel_en-US" xlink:label="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Liquidity</link:label>
    <link:label id="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0_label_en-US" xlink:label="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Business and Liquidity [Text Block]</link:label>
    <link:label id="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0_documentation_en-US" xlink:label="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for nature of business and liquidity.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NatureOfBusinessAndLiquidityTextBlock" xlink:label="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:to="lab_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC_terseLabel_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC_label_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Pro Forma Operating Expenses</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC_documentation_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The proforma operating expenses for a period as if the business combination or combinations had been completed at the beginning of the period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaOperatingExpenses" xlink:label="loc_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:to="lab_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54_terseLabel_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54_label_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic And Diluted</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54_documentation_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:to="lab_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:type="arc" />
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777_verboseLabel_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average outstanding common shares - basic and diluted (in shares)</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777_label_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Weighted Average Number of Shares Outstanding, Basic And Diluted</link:label>
    <link:label id="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777_documentation_en-US" xlink:label="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:to="lab_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal Tax Benefit at Statutory Rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State Tax Benefit Net of Federal</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181_negatedTerseLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">IPO Costs</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Initial Public Offering Cost</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial offering costs.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57_negatedLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock Warrant Costs</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Stock Warrant Costs</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Stock Warrant Costs</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19_negatedLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other Permanent Differences</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in Deferred Tax Rate due to Tax Reform</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total Tax (Expense) / Benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Tax Benefit at Statutory Rate (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">State Tax Benefit Net of Federal (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED_negatedLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">IPO Costs (percentage)</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Initial Public Offering Cost Percent</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial public offering costs.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C_negatedTerseLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock Warrant Costs (percentage)</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Stock Warrant Costs, Percent</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Stock Warrant Costs, Percent</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:type="arc" />
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9_negatedLabel_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other Permanent Differences (percentage)</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9_label_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</link:label>
    <link:label id="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9_documentation_en-US" xlink:label="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:to="lab_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in Deferred Tax Rate (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in Valuation Allowance (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total Tax (Expense) / Benefit (percentage)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance at Beginning of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:type="arc" />
    <link:label id="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD_verboseLabel_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Release of Valuation Allowance</link:label>
    <link:label id="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD_label_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Releases</link:label>
    <link:label id="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD_documentation_en-US" xlink:label="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of valuation allowance released during the reporting period.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:label="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:to="lab_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance at End of Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="arc" />
    <link:label id="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806_terseLabel_en-US" xlink:label="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806_label_en-US" xlink:label="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable Disclosure [Text Block]</link:label>
    <link:label id="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806_documentation_en-US" xlink:label="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for convertible notes payable.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:to="lab_mbrx_ConvertibleNotesPayableDisclosureTextBlock_019DFA952CA838BBED554E92A9EBF806" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:to="lab_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:to="lab_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_3BEC72B8A7044EAE19674E92F0AE3AF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:to="lab_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:to="lab_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:to="lab_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment, net of accumulated depreciation of $21 and $6, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC_label_en-US" xlink:label="lab_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:to="lab_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:to="lab_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:to="lab_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred compensation &#8211; related party</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC_label_en-US" xlink:label="lab_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:to="lab_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="lab_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:to="lab_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 authorized, 21,469,109 issued and outstanding at December 31, 2017 and 12,164,852 shares issued and outstanding at December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:to="lab_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:to="lab_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Expense (Benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Expense (Benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Tax (Expense) / Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:type="arc" />
    <link:label id="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37_terseLabel_en-US" xlink:label="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37_label_en-US" xlink:label="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity [Table Text Block]</link:label>
    <link:label id="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37_documentation_en-US" xlink:label="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for warrant activity.</link:label>
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:to="lab_mbrx_ScheduleOfWarrantActivityTableTextBlock_16C929373DB5A6290E124ED441D9AF37" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mbrx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:href="mbrx-20171231.xsd#AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheets" xlink:href="mbrx-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:href="mbrx-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:href="mbrx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:href="mbrx-20171231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:href="mbrx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/Equity" xlink:href="mbrx-20171231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:href="mbrx-20171231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:href="mbrx-20171231.xsd#EquityScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:href="mbrx-20171231.xsd#EquitySummaryOfOptionActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/EquityTables" xlink:href="mbrx-20171231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxes" xlink:href="mbrx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:href="mbrx-20171231.xsd#IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IncomeTaxesTables" xlink:href="mbrx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssets" xlink:href="mbrx-20171231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mbrx-20171231.xsd#IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:href="mbrx-20171231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:href="mbrx-20171231.xsd#NatureOfBusinessAndLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:href="mbrx-20171231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfOperations" xlink:href="mbrx-20171231.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="mbrx-20171231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEvents" xlink:href="mbrx-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:href="mbrx-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbrx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiability" xlink:href="mbrx-20171231.xsd#WarrantLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:href="mbrx-20171231.xsd#WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:href="mbrx-20171231.xsd#WarrantLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4670BDC62276B595D0865419DE166C13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4670BDC62276B595D0865419DE166C13" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AC4D4F9E0904D0BEBB895427370F6B56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_5EE5F127BF9554878E8C5419DE139A36" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedClinicalTestingCurrent" xlink:label="loc_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_mbrx_AccruedClinicalTestingCurrent_597A4DFF5B7168CD35645419DE142F31" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseFeesAndSRACurrent" xlink:label="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_mbrx_AccruedLicenseFeesAndSRACurrent_2EC21AFAC60B78D91E7A5419DE14755B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_967303348C3C8F96F3C65419DE140B19" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedBoardExpensesCurrent" xlink:label="loc_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_mbrx_AccruedBoardExpensesCurrent_6C12F7955D1988F43FBA5419DE14C558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1E4F73B7AF4318871AFF5419DE144F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1E3B3301315F87DD4CA85419DE13DD91" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_E70C48582CF3A76458585419DE14BE02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_E9615C92190CE377C3E825A406FB9887" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9615C92190CE377C3E825A406FB9887" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2D6642C2B4CBD82466E625F171533C79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B8D88B7E9DB7488242BB53E2ABE6F998" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B8D88B7E9DB7488242BB53E2ABE6F998" xlink:to="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83229F260C7B4D52B72C53E2ABE6448B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_32F4129CBC27E83E49E253E2ABE65912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3B16DB6BB9CD4D0FD0DA53E2ABE670E2" xlink:to="loc_us-gaap_AssetsCurrent_A1BA817A35B0C823607A53E2ABE6B418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23CAC5C14E1A8AEAE3F953E2ABE64F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_F9812765E4C6F188704753E2ABE6B52E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9989B87C0F2843C8868C53E2ABE60BDA" xlink:to="loc_us-gaap_Assets_F25AEF499B9AC95B8F0953E2ABE615AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B8D88B7E9DB7488242BB53E2ABE6F998" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="loc_us-gaap_AccountsPayableCurrent_C6342720076B3F73484B53E2ABE6EAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_A1AAE279F786B45B983453E2ABE720A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_AEBC822F791E6A8248E253EEFA828936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_E1509ADE383C99DF06BC53E2ABE73F31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_E1509ADE383C99DF06BC53E2ABE73F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2C6D2B86701495232FCB53E2ABE6CA9E" xlink:to="loc_us-gaap_LiabilitiesCurrent_A778DFEA5B3457926B3553E2ABE79D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_A2CDDE316C5B4679FB3053E2ABE752E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_Liabilities_7A17FA173896BAE37EB253E2ABE7F4EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_D06754FE4E05D2AF84D553E2ABE7AE8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="loc_us-gaap_PreferredStockValue_184E8B7E523DA8CF8CBA53E2ABE7014E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="loc_us-gaap_CommonStockValue_781011B0964E135F0FF553E2ABE70D09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6A99B6DA461C1679885C53E2ABE74FEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_53049C059DAD2BAEAFDF53E2ABE792A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B8E4C21686F2A2972ED153E2ABE73745" xlink:to="loc_us-gaap_StockholdersEquity_52A571FF0762C004074353E2ABE7815B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_427304DE790574487BB153E2ABE663D8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_03846751268D0231389B53E2ABE70FD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E10D3F783C25DD90419767AE9B4C5E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9E38E36A6BF37030FE2867AE9B4CA871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9C799CE9456844CE4E2267AE9B4CBC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_PreferredStockSharesIssued_A2F07FC8456675460EA467AE9B4CABCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_F8547129C4F07D9B6E7267AE9B4CB5CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8CA71BEB6FA916D68F9B67AE9B4CCAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_C7CD380717C6DB7F141C67AE9B4D1FF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_CommonStockSharesIssued_6E951B5C64C914C8D1FF67AE9B52CC08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A768923F8897C205C17167AE9B4CB649" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_D006F5D2AA19219A0FFB67AE9B52F4DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_234E09FC8B732A7DB97E5557B6A0056D" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DF4D90D6B7BDA48FD0005557B6A07839" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AE811B979F0CB8C388967AE9973EDA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AE811B979F0CB8C388967AE9973EDA0" xlink:to="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_832C5EE2ED701511F1E267DEBE9449A4" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_D13D1B27A22A55C1796F67AE99752C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_D13D1B27A22A55C1796F67AE99752C80" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MdAndersonMember" xlink:label="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1F714CADB3354E6EAB7967DEBEAC881B" xlink:to="loc_mbrx_MdAndersonMember_D1F108347AFC959AE4F967E0410DF874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D69987593E7598D33DC567AE9974BA0A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DCCFD61F58FED786960967AE9974A6D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E348BBC2D196B4659DA067AE9974E18F" xlink:to="loc_us-gaap_SubsequentEventMember_DCCFD61F58FED786960967AE9974A6D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3612059E88A5F372B3E967AE99742396" xlink:to="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_CommencementOfPhaseIiStudyForLicensedProductMember_32FFDEC18CA017E3661B67D4AA918643" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfANewDrugApplicationMember" xlink:label="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_SubmissionOfANewDrugApplicationMember_D1F44256ED6ACD331C8E67D4AA9198C1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ReceiptOfMarketApprovalForLicensedProductMember" xlink:label="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_ReceiptOfMarketApprovalForLicensedProductMember_3F5FAADC656FD2CBA3FE67D4AA911027" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember" xlink:label="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember_626444D61FB769C73F3D67AE997479BC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember" xlink:label="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember_BC641374D4A901D1E7FB67AE9975326B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FilingOfNewDrugApplicationForLicensedProductMember" xlink:label="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_218CDEC30D5BC9C1453167AE9974E46F" xlink:to="loc_mbrx_FilingOfNewDrugApplicationForLicensedProductMember_91E210DCAEC3760E92F867AE9975CFD1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementAxis" xlink:label="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AgreementDomain" xlink:label="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementAxis_7757E9B08279A553CE5A67AE9975994E" xlink:to="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AnnamedAgreementMember" xlink:label="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_AnnamedAgreementMember_E6E0851A7743A5D8187F67AE9975646F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinAgreementMember" xlink:label="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_MoleculinAgreementMember_00CAB0CF2149BC274BA067AE9975F9A2" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IntertechBioAgreementMember" xlink:label="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_AgreementDomain_AACA02F31BF3973393A867AE9975F049" xlink:to="loc_mbrx_IntertechBioAgreementMember_B18AE4591D66F483000667AE9975BC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_CB5BBFFF9A42558D57B667AE9975AAC5" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ServicingFeePayableMember" xlink:label="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:to="loc_mbrx_ServicingFeePayableMember_21D3CFA69E91714A864967AE9975C9CF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MinimumAnnualRoyaltyMember" xlink:label="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3D7CF4CE0CA34E5F511367AE9975DCB9" xlink:to="loc_mbrx_MinimumAnnualRoyaltyMember_4B91D9F1E51B4B07730967AE99769B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_D315C452DBEFC837CE2167AE99767F1A" xlink:to="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7070C39FD4A8119EFCA567AE997672EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:to="loc_us-gaap_MinimumMember_7070C39FD4A8119EFCA567AE997672EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8C3131F8FD6825013F8467AE99763C6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F36058E861F5FA4A233567AE997651C9" xlink:to="loc_us-gaap_MaximumMember_8C3131F8FD6825013F8467AE99763C6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_178FAB3B6BB55FC5E8C167AE99733D76" xlink:to="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreement" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForResearchAndDevelopmentAgreement_8B0635102B982E63C13967AE99761853" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths" xlink:label="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths_4897F32B4974A281193967AE99766128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_A165250D87EB8B8A5CA967AE99769EEA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementDocumentationFee" xlink:label="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementDocumentationFee_71AB2BC4BC142149700E67AE9976F32F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFee" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFee_EEEFCA6325867B4E588567AE9977220E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MilestonePaymentsLiabilities" xlink:label="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_MilestonePaymentsLiabilities_457781D5628508EFBB2867AE99770527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_LicenseCosts_D01C3A729B6271635B7967AE99772837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D6089CDA0E61B3E4316667AE997768B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2551880306C5881CE4FE67AE99777295" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingAgreementTerm" xlink:label="loc_mbrx_LicensingAgreementTerm_BA37827DD89379A0D78267AE9977F1E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicensingAgreementTerm_BA37827DD89379A0D78267AE9977F1E8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease_538B724B89AF246FFE2267AE99770724" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PaymentsForRoyaltiesMinimumPerYear" xlink:label="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_PaymentsForRoyaltiesMinimumPerYear_464BB5A6D90981E35AA067AE99777AC1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ResearchAndDevelopmentMilestonePaymentsDue" xlink:label="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ResearchAndDevelopmentMilestonePaymentsDue_2E0904574B68F7273B6267C7AE31A8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_90805E26318017BFC00067AE99761B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_81D5A6548829592931DE67AE99765C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_64962EBD963665A51E2767AE997632E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_125154F5C2F4770176CE67AE997643DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_309853395322289A975967AE9976FF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_E29B4B46BA13433FDA8267AE9976F405" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval_B9D0692E64E9FCFBAE5067AE99773AD5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInSecondYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInSecondYearAfterProductApproval_4019136CE8A5B3F204A867AE99775B3B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ContractualObligationDueInThirdYearAfterProductApproval" xlink:label="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_ContractualObligationDueInThirdYearAfterProductApproval_FBF64E55242945FA5D0F67AE997759B4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear" xlink:label="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear_3E7B2311D51B84978F6167AE9977E836" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RoyaltyOnNetRevenuesPercentage" xlink:label="loc_mbrx_RoyaltyOnNetRevenuesPercentage_4CBC3BF2D1D4CB2DF2E767AE997781FE" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_RoyaltyOnNetRevenuesPercentage_4CBC3BF2D1D4CB2DF2E767AE997781FE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees" xlink:label="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees_4E931620A0419BAA32CA67AE99779275" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount" xlink:label="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C1B6F0F70F33E465561967AE9976303E" xlink:to="loc_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount_41BF1BC753A115014BCA67AE9977A26F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayable" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A3F16F170E490D1978594E92A9E838AF" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_0A7EC6BCEBF9E98558154E92501A4E60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A3F16F170E490D1978594E92A9E838AF" xlink:to="loc_mbrx_ConvertibleNotesPayableDisclosureTextBlock_0A7EC6BCEBF9E98558154E92501A4E60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4EFDD2A0F51F0EF368AE67AE99F8DD23" xlink:to="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C6F12BA34EB740CE2EEB67AE99F847F8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_DFF9AB949E3A7A061EFC67AE99F9C882" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_6EDCEEAE37DF8349D92F67AE99F94F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_50C82C6783D375E245B567AE99F9CA9B" xlink:to="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D30B8175F2DBBF2001CE67AE99F90636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:to="loc_us-gaap_MinimumMember_D30B8175F2DBBF2001CE67AE99F90636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B7A96678C44DA0ADC4EF67AE99F93563" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A74FA9830724400549DE67AE99F9B385" xlink:to="loc_us-gaap_MaximumMember_B7A96678C44DA0ADC4EF67AE99F93563" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtTradingTermsAxis" xlink:label="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtConversionTermsDomain" xlink:label="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtTradingTermsAxis_A7EA3BB7ED8B2216156667AE99F91F2A" xlink:to="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermOneMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermOneMember_D00AA4103CCA45481AF467AE99F99709" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermTwoMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermTwoMember_08ACDB662D78B4041CEB67AE99F94EAB" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermThreeMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermThreeMember_65340B48ACA392C530A867AE99F94D12" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFourMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermFourMember_15BE8C1A22110E82284467AE99F9B0D9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermFiveMember" xlink:label="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DebtConversionTermsDomain_33BA2331C5F29D6FECB767AE99F94BFC" xlink:to="loc_mbrx_DebtInstrumentTradingTermFiveMember_B23F7ED4543851A21FEE67AE99F96419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9A3BC7D2B909055AB17A67AE99F90303" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnsecuredPromissoryNotesMember" xlink:label="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8C3F7216ED53DA6E8FC967AE99F90E9A" xlink:to="loc_mbrx_UnsecuredPromissoryNotesMember_9B62FA5DC2C95BD432EB67AE99F950D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17268D424CC4F457BA9E67AE99FA51C9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E0B6993607E9889583C067AE99FAC6A0" xlink:to="loc_us-gaap_IPOMember_76B07DA8967FF1DEF98467AE99FA06E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3966D3274474F59BC39B67AE99F893E3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered" xlink:label="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered_9FBDDC8F7551FB3C05D067AE99FA6505" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors" xlink:label="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors_0AF1B031B925A0C0566067AE99FA57D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_828AA2AA94AC1DE8B2BD67AE99FAB0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F6127EAAF547895827A367AE99FA8495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C9DB31C65613351B5CF267AE99FA430D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_CB09B91D70CD7E101EB067AE99FA8B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_us-gaap_InterestPayableCurrent_5163ECCF72D975A553C367AE99FAA20F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold_0CAA59DF344DA2A0CAE267AE99FAC273" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument_B481A9A9B5ECE91B574D67AE99FA509E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume_8817A7FAC2ECB72411AD67AE99FA112C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock" xlink:label="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock_C5249A9EE00A660D0CF967AE99FA93B6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold_B07E96A2B3B48A04958067AE99FA8566" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument" xlink:label="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E1578ED840A043946F5B67AE99FA2612" xlink:to="loc_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument_A7B6150341D6FBB5736767AE99FA858B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5275DBF946CA8ED459D94E937EA0FD54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5275DBF946CA8ED459D94E937EA0FD54" xlink:to="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_A3A83AE9A98D23DCD7654E92500E3F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_A3A83AE9A98D23DCD7654E92500E3F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_A3A83AE9A98D23DCD7654E92500E3F93" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_34AA3934AD43517CD4444E92500F9C63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:to="loc_us-gaap_InvestorMember_34AA3934AD43517CD4444E92500F9C63" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorBMember" xlink:label="loc_mbrx_InvestorBMember_B512971B11D8CC03D6E94E92500F7A4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:to="loc_mbrx_InvestorBMember_B512971B11D8CC03D6E94E92500F7A4B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorCMember" xlink:label="loc_mbrx_InvestorCMember_C7E0100649381E0958774E92500FABEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:to="loc_mbrx_InvestorCMember_C7E0100649381E0958774E92500FABEF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_InvestorGMember" xlink:label="loc_mbrx_InvestorGMember_86F2C3758DE8ED66F27A4E92500F9100" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_67EADB0B2C08CE7E12454E92500FC0B6" xlink:to="loc_mbrx_InvestorGMember_86F2C3758DE8ED66F27A4E92500F9100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3E5E8FA47DE089C5E0254E92500F1BA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:to="loc_us-gaap_DebtInstrumentAxis_3E5E8FA47DE089C5E0254E92500F1BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3E5E8FA47DE089C5E0254E92500F1BA1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateAugust312015Member" xlink:label="loc_mbrx_IssueDateAugust312015Member_E64F764CB2100755EBF64E92500F4DFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:to="loc_mbrx_IssueDateAugust312015Member_E64F764CB2100755EBF64E92500F4DFC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateSeptember032015Member" xlink:label="loc_mbrx_IssueDateSeptember032015Member_F08024A4ED8CB12C01A74E92500F9ACF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:to="loc_mbrx_IssueDateSeptember032015Member_F08024A4ED8CB12C01A74E92500F9ACF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateOctober062015OneMember" xlink:label="loc_mbrx_IssueDateOctober062015OneMember_85048895FCDDCD164BDA4E92500F4FA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:to="loc_mbrx_IssueDateOctober062015OneMember_85048895FCDDCD164BDA4E92500F4FA0" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IssueDateJanuary192016Member" xlink:label="loc_mbrx_IssueDateJanuary192016Member_57F87CD12F365D51B8744E92500FDAB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F17A82F68F9E7A8A92B64E92500FE9F8" xlink:to="loc_mbrx_IssueDateJanuary192016Member_57F87CD12F365D51B8744E92500FDAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_FA7869B27AC9E9534B444E92500F6BFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_FA7869B27AC9E9534B444E92500F6BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7D5DE0C263ECFBF761F24E92500F0334" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_FA7869B27AC9E9534B444E92500F6BFA" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7D5DE0C263ECFBF761F24E92500F0334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D50A288DC07F71DCD8A14E92500F09AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7D5DE0C263ECFBF761F24E92500F0334" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_D50A288DC07F71DCD8A14E92500F09AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_C8FACF699B11D51562B44E92500E75D2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_55E68009496FC1AAF6034E92500FBA70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_55E68009496FC1AAF6034E92500FBA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BF1D685B35A876A50F34E92500FF6AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3BF1D685B35A876A50F34E92500FF6AA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentConvertibleNumberOfCommonShares" xlink:label="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_8FD295D8ED070C11EA0E4E9250109436" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:to="loc_mbrx_DebtInstrumentConvertibleNumberOfCommonShares_8FD295D8ED070C11EA0E4E9250109436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_05058996C97FE386A1344E925010C541" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C1EF8799EF101F81E2834E92500FEBD8" xlink:to="loc_us-gaap_InterestPayableCurrent_05058996C97FE386A1344E925010C541" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/ConvertibleNotesPayableTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3724CD29AC27EE248D264E92F0ACC1F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_B634153884F7B85A863A4E925018D4C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3724CD29AC27EE248D264E92F0ACC1F6" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_B634153884F7B85A863A4E925018D4C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DocumentAndEntityInformationAbstract" xlink:label="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_DocumentType_A19E470631485CA7D7915557B69DFF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_AmendmentFlag_A03CC5C63D82CB7696755557B69DFD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_DocumentPeriodEndDate_461E1F844038FDC0CA475557B69E5B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_DocumentFiscalYearFocus_E16B61F0ECCAEFF9EC6E5557B69E0EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_DocumentFiscalPeriodFocus_36AC47BA5DA7D3017F5D5557B69E5E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityRegistrantName_4D533FBABE546642AC665557B69E6BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityCentralIndexKey_E3D3C7CEEB312AF3972B5557B69E6C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_CurrentFiscalYearEndDate_BC258CC8A377D5432F8B5557B69EF456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_D26B8BB5975A5D5EA4255557B69E212C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityVoluntaryFilers_C93A60A8D3A690938A5F5557B69EEE52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityCurrentReportingStatus_69EFAFB109F0A73D86C75557B69E5E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityFilerCategory_B3AC5B254760CFA1CA8A5557B69E0A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityPublicFloat_D89005274B475F17B3EB5557B69E2B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_TradingSymbol_5126A220F3C3628C5D6D5557B69E70C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DocumentAndEntityInformationAbstract_CBB8DF71BF0E0AD03F735557B69D4B8B" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_044B66CE1271607B3DA75557B69E2211" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7FF2821B50EA8EFD2DFC5557B6D7E305" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7FF2821B50EA8EFD2DFC5557B6D7E305" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E327827F6F172928DDD35557B6D73D49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6082FC3B84E94B88191762B6750CE798" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6082FC3B84E94B88191762B6750CE798" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8F4CA664C600D6DDB8C962DE81223EC4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FormerScienceAdvisoryBoardMember" xlink:label="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_57761BC92DB898F011C062DE81268CE6" xlink:to="loc_mbrx_FormerScienceAdvisoryBoardMember_4B38D23C530B93FEDAF262DE8163935C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8A3F11CA8A8D5F7DE4DD62B6751BB731" xlink:to="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C29A5ED46CA7E0BE41C962B6751B28A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C40F9A1BF316CB1AE66862B6751B5060" xlink:to="loc_us-gaap_CommonStockMember_C29A5ED46CA7E0BE41C962B6751B28A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_F235079D3555824373BA62B6751B36ED" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember" xlink:label="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56D21C801003B313E4D862B6751B283B" xlink:to="loc_mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember_AB401D373931559B97CA62B6751B3D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_563CEF6925EBB051CC2962B6751B433B" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CE300DD42161C5EAEE0062B6751B9451" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_EB4486EA4DEF4A30B3C762B6751B0270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_686CDE4843CDB896F8BD62B6751B7667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockPlanMember" xlink:label="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C555A1C501A30BEEF40562B6751B6628" xlink:to="loc_mbrx_StockPlanMember_86FD30A2EF0EC646387662B6751B7455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_AE5755D83DA36B1F0FA562B6751B649C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_28794A29B9E260B6A89A62B6751B52E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:to="loc_us-gaap_IPOMember_28794A29B9E260B6A89A62B6751B52E5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AtMarketIssuanceSalesAgreementMember" xlink:label="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3D2C6044B88AE975ABD662B6751B8288" xlink:to="loc_mbrx_AtMarketIssuanceSalesAgreementMember_8952BE2C0557B47EB05D62B6751B528D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197E4A1C719991594F762B6751B702B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0C8A8A09202DEA6359C662B6751B7E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_us-gaap_WarrantMember_0C8A8A09202DEA6359C662B6751B7E65" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantOneMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_GSKConsultingAgreementWarrantOneMember_C3779D15068875D1BEF162B6751B4FBE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GSKConsultingAgreementWarrantTwoMember" xlink:label="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_GSKConsultingAgreementWarrantTwoMember_E25DC3B286208F1793D662B6751BBDC1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TheWarrantsMember" xlink:label="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_30C41BE1D68F6E5C6BA562B6751BA5AF" xlink:to="loc_mbrx_TheWarrantsMember_1720DBAFA541D21CCC9262B6751B844F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2A8461DE00A8A317850D62B6751B4AB6" xlink:to="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PcgAdvisoryGroupMember" xlink:label="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_03E60060BC060396CAA662B6751B21F5" xlink:to="loc_mbrx_PcgAdvisoryGroupMember_9CCE76FDDAD5B60F805A62B6751B7B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CA20E7FAD6DAD8717D1262B6751B75A1" xlink:to="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0F8DE56410A69213968962B6751B4302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:to="loc_us-gaap_MaximumMember_0F8DE56410A69213968962B6751B4302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B97961F9E505F2DD684D62B6751B27AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BE29E7EDA23F746996A662B6751BD90F" xlink:to="loc_us-gaap_MinimumMember_B97961F9E505F2DD684D62B6751B27AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5C4900AE902259A4087862B6750C8EBC" xlink:to="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharesAuthorized" xlink:label="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SharesAuthorized_B7FBF9B7AD58541AFF1862B6751BF970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45E11E307A9BCE618D1762B6751B8A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99521CAA4ED1659DB28462B6751B19C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_PreferredStockSharesIssued_EC73F1E9FA371C565F7662B6751B4699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_F172414EB2E7237882A662B6751B5A44" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossOnNoncashSettlementOfLiability" xlink:label="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_GainLossOnNoncashSettlementOfLiability_9C779A7971889D42782362B6751B0A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_CB390FDCC16422357E6562B6751BF123" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfUnitsIssued" xlink:label="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_NumberOfUnitsIssued_AE1867D505B7FFE8EE5D62B6751BF8AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4AEC17E673980EBB7B1A62B6751BA9E9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4AEC17E673980EBB7B1A62B6751BA9E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_158442F6B71492DBC36F62B6751B4A2E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_158442F6B71492DBC36F62B6751B4A2E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice" xlink:label="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice_412084886F720012172162B6751BE633" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:label="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_3BA3E6FACEC6CB7A591C62B6751BD0C6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_3BA3E6FACEC6CB7A591C62B6751BD0C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ECB30D39ACD055473B9D62B6751BF636" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ECB30D39ACD055473B9D62B6751BF636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A832228E9DC04C45807662B6751B3FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E4855C232C0B567EF7FF62B6751B5B7E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E4855C232C0B567EF7FF62B6751B5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C9E8AEA1B93C14D209762B6751B9D51" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9C9E8AEA1B93C14D209762B6751B9D51" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable_2C8501D0D3E25A1FCA7362B6751B2285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E5145658F8173703CEBC62B6751B6478" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_E5145658F8173703CEBC62B6751B6478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_8BF86514C9DE9D7D2A8762B6751B4A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_ADEB574B5C83C758D5EB62B6751B7648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_91C23C1BA4DF99922A8362B6751B6CCD" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_91C23C1BA4DF99922A8362B6751B6CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_26E0FB440F2D7D53DD2062B6751B410E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_26E0FB440F2D7D53DD2062B6751B410E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_98C214F2157253FD8BA062B6751B45A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8C53680716F2341FBBB462B6751B9D84" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightAgreementPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightAgreementPeriod_01E1991D7ECA798B311A62B6751B4E52" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightNumberofWarrantsIssued" xlink:label="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightNumberofWarrantsIssued_E627FAB594127CB9D56062B6751BA580" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightVestingPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightVestingPeriod_34B1D68B14B4AA94944E62B6751B0A22" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassofWarrantorRightExpirationPeriod" xlink:label="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ClassofWarrantorRightExpirationPeriod_60E56BE5AA2335E46EF862B6751BC5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_133638188CF6201E01D062B6751B6990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_821FD92BE0754D3D08A862B6751BDA50" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue_7EC6E8B6DC505AC2A12D62B6751B78E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_729917253A055E0B2E6F62B6751B996E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88A3AE3E47AD40D2E55D62B6751B14B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6A0A06F031A8F63958E862B6751B4BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_225330CBF8D49BC6DF1F62B6751BC1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_F055B4570FC230B4759E62B6751BBFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A4795A7C7E5A569B69EB62B6751B6D2D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_097F101995B5E5E9E9A062B6751B58F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DD0A4C07CC289EC8A0D04B0D120C803D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DD0A4C07CC289EC8A0D04B0D120C803D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:to="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_346DEC52F041ED29B60B4B0D120C1351" xlink:to="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_01C1E72E5526A2B83F5E4B0D120DA604" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:to="loc_us-gaap_MinimumMember_01C1E72E5526A2B83F5E4B0D120DA604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_87947B656C787F87A95D4B0D120D2AD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BD7068D4EC3F671CC2444B0D120C112B" xlink:to="loc_us-gaap_MaximumMember_87947B656C787F87A95D4B0D120D2AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1D942D1445845D441B3C4B0D120C2B7C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E2C55756044C8723D824B0D120DF685" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E2C55756044C8723D824B0D120DF685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_80BEC589B5E7A67A0BB74B0D120D53BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_80BEC589B5E7A67A0BB74B0D120D53BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_F5A70EE2C2888255B3ED4B0D120D9DAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_F5A70EE2C2888255B3ED4B0D120D9DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_00EF71D42D812D87BFC74B0D120D1A7C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5553FC47064A8C12011A4B0D120D163E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_01B127243028406E9E884401CAFFF586" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_01B127243028406E9E884401CAFFF586" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D466045B57F948D8C2D54401CAFFC2D8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A9C3F4D77277404B333D4401CAFFCBD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_787D6C1568646B29D2814401CAFF7904" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4C2BA7E0684B3810FA194401CAFFCAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EDEEF62D96DD1BCBB5BB4401CAFF3619" xlink:to="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FEF693109825EF0FB9C14401CAFFC855" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38599A2836FBC6EC9B134401CAFF4665" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EDCEFCEE5B2F429409826418F8FA00D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_780F170EFF19C993A0956418F8FADAFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_780F170EFF19C993A0956418F8FADAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2717C58C73DD85C675AF6418F8FA0968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DB30EB14E81C5B5754DF6418F8FA8F6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28C020F2A40EABFE9AA26418F8FAF84E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_209652B621F67C0002D16418F8FAB804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2968E94CB4DE9A5B9C3D6418F8FA524F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_472F28C622B23E334D1C6418F8FA5D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5CFF571EEA67095153BC6418F8FA66D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6CCDDA11B91787E96ED76418F8FAFF1E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_99D6E2231683C3E0AEB76418F8FA0174" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_34D056C8EAEEB2964A546418F8FAA7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0735A4A9C07219B875236418F8FB869B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B44DF9059774E04D6A0B6418F8FBDBFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/negativeLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2C7D06FC458F21CE6B056418F8FBCA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3773879138D23A3F38F76418F8FB6CC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F842F76865A74B8056A6418F8FB56FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_18B28BE82C91527B9C536418F8FBC755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8E023AE68435664256C66418F8FBE268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7F3B07DF29855BF31B8F6418F8FB49FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2D9EABF0E110A394294C6418F8FB599A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C7F7CA44E1F8230C03816418F8FA2171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_A1E27CDC3DEEFAA4D7106418F8FBC270" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9542B7FBA21FA3D5A3704401CB72E2B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9542B7FBA21FA3D5A3704401CB72E2B8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7D1020A5C14468AC28114401CB720A1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9542B7FBA21FA3D5A3704401CB72E2B8" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_5EEC15434223A0AD54E3443040CC6CA3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ComponentsofShareBasedCompensationTableTextBlock" xlink:label="loc_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9542B7FBA21FA3D5A3704401CB72E2B8" xlink:to="loc_mbrx_ComponentsofShareBasedCompensationTableTextBlock_25384E1FEFCF555EFE6644368EB842BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A7A0F315B888C29BFF485557B6A90763" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A7A0F315B888C29BFF485557B6A90763" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_533F2357D44E598E6AAF5557B6A9FC44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9BC20A1AF905BAE45BEE62B674DD2CF4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FB8576C44D0FB36A282762B674DD4D7F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_EA954DD178B151B6CDD962B674DDB733" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FederalStateandForeignJurisdictionsMember" xlink:label="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_F15D4D0999F7BB6F142762B674DD9DD0" xlink:to="loc_mbrx_FederalStateandForeignJurisdictionsMember_E5E18CF37F8AB88F15DC62B674DD8632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_A41755DCBF957789253D62B674DDF079" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_E44D6057404D51C89F22632D070690DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_OperatingLossCarryforwards_A6CF5D80076653E15BC862B674DDBD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2C8ABCF23F7B4DDB5D7062B674DD3C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_F1C50335A761972F88EF62B674DD7899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_E9C4A76721A44A3E0F0F62B674DDB6D5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3714B27AA187946686E962B674DD75BB" xlink:to="loc_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_22CFADDDCFA7AFDF397F62ED4825D3B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29EF3A76AE49C3E34FE662B674EC048B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29EF3A76AE49C3E34FE662B674EC048B" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_EC0FC4F783D4E9CC29EA62B674EC725C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_49933769956F598602BD62B674EC1359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9B937202997587E2DB8762B674EC0A95" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E386A025E64D12598FB362B674ECC750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29EF3A76AE49C3E34FE662B674EC048B" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_C07A1D16217E4787089A62B674ECCFAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_184D702E6577F807681862B674EC6EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0DA21EB861AB0F30D13E62B674EC9BD0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8817A5E8E6A153540CAB62B674EC8A12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29EF3A76AE49C3E34FE662B674EC048B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66C0BD2C53B34484816462B674ECB382" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1137EB8060B8E54B654F535E3B286B59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1137EB8060B8E54B654F535E3B286B59" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DeferredTaxAssetsStartUpCosts" xlink:label="loc_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_mbrx_DeferredTaxAssetsStartUpCosts_2363D29A4E252875318E535E3B287E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_DAFE677CC3B87689D5D0535E3B29EC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_261C07FA3E0F4FD67B93535E3B291D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C9C3414E54BF8CB8C2DB535E3B299C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_14E8CC879CC056028140535E3B29F866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0162F6903D24C73D5F5E535E3B29F206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0B8F09EF1BC9F90F444C535E3B284663" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3076866A59CC495BAF09535E3B29E325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1137EB8060B8E54B654F535E3B286B59" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71ED834497DF210688A7535E3B290F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_69487C85F03B9665B867535E3B291CDB" xlink:to="loc_us-gaap_DeferredTaxLiabilities_B80F0E5798D46A1E501D535E3B290699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1137EB8060B8E54B654F535E3B286B59" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1BA755A1E125E8D9C2A7535E3B299D00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EB5B010E764A7F88EA9467F5D80BD76D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EB5B010E764A7F88EA9467F5D80BD76D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1A8B1A5F7DAD91E7691C67F5D80B4083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_30BC68F2DCEC6053468367F5D80BB594" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost_8A5FCB8F79BEB870FA6367F5D80B7181" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts_AF48A80D05BD9CC82A0D67F5D80C7D57" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_E7FF13079BFD0FE6215667F5D80CCE19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_F65DD2A2A9434F3DEDC967F5D80C2E3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_C59D3F27238C5412E4FD67F5D80C05C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_C53D693D964A1173386267F5D80CF487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_24EA6543840A8B5AA92667F5D80B73C3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1299339CB8000923228967F5D80DB83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EB5B010E764A7F88EA9467F5D80BD76D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_52699E6FD998579A079067F5D80D1B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_984D9C4E670C6F8C9A9E67F5D80DF872" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent_3F3E4812F52893ABAA9A67F5D80D56ED" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent_56D1D1C3071CD65351F467F5D80D8C7C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent" xlink:label="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent_51680E7A6DBF8D1FBDAD67F5D80D57D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051293B0CEAE89D7952267F5D80D7EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C7C577A43193148FCE9E67F5D80D01A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_793F8BEC9B27A680BE0367F5D80DE5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C02FA5101437CB0B81BA67F5D80D12BD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_D632B6A17AC66ADD59E067F5D80E2A6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29DDE1F3C4F5708E4C8C5557B6A2B3FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29DDE1F3C4F5708E4C8C5557B6A2B3FE" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_535A2142AF6FC56A02365557B6A220E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_60CC4BC14F9F39CFC58B5557B6A295E4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DeferredTaxAssetsValuationAllowanceReleases" xlink:label="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:to="loc_mbrx_DeferredTaxAssetsValuationAllowanceReleases_4A703BCE239A89664D885557B6A20DAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CD196AC5B1F3ED4A775E5557B6A2C2F9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1D195DB2EB4415703B185557B6A25433" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C739F430F4F6AEA11E565557B6CC275E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C739F430F4F6AEA11E565557B6CC275E" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_DBFD3A2C863DAB449ED35557B6CC1694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C739F430F4F6AEA11E565557B6CC275E" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_C8119FD59C5AD6F85DB15557B6CC79B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C739F430F4F6AEA11E565557B6CC275E" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_AE14B1E59C4B3C7593FF5557B6CCC4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C739F430F4F6AEA11E565557B6CC275E" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AE816626D545B8D32BED5557B6CC8D05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94A1F381D6D36D65675D5557B84E2D10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94A1F381D6D36D65675D5557B84E2D10" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F50A57B6ED41AF0ACD6A5557B84E98A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DD2A9C4CC5D3457AE1FD6836202D5D04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DD2A9C4CC5D3457AE1FD6836202D5D04" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4B82ADC6B8E6EBCE57796836202DCFD1" xlink:to="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_52A0374061418E2A84F16836202D989B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24DB161B8D40C4484EA66836202D5BDA" xlink:to="loc_us-gaap_CommonStockMember_52A0374061418E2A84F16836202D989B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB2EE57691CE25D6A88D6836202E14DA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_210787ECE9DC508F52B56836202EAC57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_370E425A4250C564A5C36836202E63AC" xlink:to="loc_mbrx_MoleculinLlcMember_210787ECE9DC508F52B56836202EAC57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B32225399D4747F10B0F6836202E66C1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicenseAgreementMember" xlink:label="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:to="loc_mbrx_LicenseAgreementMember_7DF2E3A3894FC75432666836202E6059" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OutlincenseAgreementMember" xlink:label="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_927D77DCD027912602D16836202EA878" xlink:to="loc_mbrx_OutlincenseAgreementMember_0C6CEE80D5FAC35648EE6836202E3704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7537B9899D92AEFAE35F6836202EE790" xlink:to="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_581A67A994ACCE00C0BA6836202E43C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_D7EB9A3E495FCB36845E6836202EEDAF" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_581A67A994ACCE00C0BA6836202E43C9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeAxis" xlink:label="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PeriodTypeDomain" xlink:label="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_PeriodTypeAxis_3114DD0F6B042AEFD9096836202E398F" xlink:to="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AcquisitionDateOneMember" xlink:label="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_PeriodTypeDomain_5A26C894AE73B795BB2F6836202E58D5" xlink:to="loc_mbrx_AcquisitionDateOneMember_61B397352F42C19A880E6836202E57B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9D19E59284F72B62463D6836202D5E66" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_FAA1FDF2791745C69EF56836202FC49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_9B6DE4BFC7279FC545DA6836202F5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_ABC2577DF352D032C1B56836202F58D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_SharePrice_ABC2577DF352D032C1B56836202F58D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_9CFCF95149899FF0A7DD6836202F570D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_RoyaltyOnNetRevenuesPercentage" xlink:label="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_RoyaltyOnNetRevenuesPercentage_2E2DF83FBAD21ED21C556836202F70E9" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionIndemnificationAgreementTerm" xlink:label="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_BusinessAcquisitionIndemnificationAgreementTerm_4DBE7E93D91FF99E66B66836202F83DF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionNumberOfAgreements" xlink:label="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_BusinessAcquisitionNumberOfAgreements_AA62F0DCAEF71DFA73A36836202F33BA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AccruedLicenseAgreementPayment" xlink:label="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_AccruedLicenseAgreementPayment_E93C5C330453558739D56836202FA300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E07AA47F739DE89664DE6836202FE834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_44B4359A7AD41C861EE46836202FE899" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_44B4359A7AD41C861EE46836202FE899" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsConsiderationPayable" xlink:label="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingArrangementsConsiderationPayable_C26EFEB4C4B1950454846836202F1CE4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingAgreementTerm" xlink:label="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingAgreementTerm_8AEDB91131AF59945A7268362030AFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_61DDB67A9FA6A98BA70F683620309EC2" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LicensingArrangementsReserve" xlink:label="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_mbrx_LicensingArrangementsReserve_47A1D25A024FC045910B68362030A558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_C357DE2F34E1F9E84E2E68362030B450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_C26D18C996A5186DAE3D6836202E2F8F" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_B63F5F3A65357BADEAEE68362030D89E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4D6C29E5CF8FBD28AEBB5557B755B65B" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8D6A802205988B4D3B095557B755F004" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9525CDCFD1DBB601626D5557B755FEF2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_B1C28E18811D419EA3BA5557B7558FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_A3B6058C3128740F5D7E5557B75544EA" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_7FF90558A934AB1B37F15557B7555689" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AF40665ECEF88392A7AE5557B755BE0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F069FB8EF6AB083610316836201C7749" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaOperatingExpenses" xlink:label="loc_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F069FB8EF6AB083610316836201C7749" xlink:to="loc_mbrx_BusinessAcquisitionProFormaOperatingExpenses_66A1099E5ECC2556BA766836201C26DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F069FB8EF6AB083610316836201C7749" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_F2EE6B255CE06EACD30E6836201C40D2" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F069FB8EF6AB083610316836201C7749" xlink:to="loc_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_DF77F6F50FFC3E0BC8386836201CCE54" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F069FB8EF6AB083610316836201C7749" xlink:to="loc_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_F31C8AED9BEA1E2ACA676836201C2777" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A9CED3D75FC4F6A8050D67F5640CAC5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A9CED3D75FC4F6A8050D67F5640CAC5C" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA5CBF37F0BA883E2E767F5640E0EC1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_D0052E65BBA393691D7367F5640E2CB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A83B1BA579D72F9E0B4D67F5640EE350" xlink:to="loc_mbrx_MoleculinLlcMember_D0052E65BBA393691D7367F5640E2CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:to="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_BE897DBAD7A73A7B3DAE67F5640E0E17" xlink:to="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_HoustonPharmaceuticalsIncMember" xlink:label="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_338838D94CC1D71A1B9E67F5640ED373" xlink:to="loc_mbrx_HoustonPharmaceuticalsIncMember_293E0D9B585F8C50BE2067F5640E6B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_C6F680835544BDD896C167F5640EF1FC" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C992C17A191EF2B4296B67F5640E1DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_DF51B5354EBBE96E388067F56410D5D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_D324A3DEBD59C09C02E967F564107FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4241E1118FFAF6F40FEF67F5641015D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9AEDAD6244BAE6BA122C67F56410A5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3956CD6BF91836D69A8267F564111DCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5EC246E081D8E3F3CCA267F564113B0B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_CFE8F4E55306725FC9C267F5640E2231" xlink:to="loc_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_4BCCE5C9F6861AB58ABC67F564119113" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D210E90392AD69B8851C5557B88FEC6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D210E90392AD69B8851C5557B88FEC6F" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_C7312CB054FDBE1F100D5557B89012FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D210E90392AD69B8851C5557B88FEC6F" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_B63E813C1B04AA5DE7765557B8901282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D210E90392AD69B8851C5557B88FEC6F" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_562E6280B03357C77A415557B89067FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E9D33F7711B79E19C6C5557B7C65882" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NatureOfBusinessAndLiquidityTextBlock" xlink:label="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E9D33F7711B79E19C6C5557B7C65882" xlink:to="loc_mbrx_NatureOfBusinessAndLiquidityTextBlock_E046D93193D4EE208BCF5557B7C6C0B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfDrugTechnologies" xlink:label="loc_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:to="loc_mbrx_NumberOfDrugTechnologies_9222FE7B338A1B3EEE0063D6CF35A7EF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_NumberOfOtherDrugDevelopmentProjects" xlink:label="loc_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:to="loc_mbrx_NumberOfOtherDrugDevelopmentProjects_9AD64D351D9E5357F01063D6CF35AA86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FFC232BAB76DD5BE0A6E63D6CF3511F7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_B76C5127FFF8D411822063D6CF35692B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:to="loc_us-gaap_NetIncomeLoss_92D7B3F08A15213DAA6553E2ABA9F8B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_F88186BDB81443BE155853E2ABA9B3A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_ShareBasedCompensation_D880D677DE1307594AD953E2ABA9C9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_D9678797C9EA7727E6B453E2ABA9B939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_677F0A174B2FB16564F953E2ABAA597F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_677F0A174B2FB16564F953E2ABAA597F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_mbrx_GainFromSettlementLiability_68DFFADED73BAA8C0EB753E2ABAAE546" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_mbrx_GainLossFromExpirationOfWarrants_A7F80E922E713E949AB153E2ABAA0D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_B6BE7C0811B94953BAED53E2ABAAB332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_05E16880804C095E51BC53E2ABA969A1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_70DAB5E991088670542653E2ABAA35C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_29826041144A99EFAD8353EAB0CFD410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36BE89046556048C516853E2ABAA7774" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DC090F2F48EA3D0360E753E2ABAA49CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_42DA72E1E645E9B51A7B53E2ABA9D0F4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27694946786EBEB706D453E2ABAA3725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_022266AF86CEC120291853E2ABAA81C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0F230F1C0B4ADE037F6853E2ABAA4866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_203954D02E2592C7235953E2ABAA0333" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_C14B6E2423CDEC2620B053E2ABAAAE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2BEC40A62A54AA62433A53E2ABAB07B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_C14224D873EB95E383D153E2ABAB691F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5A2C921593C9D2E9FCB253E2ABABADC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0B0B4465CF69D63D4B2253E2ABABF407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_C7EDE3035DC139CAA4B253E2ABAB4B88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E5D20CE417B6BED4692353E2ABABC319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0279241E13681421228253E2ABAB1582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D76F70A69178E7A0A353E2ABAB9FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0D2D013CE5416481064253E2ABAB186D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:to="loc_us-gaap_InterestPaid_98452AF1E90844227A5153E2ABABB60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_376ACC5F406F1218FBB853E2ABABAA15" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_8043C54B024D011BB48C53E2ABABEB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_63FAE7F23A2BC1F8971853E2ABA97634" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:to="loc_us-gaap_StockIssued1_B4DB78E18D40A79A5D7453E2ABABC1A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_28D03D1DF8B0F6DD57CA53E2ABABFADF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantsIssuedForServices" xlink:label="loc_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:to="loc_mbrx_WarrantsIssuedForServices_FDC5553550163997C46853E2ABAB9110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_BBB8CB549AF816266B6F53E2ABABEE65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_FE7B82DF4DE12B330D2B53E2ABAC75DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_SalesRevenueNet_E06E80598EC87A808E2767AE9B323DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_00E0012A16540310B50D67AE9B32A78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_18845761057C1D6166D767AE9B32EDBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_B00C4A3C62E13126151867AE9B3774AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_399DF2BE7E2C4A1E591767AE9B32A38E" xlink:to="loc_us-gaap_OperatingExpenses_2B7A524013CA4E4D203367AE9B376BD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_OperatingIncomeLoss_F73A017DA1BAF185FC7E67AE9B3756E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1277714E4DA8558DD6BD67AE9B38325E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainFromSettlementLiability" xlink:label="loc_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="loc_mbrx_GainFromSettlementLiability_78572F237F2425A71A3267AE9B38C8DE" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GainLossFromExpirationOfWarrants" xlink:label="loc_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="loc_mbrx_GainLossFromExpirationOfWarrants_8CB035552B66E7A7628067AE9B38D538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="loc_us-gaap_OtherIncome_FC27EC7385D2F23C81B867AE9B38EF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AF7A6EB7DA7E9962F10B67AE9B38741C" xlink:to="loc_us-gaap_InterestExpense_B37194941CC0BC82B7E067AE9B38B325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_NetIncomeLoss_7BDFC70B68B9DEDD734A67AE9B381631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2541E28E82D53D2B993367AE9B386989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_EE9856196F2B713DF98667AE9B32B67C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_89F391C3B0887D503D1067AE9B385C5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_B44F1E3689C3D5458D016416AF38579F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_B44F1E3689C3D5458D016416AF38579F" xlink:to="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C26CC81D876FC8150F7D6416AF392F80" xlink:to="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3BEB215644659BDA67FC6416AF3964E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_CommonStockMember_3BEB215644659BDA67FC6416AF3964E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_64A51B951E07E419DEA26416AF39D6A4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SubscriptionsReceivableMember" xlink:label="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_mbrx_SubscriptionsReceivableMember_84C385F82AA0CC677DE76416AF39BEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_EB0CC7AF9AF65098D1F66416AF39C602" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_997F564460EF96EE1FA36416AF391E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CE2526DAC32A3378745B6416AF387879" xlink:to="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_SharesOutstanding_FC98211014BA3CE392136416AF393941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockholdersEquity_1926EC3DA75409E5E98F6416AF3951CD" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesPrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances_AC074C40B32F2E6199B46416AF39E096" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValuePrivateIssuances" xlink:label="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValuePrivateIssuances_F650A4245E829A9430FB6416AF3988B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0A09BDB4ADCE1821F3AA6416AF39C6A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_187FD0AF5F0BDA68A33F6416AF39AB75" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForTechnology_0633F7648329037AE5F56416AF397A90" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForTechnology" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForTechnology_0E0896BF3B8C3A51DEC66416AF3AC631" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_438991AFAAD78CA9FA9A6416AF3A009B" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts_D704F3877149DCB02AAC6416AF3A66AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EF9C54713436F6C498326416AF3AA119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34FDDACEBE31EB826CD36416AF3ADA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_9ABE4C59AB1F7D1B52BD6416AF3A2427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8C3E2C56789A752276B6416AF3A8B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_F781EC9F749EB31101BF6416AF3A7534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_09FEC3939EBF67048C586416AF3AA43C" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockholdersEquitySubscriptionsSettledForCash" xlink:label="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockholdersEquitySubscriptionsSettledForCash_F22A042A45A1932FFD396416AF3A4DC8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits_386E75E9135652FEAE946416AF3A4882" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueSaleOfUnits" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueSaleOfUnits_68A4A4383DDD334DDD9B6416AF3AF999" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised_B1121AB1C1966F01E7666416AF3A9191" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueWarrantsExercised_3BCEC4AEDCAE4AB661B36416AF3A43B7" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering_117097DD32F569CE82B36416AF3BD967" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering" xlink:label="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering_101FD9D2BF9AA77347CB6416AF3B145D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_NetIncomeLoss_789F9618022D5D4CD5126416AF3B4332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_SharesOutstanding_F9CCECA5BAD3D45C46886416AF3B1533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8163BE45BE0D6A86ABA76416AF39E59F" xlink:to="loc_us-gaap_StockholdersEquity_DB826EC502D2C8B94BDB6416AF3BDC34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_82CC915F4471234262FC641831509001" xlink:to="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_236BD9C6DE87063E176C6418315040F4" xlink:to="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0CB52464896704E571D0641831508670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B739994722DF744D776B64183150B133" xlink:to="loc_us-gaap_CommonStockMember_0CB52464896704E571D0641831508670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BE23625313422DAA944F64183150A2B2" xlink:to="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6DF3141B4131F9F3653E64183150A37D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6DF3141B4131F9F3653E64183150A37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_D54CC158977CF434CEF4641831500F5D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits_C027653CD4221D47218364188FA7DF97" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts_C36C5B5107986C60F512641831514A4D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering" xlink:label="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_934823D6E60D95BD39036418315078D4" xlink:to="loc_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering_24779FAC0A7F376C22EF64183188E415" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E5A12E12EAB488562D0B5557B6D3366C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E5A12E12EAB488562D0B5557B6D3366C" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_B8F4F6CCFF40F7EFB2F45557B6D3C988" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_40786B84B395683D9C506418F8BA2B6D" xlink:to="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A2D93B26991BD42D8AE96418F8BBFDC3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_97B25697A1FE181D155A6418F8BBD490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40BB1EC9F33C9B16C9226418F8BBAA2A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_97B25697A1FE181D155A6418F8BBD490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_554C3A8B2F909C3074306418F8BB2877" xlink:to="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5E882E81851E8742B4F46418F8BB3196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_74A6E03A8C98A6F1B2746418F8BB7C9A" xlink:to="loc_us-gaap_CommonStockMember_5E882E81851E8742B4F46418F8BB3196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E00CE96F5DD96CD6921E6418F8BB0AAF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:to="loc_mbrx_SecuritiesPurchaseAgreementMember_598699034171FA30DAE96418F8BBAF85" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_PlacementAgencyAgreementMember" xlink:label="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57626F69563ECBF70D466418F8BBA058" xlink:to="loc_mbrx_PlacementAgencyAgreementMember_F575994D70C69B2F03C46418F8BBC356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_B0438AB948C10F04B4116418F8BB265D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_IPXMemorialDriveInvestorsLLCMember" xlink:label="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CBF23148665D311E08446418F8BB4C77" xlink:to="loc_mbrx_IPXMemorialDriveInvestorsLLCMember_AACBCA74B0C73EBF67DD6418F8BB5977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_5653D8E145074BBE650E6418F8BB9562" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LeaseAgreementForCorporateOfficeSpaceMember" xlink:label="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_C2646B03429C0C9D50A66418F8BC803E" xlink:to="loc_mbrx_LeaseAgreementForCorporateOfficeSpaceMember_84FEA1B5B777C8C03F9D6418F8BCC06A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_D9D3428CFA1F4105D2E06418F8BC1EAA" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScienceAdvisoryBoardMemberMember" xlink:label="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_441757771234ABC871E96418F8BCDCA6" xlink:to="loc_mbrx_ScienceAdvisoryBoardMemberMember_7BC57FDD69E00EAA7CE46418F8BC18D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00DC1149A6539A3DD75D6418F8BCEE1F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C48B1AA5CC11FB300D06418F8BC4EAD" xlink:to="loc_us-gaap_SubsequentEventMember_3CB9151556AD611517946418F8BCD2AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2D46D251E8787344F7BA6418F8BA405E" xlink:to="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4DBE260ADE5DDA96BAF86418F8BC0B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0532688A8484361E4AAF6418F8BC625E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6AAED42385C5CB3F3E906418F8BC64A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_67EC0763280F89FD8FB16418F8BC84B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52A61D2CC7BEBE166B5D6418F8BC3776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FF6039B9A28327BF9B9C6418F8BCAF68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_D92D8D381E49A52AE2336418F8BD4A24" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightInitialExercisePeriod" xlink:label="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_ClassOfWarrantOrRightInitialExercisePeriod_EF744876DE055FCEEE2D6418F8BD0336" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_ClassOfWarrantOrRightTerm_93D171DDF7AC851D02996418F8BDAABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A6E23E9FB14040E0E5726418F8BDC8A6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A6E23E9FB14040E0E5726418F8BDC8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7B25CECDC1B9B39D5B466418F8BD27E4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds" xlink:label="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds_01D1A060EEDD855FB61D6418F8BD08B1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions" xlink:label="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions_A9DA6C231E96882C1A086418F8BD42B1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockReimbursementOfExpenses" xlink:label="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockReimbursementOfExpenses_7F279F1BE80DD7440BF66418F8BD3A0D" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockRightOfFirstRefusalPeriod" xlink:label="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockRightOfFirstRefusalPeriod_DD3807AD8CAE99AF84616418F8BD7184" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod" xlink:label="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod_BE9539BA53190248E9C56418F8BDE78F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_LesseeOperatingLeaseAreaOfOfficeSpace" xlink:label="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace_8BEAA1BC5E13365A2CE26418F8BD27A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2091D1D4B3AB765AD0FF6418F8BD1354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_9404135250A9125C63AE6418F8BD9FA6" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeasesMonthlyRentExpense" xlink:label="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_OperatingLeasesMonthlyRentExpense_012922F50E1F96FB57546418F8BD6065" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent" xlink:label="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6AAB09671971CFE0FD7D6418F8BCB046" xlink:to="loc_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent_D2939757F1D94F788FFE6418F8BDEEBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8B0051B3DF73132EC8D84F201AF30660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8B0051B3DF73132EC8D84F201AF30660" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23D76DB7B243FE24EC1E4F201AF3F83B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1C4D3C658E45D22ED9FD448627F8ADBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1C4D3C658E45D22ED9FD448627F8ADBC" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0D6C4B1CF2C179F61F54448627F811CE" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityCurrentMember" xlink:label="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabilityCurrentMember_990BDBD98CB476CBADF4448627F9BECB" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabilityLongtermMember" xlink:label="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabilityLongtermMember_4290E6DE6B999850BD66448627F9B611" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantLiabiltyMember" xlink:label="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E908D90CCBD84FD8550F448627F8E040" xlink:to="loc_mbrx_WarrantLiabiltyMember_E18230DB5B7EAF842C2F448627F9EB16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CEAB340D1A95923943B0448627F94910" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_071C1226A54A49999ECE448627F98F89" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_D3F3D7429155EE97E277448627F9F37F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2276BA223FE3F1FAA943448627F8ABF1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_C3193F04A70DB619F163448627F97A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_961AD3CBFD0B941DD1FD448627F98079" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent_876F73368C102A4B3CFE448627F9E710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_87CC398685631A0C5BAC448627FA44B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_787E65C4B92814C3B9E7448627FA00FA" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations" xlink:label="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations_C396E9D9AFCF79C6EBCF448627FAA324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1E93EE9406C2AE3D5514448627F9A8FF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63774186AA779D4AA9E2448627FA5698" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CA12E0E7F62A759BE4802A3419838D97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CA12E0E7F62A759BE4802A3419838D97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0766E38F187FFFA4D40D2A577312446B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_FA5B26B9254721DE7A162A5773478CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_17AC78DC4B9B6C0404C72A57735A4CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_16BDBB505E6525B6B8312A57737C3FA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9C2981662DDE82000A5A2A5773210431" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_16BDBB505E6525B6B8312A57737C3FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_780FBF6CBBE49D74D0E62A5772DF0103" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_FB0AA8E5FE8F9A0BFDB12A5772DFFF42" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_9F93F3BC637A9AC8D1A72A5773017765" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EDEF1572ABC380285CB662B67634977D" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_30B9D6EAE52E6A87C45B62B6763407FD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14DE6365CFC4396F81D162B6763454F2" xlink:to="loc_us-gaap_ConvertibleDebtMember_170A11F0D632CFAD2FDC62B67634462C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_5693E4AAE6CADE41472962B67634535D" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1EE7D36D39B224FD1F6562B676341208" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A4A119CA2C0211F8720D62B6764395B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_35B48CF056D16886EC5062B676431CC7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_50898D70DB3264C67E1B62B67643FAB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FDD2FA233CA336E0B42D62B676438C4F" xlink:to="loc_us-gaap_WarrantMember_50898D70DB3264C67E1B62B67643FAB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27AE02863883508FC6D962B67643C2DF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_ComputerEquipmentMember_EA34B4BB1985317C0E1962B67643DC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7DB6C3107F104AFE88A762B676437CAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7801146E8E37B4921B9262B67643D0D9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_43CD2463D87A028A6E1762B676435124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E3EAEEF23013EA620B8C62B676430DB6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_MoleculinLlcMember" xlink:label="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7B72A40EC5699F4F8FED62B676430AB1" xlink:to="loc_mbrx_MoleculinLlcMember_3A7C32AE1FB078C99BF262B676435C87" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1FB2BA8806F2C75137E162B6763480CD" xlink:to="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5CC7144BFCE163A5083662B676430EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_CashFDICInsuredAmount_8136C33C60D5DA4994AB62B67643C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_39CD9165E713C982BA7162B6764371EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_2CEB11956DDA9BC88E4962B6764367C1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C6783095F21023FC21D262B6764367D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_UseOfEstimates_782A20D3D8214BC3D1524F201AEFD732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_46D421D54B1BACBE4B2C4F201AF09976" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_GoingConcernPolicyPolicyTextBlock" xlink:label="loc_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_mbrx_GoingConcernPolicyPolicyTextBlock_97E2DCE467D74DCED0324F201AF08F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8322303DC0AB2B5FED2E4F201AF0A107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C174555E1CAA590C81E34F201AF03357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_89F4277F1DA9D32D20614F201AF0CBEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_AB7C5BB99C168346E5C64F201AF0CC3F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock" xlink:label="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock_040235F03F11D84A26684F201AF0799C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_D4AA228B52115487AB524F201AF0DCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_640784830E8DA0BEF9AA4F201AF1BEDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_F581C0B8D48811CBBE114F201AF187ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_B89964952F0975B2209C4F201AF1ED73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A899E5A1BD415C9A75F54F201AF1A5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ACCAF69AD20DF70E4CB44F201AF1C85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7F4D594F86969BBE43B4F201AEF078D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DDF681BA06B9C1B629D14F201AF11942" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D1A1DA4E166EEFE801BC4F201AE8102C" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D1A1DA4E166EEFE801BC4F201AE8102C" xlink:to="loc_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_7481B537D5B634860E084F201AE8CA7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D1A1DA4E166EEFE801BC4F201AE8102C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3FFEAB11C02DD4F5833B4F201AE9BA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D1A1DA4E166EEFE801BC4F201AE8102C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1A1001D8249AB05C73D14F201AE9D731" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiability" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1A98B1EB3FAB5088F6D54ED410696189" xlink:type="locator" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_WarrantsLiabilityDisclosureTextBlock" xlink:label="loc_mbrx_WarrantsLiabilityDisclosureTextBlock_09394A6FC0AFED5A1E974E92500A75F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1A98B1EB3FAB5088F6D54ED410696189" xlink:to="loc_mbrx_WarrantsLiabilityDisclosureTextBlock_09394A6FC0AFED5A1E974E92500A75F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_623F2282F03BE97AC13B63D6CE74B725" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5C765497036090B716D463D6CE742CAB" xlink:to="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_UnderwritingAgreementMember" xlink:label="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4DF9090C0DB9F76301EA63D6CE74FAD3" xlink:to="loc_mbrx_UnderwritingAgreementMember_F68D1C951FBEB09D49D363D6CE74A9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5173123763D8F672C11F63D6CE744DEB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesWarrantMember" xlink:label="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesWarrantMember_93F24E261FF631DFD49263D6CE74EE97" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesBWarrantMember" xlink:label="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesBWarrantMember_5EED59457CD697738C1263D6CE744681" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesCWarrantMember" xlink:label="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesCWarrantMember_FAECCDB3A0B2C5FC00D663D6CE74999F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SeriesAndSeriesCWarrantMember" xlink:label="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58E150AB9A29BE6BBF7B63D6CE74A2A4" xlink:to="loc_mbrx_SeriesAndSeriesCWarrantMember_0F19E9B936BB50E1C8BE63D6CE75B85C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_738F46F96268D3331B7163D6CE758771" xlink:to="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:to="loc_us-gaap_CommonStockMember_DAA19E5236F68D5E858763D6CE7568CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D04972B5B512237BC8B663D6CE75F3E6" xlink:to="loc_us-gaap_WarrantMember_983B89AAB3AEB88D754D63D6CE75D3CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F0AC95F530413BC6A43663D6CE7532F1" xlink:to="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:to="loc_us-gaap_MinimumMember_73513ACBBCD7214775A463D6CE7506D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0BA92E67FDFC8DA8320363D6CE755743" xlink:to="loc_us-gaap_MaximumMember_FC77177A8D0C9BD39AC763D6CE7AC5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668AB007F086B678BA5263D6CE74FCE5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts" xlink:label="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts_08E0AA2988096BABAA3963D6CE7AB5A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6241E91CDC50B6D7294E63D6CE7B341A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5E9DA65A8F910C02FC4063D6CE7B5F50" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightTerm" xlink:label="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_ClassOfWarrantOrRightTerm_2F62499908A8295BB8C563D6CE7B9395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1A982496EF12820CCE0263D6CE7B631A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26EC7D503871C70EA7FA63D6CE7B8FC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6B0E3774600AA4C66F1463D6CE7B9300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_SharePrice_5C91F535A5B6410E0C6C63D6CE7B441F" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount" xlink:label="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount_221E7E12A6E54E9C9D7663D6CE7B2F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_76D1590FF413BE94523463D6CE7B4607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_438A3E2043F243D09DB663D6CE7B4FB8" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_87FE4AB1F44B6F36D6A663D6CE7B4444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90CCC115A3BF4E8C251563D6CE7B5A94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_568081ACA3E0FAB252A363D6CE7B2A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7F279A203F71FFDF231963D6CE7AD3AC" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2A8A0FDBA8921556350363D6CE7B4B0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9438E586F27B4B3C8C274F201A95AC42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9438E586F27B4B3C8C274F201A95AC42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F4F587ABBDB1664233084F201A96ABBF" xlink:to="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A294C553CCDC25FAEDF94F201A96AF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6EB78CB54DB4B54DFB684F201A965E90" xlink:to="loc_us-gaap_WarrantMember_A294C553CCDC25FAEDF94F201A96AF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:to="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_28C55F98A246003FF9A34F201A963688" xlink:to="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_66CD5B5AECEA30F8CB914F201A9602A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:to="loc_us-gaap_MinimumMember_66CD5B5AECEA30F8CB914F201A9602A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2DAF3BAEE6629DB9DE314F201A963746" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_16941C8CC00A9BE869C54F201A96F65F" xlink:to="loc_us-gaap_MaximumMember_2DAF3BAEE6629DB9DE314F201A963746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87BB5EE0170B8DF6F93D4F201A9569EF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0D7142BE07EDB87A67104F201A96846F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_04FDF7C470B73F9164AB4F201A96042C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_F67278B2FB61D0DB12784F201A964A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797B5EA7492D22E46AAE4F201A9622EB" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_472B5627B817BAC8D6E24F201A966D01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B0270DED6756A200EB6468361F6E159E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B0270DED6756A200EB6468361F6E159E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:to="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8BD5250B0749053CC59368361F6EDFE7" xlink:to="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4B05B00F025880BCCACA68361F6E5EE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:to="loc_us-gaap_MinimumMember_4B05B00F025880BCCACA68361F6E5EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9F95D4CF9B01BF77A2AD68361F6E5B9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D9106720E43D0D5514A468361F6E88E1" xlink:to="loc_us-gaap_MaximumMember_9F95D4CF9B01BF77A2AD68361F6E5B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EB16850C4A620B200E1E68361F6E8672" xlink:to="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0C9F22CBBECBFB42B77768361F73BD63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30CE26F8749903DDC61368361F6E8DA8" xlink:to="loc_us-gaap_WarrantMember_0C9F22CBBECBFB42B77768361F73BD63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BCE707B3B686E641956A68361F6EB080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C5D4DF9B4ED4788AE4868361F7462CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B72D3AC6D4E45311355B68361F74EF57" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_597E113C88C21368680068361F745D17" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_946F3C9465288327DC1E68361F7435BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6449F2389FD64174DB5C68361F742FCE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149854EF5E7A9D4FC5BF68361F74F5FD" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber_1DC0875D571F2AE66EFF68361F741035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5777D6149A94C822F76368361F74A50A" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue_F7E7B1EB6CB12C98671568361F741AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_4A6BD19E694B0DB3743868361F7523FF" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice_6B3EAA607D3B810CFE3268361F75D0FC" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice_E6B16156039DE306FA4E68361F756900" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice_89675CA6B79E67916FAB68361F75A5A0" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60EF940A2C2F7087071968361F742EC7" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_ABF1A6F741E299ED31CC68361F75DF22" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice_B36667DDA5255F6E874868361F758EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CC1F25A9091F0D541E8468361F74571D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_02A05A806E18DBD1D92168361F75E9A1" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms_19FD0296847D75F1F08A68361F75C0C0" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms_FDD28389DBEBD8ABED7768361F75CEE3" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms_3FC995602B681D750DB068361F75D997" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_47F12A126F0DF852B7D268361F7595A9" xlink:to="loc_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms_A401634EE0D501D41B0768361F75FE25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.moleculin.com/role/WarrantLiabilityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_14C3C7AE20DC2464D8484ED441D8A867" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_998BEFD8A6525D2B38504E925008EAB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_14C3C7AE20DC2464D8484ED441D8A867" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_998BEFD8A6525D2B38504E925008EAB7" xlink:type="arc" />
    <link:loc xlink:href="mbrx-20171231.xsd#mbrx_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_mbrx_ScheduleOfWarrantActivityTableTextBlock_CCFC31D5A8F2A2ED2E194E9250085640" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_14C3C7AE20DC2464D8484ED441D8A867" xlink:to="loc_mbrx_ScheduleOfWarrantActivityTableTextBlock_CCFC31D5A8F2A2ED2E194E9250085640" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cancerindustrychart.jpg
<TEXT>
begin 644 cancerindustrychart.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  .@ 0 #     0 !  "@ @ $     0   :"@
M P $     0   /D     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ !K_V@ , P$
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MCVAU>#PM<75S_P )#/I(7S0YNU;[,ER\/SK%Y9 R%.6XK?\ B;^VKXLMM?\
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M\2?&C4M+L_LUP)'@M89(6FU24*CJY^RB-P,L><9S0!]T4444 %%%% !1110
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M<G.;NWU85G:Q_P @B^_ZX2_^@FM&L[6/^01??]<)?_036E7X632^)'S(.E%
MZ45\FSZ00@$8/(KZ7^#'[4_Q/^$$\&GV]TVNZ I ;3;QV957_IA(<M$?0#*^
MJU\TUN:9:8'VJ0<G[@_K_A657"PK1Y*BNC6EB9TGSP=F?T%_";XS^"?C'HO]
MI^%[G9=0A?M5E-A;BW8]F4=5ST=<J?7.0/6:_G8\(^+_ !'X$\06OB?PI>O8
M:C9ME)$Z,.Z.O1D;HRG@U^UOP#^.NA_&SPR;N,+9:[8!5O[+.=C'I)'GDQ/V
M/4'Y3R,G\_S[AV6&_>TM8?E_7<^[R3/XXG]W4TG^9[U1117RY](%%%% '__4
M_?RBBB@ HHHH **** /!/B+X+\%^%]&U#QS+HLNLRV*S,ED]S((C)?W"/*RE
MRWEY<[C@A%!;@ DUY9IL7PXO-,UO6SX--Y+)>,LUJUY-(5@O8HY97CC* IF5
M%26,+G>IR< "OJ'QU=^)+'PIJ%UX1@%SJ\:KY"$;LDNH;CN0N2.#TZ'I7BUM
MXZ^/:0Z9;W'@>*6YN% FF$P14PP7<XR<!@"Q4<@%>^5 !S7PXTCX<?%BVOM*
MU7P2VG(C?:I?,O)Y97F<LCO)("I;S=S%6#L)%W'TS](>*-?L_!GAU[W:#Y*B
M*WC))W/C"KD\X&,D^@-:^B7.I7FD6ESK%L+.^DC4S0JVX))CY@#W&>E?,?Q=
M\1MJ_B,Z7"V;;3!LQV,I^^?PX7\#7I95@O;UE%[+5G%C\3[*FY+?H<&=>OKB
M\EO-0D-P]PQ=R>N3Z>WM6Y%+',@DB;<IKAZL6]S+:OOB/7J.QK[VIATU[I\E
M"L^IZ/I]YY+>3(?W;=#Z'_"NAK@+6\BNU^0X8=5/45T^G7F0+:4\_P )_I7E
M5Z33N>C1J]#8I1U%)2CJ*Y3I/PEU7_D*WW_7Q+_Z&:H5?U7_ )"M]_U\2_\
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M+_@GP/%N/E"M"G'HK_?_ ,,>VV^N*X!E7</[R'(_+_Z];$-S!<#]RX8^G?\
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M6'C4ZI_G_P ,?5<(5VJ\J?=?E_PY]<T445^:'Z&%%%% !1110 4444 %%%%
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M.A"'+8.5'XCB\5.O5E5J;L_9,+AH4:<:4-D>YT445S'0%%%% !1110 4444
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M5!]BUV^U70[VS?2=7M-(CM,1/=22WD=J8S\LABP7N0-PD*A1N)'('/']HWP
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M2%IUS&F%E+J H  '%0)\(OAZL(@.EET5&C7?<7#%8F0((U8R$K&@ \M 0J,
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M !([@'I_*G4 %%9$^OZ#;:K#H5SJ5M%J5PNZ*U>9%GD7GE8R=Q'!Y [&M>@
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M1/GJN[_X+?YMGK8+ TL/#DI*R_R27Y)!1117&=@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pg1img1_10k.jpg
<TEXT>
begin 644 pg1img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *P#) P$1  (1 0,1 ?_$ ,<   (" P$!
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M^P_[/V\,<_<L$DD$*K,5!-/NP)(F8 E.I->A(-!I;W3L#FOCS;_[:KGYKB>
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M4'S&NI&-ODR>.@R,:21I<0I(%<=KJ'4,%=?)A6A'D=44,?\ ]O9&_P#?Y/\
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M.7F^Q.(&M94YR.9C&-;6 (B%CJ[;9IS%,P+[8IP$-:;8O6X)P9#<A3ID4*F
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4&C1HT:-&C1HT:-&C1HT:-&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pg11img1_10k.jpg
<TEXT>
begin 644 pg11img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2P&\ P$1  (1 0,1 ?_$ 0D  0  !@,! 0
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M31$T1-$31$T1-$31%HX^T7^WTZ3/LR;FKC_J"Q'U7*V!PF"E<F*_AHR>.+>
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M)^F,TG0H1%:L->MQWN/2?B'0%Y,>BCHOSG]@YFVU=0/45=,Q7'H%NN8,H45
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M).'<AT;%6597"&2+'7';*DY7A8:(L+^CV0HIN(N9^@IUNZBY=F1R@5-RW4*
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MKNP2<.FN]:8/>^J?ZQPO_I%K_.ZM>XZU]$?0JWO)R[],/2H#<*@ #QV.',0
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M7F6UR?UH;ZQV%5G]GC54YKJ*9N%$"'+"5&R2!.,-S%75318HG#L';@]I-O\
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M^UJ(O\DT5Q7LL+ZC?F;E^*M5%NBN=FE&7+$!44Q/$.04\AQ/4JQ]W ^KKE<
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M;8ZSP%$3-RJE62$Y%DS4[C6[O7*M:ZW)HOX6Z5N(MU;7,51JXD:_.QS65C)
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ML,T=(R*]BEE%!G+,_P"$WSOH]%O%ILR$_BT>#;M$0UX/S-S5+K\YNHY0]E2
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M"+=KN5TE&D0=--<3',"BI1'N[=6-C:Z@^W<W4'M?:FN<#86UPV^:JVWG+4=
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M76[?6.8 @=%!7?MJMLY;MN7Y-)OGW5U,R^%,C6L)8'5[0>2W9E]7)7';@KD
MD7R&'?\ :\=90SL?-B< S;CM6F0Z>U@?>,DXENY^4'KV[#0J(IE#O'\/QZJ<
M6+>JF1FY1%( [1'\/QZ<6+>F1FY0!,H]P_A^/3BQ;TR,W)RR@.V_;]_X].+%
MO3(S<HBD =X_A^/3BQ;TR,W* )%'MW_#\'PZI3/;D>^O9X3_ -$J2:,Y6%H[
M-7_HJOO9R?5-P[AO]9_'W?\ NAOOY]8_BM]X,]?_ $Y_C%N6']'U.GVS_L"]
M0.OEPONVFB)HB:(FB)HB:(FB)HB:(FB)HB:(O-GU"HB.=\P"!>+?(=H'?_\
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MM*]5<5Q7XB<QVVN<R2:UI1?W>Y>,7!H=2@':#>SA2G6!4XK)'DF =P';LVV
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M7R<U6[[7V^;.\D8.^Q%W$ANWP0BF6IJT-(%*GH*K:/SKX^,YGLW317H@.03
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M:NIDB)8Q@X /F+L8A$3H%<(F[2*'$QBCVZF9;QQNS,P*JQVY:T,<0X#> /P
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M!S8Y* R.90U[)IFI^*[]R>E56N="<S(F2$X=K\7]TVM>T.C9Y5 R/&42B <
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M3J3@/ZP> :<0[TI)U* %5WW O%VA\W;O^#\8H[>?;M\P".P#4XL4=@^XE_E
M33]A5<S'7K+>,&A KY:8_&I;&2\5.).%X.7C)ENT?.XMRYBWS2000DH]86LA
M'+J-%E2H24>\3,FX0-PJ)'^:8I1[-4+287EL)FO:VAQ.]5KNWGLKDQ21N+2
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M IPCN*<DOP^ Z9W? IPCN*<DOP^ Z9W? IPCN*<DOP^ Z9W? IPCN*<DOP^
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MS &1P:VM!@,V&)[.TK"W6@/OY8Q):-M[<-D  /;?PXW.J*N/$. )<P4<<!M
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M$9!@$7(KGD(YJZ,H^8\:AF;T#*&YS<1'D*B)>(P%*.O3FO;T8"B\*?"UKRT
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M ;   ;81 "@!0XN$-N(0+N;?<1,(B([ZR.8CU2:+&26XC=E8<[=_["<@WG]
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M.]8#H.!(H>C%7$W+LNG64DDDD4L8+0',)IFH26X@'"F/159ME0*4 +P#N
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MC3^6=,T[^1:74_*H?P *["1"(I)H(ID101(5-%!(A4T42%#8I4DB 4B90#R
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=G_U=4?[?_IOJ_P +^PJ_^A_^&;?_ )>S\/["_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pg13img1_10k.jpg
<TEXT>
begin 644 pg13img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!<@'P P$1  (1 0,1 ?_$ 2$   $"!P$!
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MJ?H=XA_UG_\ (0?C*V&Y9^4LB$,X4R?DC31R(_#@3*<NO+V09@_'[KNQI3)
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MKJ3FQ,N!'%L=WCY1_=5>00$A;=%J;SY3ZU FI/E*GHB*(BB(HB;KK$8 U#T
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MZN+F.\Y4;GBCA6M"3P=7%)[J.]R;2G');*<RYF)&&@X-LH]E)1]B^)-FK1%
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MDT?J_.'?3<8!W<N7'^^41TWUD,&Z.NTF(#L$!P;&["'8/G;0J'O6F_FSZ?\
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MR+A@+C1H--YI3!<P/F!ND'? EU#&)8-XABB! (3Z42E* ==?3:>TM-+:+O5
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M4B2TOC,X/KAK7S(9C-\N>3YR&(*RJ,[.XHSYCI]V_P 1R^:.!F3,V- 3A+I
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M"22CE00WE%C[RJAQ$QC"(WHBYT/5Y$*3\HH]=(4H 4H:1\M@@ ; #>CXTPV
M.TQAHBZ<Z(BB*VR4DWCD#*K' MK]([ V"-QMMZ*(F#\QGK =%N6XO^'F2']+
MO$3JP^)PJ:<IDLH!1L4Y(\JJ16:!@VBHJ8H6VUD(;426_-\OP*PFNS%.8SP"
M63E?YDX/F8TNQW4_'V#R)B\H2D!;1LNL@:19D8/G3!0SCNPG;[ZAFPF I3")
M0$+U83$Q$Y1WAL5V&F>(M^4"/2M7?KD=),FRW!H'*X&/5DBXH^3E7:2)!,HK
M' U,V>*(V 1.H@3S]WZ8 &O1_P!7;K?2.E-=8S57MBDOW!IK08G=B0O)7UV/
M#[4^NO"&STK0HW3:I8/SY0"31OD!VKF*4*W.8QD53;IA P%%,2F(!PONJ$$P
M'2. [!*8+U]0F1:58EK[*5LAEC#B :@ [#M7Q*OH]<L*:3JL#V74!H0X4< ,
M*$<."\A*4+^>/FAO"(V* %O;I$UKWJK[Y#P"QV:Z^0?0ESY==&LDUVU@T_T\
MPZ/7D7LMDD0M.+(D,HC$0<<^(\DWSTR8F!! K(IMPYA*!S^: 5SCQ=ZGZ<Z<
MZ*FN[BX8V^EC=5F85KB *5WX+L'@KX?=3]>]>66EVEO(^SSB6N4Y:,(K0@'8
M=J[NBG1Q_'&#<0"S&.:,R"8=T1*R;IMB#:PA<2D 1V5\>KR827,MS&"<SG'#
M'VC5?H&TFW<[0K2&\P? UD9K^M%/AHM<&KOK0-&="=:1T8U"1R"+5+$1,FIF
M$<R2D\<:#,%="BB\2:K>DF*:*;?>./!.!?C#LJV9:3W@YFY9!\UO;G)&0$X[
MA%U7G\/UWT2S?$PDSX<\Q0KF4:+91A>4X;-NF4PB<JT*]:/$I*,DFPJ(K)*"
MDH!U$EB[ $IT+X#E>JD3B\9SL*Q#+^4;)\Q#,H^>U$@I-EJ@IC4WG>1.\-(3
M+6\_BT8=@@GAT@B]4;P&/NTBM]U,QA7:@FIPCCQ#WE557K*>4:"D\3RV)AE(
M6-E9K =)\992;7&HQ%5N]TJ=.7R3DAR(&,F:>!8$C6VE2$0N:B)-\/Y.LY;-
M-'\GG<GTV:9WHUA&-8OCD1"8,=GA4V+(C(\PIJ''(OR&EGZ0H%39+MA2[FIQ
M%DR[ZIK$7C*<D.3.<>RS%(S4J#CH'4K(XO-=1P-B2QU4,FBV,HS5;80U"2,Q
M@\7?-7J28I+%,=(J&\G8RAJ(E#D.4][$9T;47"9[#F[TV)PF&$QK+,+3F,,[
MBTQ-/&Y":-&LW+8Q9M0Z""I%"B7BH@HW5$4S ($5]CLMP+DTY><0QG.LYB6T
M'I?B[6"D<I>-DH1D]79%4,)8^+2,8J*K@YMUNS0 XE"Q2[  :(M46HOKT, B
MY9RST\TYR[+8]-<R19:6?QN+HJD*.]Q$6BA9%^4!L.Z(B7S1V@%78@E(J."Q
M+M9<QQ8(]A(]"2Z7]9UH!S*0TMI]JQCDYA#+*6!H9PG.BVD8%=%RF9,4S2[$
M2=R %#;Q%CI^:8 O:LKHNI:EH&I1:OIY(NH75%.&P_ M?ZGAT?JW1)NG.H;<
M2:5=@1N!&PN(#';13*XAU:[MZU/:]Z%R6DLV5TP<I3FG\R/>,/RUJH15B\:.
M+&08/'">\W;O"%,!2!<>( 7Z:^H7@CXU:1U;H;='U!P??-%*$BH-/+O7Q9^L
MY]6'J'ZO_4C<A-[TK? R1RL!(C!<:-><H (W8FHVIN@ !@V&N-Q#: EVA\8!
M*.VY3 (=@UV[3FR.O71O'S%:CR+S-)>W5K*QY +&Q!K>QN-/.E T[TZR74[)
MF.(8HP.\D':B1G+HP"#*-9"H .G[U8+@BDV1N8 &PGZJUOK_ ,3=!Z%BS7CF
MM?3B/-M(6[>''A=U7XIZQ[MH$+Y#F%2 305QV [!BMQ&FW,WRW\@F+%P*'D'
MN>9X#@SO*_FL#1VX>3)"J%4-+2JRWHZ-*@DKPTD@45.!0O:]?)_Q3ZXU/KG6
MZR.+F9S3R$FGP+[J>#7A'H'@[H@?9%O/#!7M=E&;;Q-4IT#Z]J"3D$V\YH[E
M3*'!4A._,<EBGC_NXF @')''02144L:^Z9=(OU5[7T5NFOCE$3_D+J#.H+B_
M<7F,MAK[5-ZW <M/.EH]S,02DIIYDZ4@[9%#TMC[X!8Y+#&"V\,C#J?7B(F$
M; J03I"(;#"%6]S#R5DK>?GBJ>4BL18@'((" @ [! ;7"X (@(@(U:--1571
M%%ZU%011$41%$11%YK7X2EB[P[AK%^4-AV=7346^T,:8[>"E<UCFEL@JPC$<
M0M5G.'G4[KAJ#C/)!I3)J-)#+")9#KADK!0Y1PO3U%;C#'G53,"B;Z6*F(&2
M$0OO)E$+'M7>?!_2['HW1-0\>.JH0;:RK#9VS\'SSC,QLC&F@<UI%203O[N"
M\2?6/ZCUKQ.ZHTCZMG0\Q%UJ,[9M7N&>S;Z7$6F>!S@'99)87$!I:VI#1G%2
M5L9TUPC'=.L0@L,Q-@C%X]C<4RAHI@@4"IMV;%/A)@:P )UE!N<YAN(G,-</
MU'5M1ZAU2XZCU9Y??WTAE=V!V+13=0&E!@*47L30] TKIC3K?0=$B;%I=G:0
MP1@;VPL#&U.-30"I.)VE9]5JLRK:]%7=$I$1.41L:U]H#U[-OFCMJM&&N8>]
M1P'PJ1L+;POMKG"(M[I[4S;G Y<S:^:8JMX%V,5J?A+]++=,)Y---)W&Y5%%
M[PDS0=@(*)L9DB)45"] FM>NC>%76<72NO17&IQ<[09 8[F(DT=&\%M2*C%N
M:NT&F]>>_K ^%,WB_P!",M=)>;7K?09?>;28"CB]@Q;L-0]N [I[U.TKWY..
M8M3F TO!3(&OH75+ G:F':I8V>Q'L=DL60J"CH6YO/*UD>$*A!M;> P7V58^
M*O0\7374<EA:.$G35R!/!,"2'-=CE!V=VM#0[ABJOU>?%U_B9X?QW6H-,75^
ME2&VOK9V$H,?=SEM:C/@<<N-0GB,#*&*H*BI50WB[N[;S0W=H#8 L-ZT$/;(
MP/8TM9L%>S!=[C:XRR3L-;20@QC@ *.'WU=Y5PHJZ*(BB+F;_*L?^SETC_Z=
MW+!^[<NHBZ5(G^U49_<]E^YDZ(JXW1X_THT1341%$11$41>#INF[;.&BU^$Z
M06;J[HV-PUDS)GW1VV'=,-J(F':&<CN0Z!DTUA,8YRN:F>TYTM;1,1 :6Y6[
MT/?XB\Q:#;]SC,4EW<?HI%Y8ZB6S(I$043DDG@D3+]>N B)%7,?5Y<OZ&$%T
M[D!S6<Q,W+5D?*LZ82&1E07=:;9/E09B^>&D(IA'/FN6-Y@H"V?(*) @4I;)
M[P :B+%?^KBPG(\9U!QW6/7_ )G-=G&;Z>8QIE$Y'J#J+$,)O3>!PW)H[-L=
MFL"+@&*89#M-0&N9P<=)K9$^:/Y=TYCD"K+G2 Z:A%7CZON%DL9U/99ES(<R
MN?:@:FN=*UC:NY1E>%GRS"$-&)D<BP%E@..1. Q>F,$BSG5W#M\<T"NO*KN5
M#.U%;$ A%1K>K>TP<YDWD76JVN"^DX:T-N8B5Y;QR7&$]%<@UD1DQR9;*)9@
MEAY,S/$2.>VR-S )3*4 M-AQQ9[HF3$B4G(^2_$9'3K3[!</U0UATME]+-0\
M@U+P747!,CA4,OC)S*GV1.\ACI-I.XW.8;D^-2J.4.D%6$G%.D.&"9@ %4RJ
M41*-RR\M^#\JVEB&E>"262SS-;*<SSO(LGS!Y'O<FRS.-0\ED<MS')Y@T-%P
M4$U=3$[**J]W8,6;- @@1)$A0M1$X*B* ]'NA[X412)]!O\ /%/TXT1<R7J]
M?^\5>NE_Y(N6O^]L91%TXT10$0 !$>@ $?$%0)H*HF"\[',5'Z#Z4YOGC@P*
M'QZ+,,:R#> [^9=K),HEL6W2*C]8EPZR;W94]H!++E?BU4[EQCA+FX. 7#[J
M#J9E>I69S>:YC*.)?(\A>J/I)VHN94$E53;_ ')J(^:BT9@/#(0@%(!0Z*VD
M11PP<N,4:M8,DDLYD><<%OM]33S6Q4.1_P ON4RJ+)ZG*.<HP1)VL5%)ZB][
MN>?AFYSV2*XXAN*BF7:<=X K7;J%Q?GIL-?0MCM9FA@ ./VUTE3>/XGJ5CYX
MJ62;O&;E&PIG IS$N02B( >X&*)3" AT#6/FCMI[J&[D#N? _.PASFT=QP(K
MLWU54QO<YSGY7%XH:M#@1Y""%K:S7U2/+_EDTZF0@V""CM8ZJG=5'L?OB<1-
MO*E9KI)J&#M$+UV6Q\>/$_3G!]AJ1:X1AF,43NZW8.\P^G:N$]0?5F\&.J=2
M?JVO:0)K^0U<YL\\=3^QC>T? L1+ZFKE]$3<6)(8I@*&[Z4F!#8;>&X=]L-P
MK)_\1_C%_2K?YO;_ ,&L'_PA_5]_H(_SJZ_A4^?0'E&T9Y;8QVVP7&XN*<.T
M[2,@@GN/'1+D,(.'JQCNE2D,F&[<UB]737-.KNO^J^MKATG4]VZX)(J &QC
M >RP-'P+K70WA3T)X=F&3HVP;:2PQNC:[,^0AKCF(K(7$U.\XKRYB=7\8T_P
MZ8F)B8:1L3#LG3Z1>.#$(DU:MKGL*BA]U9PZ(02ID+YQC"%JUVPY<7S#/R;S
M0@X[>TXK=;IA,#F;&AV?]LW8?A7#AS&:X/-;M9,VU.<JK ADDF)H@BYC<=O
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MW."9S*)G(8N\2XD$ \!K]%:I=69ADY9"W,:BV1@FC-0M\_*;S:RF*<I<=!A
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M.:[%R_W%1+&%(8IB@%[V[=@@(#U!41-5KLPPRE/<RW9OP3!.?S(L0P7!M/\
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MR$]P8KJ3K,9@'>TH>BB>'Q!_2U-[\.U1]R:K%E#2/:XS/+2?#+'(Q$BL_66
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M7@'*:%B&A"1_P8=1E! +;N9F]T(1N>P;>CSJA:3GZ)>#LYA]05SJ4(_2"/\
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M$-W&!H0SJ):8Y")Q#PG?UUBS,@HHB^*9JHY%,=WS0$.B>+WAQ<]4]4VTVES
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MY04$V#+N[L'?=E4> 8O$*(!OB(6\%0M-<CLX6,$7=;L(%=]=Q5/4^D7ZF\7
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M6$-MC!:];C[Z'V','=>,/,N<3VCV73LKLU92:IYL(4"0T2F&S<C6@ '8 -R
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M\VH$;?\ F-49Y;2-@<Q@Q1C;W/0/.?@D3UB>8YAB#.)B,0Q()63;G='<J8U
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M*KCR42;&%IB-T^R7$H&:0&*:)*NU($44&YS'4;FHB;,7U*6.%  _ZS+UQ(V
M V\^&0C>P6N/^!?340:&J*@F?4PQ4="S#N,]8]ZX:9D6\<Z<L(H>?6<;C)/6
MR)UFL>#E;"^$V!ZN4J8G, @3>WK#:U1;[8/:H//<(6K?U3OY/QJ%R-:O3O,G
MK)S5:JN-0,DRB=R-?1;3/.)0NG:Z$O(NWJ;/5^?>-6Y]79DI7!>]K%9LD%G
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MF""_8%6C@(R;PL?&IER3*6<K,J"QRYCE;-H[GO1C15_#XZZBB-6B*_%7! 1
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M#R;-QOEL?BE1L4/."L=9:W"&N<UH!H?3Z%<R=-SPR7D+I7%MDV!Q!=M$[BT
MXX[$ANK3;)=!I#%VL3-2F58;E>+M<FCV&0E0,JBT7<.6*\>DY:.7;-)=NJU!
M8"HJ;Z)7!4UR%/LKHO26NNU+3G6<KG%I%*$U'H6@]7=(1-R7VGL9%=,-2Y@#
M7>D4*;;EF *3;0FH>%-EY/&950JCML@3BOX5[Q2$=M%T$P,)RIKW$#@&];P5
MS7J;HZ\M]?L[^UCS1&Z[P PI2NQ=ZZ!\7=/9T1?=+:K)6\9:4#GFKB2:;2/M
MK,M2M/9IVQQ!O&1;J1?.UU$4F[<AS&$#LD3"9R.[PV[=,.F]MH#6>\0^G]4U
M46[+6++$T8@"@.W<,%JGA+U)IG3-]<WMU<ET+C4-+JCT8JMQ^56TD8FQ6#[L
M[S"1%->?D# "A(L3;$(]L 7!55,]M[>V@-;+T;I[>GM-HUC8KD,[Q: #7;B1
MM6E>*VJNZOZ@DO;:1SM-DD;D94Y  T T;L&-3@-I3L\!Y7<8U,1TUR+,<FR>
M1D<\7,D[E&$2QEH>&EG1)%R>%.H,L!FDTP&-^N(KIHE42<@=$#;MQTO4.I'O
MO+@T+G-KM.W9O66T?I6)]A%$:->Z@!X=H2@P_*! F8:=2+U_+QD-F<KW%TFS
MQXJCW'&$P5X?#7[APJZ(RE33#6/5$Z9#%X)MP3#<=MO#U))'7E5P&%#2IX=E
M%=:AT6Z2/E7S^;%P?WAZ"4A$WALW@&G4EJCIMF^1G+C^4-X22B7[1LI&G*].
M^!FBJS!X<1613:)\195--JH=R4A%-\-NTZ'UC=6VI0QLED:UYQ <16G$;Z+7
M-3Z!L;_1YV-BBS0M[G=;W:[<O"M-R5S1'6B-U6CGK%V@E&9=!B129CRGNDNW
M,<=QZR*INJE1.)[&*-Q3'8(VM7H.WUUUY-&QKR*TWG%>8-:Z6N-(BDE<*@52
MZBCM'JV]'@ZNH>JLV^YD:\MS.P/%:G$TNB:XC$A>W +X/$']+5-]W*&DASO2
MJK8B30!>9TA(6Y0 PW#J"P7&PB.SJ"J'/N1WR]]!VE1Y3GG*VM2FZ:TZVMM/
ME$,<@@2?Y:_(<"\4 [K%(VN+QP4+B8X#\4INFM<U[J/W0-CSG,6G>MRZ2Z;N
M;FX)FJ8\XP.(V<%;L TC'4_$H/.\VSK*9-6:R$(R23AHQL_B\9 [QO'LVLF@
M>6;J1CITJ[(Z2,= &ZJ( 0%!4$2UPSJ#K"\YQ;%-*#MP<Y>G=)Z$T^6S:6PP
MA],3E;5*(ZY28A*.&<&8G301L[&&,)L=+Z7)B_I$^+H9:!E#BR%PKD:!D!;[
MUP1#?M<;UJYZC=<N#[@E\@WDU/I*O(.C6V[RR$AK3PP"1K(]'T<2A=5\FT\S
M7)6KG3%X47""K!FV92$2,TVBSI/6!91PZ.X,JNLZ5,FFHW;(([IU-X0ML^A]
M67$5Y&!)(TEI&#B*5&Q4]4Z"@NM.DC<UCMAQ .PU":/,*.-:"@P,W;LM0HA!
M5=JD2R;;(&11$ZXHCLW%@L)A*/6-5.IM.BUZV+V1M=<$>U09O3M5UX5];GI+
M53IUT\FU:ZE"3EX4IB%68EA$TC@.3).V3UNY:A- HU4;'[PH<D:4Y$D2B3B'
M Z@^:( -[!:L;TUTK?0=$W-E.7NE=>2$5)) +6@ 8[%LG6W6VE77BE:=30"/
MW2+3XXRT 4+FR/<32E*T(W*TX5AQL"30S[-FBC44 /Z!AE LN]=* 4Z)SD-8
MQ!2&PAL\T>RJ'1?2@TV]<^Y8TX[Q57'BEXIP]6:4RRT=QB>T4/+);Z@$ZC1^
M R'F!D9MED&2R<4RBHI*1BL4QMND[DIHZK]%JHDRCEEVQI!E#M%P>.@$YESI
MI&*D B-JV76^J);>/EQO>V+90$@<-BY'T3TQ#*[F3L8Z:I-2 3Z2E]@>4J$R
M-*)#&IJ=,9YA:LZZ<R6.$(F7(9.7E,:Q^#22:KK*B5_+1*PF65,F+=I83E$P
M5I$G4SHF%\=0_.!@:$C>>T"NQ;Z>E9/?3(9"(RPC;AV#:L++R\8H.0Z<0\3F
M&9P<UFT"I(<%)@QCE8V52FGT"NQ2=N)5!B5M&KQ*RZW'5(8Z)"IE$51$:R-G
MU-*UKI 3F';B<*[=RP>H]#6]V/G6L?7B 4E."\P,WA>9+:=ZGN0DX].6<0;3
M*W*:K5=LZ;/%&H>D"'(DL+)PJ38H8H'*/FCL"NP]*=6O-JR%[W$YCM)X^I<5
MZUZ#%K(\VK&L9E%,H W=B?0*=_.*<#@8-X#%M8Q1L)3AN[-T0'973VWCKA@>
MQQ \JX]':OL971SC,>W%'!'M\OT*K>\NXGTIR7<$<'JOT^SLJ1US("UP<00>
M*G;&]H=NJ/2D5UPTO+J)BJC5N8I95F(KL%1* \-0@":YME[&Z*PG4Q?>6E&D
ME]-NTK8>E=2ATVX^<:"VN(IA\28[AZ$_C\ZACLDR5920.F[% ')3\ PF6LF8
MAK;0$]CAV"-<ABTJYEO7-FJ['?CZUVV36+:336W%J1'&YM0&]T#R 46P:&TU
MCB(-C3KA:7= 4#"DN=3N:9A'>$"-P'<N!NC972]+Z<MHX1,Z-E6BOLC<N1:S
MKUP9BWF/(.&TK(U<(Q3=%(()D("(C<$"E$!$! Q@.(#M$!K).L;-WM11G]J%
MA&ZQ<,]F60>0E8:_T/TZD5B*N8%LH&]<Y%")G3V#O% 2&)8P :_55,Z;IQVP
M0_>-^)9"UUR^<' 3S;!]TY*4PB&D2T;Q[!--!FU2*DW11*!$TTP$1W2E H 7
M:-]E74<<<4?*B:&Q\ *#T+7=3MXKN7G3-:^7BX GTE0DX9K+LE6#U#O;1<HE
M53-;=$IRB4Q! P6,42B(#X!HZ*-S<CVM+:;",%8V=E#:S^],8ULE:U  /I2?
M1^BFGD:J99"$; <.A+AE%(MAM8I * 6]JK;Z.T\/#Q!#G&_(VOJ6[?I?J'NI
MMC<39:4'?=@LK2P3%2$X80+(R8$W!^L$)<EA+N#O /FV-T5.;*S=MBC/[4+&
MG7KUWM3S']LY83DNDD4X:.5\:%: D.&<R0MU3D:K[I1_:[A @@4Y3!T7 0L-
M8S4]'M)[<F.*,/ W-%5EM%UR3WL1SO<^-QQ#B2/A6O?,VN1SDVKC#.-5?3G>
M^Z+))@<Q -L CDQB@)4DP+8;#:N:#0+D7#B2[)79N787W]HVT#K,-BD(VLHT
M^D43\.7_ $A)I9B)VSLP.)^<6))3;@   ,Z*6R#<@VN!&J1[=EP&NIZ5"^T8
MP1=PAHK3#=V+BO5FO/U-QAD<Z3*2,23L--Z7G@>'V>*MG=>2F'%[LWE*U>WA
M(LW!NPD8;O0C@>RX_!5O[W-\LJGR7?)]2D50^LJVZ>'[8_'+[0U9W4TCXWDN
M)/+(VJ,L+ ;-SFMSF\ V#908>1=5&C"9 T?TM+N%L. 8IO!NA81]!,A&X= [
M:^3_ %8!^FUU)]W[Q+CO]MV]?H#\/K> =!:5 &-Y!LXZMH,I[O#8E:K'+=44
M1%$11$41%$11$41%$11$41%$11%*?XH^U5.8@1DG9AZTH2"!MHN4K6)*^J^I
M(FN%\WR6WM>E7(=H==?4WH>5OZ$Z0P'O-TZ$'L(:O@EXI6SW>).ND@5^E+CA
M^<*3CA%[1\7ZJMHSCBM#]T=P'P*()E 0&X[/9VC3..*>Z.X#X$B/,0M*-M)L
MI]$&.1R>/43!4@^<7B ;?+;8([Z=PK$ZTYQLOFSCF'VUL?2MFPZPWG !@:?M
M+7_HT]]%OXJ3;@W,HR=LGB)'3<CA 10,F=9NNV6$J;ENONF3.01V :X;;"'&
M-<MX+IQ;(>\N[F[FM<DMH*L;3'[*+:?B&MK]BD5R8,9Q6,1C64=%L(R/<HMH
M%LV7DW9"8^#F0>NRN <R2IS*;Y]TZMR%+N%"M*^AH)7_ $?;YG3^0BM?UU U
M7=[UC>2MDC;C;R/AD)/RK?%N_BK+F&NKV0CD(Z.4>3_HQ1J=H_F(-Y*.C)Q\
MBI*MF*[Q\4I7D>:16,)TSIVX1C '366@Z(U" 'FPD,=P+3MWX$JG#UG>WMQ<
M29FTN1"):N HV!Q<#B17:=E2F+:Z9/)9J2.9ACJ$'$02#Y&$@82*>M(Z.-*/
M1DY5V!7;A^Y5=R+Y3>.8RQMPJ9"$ I M6SZ3H-YI3QR6&F\U"'79]1U!QCH[
M33]U44IY":_ LQY,L<F@QW.2S,>Y:1#B::+1!':1D=\YVYPD02(< .)>, #O
M6L-]@C75M%Y$[7B]8#(Q@+:XXU7(.M(1:ZB+C2Y>[(2'4.ZE>S>G?NL60;,G
MZC9-,509NN 4I!$Y5!1/:Q@"WQA"K_.^1IYD(S#9L6J6E[J#;@1R2.;;'::G
MU!:J&L7,)YSD1I-D]!RM.OE3"9!0PJ$,N<4CD$I1 UTA+T"-:%J=M>27$Y$9
M!=L%1P XKLUG(SZ+M3;/$D31[5:5Q-:@T.WL6Q'336&7Q:)Q]DUQV-8C#'C7
M#F488Y(#*S@PJ;EO!I3I@<BR<A&-GRA2F(W(KN[!4&N8Q]%ZC(^X?-$07M.7
MO-Q)\^"VB?K1]JV%ELX%S' D>1+*/,8B JJ-L@4274"*,A!3<>_:1#%Q!&3&
M)5BV;@R31DJW*W @;IA P&&X#O#5O'T3?6[*OA(;QJW?B=ZJ2=?W5T[(78GR
MIG6JFH#M3$Y'&6L7CS4CV.CHZ9G(Y@=C.3D3"OC2L/&/G17!VBQ6S\Q#'5X!
M3K[EA-8H5<6.AM%ZR5PQB./97#[**H[J348X7,:"1-AMVT\_:FX<MAWP<PL(
M2+'>9J1DV28*B%DC1@)&73!2XB5-,[LB9=HB%ZZGHT[VW[#&:QM(Q6D=5Q13
MZ.]MP VX<#@ML_ OML/5T[!MU=8=5=)=*'G/7;BN$-LBP9 !0>13%0\X-GL\
M=2.=5I#<2JD=H[.,!\"G.@&Z<0 3 !3B)0&PC8HCUCMMTU=R21,LR7'YRBC8
MQAFH!DN KY5I_P!0EGJ^LV5J2O%46[ZDF@93:(-DR#P@+T[-RN/:ZX2R%TQ(
M%"!Y%WC2&P6UL);:FZOEHGTZ.:FO87&D8%E'XXU^M((.<@]'G).N8MK*HS[6
M">/P=ILSQGI9(%=XZ!W #YH'*4 KFE_I;+F2K"7+;+'JR\M^XS8$XZ5Y@%6_
MUUO,'=N58P8H^.QT>\?8XFV*Z*\3,DS'BM2N"NB J543"KQ=HCM$:C%T+J1I
M)R#0G-7,W>/+P4GZ;7@><Q&WCV^5-3U$U/GGT1/,&V-1Z+N893L4KD1,?<M\
MA+ 9&^](S4$1V5;N@MGKDPE RJ*ARH[Q $MP&LG!TI?6;Q/-%1C>T'U%7)ZU
MNY6&*(@O(._XRF4:>0.0N];,*",C9*R4\F+]9-LOP$HL!5[X==P<A2@5<% V
M#;HKH.A:?(Z@>TY5J5U#:QPRW\KPVZ()&^IW;%M;<84W,[,KNI!YUS&"Q@&P
MV*(VVW H 'N5OHL(X!D:T"W(J3V[UQN36=5D?(RZJ!S" :U[N[>4QSFP@95O
MD>*D:M7#F)*"I3F12.HDFX,5$ .?< 1* B4>D*T[7!#;N(LQ5QX!='Z,EL3W
MKN7&F^OQ+)]!<ND<!74D4L<C)<YS1RZ*4U!.Y/T;)0[X'<3+11FZK5PWD&#L
M 4 0/N*I%W#EZJTC5NEKN[;2&,N!'$;_ "K?;/73I=7-(%.W]5/(A^8$[&(9
M1[N5F<>78*$=ED&D7(LW"ZQ'+^2WW;QN3=<-?24HL8J)[%( @-[UK$O0FI!N
M?DDD;*N;@*8TQ[%5?UY<2N,4+ZDXD5X>=)UGNL9I15>3<1>&94S4;H($9/8P
MZK%)PC.N<G;R+--HZ8O&+MI-2*ZA1*J4BJ8BFH4P"%6T&BMMGY+@%KJ[..[%
M&=6Z@[$CX?U5JUUEE7DW)SDX_7X\O*2,A,/%]W=%9^\<+.5C@4!-N\5\XWRE
MN-A-8.BMZZ>MK6&1K :$'9ZMRI:C?/OK W%P-M14]BW Z9DD5M/,)5E=XTD?
M%X=.0,?8<7 ,6YE#' >LQKB-=HLW98 &G<O._443'W1,.YRS7@$[1\OPU6Y@
MXK%?-\4< O4/O_#4#)P5&78.7B:J<J0  @&YMV#O -Q#LOMV7"HM=&_"78HQ
MQ14JXT<L?>8AC;Y\C)N(QN=\W.F=!442&%)5$V^14!$+WO5M)9V;9#)'0FO!
M9%NJW4<(M65Y#10*_"B B(B([=ON]?751MW<,/+:WYHX'R;U8R-9.[/(<4<$
MM5<[5'E6WV! -P'HZO9VA3.U0(9'^2W[=RCW:_3>_M_1IG;N4>Z1WCBO8$"V
M#IV![H^[>F=O%1^;.!P"\P;[0$=@!X?HC4S*/<&-Q<5 6UI2M>]Y#\2]>"7H
MJ9['1FCJ>E3"" BHV>12F0 0V#L"XVZ-X;6MXJM9KID!#'URG' $^JJGCACC
M^?8:!OF6.L,1@8UZO)-(IHB_='$[AUP4S+',.P!,?I&P=%6^2&?O0BI/F]:R
M5QJ]Y#:\QM3"!M!^UM62<$H=?D  \5]E7H+&MIOHL2(K28<Y[N^[$X':<>".
M"2WL'\VI72'8U.XWYMGY-0X!?8'T:ES.XJ%(^)^SS*!DB 0_\X/4/RB>W5*:
M0"&3,?N"J=U$XBRD9BSWP8^8+J:T:#_)%I=;H# <5\7H-GV[:^575>/6=T1_
M*)?PW+[]>'N/0^D@?R./\%*K6.6X(HB*(BB(HB*(BB(HB*(BB(HB*(BB*13X
M@^Y[X5;W7Y$^4>L*9GM+E=U?2MJKJ.(A?>S;)AV7_P!=W6ROJ/T-_N?IO^:1
M_@A?"/Q3_P#N1KO_ +I<?]H4G/##Y(^6MK6A(X8?)'RT16J<@FD_$OHIZD51
MN[;G24*H%PL<HEN%]EPWJM[J+G0EBN+6[-G.V8;=GI6MC+-&LJTSGW!XZ.<R
M< X<'.S.@4Z@-U%!W@W@ +[@7ZJY_>Z,99SAO77[#7+=]@.:1L6Q[2KEJRA;
M26+U=/BSR?@W"XM'[UNB$B[AG:14C"5W'$$[ABW J@""PD @!M$0JG;=7]-:
M7?-Z*OXF,U-O?YAH*B3O  [Z [%1UKH[K&YZ8'7-@'R=+/>]D;;?\J'QG*_F
M5)&7-LP&"O(,T4RB!4DB%OL**28F,6]K$#= 5  .NP>U70[>'3K&+.QPF$F
M&W+5<2GM[JZ;S>K)#:6]?FN543.?]R)*AXH33-0#:<0J-UCL*^-9W%-7)3=(
M*($ 1MML(E#M"H_1\/!9.RNM7@CRND-?.JUM%M6*14&C9-ND7XB29=PB9?D
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MX-EJINENHJ1V]G=.BXD,K\#E<_1K7LI'+'S>!)^)1X0F*8HD Q3=(;;#U6$
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M_@L8K@AWL+ 8JC ME(N5Q7+Y2<=Z@$?3A3H'C29&G.(F4;*-3%,I$(W-NF$
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M^[K]I1X1O8 _!5/,50[_  1PC>P!^"F8IW^"APC>P!^"F8J(SUV*'#/V>_\
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M9%Z/2&Q)!DFZ,FF]%4 N"9+CLV7'97/-;Z^CZ0U5UEK\,DMI( ^*2,48QA-
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M&GV@Q_-,J/)W?-Y%']._$/\ K!K7\[F_&4I=2];2!8NN>K);"!@$,A; ("!
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M,]K;ZA9D!C+V-N5T+=N>3G%[WDD4[C:X[%C67:"3+"*'+L)?-]0<$4%14DS
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M,_S<YYK7#+Y'A>0:AO-"\"S7EGU,P;E=Q2:" :Y$3'(-CZ)QU^Y=<-!BC+R
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M;;:?9ON()3C/(,(@=]:MI3R'8EP]#:,:-$!:95:ZM:AMP R$-&KG3PR#7+M
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M6!EC)Q<VOE"G%$W:.VU[]=NB^S;:I@)_DN]!4S'Q$T+F^D*'=S=H>S^AJ/\
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M2=GE^A3FGBG)=Q09(G#.6UA, VV7^E-U[*HW#LT#S^M*N8&EKXP?S@^TMQV
MV^9.(6Z/FU$_WO0KQIK?^NIOW9WK*^D'2'^YEK3\R%GU8Q;0BB(HB*(BB(HB
M*(BB(HB*(BB(HB*(O%P-D3_T/Z<M3Q^V%4B]L>?U+31G:=\URP;7_P (9;JO
M_HQ6O7_3,@;HD _6#U!?-/JMH'4^HUQ_CDOX16*<,/DCXJSW.' K7\K> 1PP
M^2/BISAP*96\ CAA\D1]P:@901@"F5O */##Y ^(:EYB91P".&'R!\0TYB91
MP".&'R!\0TYB91P".&'R!\0TYB91P"F*0H#M(/1V#3F)E' *>Q/D&\7T:<Q,
MHX!%B?(-XOHTYB91P"GX9?D>0:<Q,HX!'##Y ^(:<Q,HX!'##Y ^(:<Q,HX!
M'##Y ^(:<Q,HX!'##Y ^(:<Q,HX!0%/8-BV&W2(#:W6'NALJ9DXC<'D$@%6M
M];W,]I)%8O;%=EO=<X$@$8X@$$X C IPO*ND4NA>$G!,H%5<99:Q1 X#\\)W
M>N8H@ W"P"(W,:P7'97'?$(R674=^UI!EAH:\06M-!O&U>@/!"X^ENA(->O8
MXG\VW,F4MQ%'EA!)VDD5KPP3B0W2AUE$1L6YCE*(@%S;QMZQ0 -MQK4V,DD8
MU]P]U2*C*2*#MVU74&O$3S1H#7&H#10 =J $=FPUA\ZX*&/=/:(J$*0YC"4"
MA?S@+0LCQH^4T_7*Z:<VROI5LEVSA_$2S%"R+A['/V:"BZW"2(LY;+MT!6$P
MF,GOK#8/,-VU(]D>S/-]\I8HH8G9G2';LQ6OF3Y>-9IXV#/(N#@M)#8]C<1A
M^3,<:S4K*3RQNTBI-J[RQW,8U&0Z+*2:*OA0:%)OOE4UEE#JB4"E"R?;#,0Z
M:4$TIB?0LNV[M,F4!SCV']19?E7+_K*W;/1TZS3(6IGF2Y0>18R6?STF[D].
M32N,/(7%(XLH\W8A<R#-\@FL4Q%&Q7.Q00/<)#:ESLAGD)'ZXJ/O%N,>7)]\
M/B2;/>7KF6:MG$J24<Y1(+PWH2)@934Z0C0QR(>K9*D^0B'Y0<MBS$0@_8*H
M+E444<"U!$ZH)!NFE99LCF+WR2.:6XT=VU]>*KOU >Y>[6S8V2%]:R-S&E *
M845;E_+=K5EJ#7'G260]Q/(3RDQE$AK;.+$E,36@VJ.&X=)04<W33?R&+R#<
M16>7234$@JAO@J!2QBC,<XE=+*6'<'&I^RJFCOXHVAKF6Q V]S]579OH)S M
MHP8)M.OF<D:4,LQSN/U*DX^/A\"7<+G=:?!C39)'C2S_ 'S6D0^ND<J"IO *
M);79CA<02^0C'[HUKOW+'F:U!(S'TIXVF>'3&$M,EA73Q\^A2Y2J]Q!*0F9&
M<>,,=<P\&@L@[?2*RSY!4LRW?*E0.=003-<! !"HQ0PB4]^0 5W[]I\M<%0G
MFA+!RBYSJ\=R4LHB(CYBE@,)=X#B8HCOBF42F(H8@D,I8+B(#X*N<D-*\R3[
MY6G,=P=Z4" @-C 8#!L$ $XV$-@A<1"X@-"R/<^4C]DHA[B/RUTSL9(6M]%%
M2.R[S5V)BB)CM7!#F$!$QTA1.7A&,&Y<AB[! 0'9VT@AC-S&\F3.)!0YMF(H
MK#6)'#1[L^\7I_BLN!F)!^;=@<-BU@Z6)";3O%K;X",<8OG&X@&*G(OTR@ &
M^(($"WFUZ2UIQ?>"VKC1N/[4?;7BGI(UTX7+L138L]X'@\@U1>.7&(3B1O6>
M< X>\#V3A3X4< >SR#5'!2U;P1P![/(-,$JW@C@#V>0:8("TFE$<'P#^='X:
MC13Y0IBI;M]@C?P#2B90IMSZD?$-*)E"-SZD?$-*)E"-SZD?$-0. JF4<%'A
M^ ?$-4^8."A0<$</P#XAIS!P2@X(X?@'Q#3F#@E!P4-SZD?$-5,%'*$ 3ZD?
M$-'$-%5"@X*/#\ ^(:I\P<$H."D41\T36Z -U;?BFJ62X#87MIM:56MH/>+J
M.)IH<P6X+ 4_\"<2&]K8[$EMU_VO0'\VO'NMN_TW*/\ &N/PE?17I!M.D[:#
M>(@*^A9S6/6S(HB*(BB(HB*(BB(HB*(BB(HB*(BB+P<_K!_Z'].6JD7Y0*I#
M^4'G]2T]YNC_ (994)0O?()41N%]O?%>P*]8Z!(6:1 ,?R;?4%\W^IH\W4NH
M&O\ WR7\(K%^";Y(?G1^"LQSSQ*P?)/$HX)ODA^='X*<\\2G)/$HX)ODA^='
MX*<\\2G)/$HX)ODA^='X*<\\2G)/$HX)ODA^='X*<\\2G)/$HX)ODA^='X*<
M\\2G)/$HX)ODA^='X*<\\2G)/$J8K<1&P@'1\GZ%.>>)3DGB5/W4>SR?J:<\
M\2G)/$H[J/9Y/U-.>>)3DGB5/P3?)#\Z/P4YYXE.3VHX)ODA^='X*<\\2G)/
M$HX)ODA^='X*<\\2G)/$HX)ODA^='X*<\\2G)/$HX)ODA^='X*<\\2G)/$J(
M(&ZP#Q6\MJ<TNHW':$,65KC7[EWJ*<!RM%$NA&!@(!;O&6;;;?\ ;?.^2N7>
M*'^]&JGL;^!&NO\ U??_ +167_M[_P#MWIPA2 8;B%P$Y=X+;WUM,1,8 +]6
M8Q0]J]:CG+8HQNY8]077&M#J+7G,ZNZI,-2L]Q:-G9HJC9WJ3(P,2VP%]FAI
M"=Q_+<4QW#\;5.V5*GC$!)02W%5WN 5<[@5>\IVW341,XTIM.U9"&##,L<R_
M57F?.E%C!04Z?)N[Y%)97B*.FTLG"X!D\1(O4\>C8S*DGC1',HY\P.D<Z8'6
M3=F$QP43 !3JF)CCGK4'CM[5>_1^FG$N%3M\OH3A-2LSU=QF7A8S'^_.G@8=
MCCF'/'X:K*L=0=0'TJBSR/'YYZV.9OAC)A$IB[15,=N7SQW536%,:+I#*.[B
M[U#:CK.P@;S(G5?N[=R3/*HS4F)T/T05>2FJ$YFR3TD[D,;'$G6\GEF128\7
MT1-SV.E5<8TNR,_,$<H\;FB"<$Q7()D IPIB)XJ1AC^J52YC#AM6!1,)KQ#O
M3!%Q>ITAA^'YCGA,G"6RY^>5RF!U"RS((=N>$3=F<S,JTT^P]!BXCA:F!%$5
M.(414N(5X@&'OD9CB/(KF&&RFC+IR&D&BN3LNJ&$M]//F4MJHIEN/81+M,B:
M9<PS#+HV00D<?>S#;*".DS/(^2^;\VINNV+@?29EDB W*8A"E4GKBZHP^P*I
M[GIF SC[/,E)RS4W79GIUI+.0T++LY'(\>GW.5R#K#7+R53RN.18ABL5(P$:
M@]/%QN2F6575.9) 3(E*4RK94XE&42-&%3561T>P)KF'V>98-EDYS:O(3$G"
M!GK68E<J7D7D5"8KZ.:PR&+9VG'QF/*R3EPHX4A,KQS=.X<JJ<11,MR"4N]4
MCYZLHT[U,-.L[8\QA!<<*?8%:"ZL<U[Z.,Y:,E6#)M#.G\N\>:83;AY&Y+Z$
M35D<40CRM6QW<4T>.+-7+9N^4!3> #K[AA"D72<3B5$"WVTV)^FG$K,3N X=
M,9"P?QD](X_'.I=A*,D8Z1;/U$ XY'C%!9=)JL)@N) ,-K[;#<H9"W+C'5VV
MI6,NPP3?-^S0++77]:NO_%G'_P!2>KN#\NS]FWUA836/]47?^:R_]FY:Q=)R
M'-IWB@@4-WT>O?8-P_LG(>&O0.KR_P"F&XXG+^"%X[Z3@_T& . 2B<$P_2A[
M8@(_F5+<S4EW[%L0@'NC:8=XJ/!-\D/SH_!5#GGB51Y)XE'!-\D/SH_!3GGB
M4Y)XE'!-\D/SH_!3GGB5$0XC%0X1_9?X*CSO*JW(".$?V7^"G.\J<@(X1_9?
MX*<[RIR CA']E_@ISO*G(".$?L]_X*"7,:8IR!Q4O"'Y/D'X*GQ4W([4<(?D
M^0?@IBG([4<(?D^0?@IBG([5-PC]GO\ P5)S:88J7D! I'[/(/P5$29C3%1$
M XJ7A#\GR#\%38J/([5$R1A3,%K>:<0'^A-5O/[+OV*FLV!FIQ#M'K6W+ ]F
M%8K_ .[\5_>Y"O(>M?Z\E_='^LKZ%=)_[N6_[F/M+,ZLEL:*(BB(HB*(BB(H
MB*(BB(HB*(BB(HB\7 71.';N_IRU.PT>**I":2 ^7U+4;FS?_##*+" ?V?E1
M]O\ ;BO;7J?ITE^CP%V)R#U!?.CJF.G4VH9:T][E_"*QT&UP#S@Z/9UUFZ#@
ML%E=V_ H]U^J#Q_1I0<$RN[?@4AVU@V&#I[0\-*#@F5W;\"@1M>]S!U=8>&E
M!P3*[M^!>G=?J@\?T:4'!,KNWX$=U^J#Q_1I0<$RN[?@1W7ZH/']&E!P3*[M
M^! -[= A[/=I0%3,8XG?\"CP3=H>SW:90JG*/ HX)NT/9[M,H3E'@4<$W:'L
M]VF4)RCP*.";M#V>[3*$Y1X%0X)NT!]GMTHU2N+8O;&U1X)NWV>X-0HWL5'.
M#BT(X!NT+^Y\-ZEJ]I]FK56 A<T#-1_VU R!MT1!0A1MTF^*'A';T#5>"9O-
M:'1U%=VWS*XMK1KI_G270Y75 _8G[:6?EC>MV^A&%"NY2 B;K+A-8VZ*9"Y;
M/F$PW 3;I=WZ4#"'38=M<CZ^N[NXURYEMK66628C!^7<T8.HX;ANW475_JVA
MD/@CTQ#<&)U]SGQW+I<U9(^9,<C\OW/LG"AP2:0?..Q45B$LKPKYM?.?3Z?U
M.@SDR9C(LSX]!0,G-),9%V"+<L?-R*L.HF)"B=%(#@8IA #VT9^HWEB&LUV-
MEM(?8;O<W83@3LKYZ+M%II,EW%SKAP%2[+[M7+0$^WS!7-N%,*+%9OF^6C<.
M'5>%TS9,<>F'D(B#L)B)?Y[*MD)6(89 U=XNQ!A(%=BDN -#%6=%*=(@K@0#
M$"I1KFF%I#Y(2,:#O;.TTVK+PZ%'0$27_P#U?Q*^8SSFJ33/*E9O3N1QQ3&<
M)FLZXBV1LNXR<7'0(3J,<Q=/DVC@)86RAB'2[L!$RAQ$3F((C5L_6M(+JB2,
M"NS&A^VJWZ'W[CG;'(0=A-*]A\JRW'>9>3R? \FRM+#F+-]#Y[!X#'8Z7)VP
MD=NLJ=,6N*R$[)LR)L8*'D@6*[46!1=-)N(;AC',8A'TSI;N[&1([@SVO-6@
M\JFAZ,N>8/>&S1QXU<S+F'DK48K!DN;C*RAF,A,Z;QZ$+IEDB>-:@2L-FK2?
M.V?NY@L$B.+I,6!0G"J'7 Y]\S59)!0P 0QR')4QUFV<03%<5!K]S\:NQT5:
MC_#7O_5_$LJ@^87.5?X4I+)<=QAE%X+IWIYG,0QQ3*&N3.Y%CG03:K-)^]2(
MU:Q9R]P;]Y*X3!!N4RBI%%4PJF_6H#B(K@G]K\:INZ&L7>U+>_\ 5_$DDS#F
MMU^;9=D.'8YA6G+1Y@YF;3,5ELV7R)D\<3+W2@D2O".HZ,2.LC'16I9CJ(K
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M;N101 $Q 2%3*("%ZJOMO#<1<SF=0Y./(M=O#VT9_;^QG/Y'2SXMG^47=/\
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M6&S:!P$0&]PK7-4Z1ZAT.8S2N+['9V5.S=Y5LNC=3]*ZL!J&DW8?&X4$=6X
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MMI@ZK$O<0 >FVVU5;.X#8#(_@CK8SSB)F\T29'DLGS;>1B-['\<,H9-2:<$
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M'WZUGAIJOA]XAN$C7G.^HDWT./M);L&E@$K4HA>^[N%^-YQQ "D(&T1,8U@
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M$Q^(51&&: <R*(#ND*FD8G17EGP0L]3ZQ\5-4\5=:S/CL@XPP.V&,"@I7#
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MH1RP9+H)!R#D'V9)-F>EF1M"*JI1.#3+4B^8()N"V3:K1*I%.Z$N504'Z6Z
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M:<:4W K6%ZK3E]B,^E\XU<R6'-(039FZPS'5)1,'!I=Y(@H[S&7!0]P6%Z[
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M]X!(  4=Z^W9MHB!11%/@BDF*-@+PA(7A[H6L7<MNV"W1:B*<  H 4H
M  %@  V   &P  *(HT12G^(;^='WAJ(VCRJ23\F[]B?4F%9&G_9Z8$0$=Z1=
MCLOLNL;97<-,D+;"(#Y(7ES7X\^JRG]<?6K+PP^2/B'X:O\ G%8;D=JGX'@_
M34YQ3D=JB#>_2%@L(B(@(VL ]7A'94KI"X4[54C@94Y_DFGE2>YEE)H<B,5$
M(E>9#)APF;:X?6=\-JZP_P"9)I -QO5AJ6J"S@-=M%<Z!I&I:EJ'*(/NY*Q&
M"A4XLBKI4XNYE[8TG(J7,=P81N=H7>\XC,AOBVL;9MKDVJZ[<75VZ*,DQ8#S
MKTCH?35GI,36D /&)\I5^L%QV7#L'8(AX1V]-8IH+#5^TK-7N5^4,V543&WK
MB81,8UA$V[N"&Z&Z4H[A@*H!2=8A>KA3*2B)'-7]<<1T4CFLEE43F\P1ZD[4
M:M<(PZ8RYX<S0H&,DJE&)&*V.M>R>^8-X>BB+19S/YUS;^L0RJ"TSTTT3S32
M?0^$EV[LS_4M(D&ZR"2W[$F<E;(++N4VT2!C*,(Y,HGXA]Y02FV5SOJ;1M0\
M0+E^@0$QVEBX9CN<",W;Q[%N^@W5GH5NW4X*"^>TEW&M2!\"W%<GO+%CW*WI
M4PPF.$TG.OKR>49"Y("3B<FE4OVZ[72)<$4#' A4$P$0;I)%(7I&L]TYTY81
MVCM$TIH@FC;ED<,,W%8#J37+WJ.Z:^4G.T]U93S(:#1^O.$F@R.S1.41#TDW
MAV0HHE4=Q$\U;\%%PFG< ,V=(E%)TW"Y%T3G =MA"CXB]-:+UGTB_I'J6%L_
M2ETSD<XBKH)'=P/;P(=4URG8J6@=9WOACJ#-3L@77$A =3>#MWA:PM+M3]?.
M3;+IB-S;2'*LFP3('IG.1L<&:K3K(90Q"-E,SP-8"\4IWJ21"O(IVFB"ITRG
M P&N(\$\,^C.NO MMQX9WDKK[I&)[9=/N":YV2DN>RO=]CN_<-Q)VKM?6>L]
M+]>V.F]0Z>&1ZNULIN#O)=ER5V[*.]*5#FFYV\1SW1R:P; ^7/7S5#*<SB%F
MD=%R>G$MA\7 /U@ B#Z5FY,4@(XC5[+E3:B=85 L'F[0](]26NE]4]%'1-2B
M!<YNPC:?A7(=)AN=*ZH;K%M)0,=4'@M:$7I#K:BMI+JWK=R]34G/8$_;O73.
M+.B]:9=$QKOO"".21S)99W$2A3B59J;Z^@"Y1WK%.8 \8]#>!W5O@YU<_J+I
M)HU#1;NX=,Z%V(@#SWF@?-T-*#:X8!>E=<\5-+Z\Z?=H.G 1:M!'RY7C N>T
M4)K4[UMMR7UD>.0. -WV#\M_,5DN;JH*-HG"'6G;^)CVD@5(A44)S*'"Q(Q&
M-,Y3#<.V,=11*XD#>L%>UKC4+22*'J:.HDMFYI8MU2,M*>4\5Y5L=%=:ZE)I
M^JOYL4SR"3CV^L+7-HER7\R?.%KN\UTYKXY;%<<DYMC+.L4<K%-(N64.<AX#
M%B,TM].'QE@B4"'(H<%EB@.\ [QAKF?3_0HO^I).I>M!SM*>XNC:[$"N(V\-
MRWR7JU^B6)TRQ/S-*8<-BZ/XJ-9PL:SBXY))NR8-P;-T$DRE*F*0%2)NV  !
M+A$* %Z"[NSIKJMAI]S:WCKMKJZ?&:PLW".F( \JYOSXM1D?87 ^=G=G#N!
MHM///AR391D,M+:K:-QQI%S.+-WV3XBT<>CGJ\]&'2<L,FQ5W^LI9&S%NF8Z
M)A(5<$DQ =XNW@'BQX.2=;:RWQ(Z%/NW4MD!WVX.S-QVTKNXKJ?07B#;=/7#
M>F^N&^\],X=UV(IYS]I8[R]^L)R_ W#'%-><"U;PO4''D#0Z.I,#@\M,0\\0
MC4&_>)]K%H/EX.>?H"(NR$(=LH8H'*<#")0];] ^)NN=1Z;;Z7UY:M+8H8F2
M.(/>=&T NQ<=I%=F]>1/$SP7L.FM3NM;\.+MU+NXEF8QI]ELKW/:S!@]D. V
M[!M2Z2'-3A^0NE%,%QO/]2,B<<0PQ['&)"),[=.3";>DI7)$(AM%AO&OOB!Q
M#J 1KINK]1>'$=O(/>2V<,)#1\H D#V>*YIH'AKXEW5PS4-3@#[<.H7.X.P^
M4M.NOCO5S(=4<JS?4_2'4;'WLTLP3@FV.8RMD*&/1D:V[J2,D21)5SS::Q@X
MW?TKJ&,?<,4"$+7&?";Q^ZWO.JKC0];MB>DV.<&R.K[(=04[_ 5]E=.\2/JO
M]%WW2S=8;<4ZER Y!3VJ5I['']<LZT'U@B</8**99I:ZR- TQ%Y!#*3!)S$,
MA@)R 44%J=-VDV(\+"OA, .VAP^N@4-PZ9@$1])^_=,Z[GGTFX'*SEKJ[G;Q
M[.X'#X5X8N^GNHNC[EVG:_I4TM\#FBE:!EY->X,75V@U[-B<G"<UV2LXJ1,0
MC5'(9!_GTJWR=HZ<-7\4]U%<Q"TXM&%;J)BD*"$8=NAO"(E2<& 1N #5VWI?
M1[I@#ILS0&X5&.79NW[_ "*V=UCUE9.)L,MJ*DT<'5%=V!W*SR?-#E+G%UH2
M?5'*7X1.;0C">F9!VYE8^*S>,18/&*9Q7."S>.41%=N4VPJJAJD^@^G(I ^R
MC?;O!!J[+2K3MP%<?4I).J.K+W2W1W[FW+""*-#M^VE2DAD]49E_B,R;#-%7
M;S-7V!!IW)YI!(2KIDYQX$&S-XY:XVBV2:)Y))Q[4J#AQQ5"&*)UN&!Q,-2:
MA=G3[%US=ZA%/:0NYG*!.:K<1N H!AMJM@Z(T_4]5!L]*TJ6&\N&\I\I#<K8
MW"CG"CJYMAV$=BSWE9R'1C0+#);4O*M%>8'4G5^19NX5+'T-)I4R,8W7(=,[
M&'FG/#AO1[P#@5:04. J)@)0"UZX-U9XJS^+&GS:#8M,.F0@AXV!P&!WG@O;
M7@MX"V7A"_Z<LRW4+^Z +G.Q,5<<,&4I4\4W8FC_ ##:P8;EILQY=LBQ/ DL
ME<3FGK:.>-'6486U75XZ$,5@H[(ZE(/NV^@HH0V^FFI8I1W"U\Z>H_J]:GI_
M7<WC/X9!LK=/9'[[8GV9,CL'90&UKE<3W]VQ?0/I_P 7;5O3/]F6H.[S"^3W
MK[KY^KN76NQFP=WSE;;M)>>73O331^+QM[R\:\8]-X3#M8E+$L-TWE9F)FQ9
M(';I?-N;+PV*:0[-\')DU"=)KB%>NND+EW5.CQZQJK3:7]T 6P;!&&XD4[V[
M]<5YOU;17Z#K,]UI$YOVO#JYC7*#6IV,V56O34+3[G&]9-KA$Y)E>!2VAFC^
M.&%CC$7D(I&>X["OEB'D7S=BB=?TCF<X1$AE%E-U)),I2 8 *.]I&NZ+>=3=
M4#0;D$Z.'#R?#\2WG0=3LNF>EOI^V</IAS#LV_:/PKH)T7TCQ?0_3K&M-\/8
MI1\/C;!%FB! NJLLD(*BZ65$1,=9T<3&5$?IC"(=(UTZ'1;?0-+N>FM.H(Q"
MTLIN=F'V@N9S]0SZL]VK:B,UQ?GDNKN [U=J;KS<\LTAJRVCLYP!9FQU'QEH
MZ9((R%SQF2P#DY#O,<E0*7B F8A3"V6#>.W5-< L(@/(O'KP?T;Q7\/+/3"P
M.ZPM7 Q2T&9A[U:$@\<5T/PZZSN?"S4&Q3N,N@3.!>S:"/)AYTTC07FCU*Y;
MVY=)]8M%M5W^#1[A9+&7^,X^ME,IA[9<X@,2HC&JKCD>*H& .ZG()7#1(0*<
MMBW&CX3R>)>CV%MT!XBPB2PT>(1QW.),@Q>TDEQQ =E]D;%G/$X=,]:7LW47
M3N6'3[DA\;!AEHT-=ACM<"?.D^YY^:";UQAL=T]Y>^7'67+,\C)F/G(K43)\
M.<X?CV.F;&3*NDQ1F5FSJ6%\@=9!8"AP.$L("/FA6X>)'3]QXG]/7W3DEHR;
M29+62-TKAC&US:%[<=K=H[IQ&Q:GX?\ 4^H^'^JV^L-^=M;.=DQCW/:PU+:5
M&T8;0D%TMQO+- -=L?U^U3Y;<V?R"T(#2>B\0*CD;*/E78""^3X:JU.<AYLC
M4Q6[A%=,IA3*)BFX@C7G[PF\.NN/ #4H^@#$-1??L:^"Y(J8X:5#2:LI0.'W
M)V+JWB=U)H_B[IWTS[R;&X/>$0-!CNI1_K6^S2373$=:6#I]B\/G$-W$C<SM
MGFN(R^*.4U'('LW:DEDD>^"CPAX@IW ##V"%>MX+*WA>ZZ$I??2 -E:?N7,P
MKL^Z).\KSVYMY!;QV4[ ((JAC][^-<=V&X;4L8" @ ]H;0[![*N5111$41%$
M5,[9HOD#-W!1%,0WDS%V*(K!82K)FZC%M5S:7TMG,"SV3M5AJ%A'?P&-_M46
M18ID*C98(&:.F9<I2FCGA[@FY1 =T"',.WC!T#VB%=6T76XKR(1O-"N!]1]-
MRZ;.Z>,;TI8H@(CO 4HB-]VP[ 'K]K;61,PJ:<5J_):<2!51[N':4? %Q&H"
M3-@G);P".[>#]"-353E-X!2"B #NVV^:/1;Z;P^U3<5-&T-FC V9PGN8]L@8
M;^Y3/]RDKA5]_K9_E/K*]0:+_J2+]@/M+(ZI++(HB*(BB(HB*(BB(HB*(BB(
MHB*(BB*12X)GMT[H^]4#AZ0J<U1$ZFW*?4F03K:\U+#81O(.AZNM8W1X*[-9
M3PMM(A(2'9!L\B\SZM'+)J$KA3VSZU:N[> ?T-77O-KQ=\"QW(FX!3<(U[ 2
MXC[735>WC,K<TAHIA;3$5PJL5R[(FV,Q#AZ<#"Y I2MFP  JN5SB!4DDR!M$
MQE!#W*I74ON;2\8BF]0BTV\O9VP,&%:X;<$D<3&+I*N)>7LM-2MSO!,(CW-(
MWGECTQZ4SI7*)A#KKEVL:W<WLQMBU@CXBM5Z&Z5TJ+3[(/<P<VF]7OHV>R]8
MED++1]&][?CV^19Z8&>0R9B/)V(\52S@3D$X4.Y&,R;R?*H5%3HHBIW+1J\3
M%)VV0<IB%MQ=,JI+[Q3%-NFN7?();E'J&B*"#%@U,86C)JUWQ$3\!!),PB(W
M$>(0A5-X1\/N5/(_-&UL $,@]IS=K_V5:CLPHJ#8G-F,N=Q!^YPH%5!8MQ*%
MA'9<1$P[O67;U#5.Z:)PPP_,R--2YFU_[*M?@5WS,00 ""HW#K 1#Z8N\8N\
M7Y.\02F* ^ 0&J\<K6YXI6-DL'MH875R$T]O#O9JX[:5*0OCCF=+/&V:NY]:
M#R4HJ1PQ9/"@5VU;N@ !#Z^@DH;='H*"ABBKNEZ@WJM[9HAC9#<?QB&)SC&U
M^R,.VM;2AI@-M=BL7V[C++)!(^)DM.ZVE&TX5JJ5*#@T3%.C#QQ#D$#$/W8@
MF3.7XBB8C<"*D ; 8  0J:[;'=2!Y:& ;AL^%5H&S01&(2O-=YI7U*K6:-'"
M14%FR"K<HB(H*(I'34'Z43W3X@"7ZDQ:EG$KRSW.1ULQH[PCI20\79@<3V45
M5KG10&*U)BE=[3V^T3Q-:BOF5&6"@R"(EB(\HCU@U0 ;A\4UN'NW*'@V]=ZJ
MW(MKA@8(8V-^ZI7O_LJGCCA14+9DUO#)$^5\KW_=NIF'DH %<DDTD2<-))-(
MH!8"HD!(H!_.I@4+^'IJ,[_>(1;R <D; J[7$-RN[QXE3^T%@#H .@*6TC[:
M^CO <S(XBSEGV""0:FF-13#%471-=$Y@PD)]H;1V#<@=T>D+@("4>K>*(= _
M"&VVRJ4 =:Q7,-NXL9<UK3[FM?9].]52(Y+0VERT2_KG>U\% L9?8;BDF.](
M8_%.SB7=,=9H01.%[W'L,':%AMTU0AAEB:&F5[@!3&GV@EJV*T%&,::;*UP5
M1&XQCD,;?BH2-8"-@.+9J0HJ 7XH&,;>,%OJ1"JQM]/>/GK>-[Z[3FK\!5.]
M=J5W'RH[R>&*H-&!E,#7>TJHD8&$EB&)(P\8[ =A>.S34X8#T[@#]-V&&Y@[
M:KW<@GC$5NT6\8W1[_+FJHN8)&-;/61[?NCM^##X$DD_H!IU,BL8(5@V47OO
MB9HDL!@ZP,8Z9C#<1]NJ,1FMB/<I'0LIB&['.WN-:XGLP5:Y<R\C$=VQDC0W
M**C=P20O^2?2V14,JI"PA]X1-8C04MX1[13$!$:SUMU'J]L*-E<:<5HFI>''
M1>K/+[ZPA>X_LOM."NL%R::20JA%/FO!F4*8#$*HQ(X'>#:%N.!PO[=7%YU?
MU%?MR7EU(]O T^T%3T_PTZ*TR+E6=C$SMQK\)3AH+3[$\?:IM6<*Q(1(@$(B
M+5 $"AV@FF0A>@+6Z*U>9G-?S 7-D)Q(/M#>TUK@=^];U8Q6^GV7N%O$P0^3
M%7X8&%N&[%," %MPI6Q-PENC=(-RE\-@ 1JX:^&&/EV<3(:[2VM7>6I*6YGM
M,PMI7L8[:!2GPA5Y6S<B8HE;HE2&UTP3+N7#I$"" D 1[;"/AJD<T1A=IQ-J
M6.)EY?\ W@$@ALN:N#<0,N4T<:J6&,0R.DQ<7<?U%1C"PQCJ'/$QQQ4MO +5
M,;6VA:X#<>V][U/J)BO^\V-L,E00YE:BAK05J,=A5.&&6VG,UO*]H=M:*4IP
MQ"K$FK-N0$VK1NV3+>Q$4B)@%QN(@*92&O?HOO6#951DK&-HV-G-^5CF^)1=
M$Y[ZN>[E?(PR_&JD3; "P6]VXCVB([;VJTR.JY[G$R.%*[U>%\;H3 6-RD8;
M>Z>([5 1N EVV'PVL/;X:J:?73V2!IYDD@]IVUO:*8>E4K+^*QNCG/O##\O=
MY,M%;G$5&NQWG3)LX-YM^*B0P"!1N B6P%,H ]!AN(5!CKGD1P7,KYF,K[5*
MFI)QH!QIY%;.@DYA,,KXX=S&TRM[!6I[=JBG$Q*([R48R(I<//X!1V!V%V 0
MWA+:J]U<7$\D1MGFVMV.!?&RF65HVL?F!.5VPY2#P*N 7B,QEQ((7NY:-'AB
MG<M&ZXE-< 62*J0H6MND ]Q*%O#33[B:QCF#W&>>1Q+)'TS1-/W$=*#*!0=Z
MIH!BH3-$T @.%-XV_$ANS8M ,#5DV; :XV1)N !C?&-TCM&U6Y9'SG3M:!*^
MF8\2-Y[5,QTXA;!+(Y\;/9K3"NW8-Z]P  "P?S:F1%$11$411H0"**6E)!)7
M9N5$^:$>(BC\5<!*NV7+L4071-O$ H] $,(;0JYL[J6R=FC-?*K#5]+M]99R
MYZM;^M_52FX7D7IEJM'/D]V<CS%2>$-LO8H&(L41VF35(%]G6-=0LIX+J%AS
M?.%H)\I&-%PK5-(%A,]K2XM:\@$TV K-P >I$I1[0#;[]53S(YJ1@%O:L.&Q
MN!:PDR[AN[5-8_R?)5;FS_):H>[S\ I13$PW$OR0_155YKFV[I7 !PKAYD$$
M0D:Z<EL@<* 4V)Y$!_:.'M_K8S\8MB5Q.^ ]]?/]UF/DVKTCI :-&C#,>X%D
M-45DT41%$11$41%$11$41%$11$41%$11%(I^MGV@'FCM': ;*@XT'G'K4KQ5
MA'8?4FB3,)-*RTDHG&.SIG?.3$.5LJ<IBBJ:QBB7Z4:ZS::CIT-K&R=PYF0;
MQ\:\^ZKH6H7FH2S6H/*S$;#M&W<K;Z G?]:7G^HUZN/I;2/E#X/C6/\ T7UG
M@?0?B41@)WJB7@&'H_:BH>+PU%NLP-9[3:>4*%UTUK4<@;WMVX[_ #)#)S#,
MVF<J4DGF.31V,8 HPS=)@LHF94-BKQ8 *814+>Q;W#;?IK4-8U[G#E@X!RZ7
MT=TS=V$OOE^*Q<L@5XDBFX<"O;YFY<(;<9R ;; O&NQ$1V[1\P1$P]8CMK5S
M21YE72>:P,Y4:A\S,M^YB?\ M:\^QU%SLQJJ64MP*A\S,M^YB?\ M8]^QU*H
MH^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\ :Q[]CHB/F9EOW,3_
M -K'OV.B(^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\ :Q[]CHB/
MF9EOW,3_ -K'OV.B(^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\
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MF9EOW,3_ -K'OV.B(^9F6_<Q/_:Q[]CHB/F9EOW,3_VL>_8Z(CYF9;]S$_\
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MM4CEM'-#FYJ[*J!Z9OFN:^Z!S9NW9Z$Z2&**,1&$, E,2/:@)1"QBB"!0$!
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GI_O%*;_^3_15$?ME3?L_P7G4P] ?%Z.KH^*/DJ&_>J_^#W;/,O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pg14img1_10k.jpg
<TEXT>
begin 644 pg14img1_10k.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!) %" P$1  (1 0,1 ?_$ -L  0 " @,! 0$
M       '" 8)! 4* P$" 0$!  (# 0$!             0<( @4&! ,)$
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M"Y;L6H6;2<;KL9,U"$8QJ\>_#B=*M[7M9ZA\T7/Z*# & , 8 P!@# & , 8
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M_84WZM^6'"_*;-]W?,*YLY#T?F2M;F9IUBY/P7';CZU?NW%)>0G;/*'LQ@#
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MZ_/X];+Z ;)\DUG_ +S<\K\IOID^+;O:\7W8]E\Z?JY^#,?L.=[T/G\>ME]
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M3?KEG6[',O+F!S%BI+'S\.SD15:T5ZW&XE7IIQ4\AG^=0=V, 8 P!@# & ,
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MY\<,NICBCUH:,+WOIH8-[W]36A!WO?\ Z<<+ZF*KK/[R%& , 8 P!@# & ,
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M/N[^3C9R\=[X78^=-?ZIM,S=<R(, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2A^E(VMYO"9'& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M66>8Q/3//G]7+MQ*6)(S%6BNHE$IV\.$P6.3,A5L"!VB$X;7%I4&$"3NJ12
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M#M.7<AL;7\X9;.Z';&-(H.(*-- HR%O,@& , 8 P!@# & , \V?JP7Q=-/\
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M$)+ZB]5ME?G\U6R[#*RI^IK*L/CAR5BG'6'UY KMLZ=(*CCKAI;"9'*9]([
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M;MN-V#K"237B:JC(J::JMS/IG,HP!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@&-3/\  ^6?BT^_>M5@&$4!^H>D_P!D=;_F:S97O!+F0# &
M , 8 P!@# & , UR^IJS:747''<(>IK)8;9KM=.NP$NS(_(![Z_6UL_96O\
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M_P U?FE_>D BI)1QK=I%&E+ D<]+'(%L[2(E0CI*E[@DP6AJ Z-$#6]%#Z*
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MV=F:(\UH61@:FUC96Q.!(VM#.A2MC6WI2_86F0H$11"1(G+UO[4!8 AU];6
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M^VG:-/4O&I6F*$9BV)Q)JA31MM2"#H#>4%D9B=&!#O>C#="'OV[P"0< _D8
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M+B\11'(&<#HN,<EX4YZU4X&:4KC0A,4#\0L'TWO6N@>FOK8!(6 , 8 P!@#
M& , 8 P!@# & , \H4)O;E1!:7AW-0GF)>DUFSWZI4FXMCXTS9T@TDJ&PZL<
MN5K[3NH9%(N.&))BT2M@@X-N"9<D>!")\"(0@=WUZ<VEN\!RV5H6:2>L;R(?
M)K<$<AG'NJ9XA24ORON*@U<6E-LB:IH5Q0F;>ROL563Y\K1D@=BN4RCYIYA2
MN$J75O:';1:%0::,6Q:G"NDE#,YCZP-GR6M)Q<'&NAV:RJI(NFD*8@EBA]_Y
MQV#IA1:.YKEFL@K2L(^\V++&.JW%];8YX2-)EJP3@-2<H[DI-L(G#T=(H29R
M-YG6!8WHIV_S%K*5,->VB?1S^_-DEIZ5.$C:8G,8_,-Q=T'&GV21B-/A)Z56
MW' -2N34E7(#A#3'E]Z4(6U/2H3I*55=RUYK\8R;'FZF/\KK2IJR]<3Z6XZ)
M?4.,@D#D2KEO>4^5Q>0.":30)E!(4?'YEC2@A<J.4HCCQJP%ITOVQHC-*)E)
MKL#U;.4, BD\A2_CG7KK?E*\FWB@[LE$&/MZTZ-B\=2U"VW%';+:8Q (<ZWH
M[-LA;G@EL7)RFL[W:4@&I7&")$4 :B%"7>(/-7D7R5YV,+2-XJ(SC1-_3PJ'
MD4BBT%E2N8)6J9RZP9;$G5\CDP/K^.N<A4#DT>6MAZ968C3IFQ(G-V0!>)40
M TDO#4$)<D8M=4']153 FCFQS)25FX\0N0'-15 &ZRX.WLR695E9D=+8JU8S
M!U:N.:ZF/:G8Q$<B,TJ7]QH/96:WK>]ENZ!T';2OUG;$CU)QFU$U%0EP<W[T
MQJ[Y\&,(IN])TQ,JG%Y0:I#*V NTQFFACR5'+#59;D(OOQ')] V3V=BWIPJM
M/"*'8H?5.Y;1&[MUM<G'N@$$7A7-BG^'-K/U=VO8+^^^;<AX EL6N)/7[0]U
MVS)'%!$694 I]\>>G.6J1Z"C(+"$0\470*'3QSUA+Y]T(+=<UH2I$-)<F:?Y
MDV7Q=31FQI4[V>T+N)\,E4Z3M-]-BJ+(V!$CGS)%3>\.8CU F548 A0$8]]<
M<*%"R%M\T^4<1])"X><#W7=;UY<9M*#M>JXM$Y [V2PQ6*39KCA\(DDO6.[!
M'0.$AC3=(ANCHC*3F-Y?A>Z[PX';%N45:= Z2NLOMN;>FI!W2^I!SWF',I.\
M\20VHHXPW2]0MWF]AV ME$$C[%<=*2>'LK"MKRF-/LX*2.J+;:](RD:DH:<8
MCRPZ%:5^T&.$^H#RNM*S.(\,GL'D''Q^0^H##:MG"J*,EH1.OKZJN:<7KIL1
M*C1,MW02"V,C)C\JC91+DE5-Y81J4:920<,@\.M*+S"A^2[DYR%1?^7U@W))
M)<$T3WZXQ"G%JZVBUJ74Q4JWSDA%8N[J#5FT>TVS7&.K#49N]$ZZD&;UKIOV
MY4EQ#I)FWZHM]-5VGI7^C:LUQJ;?4#L3T_UTG:; EBRZ5$KB\-=9FR6$CAYL
M1*BFF 21L\.K1[<C%9IYG4GL!#K8Y14\-!0AQK]:VWH76\3OV\^/E;IZ=Y \
M6>0G*+C:TU79#](+)0MU%IVAS3P>[BGN,H(^TKI@SR!(/;HTB/2-:GO"#2S1
M!ZXX>H4+(,_J"\IX0\T7#>0=+\=F^471R?X[TZC74[>:N:MC= ;^J^<6 %Z<
MXRYLC;-XU,8DNB $("W-*2UOI9XE*$\19>];40H5L<?4YL]\M"M;D4FLL&KR
M!0GU?44KK-1/P,E96$OX:SR 0VL)/,I>Z,IQC 8XZ[XP1I9"@*(;@8$HM2+9
M8!*='B%# '3U3^<%I-$9BT.@U4519\0YQ<':JEKBK36Y'HM85=<IF=;(62.@
MB]P5$U6/'VE:I0B1N;QY>0<H;1EKFGM:,#H2B%$2G6'J$<FG.1'<?Z,B,0L&
M[)OR*]1)X)D')ZV) 7 8I5'%2T&J+[CC$Z0^#)GLQ4].$G2I6=NV0(AC;RAF
MJE*D.M;Q1;^@4,8?_6ROB15F[W+3/&ZK5D%KOA)4O-6U$5CV?)VF3$LTKL*P
M:\F]<P4$>ASHUOCLA<("I4-+JK-2)#TH.T:5VSBRPN$4/12P.Y4@861^(*,(
M(>VAM=R2#MAV:24Y(R5A91NP;V#9A8#M:%T]G77LSB0[? & , 8 P!@# & ,
M 8 P!@# & , 8 P!@&D&A_X%7SM47P2^;3\[7XDS_P B[WW@]Y?BYYF\^_ON
MG[Y?X<]__-/'=YY;]W]OO.Y]G7.3XJ;=PVG!K?\ A<^],X_A]_ ?YYWP_P"3
MOP,\9\0_=OSOP:[X@^2^\G^$/@K[_=WYGY1_AKQOB/#_ '3WV-O3N!7SAA_"
M\_A$\1?C_P"[WN#\2I+Y/X_WC^)'SMO>F=^_?PN^!_\ C_WB\7YKY;[M_P!9
M[L=SV_ZCM97Q<1=M=AM$!_#G_AYN/<_"C^'9\/W;SKPWFWPW]R?>13[R^=]Q
M_B3Q_OCXCS;Q/]Y^:=]XK[H[W.*K79O&WRDO<I_FC_->EGSL?<#YKGD,<]XO
M?KQ'NUY?X]J]SO+O"_WYY]YQX+RCR_\ O3QW<^%_K^QA5KLWD-:BG^!;\VJM
MNY^&/P<^-4^^'7NU\;?C)\=_=\OXI]W[L_\ ]*^_/N?W'O%XS^N\G\-XW[D\
M/E]*OA+M+94C_#,^-7'7YOGPC^,?S4P_-^^&/G?;^:9YXX>&[KR'_#/N9[T>
M-\-YQ]U>9^*[K[H[_)MIX!M)_E_S3?G0,/OO[A_.@^;O/O)O/?$^?_-N]ZV/
MXB=[XG_#_N9[U>!\;XC[?M]G_L^UC;3P$-6=9?Y?OW+N+X9?-P]R_@^L^,'E
MWOWX3X&?%B#=WXSQWW5\.OBMY'Y9X+[A[[L>"_J.]SEZ9=I=24_PUOB;*_>O
MX6_%'YYG'KWL\7[Q><?/3]PVSYNWC.Y^Y_?SW!\+Y9V/N3P_9[W[;KG'TO,0
MK-6_\#CXK\E/AS\W_P"(WPVY _''PGOEY)\,NRN^<Q[@^8_X%\FZ>(]Z_<;[
M;KV_%>WKE](NWI-IC'\!_FZ,OE_N1\V/X+MGEWG'AOAS\"_<@CP/F?O#]Q^Y
MGN%V.]\=_5^"Z]][.UG';7PD-3O&3^ [[E<E_F]_-M]R/A J^<5Y_P"]/@/@
M#XP[O.Z^+']?\&O-NG<>0?W%X[N.Y_K_  ^<GQ%VDD<=OX.WD54? ;X5=GYT
M*?X<>/\ B/\ $#YTOPDDGD_G/Q"_YC>]7P6\R\J\\^X_)>UX/^J[.1U&TG)W
M_AP_P_&+S?X7_P //RB'>1=][P?#3R?XD-7N9X?L?W]W'Q*\)W':]OBNSVOM
M.N7TN+_2(?I?\.+S1'W?PP\T_B$N?@^S[P=]_$2\@4>:=C_=^)ON]WG;Z_<'
M==>GMQZ7F!5^A?X&_OGR-^"/S<//?A5:WQQ\1[Q>Z'P1\W4?&CW4]]O\ ?"S
MSOM^\'NA_=/B.SXG[;L9'Q%VF&17^ E\U6;^[WP-^;I\9ZV]\_,?BC[W_&GR
M4SX._A!_SM\Z]U.^]U_"?U'D_B/ ?<??Y?2KX1M).CW\%#X1,'N_\W#X+?#G
MF1[O=CSCW,^&WF,8^>3X+Q7W)Y7YMY3YK_VGB>X\']OTQZ1-I@K%_ T^$MF>
M6_#3X?>^7&_XH^;_ !M]\/B=WSU\VCSWW@_YG?%+N_&>4=/[\\%_Q/N;N\>D
M7:9#?O\ !+^%:'XV_"'W ^<3R"\I\N^)_O/\?_,!_.;\G^'_ /S%[7C.GO=X
M?^YN[[OQG]7W>/2KX1M)>?\ ^$Q[DVMYI\!OA[\R>JOBCY5YE[J?,;\=)?A-
MWON__=GPT\?YIX#P/]?VN\[7UL+BZ.LAL]8?*/(F7R#N?(?*6[R3PW:\/Y1X
D,GRWP_;^W[GP?8['7V]GIUSB#ML 8 P!@# & , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>wp1122inmice.jpg
<TEXT>
begin 644 wp1122inmice.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  .@ 0 #     0 !  "@ @ $     0   52@
M P $     0   +8     _^T .%!H;W1O<VAO<" S+C  .$))300$
M.$))300E       0U!V,V8\ L@3I@ F8[/A"?O_  !$( +8!5 ,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_VP!#  (" @(" @," @,%
M P,#!08%!04%!@@&!@8&!@@*" @(" @("@H*"@H*"@H,# P,# P.#@X.#@\/
M#P\/#P\/#P__VP!# 0(" @0$! <$! <0"PD+$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ !;_V@ , P$
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M (:Z'96UY:1R7B:B=/CLY99[6RMIIM0LFU'RS<74T<<9AM0DDFXCF6-5W,Q
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M+:+3;:T5W=>MWTZWZWTWM]P#I2T"BO1/,"BBB@ HHHH **** /_1_?RBBB@
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MMM4;ED *E3P<TI7MIN)WMH>CK\6OA:[!%\7Z268X %]!R3_P*MK_ (37P?\
M]!RR_P# B/\ QKQ#1?AY\)_C!\)X]1TOPWINFS:Y8LGFP6L4<MK=8*MM95#
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M9)-Y%TIE\PGEGRN]BQ_B-5[;X<V4T)FAN(OM[[5E26)-I?:-R+)$%:/G^'D
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M_%4?;]2_Z!DG_?R/_P"*K7HI@9'V_4O^@9)_W\C_ /BJ/M^I?] R3_OY'_\
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M17]46OAWJ>IZ5#>^![NT>:YT*3:F70$VLOS0GD\X'!(X& *])^WZE_T#)/\
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M[U-K;5"NC#E71@,JRGD'UK*N=2\+:;JO]A7-M<^>IMU#8D97\^18E;<&Z!V
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MS+&21KZ#X$_:8EL99-3O]6MI--DGFTV)M113(6OK62,7 ^U71D46XG79-/*
M"023LP[:V%TN?>]%%%( HHHH **** /_T?W\HHHH **** "BBB@#S#XU:WXC
M\-?"+QCXB\(3I:ZSIFE7=S:RR1><J20QEPQCR-V,<#IGJ".*^9K']I/XG:MX
MBU'0-/TC2QMU"'3X)'.]H!)JMOIR7,T,5R\KQ7$,S7,6Y8!M"A6E4F0?8OB_
MQ3I?@GPUJ'BK6O,-GIL1D=8EWR.<@*B+QEW8A5&1R1R.M?.L'[3MG83ZR/%F
M@7&D'3+F>V6SD>W2Y/ERQ1(TDLDZ6JY,F>)B",%22<4+<;V.)T[]HGXF""RB
M\2IH>C)J:VDAU6:"Z6PTY))-1A<W*M.I;S'L46,^9&%:<*Q;:"]&#]J7QEJ%
MQ,UH="MA::7I]Q?6=TLZ7EA=Z@;?=E/.$D\%K#*]W<L(8]D01"V\N8_5?^&K
M?AV^B0^*(-,U>?0IK?S3?1VT9A28:8VKFV9?-\SS1:KGA#'N(0/NX&I/^T=X
M3M);Z&\T'5X+O1?/DU6%H;<R:;:VZPN]S.5G*M'LN$<")I)-N[Y,HP#$SQ.'
M]HCQX?$$KW%[I=AI4Z16RZO=0S'1%\F?5@+V-1(LFV]%K#'&#.5!Y5I,J'DD
M_:-^,UUIUUKUMH.F:;;V]CJ%X;*[@NWND;3=,L]1>-W62,;I6N'A7Y 4VAR'
M.8QZA=?M9?#.SMM1EN+:^BFL-272UMY/LL4TMP1._P!V2X40@);2/BX,3%=I
M"G>H.SH/[0>E>,?%?AG1O".CWMSI&O3R02:I/&(8(Y4TXZ@(50MYOFA2@8-&
MJ@[@&+*10@/#=<^/OQ 36XM&L&AL1:^(%CCLY%DDU'6;<:M>021VC\(L:1VZ
M(^48C?\ >3Y"_2^&?VB/'^O? KXD?$BZTJR74_"FCSZA9+:,LB-.MBUSY$T:
M37&'A< ."ZN0?FCC;*UZ7JO[2WP]LO[3T^ W/]KZ?!-(;9X#N$D$US#*C;6Z
MPFV>24 Y6(JXSN6N'L_VH;74+^33_$7@V]CT-QJ$5S.OD3*L5K?Q:?Y\D9D&
M8)#-DJ T@PPV, 32M=-(=[6;.(\7^)/'OPXUB#7[#Q)JWB6.S\-Z7?M#/-$+
M&2YNKV*RFNY@!"HACC<SNGG1H I)9%RPVM'^/OQB\22Z7#INGZ+9I=2Z;:R2
MO'-=)*VI7>H6RW$1M[CRQ&B6:2[!)(&WE1* !(?7?$WQ<\)_"E?^$'T70[R:
MWT&WL[-7MHT-E9R7$;BRMY6:02@,L8&41P@*[B"P%8V@_M+:!>V^[4M,NV:V
M^ROJ$MI&K6^FQ7ACCA>=I'1V5I789B1R%1F9549+W>A.VYY.G[4WQ!;28-6C
MT*QGOI+**7^Q(TN3?R!](.H-J","?]#6<&W*^4S9!_>>9B,\S??M2^-O"CZ@
MZZEI7BI9-9G$,]O \=G/90Q::GE6;O<J<[KB5CM:Z<-D[#&"1[-H7[4-O?Z7
MX:NM;\.W6CWFJ6XOKJ&8IC[$UA?78GM65V#J9+)HP)?*8 ABH!!.IIG[5_PY
MU:?2+6VL;_S=7U"73$R;0Q)<Q& ;?/6Y,,I87,;*L#R.5W': K8%N-[&/H/B
M#]H#QKJ>C>);<VUMH-Q<W<;6]K&L:I%!=20#[0T[-(S%(]Y:/:,-A5W#<?1?
M!7Q(DG^%VIZYJ=VFH:MX;AU)IPBEYIH;"XNK>"X:&(%_])6V+C8OS'<$'&*X
MK0/VIO#.I^%+'Q)K_A[5-+MY[6WEOG"PS0V,UY$TUO;NZ2AV>5%4J40J/,C#
ME"V!'H?[07PXT&T>"W\):IH%M86_V=3+!:1+BUL4U"&WW"Y.";682*7(1<LK
MNCY6ETL/J9/@/]H;Q;XG^%7COQI/IMG>:CX4G2*W-J/]'FCEM;>X\UU@N+OY
M83,WF>7,Q*QGA'RHC'[2=_8SG2IKK2-;NIYM*BL+FP2XB@U%+O4+BTNWMTD9
MRPMXXD9BCR(&;ERI6OH3X9_$?0/BIX77Q5X<26*V%Q<6CI-Y99);60Q2#="\
MD;KE<JR.RD$$&N_P!T[42$CX/N?VBOC)8>'8==OM,TCRY;?07ED6"6.*U?6X
M9+DR2O<W<,8B@"+#\TD>^216+1@;&CUC]H/XS7_@O4M;TS3=-TR5K22VA5(I
MKJ:.]?P[+K"7*/O\MXEEC$:Q[#N# E\C#?>F >*6FP/BOXW?M'>,?A1/\-#I
M5I8:SIGBF*-[^YBC>>:0L]L@^Q6ZSQ%PXF=AY;3R#"XA9=SKX3+^V-\6/!UK
MI>FZ['INN:S/XGUJQO8OL<MMY5A::['IL42/YZ!9D@E$P CF<Q;'=0NZ4_J5
M@?E11?6XGM8_-L?M?_%V&&2?4= TFUMM0C$UO=-%=^3ID">(VT.:YO\ Y\R1
M)#BY.PQ;>06V_..$\"?MG?$ZQN_"/AS4X[7Q%)K6K7T5Y<2VTL#-;7.LZE:V
MLEFYD0M#%';1C'D284KYDB,ZEOU?HJ2FS\J_&G[57QWD^'_A.XO1I'A;4O%N
MD>']>A>U@NGFG75=4@ADL+0REE\ZUMB7NF96RLHVJ@!>OI3XL?M ^./!'Q=M
M?A_H>DV4EO(-#$$%S'<->ZN=7O9+6Y:P:,B-1IL:">XWALH>?*&'/V!157)/
MS\\"?&CXL^&/V7_#/Q(\7ZA;:KK_ (GU]K:\U/4()$T_2;2YO98?M$\,1C80
M0K&%4;T&74LX&37&^+_VWO'7ASQ&FE:3I&FZY;QZ#<WTKQV]W;![N+0[C5HI
M(#/(LSVLKPK$,VP W%1*9%*U^FOM12*/@GP7^TK\9[[XXZ!\(_%OAC3%BO[>
MTEN;BU+Q%X[RREO3<VHGG,CQ6[*EM(/)(9P[&2,[(CU^J_&WXAZ3XT\1:3IE
MA:S:7HFHP"8W2S2330W%[;6?EP,A1(]JRM)E@XR,8P25^QZ*=];DVTL?*_Q#
M^.^N^#OB?<^$+)=/N;:QATV9K#R[B35+J.^-R)IH!$2/+M5@$C@1N67</D.S
M=\_1?M0_$[Q);1WT<^GV=G:27D4OV:(#[:6TV&\MTBD2YNECD1VE!P[%@A#(
MC*RC]%K?1M+M=5O-<M[9([_4(X8IY@/GD2WW^4K>R[VQ]36E@>E)#9\.:)^T
M=\5/$GB*Y\.6>B:;I\TVK1Z=$;C,TE@'NIX/]+@AN6D9S'%YB[OL^>0%*D25
MQ$_[4?Q7TBWNO$&H+I)AN$TN9+!X7$T$<U@TLWD*\\+3^;<(X0!FE !6.*=@
M5'Z-X%)@>E"V![C8I!+$DH! < X((//J#R/QI]%% !1110 4444 ?__2_?RB
MBB@ HHHH **** ,K7-$TGQ+H]YH&NVJ7NGZA$T,\,@RKQN,$'O\ B.1U'->7
MC]G[X2JD>W17$T4[W*7/VV\^UK/(VYY1<^=YV]NC-OR02I."0?9:* /F!OV4
MOAV?$UG?AI4\.V-N;>+1$9EMN;!]-^=@^7_T:1EW,#+T'F;%5!ZAK/P9^&?B
M#49=6U;1$FNKF9IYW$LR>>SI"C),J.%EB9;>'=$X:,E 2N<FO3Z* /)'^!?P
MO>2ZN/[(D6YNI4F^T)>W:7$31&4H+>=9A);HOGRX2%D3$CC&&(.AIGP?^'.C
M>([/Q7I>CBVU+3QB!UFF\M#]G%J7$._RO,,"B,R%-Y4 %C@5Z710!YG=_!OX
M87VJ7FMW7AZW>_U![R2>;YP[OJ%M':739#<&6")$;&.!D8)),2?!?X91_;MN
MB)C40ZSJ9IBI626.=PJF0A TL2.0N,L">K-GU&BA >">-_@#X>\>?$/3_'.L
MW\ZP6GV=IK"/"17,EIYODM(RD;@OG-]X,PZ(R L&Z(? SX5+=VUZF@(DMK)'
M(-LTRI(8FC>,3()-LRH\2,B2AE5AN4 DD^LT4+0&>+V_[//P;MM+DT9?#<<M
MG(AB,<T]Q-MB,,]OY2&21BD8CN9@L:D*ID9@ QS4\'P#^%,#(XT>25EN_MSF
M:^O)C/<9A8/<>9,WGX-O$0)=Z@H"!GFO8:* /'5^ /PC7R0- 4QP1&!8S<7#
M1%,2*NZ,R[&:-9G6)F!:)3MC*J% TM7^"_PQUVTDL=5T*.>&659R/,E4B5;6
M.S6165P598(HT5@05VAAAOFKU"B@#E_"/@SPYX%TN31_#%JUK:S7$UW('FEG
M=Y[AB\LCR3.[LSL2S$L<DYKJ*** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832494368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 16, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moleculin Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,242,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,768,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832727104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,714<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,302<span></span>
</td>
<td class="nump">5,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net of accumulated depreciation of $21 and $6, respectively</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">11,148<span></span>
</td>
<td class="nump">11,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">16,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and current liabilities</a></td>
<td class="nump">902<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Long-term deferred compensation &#8211; related party</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 authorized, 21,469,109 issued and outstanding at December 31, 2017 and 12,164,852 shares issued and outstanding at December 31, 2016</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">31,577<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(14,480)<span></span>
</td>
<td class="num">(4,675)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">17,118<span></span>
</td>
<td class="nump">14,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 19,483<span></span>
</td>
<td class="nump">$ 16,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832470080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Furniture and equipment</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">21,469,109<span></span>
</td>
<td class="nump">12,164,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">21,469,109<span></span>
</td>
<td class="nump">12,164,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831064560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">8,653<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,653)<span></span>
</td>
<td class="num">(3,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Loss from change in fair value of warrant liability</a></td>
<td class="num">(2,548)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GainFromSettlementLiability', window );">Gain from settlement of liability</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GainLossFromExpirationOfWarrants', window );">Gain from expiration of warrants</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,805)<span></span>
</td>
<td class="num">$ (3,926)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">18,569,193<span></span>
</td>
<td class="nump">9,827,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GainFromSettlementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain from settlement liability associated with the issuance of common stock for service providers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GainFromSettlementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GainLossFromExpirationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain (loss) on expiration of warrants during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GainLossFromExpirationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832346304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,805)<span></span>
</td>
<td class="num">$ (3,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred compensation - related party</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GainFromSettlementLiability', window );">Gain in settlement of liability</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GainLossFromExpirationOfWarrants', window );">Gain from expiration of warrants</a></td>
<td class="num">(1,238)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">411<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(7,324)<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Moleculin, LLC, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock, net of cash stock issuance costs</a></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">9,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">10,059<span></span>
</td>
<td class="nump">8,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">2,707<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">7,714<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for the Acquisition of Moleculin, LLC</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued for conversion of debt</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_WarrantsIssuedForServices', window );">Warrants issued for services provided</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services provided</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GainFromSettlementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain from settlement liability associated with the issuance of common stock for service providers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GainFromSettlementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GainLossFromExpirationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain (loss) on expiration of warrants during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GainLossFromExpirationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_WarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Warrants issued for services provided in non cash financing activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_WarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833582672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Subscriptions Receivable</div></th>
<th class="th"><div>Accumulated Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2015</a></td>
<td class="num">$ (745)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances', window );">Private issuance @ $3.00 / share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValuePrivateIssuances', window );">Private issuance @ $3.00 / share</a></td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued for Moleculin acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issued for Moleculin acquisition</a></td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForTechnology', window );">Issued for technology (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForTechnology', window );">Issued for technology</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Issued for cash - IPO, net of stock issuance costs of $1,150 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Issued for cash - IPO, net of stock issuance costs of $1,150</a></td>
<td class="nump">8,089<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for services</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock granted for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock granted for services</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issued for convertible debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued for convertible debt</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockholdersEquitySubscriptionsSettledForCash', window );">Subscription agreement settled for cash</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balances (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,164,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock granted for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock granted for services</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issued for convertible debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued for convertible debt</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits', window );">Issued for cash - sale of units at $1.35 per unit, net of stock issuance costs of $550 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueSaleOfUnits', window );">Issued for cash - sale of units at $1.35 per unit, net of stock issuance costs of $550</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, net of issuance costs of $73 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,728,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised, net of issuance costs of $73</a></td>
<td class="nump">8,903<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering', window );">Issued for cash - sale of common stock in ATM offering, net of issuance costs of $166 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering', window );">Issued for cash - sale of common stock in ATM offering, net of issuance costs of $166</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,805)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,469,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">$ 17,118<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 31,577<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (14,480)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for cash initial public offering net of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues, At-the-Market Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesNewIssuesAttheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesPrivateIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period in private issuances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesPrivateIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesSaleOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sale Of Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesSaleOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for Cash IPO Net of Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueForTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueForTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues, At-the-Market Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValuePrivateIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of private issuances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValuePrivateIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueSaleOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Sale Of Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueSaleOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockholdersEquitySubscriptionsSettledForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents subscriptions receivable settled for cash during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockholdersEquitySubscriptionsSettledForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819823680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits', window );">Stock issuance costs, sale of units</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts', window );">Stock warrants exercised, issuance costs</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering', window );">Stock issuance costs, stock offering</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, At-the-Market Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Sale Of Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Stock Warrants Exercised During Period, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823403856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NatureOfBusinessAndLiquidityTextBlock', window );">Nature of Business and Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business and Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms &#8220;MBI&#8221; or &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company organized as a Delaware corporation in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;"> to focus on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which we refer to as MD Anderson. MBI has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> drug technologies. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML. Annamycin had been in clinical trials pursuant to an investigative new drug application or IND that had been filed with the U.S. Food and Drug Administration, or FDA. Due to a lack of development activity by a prior drug developer, this IND was terminated. To permit the renewed investigation of Annamycin, we submitted a new IND for a Phase I/II trial for the treatment of relapsed or refractory AML in August 2017, which was subsequently allowed by the FDA in September 2017. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other drug development projects, one involving a collection of small molecules, which we refer to as the WP1066 Portfolio, a collection of STAT3 inhibitors, some of which also have immuno-stimulating capability, targeting brain tumors, pancreatic cancer and AML, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (the most common form of brain tumor) and pancreatic cancer in particular. A physician-sponsored IND for a Phase I trial of WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma was allowed by the FDA in December 2017. We also continue to sponsor ongoing research at MD Anderson in order to improve and expand our drug development pipeline.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to all of our drug technologies, as these patent rights are owned by MD Anderson. The Annamycin drug substance is no longer covered by any existing patent protection, however, we intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we have received Orphan Drug designation from the FDA for Annamycin for the treatment of AML, which would entitle us to market exclusivity of 7 years from the date of approval of a New Drug Application (NDA) in the United States. We may then benefit from Orphan Drug exclusivity, during which period FDA generally could not approve another Annamycin product for the same use. We also intend to apply for similar status in the European Union (EU) where market exclusivity extends to 10 years from the date of Marketing Authorization Application (MAA). Separately, the FDA may also grant market exclusivity of 5 years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With regard to additional potential clinical activity, we submitted in October 2017 a request for Clinical Trial Authorization ("CTA") in Poland which, if allowed, will enable a Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory AML in Poland. This will be in addition to the previously announced allowance of our IND in the United States. In December 2017, the Ethics Committee in Poland approved our Phase I/II clinical trial of Annamycin. In March we received requests for and provided additional information to the Polish National Office.  We expect a response from the Polish National Office in the first half of 2018 and at the earliest mid-April 2018. The start of clinical trials in Poland remains subject to confirmation and approval of the CTA by the Polish National Office. We can provide no assurance that we will receive such confirmation on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we continue to recruit and contract clinics both in the United States and Poland. In the US, we have one site - University Hospitals Cleveland Medical Center (&#8220;UHCMC&#8221;) - recruiting patients and active with drug ready to provide treatments.  A patient was enrolled in March 2018 with anticipated treatment to occur in the near term.&#160; We can provide no assurance treatment will occur on a timely basis, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, in September 2017 we engaged a contract research organization ("CRO") to prepare for a proof-of-concept clinical trial in Poland to study our drug candidate WP1220, a part of the WP1066 portfolio, for the treatment of cutaneous T-cell lymphoma ("CTCL").</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with FASB ASC Topic 280, Segment Reporting, we view our operations and manage our business as principally </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. As a result, the financial information disclosed herein represents all of the material financial information related to our principal operating segment.&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company filed a registration statement on Form S-1 (which was declared effective on May&#160;2, 2016) with respect to the Company&#8217;s initial public offering of shares of its common stock (&#8220;IPO&#8221;) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, we acquired Moleculin, LLC which was merged with and into MBI. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NatureOfBusinessAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for nature of business and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NatureOfBusinessAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817925648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation - </font><font style="font-family:inherit;font-size:10pt;">The accompanying audited financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition &#8211;</font><font style="font-family:inherit;font-size:10pt;"> We acquired Moleculin, LLC (&#8220;Moleculin&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Going Concern -</font><font style="font-family:inherit;font-size:10pt;"> These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents -</font><font style="font-family:inherit;font-size:10pt;"> The Company considers all highly liquid accounts with original maturities of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months or less at the date of acquisition to be cash equivalents.&#160;Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the insured limits of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">. The amount in excess of the applicable insurance coverage at December 31, 2017 was not material. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and equipment -</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:60%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of estimated useful lives or the term of the lease&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 years*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years*</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a </font><font style="font-family:inherit;font-size:10pt;">2 years</font><font style="font-family:inherit;font-size:10pt;"> useful life due to their age and condition and expected remaining life assessed at merger date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets -</font><font style="font-family:inherit;font-size:10pt;"> Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments - </font><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist primarily of account payables,  accrued expenses and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Unobservable inputs for the asset or liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&#160;liability discussed in Note 6. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December 31, 2017 (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Measured at Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrant liability:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December&#160;31, 2017 (in thousands): </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of period December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuances of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclass of liability from long-term to current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,846</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value - net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers in and out (exercise of warrants)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The above table of Level 3 liabilities begins with the initial valuation given the warrant issuances that occurred in the first quarter of 2017 and adjusts the balances for changes that occurred during the year. The ending balance of the Level 3 financial instrument presented above represent our best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized "through an" immediate settlement of the instruments.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beneficial Conversion Feature</font><font style="font-family:inherit;font-size:10pt;"> - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes -</font><font style="font-family:inherit;font-size:10pt;"> The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation -</font><font style="font-family:inherit;font-size:10pt;"> Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Common Share</font><font style="font-family:inherit;font-size:10pt;"> - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December&#160;31, 2017, the Company&#8217;s potentially dilutive shares, which were not included in the calculation of net loss per share, included options to purchase </font><font style="font-family:inherit;font-size:10pt;">1,345,000</font><font style="font-family:inherit;font-size:10pt;"> common shares and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">677,576</font><font style="font-family:inherit;font-size:10pt;"> common shares. As of December 31, 2016, the Company's potentially dilutive shares, which were not included in the calculation of net loss per share, included notes convertible to </font><font style="font-family:inherit;font-size:10pt;">1,821,013</font><font style="font-family:inherit;font-size:10pt;"> common shares, options to purchase </font><font style="font-family:inherit;font-size:10pt;">510,000</font><font style="font-family:inherit;font-size:10pt;"> common shares and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">107,802</font><font style="font-family:inherit;font-size:10pt;"> common shares.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> - A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Costs -</font><font style="font-family:inherit;font-size:10pt;"> Research and development costs are expensed as incurred.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events -</font><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 10.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&#160;31, 2017. See also policy note disclosure mentioned above on Going Concern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-1&#8221;).&#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-1 is effective for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. MBI assumes no forfeiture since it has limited history. ASU 2016-9 is effective for annual periods beginning after December&#160;15, 2016, with early adoption permitted. The adoption of this standard on January&#160;1, 2017, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823435024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Acquisition of Moleculin, LLC</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of </font><font style="font-family:inherit;font-size:10pt;">999,931</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock valued at </font><font style="font-family:inherit;font-size:10pt;">$5,999,586</font><font style="font-family:inherit;font-size:10pt;">, based on the estimated acquisition-date fair value of our common stock of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;"> per share, equal to the IPO price announced in our prospectus filed on that date. Prior to the Company&#8217;s acquisition of Moleculin, the Company had loaned </font><font style="font-family:inherit;font-size:10pt;">$57,822</font><font style="font-family:inherit;font-size:10pt;"> to Moleculin which was treated as part of the consideration paid to acquire Moleculin.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As additional consideration payable to the Moleculin unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us using any of the Existing IP Assets, then the Moleculin, LLC unit holders, in the aggregate, will be entitled to receive a </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net revenues generated by such drugs. Any such net revenues would include a deduction for license fees or royalty obligations payable to MD Anderson for such Existing IP Assets. The merger agreement defined &#8220;Existing IP Assets&#8221; to mean all intellectual property, licensed by us and Moleculin as of the time of the merger, including, without limitation, the intellectual property licensed from MD Anderson under the Patent and Technology License Agreement entered into by and between IntertechBio Corporation and MD Anderson dated April 2, 2012, as amended, and the Patent and Technology License Agreement dated </font><font style="font-family:inherit;font-size:10pt;">June&#160;21, 2010</font><font style="font-family:inherit;font-size:10pt;">, as amended, between MD Anderson and Moleculin, LLC, but excluding any intellectual property relating to Annamycin. The right to receive the contingent royalty payments described herein is limited to&#160;drugs developed only for dermatology indications and does not include drugs developed for any other indications. We have no obligation of any nature to pursue the development of any drugs for dermatology indications.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), a related party, an option, which could be exercised at any time, to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. Moleculin, LLC had previously pursued development of the WP1066 Portfolio for treatment of psoriasis, however, psoriasis related clinical trials had been terminated. Because WP1066 has shown significant activity against a wide range of tumors, Moleculin, LLC&#8217;s focus prior to the acquisition included the development of drugs for cancer treatment. However, the exclusive sub-license option held by HPI precluded Moleculin, LLC from pursuing drug development related to non-skin cancers, in addition to potentially creating significant intellectual property, clinical and commercialization risks associated with drug development for skin cancers. Re-acquisition of the HPI option was therefore essential for the values of both the WP1066 Portfolio and Moleculin, LLC.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the merger agreement contained mutual representations and warranties between the parties. Pursuant to the merger agreement, we agreed for a period of </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> years to indemnify and hold harmless each present and former director and/or officer of Moleculin, LLC whom Moleculin, LLC would have had the power to indemnify under Delaware law that is made a party or threatened to be made a party to any threatened, pending or completed proceeding or claim by reason of the fact that he or she was a director or officer of the Moleculin, LLC prior to the effective time of the merger and arising out of actions or omissions of the indemnified party in any such capacity occurring at or prior to the effective time of the merger against any losses or damages reasonably incurred in connection with any claim. To our knowledge, no such proceeding or claim exists or has been threatened on the date hereof.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Moleculin, LLC, we also negotiated on behalf of Moleculin, LLC </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> agreements with HPI. Under the first agreement, HPI&#8217;s option to obtain the aforementioned exclusive sublicense was terminated in exchange for a payment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> and the issuance of </font><font style="font-family:inherit;font-size:10pt;">629,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, valued at </font><font style="font-family:inherit;font-size:10pt;">$6</font><font style="font-family:inherit;font-size:10pt;"> per share. Under the second agreement (HPI Out-Licensing Agreement), HPI has received a non-exclusive technology rights and development sublicense under which it may continue its ongoing work to develop the WP1066 Portfolio related to treatment of non-skin cancer. Pursuant to this HPI Out-Licensing Agreement, we agreed to make payments to HPI totaling </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period, of which </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> was paid as of December 31, 2017. The Company expenses such costs as incurred as research and development expense, commencing after the IPO offering in exchange for HPI allowing us to access any data, information or know-how resulting from the research and development conducted by HPI. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any specific research or to meet any milestones. Pursuant to the HPI Out-Licensing Agreement, we have the right within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years of the effective date to buy-out from HPI all rights granted to HPI under the agreement for a payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. Upon our exercise of the buy-out we will no longer be obligated to make any payments to HPI remaining from the </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> obligation discussed above. If we do not exercise the foregoing buy-out right within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years, the license granted to HPI shall convert into an exclusive license. As such, if we do not exercise the buy-out right for any reason, we will no longer have access to the non-skin cancer uses of the WP1066 Portfolio. As noted above, this will also potentially create risks for the development of skin cancer drugs. We do not intend to set aside and designate cash and cash equivalents in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1 million</font><font style="font-family:inherit;font-size:10pt;"> to make the buy-out payment. If we ultimately decide to exercise the buy-out right from HPI, we will need to raise additional funds to make the buy-out payment. We cannot assure that such additional funding will be available on satisfactory terms, or at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The agreements with HPI were executed on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, simultaneously with the closing of the Moleculin, LLC acquisition, and were non-cancelable but contingent on the Company&#8217;s ability to complete the IPO by </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. They became effective on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The termination of the HPI option was completed on behalf of Moleculin, LLC, which was required to enable the sale of Moleculin, LLC by materializing the value of its most significant asset and was non-cancelable by either party. Further, the HPI option termination price was determined simultaneously with the acquisition on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;"> as our IPO price was established at that time. Accordingly, we concluded that this transaction was primarily for the benefit of Moleculin, LLC and its former owners, resulting in control of the underlying intellectual property and thereby increasing the value of Moleculin, LLC intangible assets immediately prior to the closing of its acquisition by us.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The HPI option termination price amounted to </font><font style="font-family:inherit;font-size:10pt;">$3,874,000</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">629,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock valued at the IPO price of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;"> per share, and </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> paid in cash in </font><font style="font-family:inherit;font-size:10pt;">July 2016</font><font style="font-family:inherit;font-size:10pt;">, and was included in acquisition-date liabilities assumed.</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase Price Allocation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability assumed (HPI)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities assumed, including $470 of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired/total consideration transferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC. Management believes all or most of the intangible assets are IPR&amp;D related to the WP1066 Portfolio, and, as such, no amortization has been recorded to date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles acquired from Moleculin, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Pro Forma Results of Operations</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following comparative table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of the first day of each period presented, adjusted for items that are directly attributable to the acquisition. This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future (amounts in thousands except share data).</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro Forma For the Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,963</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average outstanding common shares &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,401,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was adjusted on a pro forma basis to exclude </font><font style="font-family:inherit;font-size:10pt;">$145,078</font><font style="font-family:inherit;font-size:10pt;"> in net interest expense related to the amortization of deferred financing costs and debt discount amortization for Moleculin, LLC&#8217;s convertible notes. The holders of the convertible notes were issued the Company&#8217;s common shares upon the Company&#8217;s acquisition of Moleculin, LLC.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817953392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and other accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Expenses and other accrued liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses and other accrued liabilities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities consist of the following components (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued license fees and SRA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal and professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued board expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823346384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ConvertibleNotesPayableDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Notes Payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On various dates from </font><font style="font-family:inherit;font-size:10pt;">August&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">January&#160;19, 2016</font><font style="font-family:inherit;font-size:10pt;">, each as amended on </font><font style="font-family:inherit;font-size:10pt;">March&#160;10, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> unsecured promissory notes with </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> separate third-party investors. Each note bore interest at </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum and was to mature on the earlier of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> or the completion of an IPO of the Company&#8217;s securities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the completion of the IPO occurred prior to </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, these notes were to be automatically converted according to their terms into shares of the Company&#8217;s common stock at applicable conversion price upon the Company&#8217;s IPO to the extent and provided that no holder of these notes was permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> of our common stock after such conversion. Due to this </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> limitation, a portion of these notes was not converted at the time of the IPO and the remaining unconverted principal and accrued interest amounts of the effected notes remained outstanding and were converted into shares of our common stock at such time as the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> limitation was met. Until such time as the notes were converted into shares of common stock, the maturity date of the notes was automatically extended, and we were not required to repay the notes or the accrued interest relating to the notes in cash.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IPO was completed on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. On </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, pursuant to the conversion feature of the foregoing notes and with restriction of the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> beneficially owned condition limitation, discussed above, the Company issued </font><font style="font-family:inherit;font-size:10pt;">1,166,503</font><font style="font-family:inherit;font-size:10pt;"> common shares in total, reducing the convertible debt principal by </font><font style="font-family:inherit;font-size:10pt;">$183,356</font><font style="font-family:inherit;font-size:10pt;"> and accrued interest by </font><font style="font-family:inherit;font-size:10pt;">$17,699</font><font style="font-family:inherit;font-size:10pt;">. Subsequent to these transactions and through December&#160;31, 2016, an additional </font><font style="font-family:inherit;font-size:10pt;">910,095</font><font style="font-family:inherit;font-size:10pt;"> common shares were issued due to the number of common shares outstanding allowing for conversion of additional shares under the </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> beneficially owned condition limitation. This reduced the convertible debt principal by </font><font style="font-family:inherit;font-size:10pt;">$155,565</font><font style="font-family:inherit;font-size:10pt;"> and accrued interest by </font><font style="font-family:inherit;font-size:10pt;">$7,172</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist. On June 22, 2017, pursuant to the conversion feature of the foregoing notes and with restriction of the beneficially owned condition limitation discussed above, the Company issued common shares which effectively converted all remaining outstanding convertible debt and accrued interest outstanding as of that date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below represents the shares that are convertible at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:</font></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Amounts and shares in whole values)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares Convertible at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 31, 2015(a)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 3, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 6, 2015(a)(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 19, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,821,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Debt partially converted on May&#160;31, 2016 and on August&#160;19, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Debt partially converted on September&#160;1, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Excluded from the </font><font style="font-family:inherit;font-size:10pt;">$276,079</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$20,333</font><font style="font-family:inherit;font-size:10pt;"> in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common shares relating to the above mentioned convertible notes payable contained the following trading restrictions: (a) beginning </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days after the initial closing of our IPO and until the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> of the daily volume; (b) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;"> per share for </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days then the holder of the note can sell up to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> of the daily volume; (c) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> per share for </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days then the holder of the note can sell up to an additional </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;"> of the daily volume; and (d) if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$14.00</font><font style="font-family:inherit;font-size:10pt;"> per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below </font><font style="font-family:inherit;font-size:10pt;">$14.00</font><font style="font-family:inherit;font-size:10pt;"> per share; and (b) thereafter, until the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the daily volume; provided that if the common stock price is over </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ConvertibleNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ConvertibleNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817948736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_WarrantsLiabilityDisclosureTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Liability</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;9, 2017, the Company entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Roth Capital Partners, LLC, as representative of the several underwriters identified therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which we sold in a registered public offering (the &#8220;Offering&#8221;), </font><font style="font-family:inherit;font-size:10pt;">3,710,000</font><font style="font-family:inherit;font-size:10pt;"> units, priced at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;"> per unit (the closing price that day was </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">), with each unit consisting of: (i) </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of common stock, (ii) a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year Series A warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock, (iii) a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day Series B warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share of common stock, and (iv) a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year Series C warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock. The Series C warrants in a unit could only be exercised to the extent and in proportion to a holder of the Series C warrants exercising its Series B warrants included in the unit. The Series A and Series C warrant have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock. The Series B warrant had an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Underwriting Agreement, we granted the Underwriters a 45-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and/or an additional </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;"> warrant combination (comprised of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">278,250</font><font style="font-family:inherit;font-size:10pt;"> Series A warrants, </font><font style="font-family:inherit;font-size:10pt;">556,500</font><font style="font-family:inherit;font-size:10pt;"> Series B warrants and </font><font style="font-family:inherit;font-size:10pt;">278,250</font><font style="font-family:inherit;font-size:10pt;"> Series C warrants), in any combinations thereof, from us to cover over-allotments at the public offering price per share of </font><font style="font-family:inherit;font-size:10pt;">$1.349</font><font style="font-family:inherit;font-size:10pt;"> and public offering price per warrant combination of </font><font style="font-family:inherit;font-size:10pt;">$.001</font><font style="font-family:inherit;font-size:10pt;">, respectively, less the underwriting discounts and commissions. Upon the closing of the Offering, the Underwriters exercised the over-allotment option with respect to </font><font style="font-family:inherit;font-size:10pt;">$278,100</font><font style="font-family:inherit;font-size:10pt;"> warrant combinations. We received approximately </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The basis of value is fair value, which is defined pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 820 to be &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date&#8221;. The Company estimated the fair value of the Warrants under ASC 820 as of February&#160;14, 2017 for financial reporting purposes. We used the Black-Scholes option pricing model (&#8220;BSM&#8221;) to determine the fair value of the Series A and Series B Warrants and a Monte Carlo simulation (&#8220;MCM&#8221;) with regard to the Series C Warrants in consideration of path dependent vesting terms of the contract. Both the BSM and MCM models are acceptable in accordance with GAAP. The BSM requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The MCM simulates the Company&#8217;s common stock price from the valuation date through the Series B Warrant and the unvested Series C Warrant expiration dates using Geometric Browman Motion on a risk-neutral basis - thereby impacting the likelihood that the Series B Warrants would have been exercised and, subsequently, the Series C Warrants would then vest. All Series B and unvested Series C warrants expired on May&#160;15, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated by using the average daily historical stock prices through the day preceding the grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the Warrants. Where appropriate, we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2016-2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in the BSM and MCM models for the Warrants are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68%-1.86%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.00%-160.11%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5-5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of our Warrant activity and related information follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Under</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Price</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise&#160; Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual&#160;Life (Years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,235,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,728,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,087,717</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Activity During 2017:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;14, 2017, </font><font style="font-family:inherit;font-size:10pt;">8,235,923</font><font style="font-family:inherit;font-size:10pt;"> Warrants were granted, as discussed above. During the year, </font><font style="font-family:inherit;font-size:10pt;">1,833,984</font><font style="font-family:inherit;font-size:10pt;"> Series A warrants were exercised, </font><font style="font-family:inherit;font-size:10pt;">596,300</font><font style="font-family:inherit;font-size:10pt;"> Series B warrants were exercised - thereby vesting </font><font style="font-family:inherit;font-size:10pt;">298,150</font><font style="font-family:inherit;font-size:10pt;"> Series C warrants - and all of the vested </font><font style="font-family:inherit;font-size:10pt;">298,150</font><font style="font-family:inherit;font-size:10pt;"> Series C warrants were exercised. Of the remaining Series B and C warrants, </font><font style="font-family:inherit;font-size:10pt;">5,087,717</font><font style="font-family:inherit;font-size:10pt;"> expired on May&#160;15, 2017. Therefore, the associated warranty liability of </font><font style="font-family:inherit;font-size:10pt;">$1.24 million</font><font style="font-family:inherit;font-size:10pt;"> was extinguished on that date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_WarrantsLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants liability, including all tables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_WarrantsLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823421008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company amended and restated its certificate of incorporation to increase the number of shares authorized to </font><font style="font-family:inherit;font-size:10pt;">80,000,000</font><font style="font-family:inherit;font-size:10pt;"> of which </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock are authorized and </font><font style="font-family:inherit;font-size:10pt;">75,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock are authorized.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> issued preferred stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Settlement of a Liability</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company issued </font><font style="font-family:inherit;font-size:10pt;">79,167</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to a consultant in full settlement for prior services rendered to the Company. Settlement occurred February 21, 2017 with the issuance of the shares, resulting in a gain on settlement of </font><font style="font-family:inherit;font-size:10pt;">$0.15 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in gain in settlement of liability on the Statements of Operations. The obligation of </font><font style="font-family:inherit;font-size:10pt;">$0.24 million</font><font style="font-family:inherit;font-size:10pt;"> had been recorded by the Company in accounts payable and accrued expenses as of December 31, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Follow-On Public Offering</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the Company completed a public offering and sold </font><font style="font-family:inherit;font-size:10pt;">3,710,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. The offering price per unit was </font><font style="font-family:inherit;font-size:10pt;">$1.35</font><font style="font-family:inherit;font-size:10pt;">. The Company received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> after deducting underwriting discounts, commissions and direct offering expenses payable by us. See Note 6 above regarding Warrant issuances related to our February 2017 public offering.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">At Market Issuance Sales Agreement (ATM)</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 15, 2017, the Company entered into an At Market Issuance Sales Agreement (the &#8220;Agreement&#8221; or &#8220;ATM&#8221;) with Roth Capital Partners, LLC and National Securities Corporation (collectively, the &#8220;Agents&#8221;). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company's common stock with an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any sales of Shares pursuant to the Agreement will be made under the Company's effective shelf registration statement on Form S-3 (File No. 333-219434) which became effective on August 21, 2017 and the related prospectus supplement and the accompanying prospectus, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September 15, 2017. Under the Agreement, the Company may sell Shares through an Agent by any method that is deemed an at the market offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of the Shares may be made at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including a minimum sales price that may be stipulated by the Company's Board of Directors or a duly authorized committee thereof. The Company or the Agents, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering amount equal to </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">, or sooner if either the Company or the Agents terminate the Agreement pursuant to its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company agreed to pay a commission to the Agents of </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds of the sale of the Shares sold under the Agreement and to reimburse the Agents for certain expenses. The Company has also provided the Agents with customary indemnification rights. The Company is not obligated to make any sales of Common Stock under the Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 2017, the Company had sold </font><font style="font-family:inherit;font-size:10pt;">776,016</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock from </font><font style="font-family:inherit;font-size:10pt;">$2.05</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$2.71</font><font style="font-family:inherit;font-size:10pt;"> per share with gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> under this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company completed its IPO and sold </font><font style="font-family:inherit;font-size:10pt;">1,540,026</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. The IPO price per share was </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;">. The Company received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$8,464,183</font><font style="font-family:inherit;font-size:10pt;"> after deducting underwriting discounts, commissions and direct offering expenses payable by us. Pursuant to our agreement with our underwriters, as additional compensation, we issued the underwriters warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">107,802</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock exercisable for a period of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years from date of issuance at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The relative fair value of these warrants was </font><font style="font-family:inherit;font-size:10pt;">$374,763</font><font style="font-family:inherit;font-size:10pt;"> and is included in stock issuance costs calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of </font><font style="font-family:inherit;font-size:10pt;">1.39%</font><font style="font-family:inherit;font-size:10pt;"> (2) expected life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years, (3) expected volatility of </font><font style="font-family:inherit;font-size:10pt;">80.61%</font><font style="font-family:inherit;font-size:10pt;">, and (4) </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> expected dividends.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period from January&#160;1, 2016 through May&#160;2, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;">234,297</font><font style="font-family:inherit;font-size:10pt;"> common shares for </font><font style="font-family:inherit;font-size:10pt;">$702,894</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;20, 2016, the Company agreed to issue </font><font style="font-family:inherit;font-size:10pt;">24,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to PCG Advisory Group, the Company&#8217;s investor relations firm, for services provided. The fair value of these shares was </font><font style="font-family:inherit;font-size:10pt;">$157,680</font><font style="font-family:inherit;font-size:10pt;"> based on the market price on the grant date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">    &#160;&#160;&#160;&#160; GSK Consulting Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2017, the Company entered into a consulting agreement with GSK Strategies, LLC (&#8220;GSK&#8221;), for its investor relations operations. The consulting agreement covers for a period of </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;"> months from the date of July 29, 2017. In exchange for the consulting services, the Company agreed to issue </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> warrants (collectively, the &#8220;Warrants&#8221;) to purchase </font><font style="font-family:inherit;font-size:10pt;">100,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">50,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at exercise prices of </font><font style="font-family:inherit;font-size:10pt;">$2.41</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively, subject to approval by Nasdaq of a listing of additional shares application, which was received in August 2017. Each of the Warrants vests over a </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;">-month period in equal monthly installments starting July 29, 2017, provided that GSK is providing services to the Company pursuant to the consulting agreement on each vesting date. The Warrants became initially exercisable on August 8, 2017, and expire </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years from the initial exercise date. The Company recorded stock compensation expense for the non-employee consulting agreement of </font><font style="font-family:inherit;font-size:10pt;">$104,000</font><font style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2017 based on the fair value of the warrants vested as of December 31, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> &#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of 2015 Stock Plan</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On December&#160;5, 2015, the Board of Directors of the Company approved the Company&#8217;s 2015 Stock Plan, which was amended on April&#160;22,&#160;2016. The expiration date of the plan is </font><font style="font-family:inherit;font-size:10pt;">December&#160;5, 2025</font><font style="font-family:inherit;font-size:10pt;"> and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants under the plan is </font><font style="font-family:inherit;font-size:10pt;">2,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares. The awards under the 2015 Stock Plan can be in the form of stock options, stock awards or stock unit awards. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of option activities for the years ended December&#160;31, 2016 and 2017:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option grants has been estimated, with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.44%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for the years ended December 31, 2017 and 2016, are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted during 2017 have an aggregated fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> that was calculated using the Black-Scholes option-pricing model. At December 31, 2017, total compensation cost not yet recognized was </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and the weighted average period over which this amount is expected to be recognized is </font><font style="font-family:inherit;font-size:10pt;">8.7 years</font><font style="font-family:inherit;font-size:10pt;">. The aggregate fair value of options vesting in the years ended December 31, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> options were exercised in 2017 or 2016. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the above paragraph and table. The expected term of the options was computed using the &#8220;plain vanilla&#8221; method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 because we do not have sufficient data regarding employee exercise behavior to estimate the expected term. The volatility was determined by referring to the average historical volatility of a peer group of public companies because we do not have sufficient trading history to determine our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a separation agreement with its former Chief Financial Officer in October 2016 and as part of the agreement, options to purchase </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock issued to the former Chief Financial Officer were cancelled and the vesting was accelerated on the remaining options to purchase </font><font style="font-family:inherit;font-size:10pt;">50,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823377792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes consists of the following components (in thousands):&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes activity related to the Company&#8217;s valuation allowance (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at Beginning of Period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Tax Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Release of Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at End of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands): </font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(amounts in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Tax Benefit at Statutory Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,335</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Benefit Net of Federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPO Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Warrant Costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Permanent Differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in Deferred Tax Rate due to Tax Reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Tax (Expense) / Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a deferred tax expense of </font><font style="font-family:inherit;font-size:10pt;">$1.56 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2017 that is still fully valued against as of December 31, 2017.  This expense is attributable to the Company being in a net deferred tax asset position at the time of remeasurement.  As the company maintains fully valuation allowance, this amount can be seen on the rate reconciliation as an adjustment to deferred tax asset and corresponding valuation allowance. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Start Up Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Net Operating Loss Carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Loss Carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred net operating losses since inception. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had total federal operating loss carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.07 million</font><font style="font-family:inherit;font-size:10pt;"> which expire commencing in 2037. The value of these carryforwards depends on the Company&#8217;s ability to generate taxable income. Additionally, because federal tax laws limit the time during which the net operating loss carryforwards may be applied against future taxes, if the Company fails to generate taxable income prior to the expiration dates of the carry forwards the Company may not be able to fully utilize the net operating loss carryforwards to reduce future income taxes. Finally, the Company has not undertaken a detailed analysis of the application of IRC Section 382 with respect to limitations on the utilization of net operating loss carryforwards and other deferred tax assets. However, the Company believes that this matter is not material to the overall tax position within the financial statements due to the full valuation allowance against the net operating losses and the lack of utilization of the net operating losses during tax years open under statute.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts business in various locations and, as a result, files income tax returns in the United States Federal jurisdiction and in multiple state jurisdictions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had state operating losses of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.81 million</font><font style="font-family:inherit;font-size:10pt;"> which expire commencing in 2037. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. The Company has cumulative losses and there is no assurance of future taxable income, therefore, valuation allowances have been recorded to fully offset the deferred tax asset at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of </font><font style="font-family:inherit;font-size:10pt;">$2.56 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.40 million</font><font style="font-family:inherit;font-size:10pt;"> has been established at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in the valuation allowance for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was primary due to additional operating losses and capitalized research costs. The Company may be eligible to claim research and development tax credits in the future, but has not conducted a study to date.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrecognized tax benefits from any federal, state or foreign jurisdictions. The only tax years open under statute for the Company are December 31, 2017 and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s policy is to recognize interest and penalties related to any unrecognized tax liabilities as additional tax expense. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> interest or penalties have been accrued at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, as the Company has not recorded any uncertain tax positions. The Company believes it has appropriate and adequate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes its recorded assets and liabilities are reasonable, tax regulations are subject to interpretation and tax litigation is inherently uncertain; therefore, the Company&#8217;s assessments can involve both a series of complex judgments about future events and rely heavily on estimates and assumptions. Although the Company believes that the estimates and assumptions supporting its assessments are reasonable, the final determination of tax audit settlements and any related litigation could be materially different from that which is reflected in historical income tax provisions and recorded assets and liabilities. If the Company were to settle an audit or a matter under litigation, it could have a material effect on the income tax provision, net income, or cash flows in the period or periods for which that determination is made. Any accruals for tax contingencies are provided for in accordance with U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company does not believe that its tax positions will significantly change due to any settlement and/or expiration of statutes of limitations prior to&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance. As a result have recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The deferred tax expense recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act.   Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.  The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818074704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sponsored Research Agreements with MD Anderson</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2017, we amended our Sponsored Laboratory Study Agreement with MD Anderson whereby we paid </font><font style="font-family:inherit;font-size:10pt;">$302,500</font><font style="font-family:inherit;font-size:10pt;"> in 2017, and the agreement was extended to October 31, 2018. On December 4, 2017, we extended this Agreement until October 31, 2019 for total payment amount of </font><font style="font-family:inherit;font-size:10pt;">$346,687</font><font style="font-family:inherit;font-size:10pt;"> spread over that period of time. Of this amount, </font><font style="font-family:inherit;font-size:10pt;">$236,687</font><font style="font-family:inherit;font-size:10pt;"> was paid in the first quarter of 2018. The final payment of </font><font style="font-family:inherit;font-size:10pt;">$110,000</font><font style="font-family:inherit;font-size:10pt;"> is due on July 31, 2018. The expenses recognized under the MD Anderson agreement with regards to the Sponsored Laboratory Study were </font><font style="font-family:inherit;font-size:10pt;">$291,687</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$33,000</font><font style="font-family:inherit;font-size:10pt;">, for the year ended December 31, 2017 and 2016, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annamycin</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of August 2015, we obtained the rights and obligations of Annamed under a June 2012 Patent and Technology Development and License Agreement by and between Annamed and Dermin (the &#8220;Annamed Agreement&#8221;). Therefore, certain intellectual property rights, including rights, if any, covering the potential drug product, Annamycin have been licensed to Dermin and Dermin has been granted a royalty-bearing, exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products in the field of human therapeutics under the licensed intellectual property in the countries of Poland, Ukraine, Czech Republic, Hungary, Romania, Slovakia, Belarus, Lithuania, Latvia, Estonia, Netherlands, Turkey, Belgium, Switzerland, Austria, Sweden, Greece, Portugal, Norway, Denmark, Ireland, Finland, Luxembourg, Iceland, Kazakhstan, Russian Federation, Uzbekistan, Georgia, Armenia, Azerbaijan and Germany (&#8220;Annamed licensed territories&#8221;). We are obligated to develop and provide a dossier containing data related to the licensed subject matter to Dermin. In consideration, Dermin will pay a royalty for the sale of any licensed product in the Annamed licensed territories and pay all out-of-pocket expenses incurred by us in filing, prosecuting and maintaining the licensed patents for which the license has been granted. Dermin also agrees to provide a percentage of certain consideration that Dermin receives pursuant to sublicense agreements. On June 29, 2017, the Company entered into an agreement with MD Anderson licensing certain technology related to the method of preparing Liposomal Annamycin. The agreement includes a one-time license documentation fee of </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">, annual maintenance fees of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> until the first sale of drug and has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product - </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">; (ii) submission of the first NDA within the United States - </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;">; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- </font><font style="font-family:inherit;font-size:10pt;">$225,000</font><font style="font-family:inherit;font-size:10pt;">. The expenses recognized under this agreement were </font><font style="font-family:inherit;font-size:10pt;">$52,500</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2017 or 2016, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1066 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to a June 2010 Patent and Technology License Agreement entered into by and between Moleculin LLC and MD Anderson (the &#8220;Moleculin Agreement&#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights, related to our WP1066 drug product candidate. In consideration, we must make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Annual maintenance fee payments will no longer be due upon marketing approval in any country of a licensed product. One-time milestone payments are due upon commencement of the first Phase III study for a licensed product within the United States, Europe, China or Japan; upon submission of the first NDA for a licensed product in the United States; and upon receipt of the first marketing approval for sale of a licensed product in the United States. The rights we have obtained pursuant to the assignment of the Moleculin Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. The agreement, as amended, has the following the milestone payments: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">; (ii) submission of the first NDA within the United States - </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">; and (iii) receipt of first marketing approval for sale of a license product in the United States&#160;- </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">. License fees expensed related to MD Anderson were </font><font style="font-family:inherit;font-size:10pt;">$85,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$77,500</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the year ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an out-licensing agreement with Houston Pharmaceuticals, Inc. (&#8220;HPI&#8221;), pursuant to which we have granted certain intellectual property rights to HPI, including rights covering the potential drug candidate, WP1066 (&#8220;HPI Out-Licensing Agreement&#8221;). Under the HPI Out-Licensing Agreement we must make quarterly payments totaling </font><font style="font-family:inherit;font-size:10pt;">$0.75 million</font><font style="font-family:inherit;font-size:10pt;"> for the first twelve quarters following the effective date of the HPI Out-Licensing Agreement, or May 2, 2016, in consideration for the right to development data related to the development of licensed products. Notwithstanding our obligation to make the foregoing payments, the HPI Out-Licensing Agreement does not obligate HPI to conduct any research or to meet any milestones. Upon payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> to HPI within </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> of the effective date of the HPI Out-Licensing Agreement we will regain all rights to the licensed subject matter and rights to any and all development data and any regulatory submissions including any IND, NDA or ANDA related to the licensed subject matter and can end the license without any other obligation other than the aforementioned quarterly payments. In the event that we do not exercise our right to regain our rights to the licensed subject matter within </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> of the effective date of the HPI Out-Licensing Agreement, the license granted to HPI shall convert to an exclusive license upon HPI&#8217;s written notice and we shall be obligated to transfer all existing data relating to licensed subject matter including any development data and any IND to HPI. License fees expensed related to HPI were </font><font style="font-family:inherit;font-size:10pt;">$225,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;"> respectively, for the year ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into a license agreement covering a new group of molecules recently discovered in connection with research we have been sponsoring at MD Anderson Cancer Center called WP1732, a part of the WP1066 Portfolio. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> on the effective date of the agreement and increase by </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> per year up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> per year. Under the agreement, we are required to make royalty payments ranging from </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of Net Sales, depending on the intended use, each quarter upon the commencement of sales, with a minimum of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> per year. Additional payments are due upon the commencement of a Phase II study </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">, submission of a New Drug Application </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">, and the receipt of marketing approval of a licensed product, </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WP1122 Portfolio</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights and obligations to an April 2012 Patent and Technology License Agreement entered into by and between IntertechBio and MD Anderson (the &#8220;IntertechBio Agreement&#8221;) have been assigned to us. Therefore, we have obtained a royalty-bearing, worldwide, exclusive license to intellectual property, including patent rights, related to our WP1122 Portfolio and to our drug product candidate, WP1122. In consideration, we must make payments to MD Anderson including an up-front payment, license documentation fee, annual maintenance fee, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Under the agreement, annual maintenance fees are </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on the second anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;"> on the third anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$60,000</font><font style="font-family:inherit;font-size:10pt;"> on the fourth anniversary of the effective date of the agreement, </font><font style="font-family:inherit;font-size:10pt;">$80,000</font><font style="font-family:inherit;font-size:10pt;"> on the fifth anniversary of the effective date of the agreement and </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> on the sixth anniversary of the effective date of the agreement, except that such payments will no longer be due upon the first sale of a licensed product. Under the assignment, we agreed to make a minimum annual royalty payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> for the first anniversary following the first sale of a licensed product, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> for the second anniversary following the first sale of a licensed product, and </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;"> for the third year following the first sale of a licensed product. License fees expensed related to MD Anderson were </font><font style="font-family:inherit;font-size:10pt;">$95,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the year ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One-time milestone payments are due as follows: 1) Upon commencement of a Phase II study for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">; 2) Upon commencement of a Phase III study for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">; 3) Upon filing of a New Drug Application (&#8220;NDA&#8221;) for a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">; and 4) Upon receipt of market approval for sale of a licensed product - </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">. The rights we have obtained pursuant to the assignment of the IntertechBio Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with&#160;</font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> employees to provide certain benefits in the event of termination where the base salary and certain other benefits would aggregate approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> using the rate of compensation in effect at December 31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823406864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Appointment of Science Advisory Board Member</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January&#160;11, 2018, the Company issued to a Science Advisory Board (&#8220;SAB&#8221;) member </font><font style="font-family:inherit;font-size:10pt;">10,000</font><font style="font-family:inherit;font-size:10pt;"> options with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.89</font><font style="font-family:inherit;font-size:10pt;"> with </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">-year annual vesting.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$9 million Registered Direct Offering</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors for the sale by us of </font><font style="font-family:inherit;font-size:10pt;">4,290,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$2.10</font><font style="font-family:inherit;font-size:10pt;"> per share. Concurrently with the sale of the common shares, pursuant to the Purchase Agreement, we also sold warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,145,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. We sold the common shares and warrants for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">. Subject to certain beneficial ownership limitations, the warrants will be initially exercisable on the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month anniversary of the issuance date at an exercise price equal to </font><font style="font-family:inherit;font-size:10pt;">$2.80</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustments as provided under the terms of the warrants. The warrants are exercisable for </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> from the initial exercise date. The closing of the sales of these securities under the Purchase Agreement occurred on February 21, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net proceeds from the transactions was approximately </font><font style="font-family:inherit;font-size:10pt;">$8.27 million</font><font style="font-family:inherit;font-size:10pt;"> after deducting certain fees due to the placement agent and transaction expenses. The net proceeds will be used for planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The common shares were offered and sold by us pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on July 24, 2017 and subsequently declared effective on August 21, 2017 (File No. 333-219434), and the base prospectus contained therein. We filed a prospectus supplement with the SEC on February 16, 2018 in connection with the sale of the common shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants and the shares issuable upon exercise of the warrants were sold without registration under the Securities Act of 1933 in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a placement agent agreement (the &#8220;Placement Agency Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which Roth agreed to serve as exclusive placement agent for the issuance and sale of the common shares and warrants. We have agreed to pay Roth an aggregate fee equal to </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received by us from the sale of the securities in the transactions. Pursuant to the Placement Agency Agreement, we also agreed to grant to Roth or its designees warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of the aggregate number of shares of common stock sold in the transactions (the &#8220;Roth Warrants&#8221;). The Roth Warrants have substantially the same terms as the warrants, except that the Roth Warrants will expire on February 15, 2023. The Roth Warrants and the shares issuable upon exercise of the Roth Warrants will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. We also reimbursed Roth for its expenses of </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the consummation of the offering, we agreed to give Roth a </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month right of first refusal to act as our lead underwriter or exclusive placement agent for any further capital raising transactions undertaken by the us. With certain exceptions, the we also granted Roth a </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month tail fee equal to the cash and warrant compensation in the offering, if any investor with which Roth had substantive discussions with respect to the offering, provides us with further capital during such </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month period following termination of our engagement of Roth.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Agreement</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2018, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with IPX Memorial Drive Investors, LLC (the &#8220;Landlord&#8221;) for the lease of </font><font style="font-family:inherit;font-size:10pt;">2,333</font><font style="font-family:inherit;font-size:10pt;"> rentable square feet &#8220;RSF&#8221;, which we will use for corporate office space and meetings. The term of the Lease is estimated to begin in May 2018, depending on construction, and continue for an initial term of </font><font style="font-family:inherit;font-size:10pt;">66 months</font><font style="font-family:inherit;font-size:10pt;">, which may be renewed for an additional </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;">. We are required to remit base monthly rent of approximately </font><font style="font-family:inherit;font-size:10pt;">$4,300</font><font style="font-family:inherit;font-size:10pt;"> which will increase at an average approximate rate of </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> each year. We are also required to pay additional rent in the form of our pro-rata share of certain specified operating expenses of the Landlord. The newly leased space is located in Houston, Texas.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832642912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition &#8211;</font><font style="font-family:inherit;font-size:10pt;"> We acquired Moleculin, LLC (&#8220;Moleculin&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">May&#160;2, 2016</font><font style="font-family:inherit;font-size:10pt;">, and, going forward our financial statements include the operations of Moleculin, LLC. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired will be recorded as goodwill. The Company obtained input from third-parties regarding its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed in connection with the acquisition of Moleculin, LLC.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GoingConcernPolicyPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Going Concern -</font><font style="font-family:inherit;font-size:10pt;"> These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> since inception and had not yet generated any revenue from operations. Additionally, management anticipates that its cash on hand as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> plus the additional cash generated from its equity offering subsequent to year-end, discussed further within these notes to the financial statements, is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents -</font><font style="font-family:inherit;font-size:10pt;"> The Company considers all highly liquid accounts with original maturities of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months or less at the date of acquisition to be cash equivalents.&#160;Periodically in the ordinary course of business, the Company may carry cash balances at financial institutions in excess of the insured limits of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">. The amount in excess of the applicable insurance coverage at December 31, 2017 was not material. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and equipment -</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:60%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of estimated useful lives or the term of the lease&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 years*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years*</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a </font><font style="font-family:inherit;font-size:10pt;">2 years</font><font style="font-family:inherit;font-size:10pt;"> useful life due to their age and condition and expected remaining life assessed at merger date.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets -</font><font style="font-family:inherit;font-size:10pt;"> Intangible assets with finite lives are amortized using the straight-line method over their estimated period of benefit. If an intangible asset is identified as an in-process research &amp; development asset, then no amortization will occur until the development is complete. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its statements of operations. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> material impairments of intangible assets have been identified during any of the periods presented. Intangible assets are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments - </font><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist primarily of account payables,  accrued expenses and a warrant liability. The carrying amount of accounts payables and accrued expenses approximates their fair value because of the short-term maturity of such.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Unadjusted quoted prices in active markets of identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Unobservable inputs for the asset or liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of our warrant&#160;liability discussed in Note 6. The fair value of this warrant liability is included in current liabilities on the accompanying financial statements as of December 31, 2017, as warrants are currently being exercised.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock', window );">Beneficial Conversion Feature</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beneficial Conversion Feature</font><font style="font-family:inherit;font-size:10pt;"> - From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The Company estimated the fair value of its common stock on the dates issued. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital, if any. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes -</font><font style="font-family:inherit;font-size:10pt;"> The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation -</font><font style="font-family:inherit;font-size:10pt;"> Stock-based compensation expense includes the estimated fair value of equity awards vested during the reporting period. The expense for equity awards vested during the reporting period is determined based upon the grant date fair value of the award and is recognized as expense over the applicable vesting period of the stock award using the straight-line method.&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Common Share</font><font style="font-family:inherit;font-size:10pt;"> - Basic net loss per common share are computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> - A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Costs -</font><font style="font-family:inherit;font-size:10pt;"> Research and development costs are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events -</font><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s management reviewed all material events through the date these financial statements were issued for subsequent event disclosure consideration and has noted such events as described in Note 10.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606), which will replace numerous requirements in U.S. GAAP, including industry-specific requirements, and provide companies with a single revenue recognition model for recognizing revenue from contracts with customers. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December&#160;15, 2017. The Company is currently evaluating the impact that this standard will have on its financial statements at the time the Company starts to generate revenue or enters into other contractual arrangements, which the Company does not expect in the near term.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December&#160;15, 2016, and for annual and interim periods thereafter; early adoption is permitted. This disclosure is effective within these financial statements for the year ended December&#160;31, 2017. See also policy note disclosure mentioned above on Going Concern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November&#160;20, 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update ("ASU") 2015-17, "Balance Sheet Classification of Deferred Taxes", requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#8217; processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The adoption of this standard in 2016, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-1, Financial Instruments &#8211; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (&#8220;ASU 2016-1&#8221;).&#160;ASU 2016-1 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments.&#160;ASU 2016-1 is effective for fiscal years beginning after December&#160;15, 2017, including interim periods within those fiscal years.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements. The Company does not believe that the adoption of this pronouncement will have a material impact on the Company's financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (&#8220;ASU 2016-2&#8221;). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.&#160;ASU 2016-2 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&#160;For public companies, ASU 2016-2 is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted.&#160;The Company is currently evaluating the impact that this standard will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-9, Compensation-Stock Compensation (Topic 718): Improvements to Employee-Share-Based Accounting". The new guidance changes the accounting and simplifies various aspects of the accounting for share-based payments to employees. The guidance allows for a policy election to account for forfeitures as they occur or based on an estimated number of awards that are expected to vest. MBI assumes no forfeiture since it has limited history. ASU 2016-9 is effective for annual periods beginning after December&#160;15, 2016, with early adoption permitted. The adoption of this standard on January&#160;1, 2017, did not have a significant impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. We plan to adopt the provisions of this ASU for our fiscal year beginning January&#160;1, 2018 and are currently evaluating the impact the adoption of this new accounting standard will have on our financial statements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-01 "Business Combinations (Topic 805)," which provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The amendments in this update also narrow the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606. Public business entities are required to apply the amendments in this update to annual periods beginning after December&#160;15, 2017, including interim periods within those periods. Early application is permitted. The Company will evaluate the effect of the update at the time of any future acquisition or disposal.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09 "Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting." This update clarifies the existing definition of the term "modification," which is currently defined as "a change in any of the terms or conditions of a share-based payment award." The update requires entities to account for modifications of share-based payment awards unless the (1) fair value, (2) vesting conditions and (3) classification as an equity instrument or a liability instrument of the modified award are the same as of the original award before modification. Public business entities are required to adopt the amendments in this update for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The Company will adopt the update when it becomes effective. The Company is in the process of determining the impact, if any, this adoption will have on its financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for beneficial conversion feature of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentConvertibleBeneficialConversionFeaturePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817859536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Property Plant And Equipment Useful life</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:60%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of estimated useful lives or the term of the lease&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 years*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years*</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*Property and equipment assets acquired in the merger with Moleculin, LLC are being depreciated over a </font><font style="font-family:inherit;font-size:10pt;">2 years</font><font style="font-family:inherit;font-size:10pt;"> useful life due to their age and condition and expected remaining life assessed at merger date.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the financial assets and liabilities reported at fair value and measured on a recurring basis at December 31, 2017 (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Measured at Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Inputs</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrant liability:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of changes in fair value associated with the Level 3 liabilities for the year ended December&#160;31, 2017 (in thousands): </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability &#8211;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of period December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuances of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclass of liability from long-term to current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,846</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value - net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers in and out (exercise of warrants)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,201</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818060064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values and the information available to management. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability assumed (HPI)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities assumed, including $470 of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired/total consideration transferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles acquired from Moleculin, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Results of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future (amounts in thousands except share data).</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro Forma For the Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,963</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average outstanding common shares &#8211; basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,401,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637430960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and other accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued expenses and Other Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities consist of the following components (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued license fees and SRA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal and professional fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued board expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses and other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823410816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below represents the shares that are convertible at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest:</font></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Amounts and shares in whole values)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016 (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares Convertible at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 31, 2015(a)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 3, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 6, 2015(a)(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 19, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,821,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:73px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Debt partially converted on May&#160;31, 2016 and on August&#160;19, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Debt partially converted on September&#160;1, 2016.</font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Excluded from the </font><font style="font-family:inherit;font-size:10pt;">$276,079</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$20,333</font><font style="font-family:inherit;font-size:10pt;"> in accrued interest on the convertible notes payable which is included in the accompanying balance sheet.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813089392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in the BSM and MCM models for the Warrants are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68%-1.86%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.00%-160.11%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5-5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option grants has been estimated, with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.44%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of our Warrant activity and related information follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Under</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Price</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise&#160; Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual&#160;Life (Years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,235,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,728,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,087,717</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,772</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.35-$1.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for warrant activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819871904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="18" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of option activities for the years ended December&#160;31, 2016 and 2017:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted - 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">835,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled - 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,345,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in the BSM and MCM models for the Warrants are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68%-1.86%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.00%-160.11%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5-5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the option grants has been estimated, with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.95%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.44%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ComponentsofShareBasedCompensationTableTextBlock', window );">Components of Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for the years ended December 31, 2017 and 2016, are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ComponentsofShareBasedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components of Share-Based Compensation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ComponentsofShareBasedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663938640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes consists of the following components (in thousands):&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Expense (Benefit):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Income Tax Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes activity related to the Company&#8217;s valuation allowance (in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at Beginning of Period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income Tax Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Release of Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation Allowance at End of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands): </font></div><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(amounts in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Tax Benefit at Statutory Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,335</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Benefit Net of Federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPO Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Warrant Costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Permanent Differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in Deferred Tax Rate due to Tax Reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Tax (Expense) / Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Start Up Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal Net Operating Loss Carryforwards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State Tax Loss Carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Valuation Allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,561</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Tax Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Deferred Tax Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Deferred Taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823365200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Liquidity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>project </div>
<div>technology </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NumberOfDrugTechnologies', window );">Number of drug technologies | technology</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NumberOfOtherDrugDevelopmentProjects', window );">Number of other drug development projects | project</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NumberOfDrugTechnologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Drug Technologies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NumberOfDrugTechnologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NumberOfOtherDrugDevelopmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Other Drug Development Projects</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NumberOfOtherDrugDevelopmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832957360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies  - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 14,480,000<span></span>
</td>
<td class="nump">$ 4,675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, amount FDIC insured</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment assets acquired, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment assets acquired, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment assets acquired, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment assets acquired, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">677,576<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,345,000<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,821,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832604432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies  - Fair Value of Warrant Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820434400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies  - Fair Value Measurements (Details) - Significant Other Unobservable Inputs (Level 3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityCurrentMember', window );">Warrant Liability &#8211; Current</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer in and out (exercise of warrants)</a></td>
<td class="num">(5,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations', window );">Expiration of warrants</a></td>
<td class="num">(1,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityLongtermMember', window );">Warrant Liability &#8211; Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="num">(1,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer in and out (exercise of warrants)</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations', window );">Expiration of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabiltyMember', window );">Warrant Liability &#8211; Total</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">4,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent', window );">Reclass of liability from long-term to current</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value - net</a></td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer in and out (exercise of warrants)</a></td>
<td class="num">(4,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations', window );">Expiration of warrants</a></td>
<td class="num">(1,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Expiration of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument from long term to current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisTransferOfLiabilityFromLongtermToCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityLongtermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabilityLongtermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabiltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mbrx_WarrantLiabiltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834401120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets  - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 02, 2016 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionIndemnificationAgreementTerm', window );">Indemnification period granted to former officers (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicensingAgreementTerm', window );">Licensing agreement term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">HPI option termination price</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedLicenseAgreementPayment', window );">Accrued license agreement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">HPI option termination price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,874,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Loan to Moleculin</a></td>
<td class="nump">$ 57,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_RoyaltyOnNetRevenuesPercentage', window );">Royalty on net revenues (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionNumberOfAgreements', window );">Number of agreements with HPI | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC | Acquisition Date One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discounts excluded from pro forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC | License Agreement | Houston Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedLicenseAgreementPayment', window );">Accrued license agreement payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued | shares</a></td>
<td class="nump">629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC | Out-Lincense Agreement | Houston Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicensingArrangementsConsiderationPayable', window );">Licensing arrangements consideration payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicensingAgreementTerm', window );">Licensing agreement term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicensingArrangementsReserve', window );">Licensing arrangements reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Moleculin LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued (in shares) | shares</a></td>
<td class="nump">999,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business acquisition, value of equity interest issued</a></td>
<td class="nump">$ 5,999,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,999,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AccruedLicenseAgreementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable for license agreement payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AccruedLicenseAgreementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionIndemnificationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Indemnification Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionIndemnificationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionNumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionNumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicensingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicensingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicensingArrangementsConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be Paid for Technology Rights And Development of License under out license agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicensingArrangementsConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicensingArrangementsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reserve maintained for the payments made against the licensing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicensingArrangementsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_RoyaltyOnNetRevenuesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the royalty percentage on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_RoyaltyOnNetRevenuesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PeriodTypeAxis=mbrx_AcquisitionDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PeriodTypeAxis=mbrx_AcquisitionDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_OutlincenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mbrx_OutlincenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834433888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets  - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>May 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liability assumed (HPI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liability assumed (HPI)</a></td>
<td class="num">$ (3,874,000)<span></span>
</td>
<td class="num">$ (3,874,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember', window );">Moleculin LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangibles</a></td>
<td class="nump">11,148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">11,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities assumed, including $470 of notes payable</a></td>
<td class="num">(1,224,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired/total consideration transferred</a></td>
<td class="nump">6,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable', window );">Other liabilities assumed, notes payable</a></td>
<td class="nump">$ 470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred related to notes payable, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mbrx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mbrx_MoleculinLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6664297568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets  - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles acquired from Moleculin, LLC</a></td>
<td class="nump">$ 11,148<span></span>
</td>
<td class="nump">$ 11,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633172016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets  - Schedule of Pro Forma Results of Operations (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionProFormaOperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 3,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted average outstanding common shares - basic and diluted (in shares) | shares</a></td>
<td class="nump">9,401,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionProFormaOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proforma operating expenses for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionProFormaOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832605776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and other accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedClinicalTestingCurrent', window );">Accrued clinical testing</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedLicenseFeesAndSRACurrent', window );">Accrued license fees and SRA</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AccruedBoardExpensesCurrent', window );">Accrued board expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AccruedBoardExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Board Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AccruedBoardExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AccruedClinicalTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Testing, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AccruedClinicalTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AccruedLicenseFeesAndSRACurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees And SRA, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AccruedLicenseFeesAndSRACurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834637344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable  - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 10, 2016 </div>
<div>note </div>
<div>investor</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered', window );">Number of unsecured promissory notes entered into | note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors', window );">Number of separate third party investors | investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Share issued to settle accounts payable | shares</a></td>
<td class="nump">1,166,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Reduction in convertible debt principle | $</a></td>
<td class="nump">$ 183,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest | $</a></td>
<td class="nump">$ 17,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, maximum</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember', window );">Unsecured Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on note (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Restriction A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument', window );">Number of shares underlying note available to sell on monthly basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume', window );">Maximum daily volume of trading activity (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Restriction B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument', window );">Number of shares underlying note available to sell on monthly basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume', window );">Maximum daily volume of trading activity (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock', window );">Price per common share of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold', window );">Number of consecutive trading days price per share is above threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Restriction C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume', window );">Maximum daily volume of trading activity (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock', window );">Price per common share of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold', window );">Number of consecutive trading days price per share is above threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument', window );">Additional number of shares underlying note available to sell on monthly basis (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Restriction D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock', window );">Price per common share of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Restriction E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold', window );">Number of days after initial closing of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume', window );">Maximum daily volume of trading activity (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock', window );">Price per common share of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Minimum | Restriction A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold', window );">Number of days after initial closing of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Maximum | Restriction A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold', window );">Number of days after initial closing of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Unsecured Notes Entered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentNumberOfUnsecuredNotesEntered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Maximum Trading Day Sale, Percentage Of Daily Volume</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsMaximumTradingDaySalePercentageOfDailyVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Minimum Price Per Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsMinimumPricePerShareofCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Number Of Consecutive Trading Day Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsNumberOfConsecutiveTradingDayThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Additional Percentage Of Shares Underlying The Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellAdditionalPercentageOfSharesUnderlyingTheInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Number Of Shares Available To Sell, Percentage Of Shares Underlying The Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsNumberOfSharesAvailableToSellPercentageOfSharesUnderlyingTheInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Trading Terms, Period Following Initial Public Offering Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentTradingTermsPeriodFollowingInitialPublicOfferingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unsecured Notes, Number Of Third Party Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtTradingTermsAxis=mbrx_DebtInstrumentTradingTermFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832946864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable  - Schedule of Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 276,079<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Convertible number of common shares</a></td>
<td class="nump">1,821,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 20,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember', window );">Shares issued August 31, 2015 | Issue Date August 31 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 38,299<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Convertible number of common shares</a></td>
<td class="nump">294,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember', window );">Shares issued September 3, 2015 | Issue Date September 03, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Convertible number of common shares</a></td>
<td class="nump">962,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember', window );">Shares issued October 6, 2015 | Issue Date October 06, 2015 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 30,280<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Convertible number of common shares</a></td>
<td class="nump">151,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember', window );">Shares issued January 19, 2016 | Issue Date January 19, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares', window );">Convertible number of common shares</a></td>
<td class="nump">412,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DebtInstrumentConvertibleNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common shares that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DebtInstrumentConvertibleNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateAugust312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateAugust312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateSeptember032015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateSeptember032015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateOctober062015OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_InvestorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary192016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbrx_IssueDateJanuary192016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835810576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability  - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 15, 2017</div></th>
<th class="th"><div>Feb. 14, 2017</div></th>
<th class="th"><div>Feb. 09, 2017</div></th>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Stock issued for cash, IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional shares available for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,000<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance, IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,071,000<span></span>
</td>
<td class="nump">$ 9,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Series C warrants vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 1,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,548,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts', window );">Stock issued for cash, IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,235,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,235,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of shares under warrant, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,728,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember', window );">Series A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of shares under warrant, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,833,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember', window );">Series A Warrant | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember', window );">Series B Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of shares under warrant, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expired Series B and Series C warrants (in shares)</a></td>
<td class="nump">5,087,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember', window );">Series B Warrant | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember', window );">Series C Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants aggregate amounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of shares under warrant, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Series C warrants vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember', window );">Series C Warrant | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock offered for each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesAndSeriesCWarrantMember', window );">Series A and Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mbrx_UnderwritingAgreementMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional shares available for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share of common stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance, IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Warrant Exercised, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightsWarrantExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for cash initial public offering net of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesAndSeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_SeriesAndSeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mbrx_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mbrx_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833726096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability  - Schedule of Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">160.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832688496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability  - Schedule of Warrant Activity (Details) - Warrant - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Under Warrant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">8,235,923<span></span>
</td>
<td class="nump">8,235,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,728,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,087,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,772<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber', window );">Number of shares under warrant, vested and exercisable at December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and exercisable (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms', window );">Vested and Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Under Warrant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of warrant price per share, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue', window );">Range of warrant price per share, vested and exercisable at December 31, 2017 (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Under Warrant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Range of warrant price per share, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue', window );">Range of warrant price per share, vested and exercisable at December 31, 2017 (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term at expired date for equity-based awards excluding options,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value which vested and exercisable of nonvested awards on equity-based plans excluding option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedAndExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term at grant date for equity-based awards excluding options,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options which vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharePaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at exercised date to acquire shares of equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term at exercised date for equity-based awards excluding options,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesinPeriodWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at expired date of equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841399040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2017 </div>
<div>warrant </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 20, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 09, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 22, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance, IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,071,000<span></span>
</td>
<td class="nump">$ 9,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of cash subscriptions to be received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue', window );">Aggregate fair value of options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, net of estimated forfeitures | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognized, weighted average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember', window );">PCG Advisory Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of cash subscriptions to be received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantOneMember', window );">GSK Consulting Agreement Warrant One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassofWarrantorRightNumberofWarrantsIssued', window );">Number of warrants issued | warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantTwoMember', window );">GSK Consulting Agreement Warrant Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_TheWarrantsMember', window );">The Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassofWarrantorRightAgreementPeriod', window );">Agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassofWarrantorRightVestingPeriod', window );">Warrant vesting period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassofWarrantorRightExpirationPeriod', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock compensation expense for non-employee consulting agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_NumberOfUnitsIssued', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance, IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,464,183<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbrx_AtMarketIssuanceSalesAgreementMember', window );">At Market Issuance Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds', window );">Commission payment to agents (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mbrx_StockPlanMember', window );">2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Total number of underlying shares under 2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,167<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At Market Issuance Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At Market Issuance Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At Market Issuance Sales Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of remaining options accelerated for vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Roth Capital Partners, LLC and National Securities Corporation | At Market Issuance Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice', window );">Aggregate price of shares issued | $</a></td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mbrx_FormerScienceAdvisoryBoardMember', window );">Former Science Advisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_GainLossOnNoncashSettlementOfLiability', window );">Gain on settlement of liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Obligation recorded from settlement of liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period from which Warrants or Rights Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassofWarrantorRightAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Agreement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassofWarrantorRightAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassofWarrantorRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassofWarrantorRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassofWarrantorRightNumberofWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassofWarrantorRightNumberofWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassofWarrantorRightVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassofWarrantorRightVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_GainLossOnNoncashSettlementOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gain (loss) on liability settled by issuing stock or debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_GainLossOnNoncashSettlementOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_NumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_NumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Fees Paid, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Issued In Transaction, Aggregate Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockNumberOfSharesIssuedInTransactionAggregatePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Aggregate Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common and preferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of compensation cost was accelerated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_PcgAdvisoryGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_GSKConsultingAgreementWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mbrx_TheWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mbrx_TheWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbrx_AtMarketIssuanceSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbrx_AtMarketIssuanceSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mbrx_StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mbrx_StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mbrx_RothCapitalPartnersLLCandNationalSecuritiesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mbrx_FormerScienceAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mbrx_FormerScienceAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841402976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  - Summary of Option Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning balance</a></td>
<td class="nump">510,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="nump">835,000<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares cancelled</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, ending balance</a></td>
<td class="nump">1,345,000<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable, end of period</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in dollars per share)</a></td>
<td class="nump">1.59<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding, end of period (in dollars per share)</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, exercisable (in dollars per share)</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">5.28<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">2.42<span></span>
</td>
<td class="nump">5.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, end of period (in dollars per share)</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term outstanding (in years)</a></td>
<td class="text">9 years 26 days<span></span>
</td>
<td class="text">9 years 3 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term exercisable (in years)</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding balance</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 275,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821282832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  - Schedule of Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820582832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  - Schedule of Stock based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657100496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes  - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Expense (Benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Expense (Benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax (Expense) / Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817930400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes  - Summary of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance at Beginning of Period</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Income Tax Benefit</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DeferredTaxAssetsValuationAllowanceReleases', window );">Release of Valuation Allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance at End of Period</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 1,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DeferredTaxAssetsValuationAllowanceReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of valuation allowance released during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DeferredTaxAssetsValuationAllowanceReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834399296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes  - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal Tax Benefit at Statutory Rate</a></td>
<td class="nump">$ 3,334<span></span>
</td>
<td class="nump">$ 1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Tax Benefit Net of Federal</a></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost', window );">IPO Costs</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts', window );">Stock Warrant Costs</a></td>
<td class="num">(395)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Other Permanent Differences</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in Deferred Tax Rate due to Tax Reform</a></td>
<td class="num">(1,562)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in Valuation Allowance</a></td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(1,242)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax (Expense) / Benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Tax Benefit at Statutory Rate (percentage)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Tax Benefit Net of Federal (percentage)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent', window );">IPO Costs (percentage)</a></td>
<td class="num">(0.77%)<span></span>
</td>
<td class="num">(5.78%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent', window );">Stock Warrant Costs (percentage)</a></td>
<td class="num">(4.03%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent', window );">Other Permanent Differences (percentage)</a></td>
<td class="num">(0.09%)<span></span>
</td>
<td class="num">(0.08%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in Deferred Tax Rate (percentage)</a></td>
<td class="num">(15.93%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (percentage)</a></td>
<td class="num">(0.11%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in Valuation Allowance (percentage)</a></td>
<td class="num">(11.87%)<span></span>
</td>
<td class="num">(31.62%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total Tax (Expense) / Benefit (percentage)</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Stock Warrant Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Stock Warrant Costs, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818150768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes  - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_DeferredTaxAssetsStartUpCosts', window );">Start Up Costs</a></td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal Net Operating Loss Carryforwards</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Tax Loss Carryforwards</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Compensation</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less Valuation Allowance</a></td>
<td class="num">(2,561)<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net Deferred Tax Assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822091280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes  - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,562,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 6,070,000<span></span>
</td>
<td class="nump">6,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">2,561,000<span></span>
</td>
<td class="nump">2,561,000<span></span>
</td>
<td class="nump">1,397,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit', window );">Tax Act, income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">5,810,000<span></span>
</td>
<td class="nump">5,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mbrx_FederalStateandForeignJurisdictionsMember', window );">Federal, State and Foreign Jurisdictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mbrx_FederalStateandForeignJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mbrx_FederalStateandForeignJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833923200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 04, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,545,000<span></span>
</td>
<td class="nump">$ 1,496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Payments to HPI over three-year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Buy-out option payment to HPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicensingAgreementTerm', window );">Licensing agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees', window );">Employee agreement, termination benefits, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount', window );">Termination benefits provided to key employees, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_AgreementAxis=mbrx_AnnamedAgreementMember', window );">Annamed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementDocumentationFee', window );">One-time license documentation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFee', window );">License agreement, annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember', window );">Commencement Of Phase II Study For a Licensed Product | IntertechBio Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember', window );">Receipt Of Market Approval For a Licensed Product | Annamed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember', window );">Receipt Of Market Approval For a Licensed Product | Moleculin Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember', window );">Receipt Of Market Approval For a Licensed Product | IntertechBio Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember', window );">Commencement Of Phase III Study For a Licensed Product | Annamed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember', window );">Commencement Of Phase III Study For a Licensed Product | Moleculin Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember', window );">Commencement Of Phase III Study For a Licensed Product | IntertechBio Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember', window );">Submission Of First NDA Within United States | Annamed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember', window );">Submission Of First NDA Within United States | Moleculin Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember', window );">Filing Of a New Drug Application For a Licensed Product | IntertechBio Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_MilestonePaymentsLiabilities', window );">Milestone payments liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_HoustonPharmaceuticalsIncMember', window );">Houston Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PaymentsForResearchAndDevelopmentAgreement', window );">Payments for research and development agreement</a></td>
<td class="nump">$ 346,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths', window );">Payments for research and development agreement, next twelve months</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,687<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Annamed Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Moleculin Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">77,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | IntertechBio Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | IntertechBio Agreement | Servicing Fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Annual maintenance fee, first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Annual maintenance fee, second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">Annual maintenance fee, third anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">Annual maintenance fee, fourth anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">Annual maintenance fee, fifth anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Annual maintenance fee, sixth anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInThirdYearAfterProductApproval', window );">Annual royalty payment, third anniversary following first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | IntertechBio Agreement | Minimum Annual Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval', window );">Annual royalty payment, first anniversary following first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ContractualObligationDueInSecondYearAfterProductApproval', window );">Annual royalty payment, second anniversary following first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PaymentsForResearchAndDevelopmentAgreement', window );">Payments for research and development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFee', window );">License agreement, annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease', window );">License agreement, maintenance fee annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_PaymentsForRoyaltiesMinimumPerYear', window );">Minimum royalty payment per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear', window );">License agreement, maintenance fee - maximum payable per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_RoyaltyOnNetRevenuesPercentage', window );">Royalty on net revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_RoyaltyOnNetRevenuesPercentage', window );">Royalty on net revenues (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event | Commencement Of Phase II Study For a Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ResearchAndDevelopmentMilestonePaymentsDue', window );">Additional payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event | Submission Of A New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ResearchAndDevelopmentMilestonePaymentsDue', window );">Additional payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember', window );">MD Anderson | Subsequent Event | Receipt Of Market Approval For a Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ResearchAndDevelopmentMilestonePaymentsDue', window );">Additional payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInNextFiscalYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInSecondYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInSecondYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ContractualObligationDueInThirdYearAfterProductApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year after product approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ContractualObligationDueInThirdYearAfterProductApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Agreements, Special Termination Benefits, Number of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementDocumentationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Documentation Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementDocumentationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of increase annually on the annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFeeAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum payable amount of annual maintenance fee under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicenseAgreementMaintenanceFeeMaximumPayablePerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LicensingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LicensingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_MilestonePaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of expense payable towards milestone payments under Patent and Technology License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_MilestonePaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PaymentsForResearchAndDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Research And Development Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PaymentsForResearchAndDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Research And Development Agreement, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PaymentsForResearchAndDevelopmentAgreementNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_PaymentsForRoyaltiesMinimumPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalties, Minimum Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_PaymentsForRoyaltiesMinimumPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ResearchAndDevelopmentMilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Milestone Payments Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ResearchAndDevelopmentMilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_RoyaltyOnNetRevenuesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the royalty percentage on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_RoyaltyOnNetRevenuesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AgreementAxis=mbrx_AnnamedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AgreementAxis=mbrx_AnnamedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiStudyForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AgreementAxis=mbrx_IntertechBioAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AgreementAxis=mbrx_IntertechBioAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_ReceiptOfMarketApprovalForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_AgreementAxis=mbrx_MoleculinAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_AgreementAxis=mbrx_MoleculinAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_CommencementOfPhaseIiiStudyForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfFirstNDAWithinUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_FilingOfNewDrugApplicationForLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mbrx_HoustonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mbrx_HoustonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mbrx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_ServicingFeePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_ServicingFeePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=mbrx_MinimumAnnualRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=mbrx_MinimumAnnualRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfANewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mbrx_SubmissionOfANewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841526800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 16, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,000<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options issued, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds received from sale of shares and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightInitialExercisePeriod', window );">Exercisable period, subject to beneficial ownership limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_ClassOfWarrantOrRightTerm', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of shares and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockRightOfFirstRefusalPeriod', window );">Right of first refusal period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod', window );">Tail fee period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardMemberMember', window );">Science Advisory Board Member | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options issued, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mbrx_IPXMemorialDriveInvestorsLLCMember', window );">IPX Memorial Drive Investors, LLC | Lease Agreement For Corporate Office Space | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace', window );">Rentable square feet | ft&#178;</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease agreement, initial term</a></td>
<td class="text">66 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lease agreement, renewal period (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_OperatingLeasesMonthlyRentExpense', window );">Base monthly rent | $</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent', window );">Annual increase in rent expense (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbrx_PlacementAgencyAgreementMember', window );">Placement Agency Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds', window );">Commission payment to agents (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions', window );">Warrants granted to purchase common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mbrx_SaleOfStockReimbursementOfExpenses', window );">Reimbursement of expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Securities Purchase Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Science Advisory Board Member | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options issued, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightInitialExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Initial Exercise Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightInitialExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_LesseeOperatingLeaseAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_LesseeOperatingLeaseAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Rent Expense, Annual Increase In Rent, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_OperatingLeasesMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_OperatingLeasesMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Cash And Warrant Compensation Tail Fee, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockCashAndWarrantCompensationTailFeePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Fees Paid, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockFeesPaidPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockRightOfFirstRefusalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Right Of First Refusal, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockRightOfFirstRefusalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Warrants To Be Issued, Percentage Of Common Stock Sold In Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbrx_SaleOfStockWarrantsToBeIssuedPercentageOfCommonStockSoldInTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mbrx_ScienceAdvisoryBoardMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mbrx_IPXMemorialDriveInvestorsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mbrx_IPXMemorialDriveInvestorsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mbrx_LeaseAgreementForCorporateOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mbrx_LeaseAgreementForCorporateOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbrx_PlacementAgencyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbrx_PlacementAgencyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbrx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbrx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A*W79F?^L?%9L._@UUWT7U!+ P04    " !#0GQ,F5R<(Q &  "<)P
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MS?NK2=^1K!VN7<%X]UO] U!+ P04    " !#0GQ,*5Y0/5(#  "R#@  &
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MXR$=#R'-CQ!5PQ% 0KS4(+09@D51ECF\.%@&V NSO0!*DZ%53XABX1H7&FG
ML)?(]L+PVQ7:DTR(7$YH. *F([?I.&GH)),/+&%9['!"PQ$P';E-1R#0-V??
M9 :K(.(.0@*-2,",Y#8C ?,/!!H9@J0.( #-2,"0Y#8D@4)@C 8&JX"[/J9
MLQ(P+&T,KBE-9GMY4W/KA"8EI A/SM>0YAMDR(- >,K>7_QO26XW.#0F&<:D
ML-'$, &9Y75#:,"UU:(AR3 DA0TFAOD7@4@2VPR601:[/LS,L??#H!0VGAAF
MX ?@/+6GB=+Q.'%P@=&\9)B7PJ84PS"$!,#>+% RGL6NI4-3DV%J"IM3DR:^
MF0F\8:!DQ(XAF!T>^M/<][P]%'7G/2EMSB'#:6&OE):FR_#.%'<T!\AKHY1[
MW=\FYKX=3U%C0ZMF.B$&UV/JZA]02P,$%     @ 0T)\3'W[45]2 @  .0@
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M0#7M(R$<BZC@1<0KQ#T^+BI\Y'*:B#GM+[-^P4D[7-3>^&\A_P=02P,$%
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MSP6#50*R:D>[@*-5"6?C(5Q)#%<)Z*K9-HAS45L*$LGQJFC;(#]J(%_,5XD
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M_V"S(:%RX?C)G\TX9J/AL)M^$)N_<?X74$L#!!0    ( $-"?$R19&9$M $
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M@LJ'XR<\VW',1L.;;OI!;/[&^5]02P,$%     @ 0T)\3'^R%V^! @  <PD
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MF60%-%OW0*>NKOUT04 TFCEE@*<UQ B%?\Y0T,Q! SS[89K:-/*/&@J:.6N
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MN.V]W:MI8*; R'Y^"\CR(.5_ %!+ P04    " !#0GQ,1JY4T=(!  "<!
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M:&5E=#(Q+GAM;&U3[6[;(!1]%<0#%(>D61;9EII.TR:M4M1IZV]B7]NH8#S
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MP3W76@@-)I7PP=QJ:^;1:C"HM=VF9B_GKIP-+89EX.!UZA6_ 5!+ P04
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M%I2%P5C]%W9FM0[O,]$>6UY+\QML3U+Q9E31J33T=;A6K;E>1OVW8?@ & ?
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M+X8AL2@>%X/[% &-2L*^&!F(/2&,QU]*!+<J GJ5H+X8'8C%892,:\%=C2)
M:[#;1H-NHPFP 06=+=X>TM^9/&:E\K9"F]/"[>D'(30WG.&SX3R9[X)VDO.#
MML/$C&5].-83+:KFX _:KX_T+U!+ P04    " !#0GQ,SG&8I[H!   5!
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M@Y<FE2+]TW]G9?=]&OR_F&$#.AC0LP$5;QJPP8!=:\ ' _YJ(-\TB :#Z-6
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MZE]6]3=&'X<7<<'Y;>#J'U!+ P04    " !#0GQ,_!7R6$8#  "E#@  &0
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M*;LV>.3[_JA;4V;I)"0+"8U"&(=1)9TF'*2((1[O:6C4 7'$.5U+1-82&;5
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M-,TXA68T:880 M^6BJ89*9ICBP5-,UY!,](TXP2:T:0T:6D>;_]DF)&&&:?
MW(LF#9G1)+,I)#.3Y  NNNY2>8/_\(6H=OI\5#MK>2SUX6RP>CZ#W:$^ [S+
MNP/<C[3:967M/,E&G23T__VME(U0Y?@WJI"].C.>;W*Q;=K+6%U7W<&INVGD
MH3\4>N>3Z>(_4$L#!!0    ( $-"?$Q(EO4DT00  (L:   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;)69VV[;.!"&7\70 T3B453@&-@F=5-@%PA:
M[.ZU8M.Q4<ER)27NOOWJ5,<B_PFD&]N2_^',D/QF:'EY+LH?U=[:>O$KSX[5
M7;"OZ]-M&%:;O<W3ZJ8XV6/SS:XH\[1N+LN7L#J5-MUV1GD6\BC289X>CL%J
MV=U[*E?+XK7.#D?[5"ZJUSQ/R_\^V:PXWP4L^'WCV^%E7[<WPM7RE+[8[[;^
M^_14-E?A993M(;?'ZE <%Z7=W05_L-M'W1ETBG\.]EQ=?5ZTJ3P7Q8_VXNOV
M+HC:B&QF-W4[1-J\O=E[FV7M2$T</X=!@XO/UO#Z\^_1UUWR33+/:67OB^S?
MP[;>WP4F6&SM+GW-ZF_%^=$.":E@,63_IWVS62-O(VE\;(JLZEX7F]>J+O)A
ME":4//W5OQ^.W?NY_R9.!C-LP <#?C%@XD,#,1B(=P/YH8$<#.14 S48J*DA
MZ<% 3_40#P;Q5 ,S&!@GI+!?CFY]'](Z72W+XKPH^RUZ2EL2V*UI=M"FO=EM
MF.Z[9HFKYN[;2B1F&;ZU PV:3[V&CS3)6'/O:V04C34/2,/&FL_ %Y=CS=K7
M\+'B"QIE+'E$2;T''#:3=IDY#F>.=P.(438<#R#@ *(;0(X&$,Z4]1K5:8Y]
ME#&+HHB(5$)'TG/$E#/OZUYCKARQ&Z&<:>U%^CH:'(>"<2B0L+.VC\J+([Y1
MV(F&3C1PXN2QUMZL&J$B=[]^\652TW,?PW!B$(YV<HX]/RR*#;69#/1C@)_8
M2=MXRZ>C;C<Y>?NZA,5TX@D,* $!.87E<^(ESH7D28S]L A7L,CSE#"W@D5>
M2HS+R$M]#81<2>//$1 2T\.(PLO !"7$$+@"L1DEB.$:Q/PBY-6&AT%$%H>Q
M(UR#F%^$)*-F#)</IF:DBXL#\ZL#2%>#=*EL,?7,QYYQ*EL,-#,SLL4(,L2@
M<#>R#R%3#1I<8U\<4\A]"B5S9W80C7P17C TW(>&:P(:3K3M&=!P# T'G9LY
MYXM[[K=NPX5*N+, ZPG"<5 8,(X \WQ)O^+&W$@A"5^81 XZ.:.&P"1R/6,9
M,&0<]%:FW"WGB[BFMC8FD:/>JET_!LRLX8HZ4F)B.2#67T1 K!'-L9U8 8&)
M%8A88F8$QE&P&6=@C*/@$^K&(&I[[GNWI4JR($[;"%KBI"$P8D+.2!>3(Q Y
M[IX%(F&HE<%X"70,EJX?U.BHOBXPA&+" ?=!^"=<I;2B#I0"<R@ AQX<PN=0
M)5J0KC"' G'H_BP6/H<J,G%,[2J).92(0Z*G2<RAG,&AQ!S**1P.H@G]6V((
M)8"0.A=)XL?L# @EAE!.@1"(R,8A,8020>BR(?U?F1\U#HDQE*@7NFQ('T.>
M&$:ZPAA*U Z-ZPJTPX]<80PEP) 3.TYANE0T?;LH3)<"O]0\- ;1M!:E,(,*
M,,BI6#%@2LQ(%P.FP$'2:QT*/2^BLB6>!@$*J3.OPH"I&8=(A<%1J']YV?:B
M>+2V443M1,R-0MRX54>!]O5!IU28&X6X\9)*O*2:[B^)SJ,Q7AHT+^XFI<%#
ME=@P*BF-,=3H@4GLNF*>*]D^V?-\A5</R-N_:?Y*RY?#L5H\%W5=Y-T3\5U1
MU+89M,$X6.QMNKU<9'97MQ_CYG/9_SW27]3%:?CK)[S\_[3Z'U!+ P04
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M5BG7<1<%<5@0!P5E%A&?$'V@"4U9Q#!3#)GB*1.W-TD\9>)AFB0DP4P)9$H
M$[&8D@D3(UF2V'MR"G-\[A16DH)*+(IE>JV2"YX,\F33K<\=VX"$6.8A*)79
M&AY!\?7E( XS(8"%VRS&<L(S&G+#7/U@,R 4,,4V$X5,#M,@V#4(L UNVX8!
MV4P.(NP=!)@'3VTB=J4EX[7LW5\2^P8!QL%MXS"@]'W+BVV#Q-.]';MJQ7Y
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M 8 VIYRDT%%*.DN1#G\P_#"E+?0P Y V W8('PS?(2@7?$2Q +"&LZ@]6@N
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M/@HAN5*9)<H5S^H&-C9J?I3Z=:'>N^$:,C2DN-@K5CK>\S;_ %!+ P04
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MDS+35,]%WPC[A>+MT.2#\4]3_ -02P,$%     @ 0T)\3(8ISM!$ @  Q@<
M !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULC97;CILP$(9?!?$ :PZ!
M'$20-JFJ5FJE:*NVUPX9 EH;4]L)V[>O;0@+Q"5[$^SAG]_?V,&3-(R_B@)
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M&5B4ZTZ3&DUC- B%B96M*\JB!":)09(8((DLDDZ3W)/@S"9Q10F>6-0$)$D
MDM@B29Q)K VR<17)!$4*4J0 A97J.G77(TLM#E>3IS!'!G)D (<UQSISYL!)
M:G\75X3B<&*SSD"4&8"262@S9Y8GQ8(L%D"%HMSRVLZ</?V$DHE-G8/$.4 \
MLXASA\7:;)M'BA$$"N%Z%@)E(I^PF"B)R,WD[E_5UT3D+JN=RV/-& 6N>0@#
M*,A&P9] >:@9H\#5$P'E$]OE$[FE,;1)'DDZD.#N\-+7CY^$G\I&>#LFU3EH
M3JLC8Y(JN_!9I52H&\_0J>A1ZF:FVKP[]KN.9&U_I0F&>]7J/U!+ P04
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MMCQ]V.2O=?NV36OE\7=&QP]UL>]_0Y6<?L@U_Q]02P,$%     @ 0T)\3+H
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M^&%8PX9\/M\V0(X*]]"K-\UFPW<19.*\J&? >!IBH;)A"R +6(UYW?KM=#+
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M9[]OB_^.#_X=1-H)RNTGTL[CSQ:UO]L/Z#VH*8A\8!??[)>Z>8;JV_=,&E^
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M:Y%QNK0^61?,(=D0R[GB]"Y"*XM"^>BY$Z]GD*];+H$@YE\5-7L-BY#Y;\H
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MX0O Z-2EJ9=,N^*C#>[<J^ZA)."*Q54C;0-\/D]4O5*T"H8%21WM_OU*I5=
M)2!K!79U\57L>\%@6*TQ\8Q2\DLR*JL5>4@HA\R"=)QHN3*\)<Z\^!Y#$H3/
M6?68;8_WJ'"T_A8L5[RAM"P@["J>#6LFUO,<_D?T9"GYX(9(.X8,)'5_;>[I
MZ 'R,.[<0\ Z)*F4_%&,*6D0!/KW95:LN#HDJP,%+2QQ@/PSF/_"'5?#GL3[
MT:-F1VPA. >Z&I\$<#B] [4]JEP7#Q>,+OU#'-XM;UZADD*=<-S1+-MDU)X\
MB-2,X>*>/Q_EAC"FU/:A>,]6V1U!)N%.@<:]L^J4I =;GW ]<'>IVS,*\]_6
MY2.8$W<@J-:EM GM.0R%M:B(:3-C#R?OT2X4B?G=[T#VYXM#[O7\KA3DDM*W
MLV\=)W9SMFLG^@<P&I^SS1 6[FZ*>"=9(0PIB&B:(K*ED D<\7IE]7'O[$[]
M0F9N3[3J)T=<)Z>*M4&*P(]GTTOZ+;@AVHZ!U/L=SH)WP"^RQO#LW/&Y V2W
M'YOMZ+T!;)O"?DA[0 =I,(:$J#H*2^WV\VV71KG-8'9A1=J$'JV)[03^+!V-
M'\OJMR=U'2?Y(C6D)0;;7!A8TYXE>XZL/7!\5@V^ND4@*'SKY;D 50L ,4-R
MCRC@J]E3I78=?7DLA_M(_HYBL$] JV9?J]:DX6'-Q5>A+<*>[B;RKL"T<_<&
M=@>KE\CZ"[3I$M>9*=!7HXY\+E/8X?W-TBC%KF0&,<+P5("-L(Z5@U-$:FQF
MXFZ@"SG<&@+L)+RW5FI,+>V"Y:/'17<9+B:3DAY>:KK%P,D'6TS&S.6P=8[,
MI$/AE_499(="S@^L"A#*8#KTB?^GZ([[SIMM:F$RI"I6!833MTJ4J"?#;E1J
M/Q<Y/+V0:M0(^09O0N "/:QH?&0M-8"!;"2/P . X1#Z76W/&5IJ8U==V<AP
ME7"'VM<I8 T9N82+%8XW8!]2Q07%LN&KTN?!YA6?ODYO:$/3R.QL;10PSZ7"
M]6S9E1(99O(:D2Q7OQ:#4XHGHE8]"^.T9_<X9, W3JBGQ=<816? .*,Y<=4F
M[98$5#@FP&4M+5,@%S7>( 5B@\=_6!R"O^:AR8:U0:?>1,4\EXO.;;[S/4E#
M*DH-?/CEQ.C.WVC=0*$>/7Y%#B$OZZS@*N-].R_WP^VYL'KN5-)JI%'OGP,W
M/*6TC5IZ'&GCB)Z.' 8%;H 5*+F!NNN%-$RF "Q%G+0'ZA=_38/>PC6]L,Y9
M(YI/''>IBQ7L#+<57>Z"4H5A'X$L[-%YG<K%SCV!#UB/Z.1YSNAZ<VZR@53&
MJ'2-E7<3.L#IR0=X?"3SI67N"!=BE7=;<%H9.&^':E/#)F,P%_:HA*F+1/@0
MK*2#<Z1WF??HDK<["^5QH:Z9H@H51M#,D:O"@*X>M3S)[>A.(7+)'K DP;2]
M-K]RCN]P[U*#&ADZ]DB7CFD%E1!QU84A08+!S(KZ/I<F;?A_P-(84[X"]>U9
M[K2-LGE)-%';PTH_<D-9@2M7YB+="WKV-I/>0V+#EH]K<F0$E8)ME6U56DZ7
M0[_K=P*+-EWEMV3S5%('$)U::QI=>'J#+D0OF;?%W)4JMG&0C(('3+1[3Y&9
M'Y/?R^/TXOR$A%^JR3\R_-,6@#, XCA@7\@0M\4L#E)(B<77U.WZS\URYWH5
MTCEZX(E.S+*G9QLI0(SH0:"XR56  _S2HLI >P%N4'URS^P0%\,@#7<55-O*
M%XAX"*%0K=L/4<PHM\7?]L!"A5S]9\Y]3ZO#-LPM)7<')-2!UBH7+NQ?)Y-)
M.D%,5T*P;<_I)?U\>N8@;W5::!P>)@=$DLFA  WWS-\G>[T\.3]B,PSK*#6Z
MAR"O4QSCYV[WPN_)H-K3$?%E<I8>G9[_?[B/81]@"Z6U2AL \RWU=<((/4F\
MR=RC-:8M,)=V^Q?SZ!A8)=KH SUQ-''1T,+"/>I%WV;(E3;R2Q>3N_U>]QU/
M^78>'%2-N?Q+O1CVCU_6VB(9[A4UP\X0\X7ZQ<(R/H9.>#%G8,1<KCQ36&QI
M><XB2H=%6Y*CO"">2,II&DNK 4WB43/VD@BY [K, [VV!C,<^ M[N>89Y1ZP
MZYA=SH8@W,(7XQ('JPPQW'Y%,O1I%N[[DKWL;Y.1#^X6)9_0H=P;&M)P%V#)
M5-;[6"Q#C/+!KJ#N(\^5E !4@H(CFSZNK=K,K>W5E6P)VL%\%S9.>]V@J\KU
M>3,<:,XF/="Z"T^M!*F[V0HF'+I,#L>.K-Z*+O0?Z"UZ,P!\Q!P[M+PW;]#+
MY#B]/+\D=DI84R^135^>'0N+[0>FT^+K6P+=XX)0!K-[F1R-3Z9@T##D6Z*0
M;Q[:+4;O&A[K,CTYFJ1'TPNZ)'N!G4C@*[7A_KMKP4C]9,YQ;/SE!-'5SB\2
M:DRZ[2+6MMA;Q+LHYU#D2>AE*OXTLE4].&[T*MZ"@1!B!UZ:50:7:"99!2T0
M:@_)M"^;C+?:H!V?GY&%4J.G_SP!8;WQ0%@L]!0CS$FL]MN??"\@&@JCM\/Y
M@P;3]?L^]VV337I!OLJ.OJ(=E#HBB7I\K8G?/"URB'3UBZ#A@#&RA!LT/3V"
M_WMQ8C^%4+<D*Q]/CQ+$NK^R%;C\*)SQS>>K9'IVE$Q V[&'0(]9*K34(J=H
M$O)*? >^>!:F<DO((;8%JB)>3NP)WI'I-)F<J#;XO(U[F5P>35$1.SUJG]2U
MH^Z?B;J%5-H/OL8K]JS<T\$A,<-4RV(9>YM$B-1'R@&=)HJ.9K56E^89(9$7
M4H[8'$8_[N3(GG%7+<ZDJC'M#:1YC>U$6(9C> ]=-W*O69]#_Z)!Y?G&J8PL
M4594[H"Y= @K<UM6#C\;A,W%^.@[8MY8=+$R^XML$X\XKT5L0,VQ0T5$B_A!
M+"U(7/Z]K(26),5N-U1]VQW!H@8J'<T0CC]/.UA'O(Y#OEFS+5$9X"9UPA;S
MN6 O2YX6&V]<B\"[_OS$6Q3\ ;6V#? _S$AQ51I;_6K);):QQ)55I?!UF4E8
M8.;J5"1@0"YC3I?T+9AE<*ORT0$KS08E%\)B =>.J%LA414\'KLG/:YCO/Z3
M\>7E=[W> ([U2.!(MV*<O-:>F"!>^66?H-A&Z8^6B4J8.[:XO$;)0RULWT0@
MO!1ZF'EPRD#^HDE%D8Y<04AYR'P>Z27FJ0P?:=%-=V?D<&CJTL:MO162B;[%
M\"E"OG5><.0]^.4X/DM1>NU^Y]'EP@['5X3HQ7(MT66M@*XQ1 @((3>.MK1J
M[ZW/A@Q/B]>'-1<\OXX+M>6$_=CZ2]I)GNYKDJ$25T,S_'%:%C)-+4-VK(8/
MI$W\N>_?Z@FW%2#J+00 *^_L+,7>,;&&A2*_I(8)AC/:5MQ(00S$>[L#??3B
M.#T^/>LG9'K@/#V[O$PB^$_>HCJ/:S?YSK#4Z@'^S=8^H'")<+J7IZTU>)TR
MM+U]%FBS17H77/REAX=2(WQ6M5&+'W[3 8E!R'6L\V=M[^EI>GIV.KR]Y^GD
M?)HH F:OCIW!Q'=_L_2J)QNYJ'(1-7.IJ7Q5  Z1 11;N221\_NIX147@E)D
MZ!IQ*O14*[+^:Z[1,\_G6?>G17&T(Q:OB44Z@:RJ (C-R-:I]YYO1)XB#C+?
M=Y(=#[?YDC(.(G>+3,]\%OZ+O;ZG-F-T,BH21W4?G7FL94,_9WS5X6FTO^BR
M)]M;\4-R<"6S(( 8XUB/H#UH#N2A]1)+7J-<>8Z?[&!VZ+LK?<;W;GCTZ_T[
M=M;6N ^RPZ@[U_%%.@7&AUZ%"?YC>GF27AQ/DYM\LY611%77=R931DZ7%R[/
MINGT_#+Y.-N6^/B9?>?@-K0. XUS>H'O3-%DFJ0G8*-T='Y]^&(*C%\>/IGP
M?[ -Y&<^/3]+C^## =\<UT:F"SF66YIK6SJ2]62 +3J'<8*SWC=(V)B)O3+#
M'FK"8$)JA$X0>.G+Z5%Z?'PLW4M:]V<]X'I0<K42X3:>>%2/V ?&&/& #B$3
M'&9(BAN>0,BPC4UQD(MSAC\V5E;_0*<0BEHOC]"%6;ML)FWJYL)Q&M=D9"YM
M5PZSDA0ML*X(X$5:%@Z,(EIM&NGKKAF21?7%#UKG\-^3[^P9$[_]2J$/7]J8
MY F#1[;WV#>34^KKYO8_R15<4BGI5P12D @UYX_JOHEO]\2F,,_07_I0+IM5
M_B-18J%^*3</MI" 'BB9[>5Y%"V4HF-NFH:F(GNZPQ>)\:Z']F@&^@OM2[/!
M^1__+[P[LV?MSN3HOW![8F7O]'_^9IT/;!85W,^?MV$G\8;MVPYQ]CM@(N)^
MJ^PW+?;"N=9RISMF6<\T%L!P$0X1_L *0WL^LA:X&EN#(4X=T\#TX6]A&OL8
MAIUVSV9/C@:V.G9%_ X*_4=M>,]6QS/1H+HJL$OLP02$[]F]>/*Y?(V@$W@"
M7#(733:$<!9A57(_8$L>*&.#,O."B^9VY[U$R^PQ]?N;:]"P/1SE8=66TN3S
M:Z3GIEN!:N,;O6B8^>C6TO'.=QK/MA]XPX7JPU[3;NO:CP[,]+*G:T[LW02Z
MI$3Q1_0#1JFQ!_B.%+WU/V(0U;3NSUB-<\T]")-/H/%P%@]# -11*4T(WZ%S
MM8+G&_T 0<\+9%(N*3R@HQS,2LKQ(8N#E].>&KP9"O.\5:5=<9*Z7 J($] A
MAJG)G<GG8TG1?MD?Y8]AW./T7-K:8$EVG?(-Y)J^SE A#6<R/CZEVT"%W/0)
M91S\D-@Y.S(QX7%LIFMH'3![>B_*# +MJ#@DQ8;O>L?O=%# [QE+*&9C-S M
M#)M8P]NMZ[]SA-\L#?BE=SP:$-2P$<Y41GO5.]J>>1'3+1[ZYW;]>^;&W*4]
M C>DT)U#ERI5YT:EF%WW+X'^E>H-)6$9,\_N9V0X33II[TM7V<8I17.^XCA0
M>PLX'W@=4EL]09UZ1K]O0UZY\>:#PPE]#@P7:DD$+HCWHI\M4(Z@I57[Q_!R
M9\G)*=%/J*ZQ<VXI0:=G9*\-*#Y2X=;_CBYY%E#KD(>L8,F,[M9!_)B>@_D*
MF]J^)'#'==#NR>*QM5X,A'&8:I77S&/G;;D&*F5YVXAL0?F-_V>$;KEMU+^C
MGZU$IX4'>'+)\8O!I_OV!-\%23U)4I5;PF$-AZGQ9ZRQ\MJJ0J703:H%/&,3
M&OEHM> =4G#W\#YOK=Y2>ULB]25N]Z3_A#D_/50M8=.7KYHI_O)D?&I)YI),
M8&V(S=(.LV4K4Z M*)SQG'U@AY!E!]HI:*25;R9G.< &<389_-LC79F1KN 6
M7ICUMH&X]NAB 8?\V@3TQ?1(HG'RHSB\5/)8%S[;/#5JLW5 -U18%M.\8B@M
M*GZOR!J)\FNT2K8+M6<D[KNEHK=/)O[\7LWXEU_U5C:"MGY-ZV9'HJE$V'*&
M?&-Q+U8'@=U4" ')Q-0H=;Y:@G8[NIFA^\TJ W$'\15NY:0;_^KF@VU\!('9
M/^T^&? J+(;!$C^ ,0<[D57+DA.^X[/^</TA5L8X#U+EF[&F7YUHC%,O83*;
M#"NXK>V[@JU%'%]; 8V35UI\#<OE>NOK#[P1G("(=2P;]M?V--K%)EM\NOBZ
M0_.D+6=9[U"E,8]26@R&I%,PDV#N1'RJ30:C*.YF::E-6.\R6F"H/@3("$%'
MXY>=-PAJ+Z8PGCBN5XY"9KXW2BU&J3*: $<IG=Q":[<V#=C<FK6TB6V?)[*7
MH@K#*=K03WFYRM$\25Y5Y>,*[N>'4NL!,MZ+==YL40%GEC1BZ80Y\X3-IEZ%
MOD;175)M9]TYR M,,0TMZ%2%[](E#T%V*\.%7P$/LB^Q4Z^]"4X1VU!T5/RS
M<<.M@9-WM(4LU^63E[?86"P*I=+6PD]_RRN4V?08]8S[4A$# ^VR7%.+502Y
MM*!O:.!+(@DH02']5*/JL##)?]2.G;F $NEY*'&RO\ E4SI::_<+W!'<!%=N
MXU]"R^!Q\L98J[M4!2'_2P*T9CQSR19,AJ44NEM;K@@/^;Y8-IB2N<W9BB%-
MW_6VM4=]MWG= ^"_!+?M]HPT2V/);MDQ*]CD>17@%EU8%'DXN=(:A $HD,NY
M03!;4UW(?DTR86[/8/3D>1)-293['G:H)QU.MR(_"KN_ZQ_VI8-*XMGG >J=
MC,\NOAM-QA=GWVD\X[OD+V$W+M / P^<'8TG$_?(FVCG#Z@N\A#MK-'I^,@B
M(Z^Q[S)6^>T02"89N0&NI"1BISMFS,H 6@AG?"D5\"$CV%;]FK"5^.K];+Q>
M@E%L<>B@GQ7=1?_PR;1:[BEM.:Q7<C/>J)'#3W9^_VQARFO7W>X][<9_\&YH
M#RW@=RVX?]N@H?_]2:P?L R.3]/+Z3&;6".VVU["L9T<V\-OC$T>3-/SZ45Z
M<HQ%$R$\!4^?N:>9R1V<ID<7Y^DYS*;U;#@_MX(N79U,+M/S\VG[.R?CXXOD
M+\QB\0AE=ME@'%7'Z:Q0QM(CNU+">&WWZ?R'R%NEJEGJ]BU(!N0%8E620ZE3
M&_PZ,!:DYQ3#><?'Z>7%2=>HLUI*WGFP\2[/TN->&R]^THE(59"FEV"1]!F
M\&S&G;V4MXGH&GXC_M@8[!%Z+P35(UEX[8U4(X=]8I!1==)V^%F&V3E]GJW*
MZ8G93%0C^!57W'"18.E1)/L=EP/NS(_MTE7OGM0D3>U3P P$BTLPI$AF#M=<
MKF<.QXX0:JC,+^^/FV3-]KZLJ.\]/'M!3CPN-U>PAE/[4_ X@,B4_'%Q.E2Y
M'PGG>-[W7NRIB%[">@ =E/&C?\W;X^)J,/E"@D//F!E#MNW=(AN?M55.'+8O
M<:9#2#1 #QY5&B&P)1%=VK5FM-C;I3,)9!"Y1G&&.?:O"\* T'+-!-R2J<W6
M5$:539R%3(@+V=*CB^#(U/S)L*13E\A2&[F8,][\+,%BH"FK3..QTRCUJ0J
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MSDFZ=&]<)5R!P9V/"Q_V39.7TV-^D]P\N&CSM&,O]Q9!2Q(L61HZ"PJP2U%
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ML[X'P87-:(*;B7LFLX].(HX.[IGA'E"%J@/^;UQ */F Y%=[B +"\!?9CS)
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M2 @]W&O'??Q2-^'8[7&7(H8GWM_J)7QI@"Z]N?$T5PJ1C=@UC-ROP["=!XN
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MUA+)]38M2W; =I9+L"%/@.2MY6IY(F)A))7CL:R&YUK\OSI#2DVQ>]THUKF
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M$0;X$-PJUGT0OB)CX!55G6X4O21')YUN]NH-9_L!WY($2B/W=@;'^2L=3,(
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MO?!K_.GJ0CP2E/XR,[&67ML5H"DNLRLUD:^SNW*'%XIB6$IC]44K]\TBZW3
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M/1:7@,=\'8WU=50$KZ.Z)0A,]9*_BJHXGA1U)_G('@F?OLNF]]_FZ.QX!Y4
M/$X0BCL.3NN,0XI0$0IH/K[+12DT0U^J]C A@J.]N_EOD!C O>YHEUJL#EC4
MS+KH]]"Q>=_#(G7M,)^^KZK/?+*02OSMUI%IP;.IJ"2MN BBN$6 ]$ J&)8;
M)V)BB3M'T[BA8*24:D+7"*_'S(JY\K;(=FC.MS$N.MUR4+J!-[J904A&U&
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MX9LM &WAJRV ;>&[+0!NX<LM@&[AVRT ;^'KK4!OY>NM0&\]P[,V>MCFZZU
M;^7KK4!OY>NM0&_EZZU ;^7KK4!OY>NM0&_EZZU ;^7K;4!OX^MM0&_CZVU
M;SO#60DZ+.'K;4!OX^MM0&_CZVU ;^/K;4!OX^MM0&_CZVU ;^/K[4!OY^OM
M0&_GZ^U ;^?K[4!O/\-9-SKLYNOM0&_GZ^U ;^?K[4!OY^OM0&_GZ^U ;^?K
M70*]2[[>Y4CO5%=]7#_E?M=LTZE+?@S_LV8$=\H?^WCZC./4/_>/E,[#EAB.
MGR?_!SM._8H(/]Y%WWT"4$L#!!0    ( $-"?$Q*E27=QP$  (@>   3
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MBJS#*\K:'=-:E\U?23Z,61[FL^X/Z.D74$L! A0#%     @ 0T)\3!\CSP/
M    $P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%
M  @ 0T)\3&;S"V""    L0   !               ( !Z0   &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " !#0GQ,BPQ;'.X    K @  $0
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M=#(N>&UL4$L! A0#%     @ 0T)\3'W[45]2 @  .0@  !@
M ( !7P\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $-"
M?$QU82) !@,  /@+   8              "  ><1  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " !#0GQ,N7\^U%$$   U%0  &
M        @ $C%0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ 0T)\3!\<#0:>!   '!<  !@              ( !JAD  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $-"?$QQ[5WU$ (  +0%   8
M              "  7X>  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " !#0GQ,_ZU+$[$!  #2 P  &               @ '$(   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 0T)\3'XHIN"U 0
MT@,  !@              ( !JR(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( $-"?$Q%^HH%M $  -(#   9              "  98D
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 0T)\3! :
MC<VV 0  T@,  !D              ( !@28  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " !#0GQ,!ZL>2+4!  #2 P  &0
M    @ %N*   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M $-"?$R?DK6&L@$  -(#   9              "  5HJ  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ 0T)\3!H&2\*T 0  T@,  !D
M             ( !0RP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " !#0GQ,JN$85+4!  #2 P  &0              @ $N+@  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $-"?$Q_%\<7LP$
M -(#   9              "  1HP  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ 0T)\3)%D9D2T 0  T@,  !D              ( !
M!#(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !#0GQ,
M?[(7;X$"  !S"0  &0              @ 'O,P  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( $-"?$Q>/D&\SP$  )P$   9
M      "  :<V  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ 0T)\3$:N5-'2 0  G 0  !D              ( !K3@  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !#0GQ,EP^.7[@!  #2 P
M&0              @ &V.@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( $-"?$RE9)L'M@$  -(#   9              "  :4\  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 0T)\3, ))<#&
M 0  -P0  !D              ( !DCX  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " !#0GQ,(:AY==4!  "<!   &0
M@ &/0   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $-"
M?$Q6XY5TX0$   $%   9              "  9M"  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ 0T)\3-#8"6;9 0  F 0  !D
M         ( !LT0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " !#0GQ,SY',G=D"  "G"P  &0              @ '#1@  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $-"?$Q$C',+[P$  !,&
M   9              "  =-)  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ 0T)\3%(D=U\( P  .@T  !D              ( !^4L
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !#0GQ,%*(%
MP<P#  #K$@  &0              @ $X3P  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( $-"?$P7_IMM:0(  (D(   9
M  "  3M3  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M0T)\3,YQF*>Z 0  %00  !D              ( !VU4  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " !#0GQ,"Z@XQ/D!   *!0  &0
M            @ ',5P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( $-"?$SV!RW#*P(  /X&   9              "  ?Q9  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 0T)\3-E%V>K/ P
M&10  !D              ( !7EP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " !#0GQ,_!7R6$8#  "E#@  &0              @ %D
M8   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $-"?$Q(
MEO4DT00  (L:   9              "  >%C  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ 0T)\3.^/UBD# P  2PX  !D
M     ( !Z6@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $-"?$PS7$83*0(  '4&   9              "
M <M\  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 0T)\
M3(8ISM!$ @  Q@<  !D              ( !*W\  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " !#0GQ,[)Z%,1T"  #^!0  &0
M        @ &F@0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( $-"?$RTIGRL+P,  .T-   9              "  ?J#  !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 0T)\3#\./&F+ @  8PD
M !D              ( !8(<  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " !#0GQ,=/&A"*<"  #4"0  &0              @ $BB@
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $-"?$R]4([!
M!P8  -0E   9              "  0"-  !X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ 0T)\3+H [EK; P  R!(  !D
M ( !/I,  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !#
M0GQ,MDDXG?.5  #-0P( %               @ %0EP  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    " !#0GQ,P*G3J4D"  "$"P  #0
M    @ %U+0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $-"?$P)TY4ES@,
M ,@@   /              "  >DO 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !#0GQ,%O],-MH!  ";'@  &@              @ 'D,P$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !#0GQ,2I4EW<<!  "(
M'@  $P              @ 'V-0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    .P [  \0  #N-P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>353</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004501 - Statement - Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Nature of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureOfBusinessAndLiquidity</Role>
      <ShortName>Nature of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Accrued Expenses and other accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities</Role>
      <ShortName>Accrued Expenses and other accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Accrued Expenses and other accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and other accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/WarrantLiability</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/Equity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Nature of Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/NatureOfBusinessAndLiquidityDetails</Role>
      <ShortName>Nature of Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/NatureOfBusinessAndLiquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies  - Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies  - Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies  - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies  - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Intangible Assets  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Intangible Assets  - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsSummaryOfEstimatedFairValuesOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Intangible Assets  - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Intangible Assets  - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets  - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Intangible Assets  - Schedule of Pro Forma Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IntangibleAssetsScheduleOfProFormaResultsOfOperationsDetails</Role>
      <ShortName>Intangible Assets  - Schedule of Pro Forma Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Accrued Expenses and other accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and other accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/AccruedExpensesAndOtherAccruedLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Convertible Notes Payable  - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableNarrativeDetails</Role>
      <ShortName>Convertible Notes Payable  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Convertible Notes Payable  - Schedule of Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.moleculin.com/role/ConvertibleNotesPayableScheduleOfConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable  - Schedule of Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Warrant Liability  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityNarrativeDetails</Role>
      <ShortName>Warrant Liability  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Warrant Liability  - Schedule of Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityScheduleOfAssumptionsDetails</Role>
      <ShortName>Warrant Liability  - Schedule of Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Warrant Liability  - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/WarrantLiabilityScheduleOfWarrantActivityDetails</Role>
      <ShortName>Warrant Liability  - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Equity  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Equity  - Summary of Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquitySummaryOfOptionActivitiesDetails</Role>
      <ShortName>Equity  - Summary of Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Equity  - Schedule of Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityScheduleOfAssumptionsDetails</Role>
      <ShortName>Equity  - Schedule of Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Equity  - Schedule of Stock based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/EquityScheduleOfStockBasedCompensationDetails</Role>
      <ShortName>Equity  - Schedule of Stock based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Income Taxes  - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes  - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Income Taxes  - Summary of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes  - Summary of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Income Taxes  - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes  - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Income Taxes  - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes  - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Income Taxes  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mbrx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.moleculin.com/role/SubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mbrx-20171231.xml</File>
    <File>mbrx-20171231.xsd</File>
    <File>mbrx-20171231_cal.xml</File>
    <File>mbrx-20171231_def.xml</File>
    <File>mbrx-20171231_lab.xml</File>
    <File>mbrx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001659617-18-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001659617-18-000027-xbrl.zip
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M@.+LM,!6#N,E1#A"B'!R+N$.WL$EH'BJ@.(TO8:+/)Q$@'D*WL0. >9%>DY
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MUB!E$*,02EQ%^;)2DG!38-_V!H-TW\QP3GM9;)_KX31J8I -X H@'T"<:#%
M0*(@E^9ZU@'R"(C7->:4S("FLT;Y$()!BCDQH3'06E?V6>:=EZWAONZ^AS71
M&-S.V%): G6]A38_N9KZ[F7]Y9-"YVA0SG8P+YVG-C+#@\4*<%>!!N,=#4HZ
M7DE%XW*WULTPFQ+B;3889-FT*^)DP'W6N/Y:&EF_9'0%(:7BAV5-$]Y\^"]
MM]=O-SJ^GV=@)MOT;]^Z!9TZ^?BTH?9"T^RL/ 8-B.MZ_?M>/YW7GD&ZCTE\
MRWH^61^P%^!W*<J-1B(@C)B*07NG$//EY3\>I44H+1)0&Y%YQI2%_M7%W)-<
MFF-6;6XG_R"_C[IY*QSXN;3]A>EV@3>M%3VNYIU-%@VA')8@M<%&T'%,T!B,
M32(91:4))RN)X3H4EN+Z#N1WF'73'O?Q,&6$ 'J16!\I0<2#%I* J=0QF65=
MT9.$+\=T'H%=\1SW:4,X]6DCZC'-21Z]!N;S.TIXX[@T$J(-:IG!'&3"@98B
M:99.I1 &KY")G2@U[FKSIMOLIS5T-G0+DBEPYK1&C%'D* \,T0A>/&)(&ERQ
M:QL+V#P]-B3BI.9P4J+V(>NGSC!G0TO"HO06>TP=#R@X<'+ T;$Q.@4>EZF4
MU?"-9;"6+@LT+?=3VZ8'-XG":R4]BT0JHZV57@'41JL , OR^M</],\Y*!>_
M]!A GL7<C.O1$#Y1/SMCEOY"&J,TWDX'1L#K18(7Y?W(,\)WHO,,VD$Z4M-N
M99,.?ZMZ%C]WDB^MT%<LS;C*QZK![RQ"R%3T)\?S.U?C6JGJ MV YH_DTK,;
M*K,+IY2+$%XID680,99VRT-1UAHY996Y$(?@5")!_]N+7T)SNY],!Z%,VO8%
MI<5B1"RX0H>EKMNK=S]7D7G*BW?M3HK#NMED.,XT9=]>W*PN>+',UYY2<6E'
MO?%,C-0</=]83XUV4N,Y")[[O?M4,Y\-PH]F9]3*\H[:YBX-Y_N?\6;MP^2>
MA^O4M2Y-"YY].1W$3<'U.+C]D.9DOVFW/PU'K0?@QL34MR;-[M9N7"JK0#V!
M[E(Z<"TE#T!IG$J^T[650?<J8CXKBG_,FEG['H@]'G!3-!#<FMHZ%=!Z4#*,
M"X>HAJ#2C:EM4AA1*2Z<ZW+X8J@-;O%=>S#(4UBQW1\,WWN3<KOM;IJHD[7R
MOM:#=8(=/25880C1J%-IXRAU; 92JS36S582R_QPI-Y?C\ZC:I3=% IGH+J%
M4J!-O&,<:2EH:N0IHR"<F(I"(1>Z[T>34\V]=03B*D6=Q8([3!+AK4@#?7W%
M_22'T^2G3_@(8'=OKK^^S[[[_N@&%'IG,N5I:[ICJ0D(-[5*0YSK4A%FWKDV
MQ,@5Q_7IPI=*]WT94K":1"*BB36,(<\=2OO#0F%0[CI*=63M_JCT['FI&:>,
MX9)8F6HT$>,!44)CX-82E&:E5G>J^ NF_+[DW0:O!0(=$PU'6,$_WN=4-R#L
MPE=G5[YHJN_%@;2.@\=(+;/I."-51'DZ%G2(17%-9"2W)7EQF#=9H,^@D+N]
M3N^FXJ=O4C1-$1<"C! R5*=]>I?VZPWQ"JR1)7,-88?%AQYF)XZ7 5*!-(_T
MTUVEY,"$^CM +=(<2JZ0BSA$K9$*@0+4@03GF8SE[:?[\4=FPS8V@:@"?CZ0
MLV;2R&Q^3B7KGU+T[5:[T7\8S_2<S="9MF/_<+VV$SME@IN$E-1(@$^  Z'!
M1(9=,$J5IZX5K8BI+&\AU2 P16Y^=_5CVDP8S_B;WR)YTTV7Z@XB^-+.]M7+
MV-]>[&6*D \R*AZ5H6DJL%1,14F)T,;I):<=B\6S"_V7,&_P#MARVWDHO>2E
M<ZI<B: (9<@IQAFB+F!A-/; )^Z,LTB'RHP(1J<+:"V=IQPI%#;@MR096E"@
M3H5\\COL%R[#EV/I:>INK"A$<=)Y%1G3F(F(C(V\.HX>E48.;(['?E!G/FLB
M=I7_W",-#(K*@9>#4O$)TQX9@H$& FO.4SNR"@V8$$H>G09QLC3_^+R+ !QF
MN2#P6#@7*EA%N')",AH3Z8@/FGM4F?5)Z+%(E^85??Z>=;YE^4*L]EG9JSC-
M;Z)'K!TL*R2#<AA(XZ-)1&$F.INV2:L]0M .:VH1PUHBY2.*P,TJVFV>?CW"
MPA@"+;S%:1^?4\8UZ"I&TB0QJ:S6$E6VT>92?>L),:59/:TK+K8?U5;L+5#M
M=%*HIU-9@I3TSAGB4GLL1HDCBM/H(=)/9RU8M;JIG#K<G#OGQ= M0_?3X::V
M6 HK*"6I7(B(@*,9<U,YY5PE5S"WR?1<N5E."9AJUO?4>"B5H"9E>!A3QA&-
MTKH<\]!+;5?G-W?AX7A<WG7W?09O!0!'TSX-C9L5%20[UAN4\9X[$J&Q-M99
M[8PD$"@C:DU1F,&8H?61&"FZS:[&8E=DJT*ZO71LW/]PSY&M _\9^:@DD:#5
M':(1@85F($(B]0Q?W;SWK,A9W[IPO^3D6'"A%6;IB ))G>]I<GBH)YZ"J0RK
M$P4;DK.49W*-05K$T^X,=RE4S?75YT:[DV8KUH^(/="T:R)LM$&SH%#@4GB>
MNAD21[D$G42,?OWK!U&,B=T>BSH"P,7!AT:[5>Y#^UN_-TA-#)I9UJJ+'.BG
M[![SJ_SG!FF\<:)Z.#;R*;66:F+338.-R\FBULX+"VM-6!Y9.J^":4AM6+2B
MG"S16K1*J;7H[H=&^Q2/32G\H=,8^\;F!KSDAXUIBYV-THB8ZH5#(-[XE)L+
M2IO4:#<LZ?DB^)Z(.]\=>9QY?=,MGWLJ^F;DPQ+JYE?/"^)R9?>Q-[R=N#_I
M<%4WRS-TC6[K?6/<"OU3.KJ8[R 4B;>JX[*QG2E&PP>PU\.'M"A[J4W38*&W
MZW3BPW;<WG8]S5<!>B6=2G/M,!,$>1%B@.6D-9,R2%M)^6 Z5P:X._?J!.!C
MUK[[,NH/)G'=)%MX;FMJOJ=C4(1&'4R@2D6II"4(EI2GB+CH="4^*.]KK:=,
M+1'3C/#)5AR\=S3(^_H?T7(Q)QU%45BEC->"LD@H4^!.>RE3V7QJ/EQCN9;"
M78=D<=CR<\]F8U$K:YK24OK4Z\Q+X;E)T\+>8U1(H'0:4 B/@D J'?H)%MF
M*>%X8^OW" +.^)%6NFT,4O@X\S-*6QKV87;+)! RWQO]UE@/SMHN#_*-Q<^W
MC>[U??Z)_%QM4A]C"?A'EF0C:YEO61_@^YC=-< #30TLIZ.H\W[5:P_I;Z:)
M)[2I=I_'&,B/46J,Q@Q!B'%&TKA*:PV.PH%@H^+4Q\G1YO%<FWS_MT2;5&<P
MT>;3Y@!;]]\*P2/L/"'2<Z>=1J @(03GGD@=G:F>PYZKYCH8'O.4^K+^"U]V
MX"$LMO9@QL6UDIOW?9@>,K_NY]JRE'&!MV0#NR"YR[2(,RZ-,234>I!G"5_S
MBE&%/(@T?#O4;)%S4.3SI#\.8<Z7&6Y#9J39Y9*HO-,U)5:X-$B9@L.M)?(.
MB1IF$ B+^8496S!C0UX(:IWWQ-M(66 8HB!)&)711B<,DKR&%ZGD72MV8<;N
M!G;I-&@<-=*P-J)GG&N,06&E4W_*8"Y9J*OD(7 WH\^5&_=9,UFL;FOR^73P
M;<'^YU;-+S?+Q4&4P\2P&S)6ZF"]Y=1*C0RXL8HS3K@RD<BH'5DX7%T:9?G3
M4;3>3F1^1@)0G]W=IP"X-"W9!D.%LM%'Y&R*7I0)/G"%*%LN )2_; $HN_['
MU<:(22RHP9YCIJ@743 RUL;(R<A=G=.(E)18'H-C9;H<@1,Y^P<G%I]&K(0V
MQ"-FX9^(F42<I]2+#1+3("KQZ0F1Y@@\^WLV&.9K>KR\/_?2'\99R]4J<J_+
M2(#)8Y$@1S41CG(-8=5X&9%4=5CGU#"LI20'9]P*^AR).VMT[E.MJ]2A201A
MK==61$>,](Z9H&2405)*85VQ/]D[+/U1>+0KE1[/Q'GG=W?GH[PZRNUKC",$
M7$$GM=..,\RMY,78S;2SOLPM0#]A^EC2[X#;Y@3],O[H>E8/9ZR^'@T'PT8W
M#>-;@*0(/JJ[8/M6767F6!X@[J(ZI'%<%(EH3)Q$8Y)&;Y?[;$QLRIP#TFEK
M9FVX.(?5H'#0KC=^*_BV?^>MS+J N&.22X$Q3DT%!:ROB>O&K5D\P/DHUAV8
M:B? Q:>R0JFG@I"I6VWTRM/ I$#Y[H,6-&C)M_+NCD^=HW N#P-.;?4IGXY/
M8)E/+O91\%1I.%Y]WG@75JR^C;,=QZ#9$3@XCAU.C8%.2V(\2AO:V#,F',(3
M]4D"QHZL8.#&;LD12'8$_NWLLXC#^"Q1:20C(8Y++=-0 Q[8A'.@/>72/%.:
M9'5PSIV.XW)JKJ:/&BD2F5')T61$$#V.D77T@A/TI/[*3FP;F-'PMM=/I?9+
MZ[M7;!$&#)@'FCK!>Z4@0B+%C%]AXEQ<5.0,%$*5S?(2$#/H4HW'N #$CU*K
M_K$>&=^?CITV!K>UPT/?9\-)*4E1=U8=IS<[ZIU^6;'1XSFC+ 8+7 _26:FU
M)RRU2K-:J(AJ\)L_LKUO+(Y#GE)W_<?6"BZG+1#54^<Q(C@ZXH1B.A:CX%44
MLFY+DS.$B'AJVDZ;(RR=]G! JGDJN/1I+%P(G#/O22BH1C0Q-51+2FIC@9SA
MMADYWF??\TL#,P1U-*[W+.B\)U=H"^HPC9'Q+)U!-,;RI)Y8T3HRE9/64$>"
MO<4;B=0J5#<C%NC?;X!Q(75/L.@B]]C8I+,-53QX0P.9]M;DOF[1$<J(EIL0
M:!&]S8@RKOW+>UH<7V \XX@3Z1&W)._DGK;P"R6D69T!VT+!EU#;C!9%\>-T
M%__X%"'<L0"KARA"/#BEUBI34&2AW<"2VH:M$%Q'ESR?N4=[MORL'?@KJ<0F
M=1B 0!@['0IS),'F5/JJ*Z36J]5=H3\V5;84)]-JM<>G$=)1BC?=R8&%=17G
MH$>0=I%2'<%481U0L=80!*Z5MJ= 8?52*;QRP<[+K17@/&%-M<,@O. BV<(A
MD)K92CL4_.0D7>\^K1B6%2-W/@8ON:849,B)8A\F6%[IQD6E9!OCN[GKLSDF
MQUE8:#PMF,?@K&#&1^.*$6(DHDJY,E"%GA-5-E\,3G(TCLVM Q>'*UH,4S/"
M$?F(Q; E&79QBY?W%D4DS88#SU\IX;3!D:"ITR9JNI4(QC=#[#$N[<YX'F5-
M"*J]CXIA8R@7&*6:AD(M BC5.;#'H]FF4<!2W$RJ.-76>"PCHU1J:J8-\BTE
ME>:;$FVXW+=UX+="YRALETA@@V*(L/(CROL'VL) \*B.3)H-0IL5#861AH6N
M%;<V6$$E81,_7$4C>46 *3RP$29;!"6;(G$4UE)C(^$1#'T@QL""#GZ:+Q(T
M5)IA4+PA:Y^>()L;.)'Z9++49UI;!D; :1(+J?"JJM8V]'ZV)<'&<>IR\386
M1V114%$3[8T7J*BHB>#&5'P6"+8V9.=N(>:A(N_=9-U#R.F()1140,0^:#N3
M=495Y?!S'HJ>(74V%_S(@/_P(:.,L:#CI4*%8A><ZHIGMQ]AN>UU4N>1,0[I
MY&RSWQYOMHP'B[8F8=+6)MRCU)974AR3@VJ-4]."LHB<J-BI170V!6R_Z&S(
MW:+5TNSU>1>M?!KSNDF!W&-!@J">@5;G%GG)&*P AKWE+E1#F<?2Y7/CAQL!
MW-W6[[TO ],$5RX)\YMN$W#J9,/,-)NI64,2FW[O6WN0K^7\<@;/3LZ[VZR;
M?6W7S^+^8U7S8TTP<C[9<TY%E(+RD/#W+)6RJ<7:M=F,XKV"/25&L1K&BP5(
M]2GK?VOOXJ+R(+$D+@;",<7$.X2FVQ125+LWT')[@:5@[ +H&CNDL;6. ^E=
MT%RE."$6L94TP(9JQ,@V!'2R5GZ9<&(PF0<&+(._].'^4C/PVEGNB^4'AYNY
M+!5+!PM=3.W%C+36HDB#"0H\Z6"J 2:9#+O= <45E%E%A.6"1@!2, ? .!^X
MD#$WE!,_ L4*Z%3K5: _ DJY DJ*0D2:.Y0Z?5,FTY9YD:'ATE=:*RJ\DL#U
M4&XA4\O)J2!T8H0JAK0G!!/'+;:4$:R($;:BCP2O +H1WS>%=2514\M"@PP!
M92D8V%/-Y1A6*1QVE<:C&I&=804E^C4;C+5H:B&T$W%CX-@)H8U"!.!+NTT$
M(AIK,;&,LNK<+U$'[Q)0'@/T*BK;F!2Y![>3PTI#(+_138!6050G?=0+Q.9
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M.-2;S3ETJ=T=QT#TB%)[>6JG72:#\+1.S>T/\KKF$VLE!$F-M(* 2F)J0(-
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M.H[!7K(LTEFPB)''S%N(R3T#P)+6MYAQJNO"(/R3F-M7.$6R[<\^+EL^CIL
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M5ET^L=:YY5.!DW@,?$]0^WX0N+X#X;#%?8<:U(=0HH(0=&.[*'(S"==+X%Y
M[B"C(8G+N,"1Q*;G^;;!W.KHFP[!0EM!;*;C#B#Q!S?,LL?;-%,C&G>GZ)<'
M2WNN-#W?](4N D'!IZG.%YI2;Y_$$;JIKX>S!<@3P&T<%"TK;NWY[#[-0*<O
M[X\VRYG_.<_B?!0/4>>MT=]+38\-L)[4L:0P7<O687UXI;\#QR&MY(NA#E4>
MCK4JCF]53!ZU/07>)0!,J>7BN&#/<G1J4?#-B,$#8J\IQUMVT+:#\A2@MVT
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M7-BV#$PPYI8 ^MG59G5@F\ZZ UET=2?N5)AW0MV/E?BH$D!\_!:7:8O;H[/
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MTV7/C.3^3B2XV[IE^\"F@:2V4"/!JXV?@-&6\V!VO(#;1K([=N 2Z4C;YB8
MQVG@2((3:X@(W#6A%>'6:E_2+N [O?90D3*E N@- 9#-+-?6JP!(=ZT6HB^$
M87>:PP6WSA72DH29S',-5W!::0YN6>U9[^ '=FT7CL#[*-7A2ZI+P3S+$X9C
MVE12MRKP(\0R6K@22]"NK4/'-9K+0WB%C>.).(/0C'HXAX!7S&L*=[5U#-9G
M=HR<N46%N$QXC%(7 V7? XUF$;]0(:#@EB=T%L"9A*R)CIX*W^E5B&D:0O?
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M?&5.V#[95K"2T@E,T_/ 5NK,9H%7990$]UD+14+YLC4_%,)NL=N1473 "9/
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M[%%3JLL2FHX0>3TE/V@ <JW2XE3_Z8/SKOZ+_(02U/AQC>*'BP;-2QZB3;^
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MIGA.,V.O<J1JXZ21PETNS%B_6U0WU5)%0T6]3[%I,BISH@C#G]&CJARZB\#
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M7DC!ED<XJF"LS:N7P#T@$'!9?!L#K'!-%L6)]A:4T3A"*8S&CP5:ZT"$NYN
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MQ;PU!KHT!V;W4TN^[ZB\%YI7+#1]ZKV7B\N7B_,-C"])%T#\VQ>G]$K@4I5
M;QS//38]HYS0,QUS;DY#[0\ZGX-">IWI-4ZL@6G2/K5VCES2B]>EBU>?O>Y%
M[&Q$K-^)[G>B>T73*YK>EA_G*E\SV<O6*</\UQ7-_U>48\<]G U2%IRK21JG
M#.Y[Q?2*DXH=A^KG(B:GMN*]3+QBF>A/1_=R<?ER<;Y!\27I@BYCWW-9R%X)
M?#=*X+P#UM<B$)<SHO/LJ'@(L*>:QZG^W#CWQ:[F<7KS#(12A=:=S-Z\J 5X
MEIFH'Q,MB&XR;,6^T+J$%^F,@=;"XYAW;&X(=LS3JJFMN?8099%V5W2F&VAA
MKHWB?#C/<TS6W(!]NJ[X9W8?:8^P0AWA0P:2L8$EVZ?"C\+G,_P4Y9JM/2PA
M%E7-#3J"VK#$@.GM\.HI,#N;8-:ND.A9=/.H?8V C6$1.GDQM>2 K(D1GX*$
MNT#B2F7YPO$8)P0CUWPM<G^7 /OR EQK'PL,LFH4QV+-$,?%C5VQU\:S%T?A
M%Q7G?K0TT3Z$3=5D%*KI6ON"_'6;9M% X1GF>3J,U>3F$K-';1R'-_$8#0DL
M9R=P_85<4Z[!9>-U0SF/PO0!%!=H>%BA>9S?%RC/[L.9-@)DKH\V)"]NY:K/
M__ZWR4WV[<=*:[^OUL0#93U.\WD6?0'TG7$Z_/,?__M__?L\O[H+P^F/]G"8
MSN'Z3^$CNG?P9S:/1M7=P,AV,OJ(.J;QU>*1[CS+P%[63P9/-T$[^FMT^_<W
M@8<<])_\CR_>&RT>P1?A<'9%&37AZ\!PJ)">*5C@ZM2P.0\":ALN>?./%9(W
MJ;=C1O8Z[_I4*[;>M2KII_G?IE&2 ZRH!%*DGQ:6/XT7A+P8]V7/2/&<0*Y6
M(FJO1&,%D&'S.)]5AJB80(]J?)A.IB"!J/+?QJ@JTGD.C\A_Z,1#?NY5ZW3]
M=LR):CQE*1^@3[\MX8M_-U^3I-DD'"^E# A>4S]8!:#:,!J/RVO^_D9_H_Z&
MZ'I8_7VXVIB$V5V<%$"&\UE:?5%D;-0WQ3ANBU^;5!B"&G^M6G)#:#\.IWGT
M8_6A%0<MP&]N[-8I 6OMA(']MX8+R(SG'33>]>W614-_4<A?2*7!Z\][OC+Z
MU.":NV:WG&# Y %36IYCR&&S8.6(3&LOE[U<=B^7&R<[GU N=]#RY26UTZ-B
MST_ GAE?&3/NO2/?GPO='?I/P\<,HK+.Y/M\J'=V@MVY%;[L45AG<<KF,L:H
MT>Y*$2^;9X[+_I^-^NJ,QKUN.V\^[77;_A49IV]H?Q$L\U35=B&YD>?P:8?C
M.$%<M5E1[]%G2KH/3G=-GSYQAK)[/<1H?]RCEX=>'NJ8HR_T[O-)A]O><3S$
M4A+M-BK+23[_:E](=/9]**+3-5)X=@TE3I\5.1?QNO#$1R]:ER5:Q#A]<\C7
M(EI]X+TP_M$=1-UH]:=9>AOE>9PF\ 7Z GW,T<<<NP]N]"%X+PZ].%3WB;[W
M0!^!'VR$;](P6QSIZ .$,]) KR= Z)L0]S%X+V(G%3&+])+5A^"'6G]U>K./
M+OKH8G?ZO&_[V8M#+PYURKNS.K37(@Y]L+V9ME_2&6:Z]^J?T,<'+UQ_O'Q0
MBDV_::-TCFT2GG)2ZK*K3;LK4-Y%V]=?P6SIW<TZ.YJ:%\%U?0:EUY"7PJN]
MANQP(ZO#\VN]AMS39]_<BWA]:[S3=+MK]M%SYGF<1'EN#_]G'N=P8YI\RM(
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M2MIM<[8,GEB8H \&@AR#R9=Q*&X@/82=<]MC%%':>5Y>15&4E><8(N_C-Y_
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M,T/RH10<IZYG/AA)YYR4],+2UBS4O/&J;DZU'WJ!48;H*^R1Y<K EUD0>('
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MHY@^5KHZ> GAJL)#'.EC2*L0.S*D,:0=&M*.9MZ9^6[Y==_ UT)#_#">ST4
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M+F, AU=VINV-G,A N-9O,K(^+^!'JN'XY(>A=2F"8#GU@T<13(Q9714B:^6
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MHI)$IS.-(&B-F5C$.FZ0';%+7S#Q-85]M [>>'Q.Y$YQYGUQ^$H0%0];)NR
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M( V"Y5 M#9.0D0+WA)5BT0#]1+[(Q J%*[.U8ZMF%6,2R<'!3W15LC^\+BF
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M+C6DXR;%/R678(\ ?,(23)GT<L4=R!-X^O1QAY9 B#VT9HKEOIAGU@]QO/2
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MMF;+*'E0OHK 7JE9E<U+-6^YQ6<A!8S[I\,ALD'*(T&&HK9OX5NFW*4PJ4#
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M=(/C'@[]\\;8?_NWO_Z,XXB7^+]_^_]02P,$%     @ 0T)\3'Q&IE<K%P
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MDDPDXZ"]S$<$\F8PP1%T0"V,GV/49R:GI9E))"+L_?;8[CURE!I!^D;KM#2
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M(>>/.ZAHI7Y^*KLQ]8X!+<SV-J;>_HSO)RD$&M4Q%B)XESIO+D2C)3&NY<U
MNZ:<@^Y);QUO).%I?#5TYH,<>3>R'T5\GG@IU6WFH=92&PR8JL$3*8IYVB5]
M30B-7)OY#^IS0;W;.6(+9&-?W=' 95:8;63JR<QK1J]N_Y+:428SN@NF4MUP
M5NSZ^CR+KA&E@0!AY:# ]OR,T(H##/0D)D(*+'^6AY%_;*[J^;)5>&RNZI_*
M5?]DLNJPPPV.G1KZ,]E$G0Y.C@>O<C"T) 9#^@-YONS<!F^EPJ\K,)73& QJ
M9 LJE3Q^#5XH1.WU9 9#&^.E4&H>GVI*8165><"N8=8^[C5DSGA.V9(R\,YT
M*G/B\5*& EF4[5BVGY%<8\XQCL\*"=1G&(VF*7T3<,V(NXZ.(RFK[S[;_(F*
MT21R,):!$RSU=,8.,^9U_XQ@0-T#T1J$!2ISTPZ]ZD-9 9 K8V\&!; 9W +/
MKH(/%W.'F^!N,8--@,UL4,5JG"FJ&^0\OFS;6_76@&96J98>GTH?(U+YUH!U
MFXEN,#XS"^;$8+R-..%UHKF#@MHP&+M+M13$'8;9%#W0A,8T;)65ZC,<TH09
MIUZV.I4\WWY%^DQ<2,D\')Z4S%.'2,6*ZVEVQS'!7I6@Z[JC*^2*5<Y%.@KS
MXNG/T<GR%0VXYKW!8*Y=NP)&^LWVJX[N'O;">&Y38B.V7T<; &#F\A[;<X^Z
M=)9J$#3OM[^&)5).+4,##2_P W;I$JAN&?TWMD4!2 VM.:#44=79<YO*7VU]
M<WLVJ[W#<-B9.C<SFSE<>? JMYBL(^^V%Y%EU>:?J2?F[BJE?CF^<D+3DN7*
M=GOD"]DTZ_((+<7VV_$HJKFD#*)-Q.PY'$Z:M 2QTA&@5ARF.;(#;CA'Z?X1
MNP]8%57>W@XE$G;"+BH$E#U;M,TY.SS0B')W1@-N[5FT=$=IEJW%E6_-"R5O
M8P'IK8"%I]O?!-@ 0?9@HY+G!IK?1<')>\,9]NQ51:]02V4>L#ML8[(4HVEP
MB']T/%C=6L#V;-OO%,O;\\)(P(6/$Y0M.'9FS.".BGEX#0KLA/:P6L.!/.=&
MV1"Y8UCTJX9"HIDIDA_XZ2G#@,(0C(2,O!LL[J1O/3_>S(-F20&HH]I@?-YD
M##*X[$=M0CE'',IIO!<E?4PF<2]Q[LSQ3IP&C#6G](8+P^!2G_3Q#U(-#GLO
M;(P=7H*U"<^V<ZZ4NMEC+\+;GCRU#!^IE>;QAA)U6DT)X/823&O'RNQRA\EB
MXC,>+I3,7WG1B-+88#VM/9SK/)I>$L9E^S/UN3HWIKP:ZVC-JKC1.MY[>H:#
M$IFNCJF#EL;4S1;6,@_WD[;URAY?=RM;(,DM5C*(#/:S?_>)BC>^<.E-]YI,
M<?E!R?U$&#$Z6WGI;QWB.G(CUQ-7[RG)!ED-Z,Q+*)+ []:7H3.J'$)K0F@B
M/$:">TK5C_.P .:AZ8E,A76F05-X9RH(G4MVQA,:##L!X8'8Q)M![A LY"@
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MCH$(;AH*]ZF$M\E$L-<MU+3%9Y6%XGX>]S79@E#VPKPRK:XC?H3%[JGSV[)
M]"0F0@JOUY4%#1H<RE;JHMT\JAHJ\X"%Q2D^>S^\TB:+JX[(?%C1G3UZ7 4J
MPX'E#S^K>KG]_B%JM8+(6@9AP9KX)-'2$1@7J15@Q27H@G#;I7#E5&$75T/:
M'[J%Z_T1P.+V'"_0[[_\/U!+ P04    " !#0GQ,MZ+HU7 9   N&P$ %0
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M"W?P+X5WE.*CO=)^^54*'_\*X_S.2+ZJX*_J<=W,;O(2;D;(AII5TH08!R;
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MM@300L>]+K=H,&+-=R_IB G0(T*-->]GX9F;J^OOUZ13YX'3>THD= @":U1
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M&ZSKC87G\^)#MLQ"/[=J,;79EVR>WV_V+,KXV3[#MWX/B=" 80H!TE(@%\2
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M>B>)! )0AQB&(@Q(>Q-3SLN-G/"!-.?,)40R>P?L_+3Y&"]6G^Y94TYIGL3
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M/7LN88(9ZX@@V,3]*.:%KH*,G+'F(;2>+YSNPT1I@\QPIY72(M/!DI_&(&)
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MG'@NH#/2<R*=QG'O5I>!MP!>BQOO^[L,<J@UMFOPQK#F]L"T>OTF0'IG8AJ
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M8BL<)!0$,;5C%%3.5K#3FA^Y/CU3]'Q&1D?HG%/_1Q>&_8WB9>J$Z> G(6F
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M5975U5_3[;X11<3/C4\9$2N;L-$S26PG"3 WYE$F@)UEA\A=[Z3#WI1U7-J
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M4LT1D.[$3TS^J/;\"ZR@!PN*9<Q2OLVD6"=?8T26,9 UY-OYGK]V!L6."SL
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M*LD]1SWOQ?REI86\_R-24+R3Y9U0[=2HS)2"$K/:#+UZ+TKO)=A/,$G\%'K
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MX\PMRRC,%%[RHG8IU-2.O"5AIWZ]7H:@AI 3RCP?Y[L7>0H3W_-<+\0H2$D
M?6\<)X"A)]EQ3F@,\9N5$KWA\-CMK3^\;&N,VOL]4D5&8B@*Y%^-02>1+'U^
MZ#=#/O,8C+>2CU+ V<$\"O*?2NLI(,'-)+MZ^<_[>DV!:<A_[:O=T\*#?D32
M($,Q"%U( (%M04@[$/#23()*Q >9ATL$^4,".TX",0N8((,<"?._G4Z<,\'0
MQ,SR"J5+U"(/J27<HJ# 2W)1Q8(O;<9&^= T^W*5[;=TE77G"QVS?=[2C>*N
M9#]F"Z]9H-2-PS1T<>#G/HD\"'$X"$!<&(D\:*1U8..GU;U$3M6+Y/R_SO\*
M_L5UG?^K"VO$ QP3\/.DWV;#78+0G$Y0IY/4H5'\>/P[A$R#84:9YT-?)&TW
MFQ7D7LSYM&<;)=8!95/^<)K6-E5GF]7!-GUW%+H2'E\LE_-6X4P)BN!U-D5H
M!'0;4H9F%*N-3UAU1]4>?;\:/X^ BT(_!"3Q(8)AX.9X&#])L-##>SK'G=U-
MJ9.C).#RGLD\TGH=TQ]=#9L!OR0)O;I;,F\".:_4;W.JA\=BN6/.B=EA?+?M
ME0]Z[:J4WW$3P$O0*ZEA;J]34M2+PR?I0$XH,W/.+:(EG9]-6P;1+%SD0ISA
M$&4I\1+?RP.$AO'3" 5"-V*TC6KXE*MGR=MZZ_Q.OV*YI__,*0X"*J2%]0$O
MD.V9''-UU_1ROW0LZ@R9(!X$WTH0:;6"17DCO7J=2B<90$Z1*5NR?C:\E\1Y
MYJ(<Y"[.4)2@(!B37 C'HIWW= UK/'1_BRNU\*,$W$KT:!9G?>S8!^W6D>,K
M_,2Y4=X$5E.C@EI\S*B*FWKZ/:^WW\KE_:9>UW=/"S>BP\51F 0^=(,8$<!J
M%KK18P2YRJ1TCSE=^+@;A3*1:1=$6C7-;@YD78S8AXLM] =19X);5U[='.RJ
M2?5N.@\9]>?SW5".X@0D4GES.5#MS4\H:<6=,5=!33E=_F)PXB8PPGF DS1
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M073$>'528 3HTR! TSW,\UR)<RPHJ:H%S"<K>:UN:"F&Z],$ /E12L-91.(
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MP+L?-I2R=N7R'E?UR^&PER#">C1G492'2>"Z;C0,A].8/T>I,HAA]CT638J
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M3X";D!QC?^CC$KM X!$EI5&,5[SULK'BV"[UM3Y()U2[I0(E![=/AJ(8LQ\
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M=A.AK%*<7*B$&5?IT>4#E^X@CHW=2O)Y6Z_VRQUZ?-S6WXOU L/,C:!/HI#
M/,TQ(F LA0I0QG69R[P4ILN3.L)\4:YZXOB8;IS7Z_H'*QSO?M840F]?FC75
M96*URTI&3YR=5GRGE]\9%+#&4 (E4=883*Y("HWM<Y9')JQ'35@5(+,@NY31
MO@QPVUFQO99_6&SMG8UB5S;/?Z%SLX^]F8M>;=6;'"J0GRN^FL2,%I1C3:-G
M/?4"T>*-#T=_)V4)70]Z0922! $<Y+[+GE+M9:$?8 V>6%&"F;SPZ_($<VY8
MU49*+GA"\YBJ:C#I>55MH\7K3F@C\QZW7UE6^]S+@(O[6TT&M-K7ZM*1S\]J
M1531QXXGS2=%R7%./3T ?NC#$.0(9&X^BD+WY1I<K)H ,WG85T4PYARLHH&4
M_.MTMC%4.V/2NRH:1HMSG<Y YGUKMZ:L=JT7X1;WK'JL9[5CU:0BGU_5B:>&
MOCN_%S_;.[1=^^/A*FU 8DRGFY<!#R<AC),\\@8Q2!)$FMKOR UNV)UR=.'Y
MC7[22CZVC9;H@6#$+AR>=&Z3B'G1M]OSL \Z8_1"RW1.,&(,;?UZS!M%]K+L
M(WL<MNW!2IW?RT5QZ+)N7^N>DY">\XXFK6.!9S2J'G\_'QTX<GE$\O"XKI_*
M@QS-U\=R617K;^7VH>^BA\M->5OMFD_[AYMR6]\._Z99A 0&7N2[R T]B!$*
M_!0- D$_YC];-2N&82\Y"'+L)G<'N9V;7O K9].*WKZU, @O0,R&;<7A+^TQ
MDYCG'"UT$/S*Z45WCF1W\&BJ3Z.IB'VF$O"F]IA,SJ\:-AV?_U0"\9PGG<8R
M%OC4B12M)Y_U2G[VA"1T!_R]6I6K;_6_E4^C..B._ANZ:RZ[Y,PB]'#NX30&
M ?(\X'HA/DB'_(C_ =P)93+L@;^=\+8LS=1*SII2_[-\.KC<*^JH>_'[N%R)
MV<T94LHC6V%##>[Y%+<[@R;.M]JANAP(_LH9U7&0S395<MU6V%:C'S=F8UFW
M+@LPOX\W;D(K';YYK2][_XE0Y[W<D97=NQG?BI]=,_I/Y0[=-&V:?.'B)'<A
M8</"'+IY&(8I"  )L)^$412(7>E0&LKX18Y!.H>*YW3R_=]B=S;4H+SL82?'
M4,QMG@"/;G[*G?/G(-Q_3'LMXQ).%RYC:('7CBL8>E2I#4P_@;W*J_&^[HKM
M[N^/W1MQ?A %F0]12'S@)Y08O80, \8$QGSTI&$@X^342N/\_?&-UPNU \@1
M]D^'G#(E.7/!*!!I3P>G2EG&%=W;WM9;NFE=MSS'HN;ZUOE>K/?=?[#/?[ 3
MA"OV^6JPQ8[:HF!J.<5NMZUN]KO^>5_Z*^S$O6K_BVZ/ZRVKC%I5M_0?EO1K
MJ#MI6N/M'YTE@T+U'.HBSN=B:#W&L2 LUJ1(K7WB*@:OUX_MBW";NX]UT[3O
M2M-9VCX=G=4/9;.KEHL,L3>3XC0-<!)'"<Q YO:20))Z@M>434A@W)OD)7LX
M;]T&:*.\#A/8>2:Q8OBKPQB24?'$5M 0+%^RPY4S2#US$/TVK"*QM48C61IR
MZ]3PK4A<.YH&2)BZA%W)7KFCAEHO_,A+W3A' :%[A3R+8@R#01PO2S)C3"PF
MQA3!_:YLR6!""A8TA78>-F<#XV3<V8N]>-P*;RTG/X-8#S'+6>W=L;.DFO(4
MK8*K-$_3OPR?D9^/K 0LK1_8G^T6CDHSY*>_WA?;$A=-N3K^!1;8+U*8!J$7
M$A#B/$EQDOH9'D2%*11L]#B+B--EEH]%4R3V26PG2?JV&4V#0V!_'W_0*W7U
MS)ZM/S@4_K2J_7;#='O^:TR[F3V&!ON(>),IIX.EGF92"-[R0M/;0]I#_6U+
M'>6"CI.D:1+#-'5!Y/J)%X[;ECR)HL6NWA5K20_#-X10T= H#7_1$/LGS@GF
M4?02G/A)\KQ^Z#0P=2O4S 3;RB!"D6)(6DIR@DJ\15,RF$@3S1_#P04:SBT6
MKA?Y>03=(//#- XRD ,RCNR[T6+3%F>L)'E'8D2NE02[E70L'/>"^EC2S>XH
MF#-*-O-R>@V5R-I2 -K2A::BT5NK3ADME;JC1>#&$5W4"-#E'D* 4>[",4$9
M^$#)T_,,8-C/LP,7_5Z>"SGY\B*MH&DJ*ZIO+>0I*IA@:1$WM)8RD9 *'*5$
M@GA(<,W'JKBIUA5[I_JX="F"81*G"<C= ,,H CB)XC'CEF9O]1K3-]!$:^E(
M.FOJ]$XCQK>B%-&V;GFIZG-^K6E!2FWA?=[6C^5V]_29SL\=VJS(?^VK]J7?
M1>R1+ G"$,99[GMNE"1HE,+-02(=<VL9W7C\G5<_Z?I4C GT *W"=X81ULQ^
M@[3T;TS>-H\[2FP#&9Z%4Y@:U0UC,U%JT(Z+-G6AJ$:B"YRXN4M #),LC)!'
M@.MEXV 1A -7?I/:,HF,),&+W[3D2(^$U$&7;T.JPHIZ8-0?^ME <<),Q@VF
MS83%KP07+PEB(IVH>1Y!+CQ,20[0X3P?D"2#J7\@/9BYKE+.1G"LB=,W"K0C
M!Z5D$L<@BGKR.3,G;I[C(Y+#D436.E92T^:MS(X22KP\U990L3#L^C8MFOM\
M7?]H#MO;($<DSOT ^3CU\@3&7@("XB.,V&.XO(\$*HUA;EF-8K&\*!/,:26;
M+:ES":8+JTL+NG8L+3VJU 9FG]BBHLN5#35<4,=/?V_*U8?-6,B(EKOJ>[NP
M66O5:K.GG_4_K#<'X4(_0[%//!*%@$ ,/!3C0;C,S05?1)U(*.-U@4<KE<V@
MHZKC@P:"5]"GLA<?75IH*#%B90%?:Z6Q$<C-D_,7IH53;?YZTF"L*G#0Q3DH
M,QL7Z['!!=:>V,AV\/O42M>S+BQAG_%ALZP?2E;EOH!^%N,@=Q/D =\+,H0B
M,(R1)UBPA8C8=QMG<,8/Z\GKS9Z!<'EE2H!ES0*3D?WU.I%&@'>ZH]5_[IM=
MU]JG_L*>9UE6Z_+9R-]JSM5Z:*4!B!<EB9NX8>I"0("'TT'4"")/;-7,(J+Q
MQ7>D%6L@L!WT<C;]JF2?LK\OF0??=T[;J4>?7<@&6?-8G"_DLM[48@'8"QN/
M"K4U"YU*SE^84G]E/Q8,U6:+R4P8Z8(?F'5.V.%.YH6@MFB-BB;_'[>L66W[
M3DKYN"[[*R+HH=[NJO_N^MGD2>(E$<YPXH5A@(D'P)AZP 'R1>\ :AC2N/,Y
MEG+J[/7;^%Q,86N$UX[%K5>E5\EL[7AQ9[1/WK]:9'259U$<9\0+W!C $&5P
M&"R%*!=;;I*#&%]@7W?U\I_]!<JE]+U960@YCP/,8R=X$'#FUNG$Z?^3L%Q*
M_*OA: <+J2KQ,MFO Q/1,_YG%T&W6SJUVO.&?U2[^P^;%0TY5OMB??Q+_072
M10:C.(EAG$*"XMB/283#D0!A .7: !@39X+PH#_H/J8NYS>Z265/$:Z<QV*[
M>Y(K'C!G(['J BN,(UE^\.Q&_I'PS@\JO7,0_\45_UZ#>:H59/'F*&<P;DH[
M&'HZ=<\41$R$,U=GW;\5U2:G$'TM=[MU*\90I?&TB)(LSU%&LCC ""6I2W#<
M#X<(",>KK]\X7_=0&4NFN%3\U0XF(<L.-J.$K)1B/4BIV&OT@OXG5J<VR"SH
M,ZI%C5KS5!)<)2P?PX:DB['J3M"N;_]1L.6[:Q8HSA.70-\GL1<0&$*$O6%,
M-P.QS%)1&G#"]=(6+92CD&S%_.C%U+!@+J%P:=5H0<^2I:-'EY?K1R-"O!N,
MZ]U]N?U$M2Z:^R[+.;@V'&$2IV[B>9@.!NC*)=DP'@X"7V !J0\VS>)IY1,+
M_A7PXXOJ#6,F%:ZW,CF]4.-I3R_77Z>-PL_B<R&\5L?4CKA9@QZU[MDF1C]T
MC&U9-&56=G\>':6DQ6.U*];C.4I !4B@&T8 1&Z8I,"+AE0N#;UCP5)%C0.;
M+T>\9QN2YL4A>?=P KL4N3Y4<0L>F.N$GX_.9L)=C-\&(9V_#&+^E8%_.*KN
M19WMG)H?Q0LL:, 4=M"B"<5JX]-8E3@_;\O'HAHZ!RYB-T,8$ @]-TFBV 6A
M'PW#!B 5[)*E/)Q$ "=&DKT\;-O#!!*\ *8.IRS]F<!1)^D-N,Z28GT++B%V
MDT3:5DZ35>=-)E/"29Z_T'+)'C!J/A=/[.FAA0\3GQ*FYX4A@I#D*$L".B["
M;IIGH>>JQGNBXYDOF^P%<AX[B5093!A060HSB:06#AN1_?P&LA.1V O A%A,
M%FQ;:4Q:GS=Y3 TI)2+;[FGX<M0 ($M=Z.9^'B8$!9D;1"X9$^ A3 G/<^Q:
M!Q19@A)OK?<2:0O&9"!58#.3:.HBM!9?GCXKTW':"]A$:4T6=8N935HE'G)3
MPTO_1>.%'T<PA&$4)Q'!!,=NE(5CI!B+-8G5.*P0U\GU'FGO-_17&D[>:#!U
M6?AMS/EH<":XQ<A0XM*OK5=Z+W"C 5/8P9 F%).^?BN(G2);?MA\9P_]<=__
M]=T @C!S?>(#Z*>Q'X"AF!2Y02!^-W<*H<R?@[QHRS JH+TM@W9[*;'PG(;2
MRM"G#/9.VC((VD"<WTT9V6KN-Z8TGU\PBSFOS_A<//57#M'RO_;5MCS?Q]3U
M?3^*4)Y$*4D]W_7AV$L()5[JBQWJ:!S8_/$._?R>;83K6^>V[<9<2'1CU@DU
M'Z5/C;$4;0]"LJO:O9@ONR]?S=E^F1_$"[QKP!)V<*L)Q6KCLUB1(_&^J38E
MI0#6N+!KN];_9+5P<S]P<R]U<8@RX@9Q?CAQ#]FS:FHLJ3*T<9YL)6FJH>SW
M=_I%RSW]IU?.QX_I%>NZH<B82L!+<J9QQ+6QYD'2\3F<-AX>Q)V9-R\ *<*<
M.NQA*7=J4>TM]M2'G_Z\Q"+U0AP1/_2#-".I'_DN=@<!$/&%'O74..S46=Q3
M>U53N86W,=>=/] *M_$<@:T9 "V[?&Y3V,&8)A23WJT+8J?(EGFU*39+_G1!
M&I.,!&X LM0+8$KY&_N]<#C$2:(EBZM;J,FSN*,"VK.XVNVEQ,)S&DHK0Y\R
MV#O)X@K:0)S?31G9:NXWIC2?7S"+.7>&8ELORW+5WM_\5._*0]D9)FGHHLA'
M($3TCS (T#"<&V,H4OLE/8CA>J]!KH[1-TPRN2I6>10Y4PM3 "B81GB&72O4
M/'6JY["YE!E0A=,.7E-7X^6.7P\NO-SSI7SL4PS7M\^&H^&Q[X=9$@<$0T""
M),B&.^,X@EXNE@F5'L;\Z="0BJLW*NPCCR,?^Y@%4(I]#B*Q7.6,[',.FPOL
MHPRG'>RCKD:M>9K)1SY]MPKRL]PNJX9NT 'R4^A[  8IS'P"\_00;*$L=66C
M'^&!)HV REXLKLXK!D 5#X:,XJD2$/6".:-D\P5%+S'B#(RDH;6#GO2H<B%
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M%B]Z%\A,NP'L(#K]:M6&)Z[ L_##:]D=!^?U]FNY_5XMRV:19RD ( # ]:(
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MJNIHQJLHA]?-Y$Y*E<'D/0Z=$D=M9YX'=#_/@Z[HP>64*&L_G>1&6^#T\0U
M+AXQZ@+3EG-$;?J\.BS4BY2\*^CJ',=/Q\8ED1_G" ,8>GZ<4N<#HC$<1R#A
M;]FK<U##CN%P%VHX 12OJ]>*L:RCF !>;?[B /IX0OA&4R3#H*OZCPG U^Y&
MQ(V@X$]. R3D5A0QMM6[J*KUII/1@IN\K_FC;';CUF<1A-C+H@1[(0X1@B$,
M0W)H?N K;CK$QIJF3M/YW@G5;SR<OU0;YZ'>[.Z;OZJRG2"TLI[%'*K:'$HO
MHJ;MAR"NJL[#'+[:?08GS@J.XAD80OY!#D9;W8*D-F]Z Q64Y)T ^?E8;=M9
MV \<N01$F "$_"  )(Q(/O;%3T'FJ?D!X>',GQ?W\@Q>0+CB4">VLH[ **S:
M?,$1V'K<@3C JA[!*-#:G0(_X I^X24D0JY!&D];O8.\0F\Z"$6L> ]I#]?.
MVE,2M%D-^Y.COIO76RIB]= LO""(@L1+DC2/Z(0AK&Q^D"&"D"LS969DPYZC
M.T]<'I>EE#_9W\NVD^VFWOQ6/CRNZZ>RI+^U:?;K-CXKAL2BV%&N9J/P'>G.
M9P\QEW-\0;8S"VMD-N9.F#D&:1DY=O).>\0K!.6%HUXS)K'CR->0;O44DWJB
MXM'G;1#0]Z):LSI\*OG?F J+Q/?R#/J8N#$(LR!S$S1ZA P!(3:>34C#Q/VM
MWA7K9\VOZ+Q>/[7]7;LF).TG#C4WZ.GD,_V"B>I(E2W,1^WOPKAB7D!#M>@A
M\3X\5S/HUSJ15L-W4A_ZAIU,E(3JFAIV>*/Y8=!5^*G7+OQOSLK(>MV5/;:"
ME:NQJ<]8N[J(21J1!$=9"ER 4A]Y_M@%+TX(US6OF44T7E U],JZ?7:/MNXK
M2N\ZP47??YW'FAP)L?=A2!E?AB_[,CSX,GS*EUT/5QUZ_8Z;J!UN1;R/62#Z
MG+#ULT&R>=[LLT+@56(3-CB76IS?Z!:D(RT X=6#RQ;8A'=/3OID79\"."W^
MIWK#B@:H6$S2IMU*'O\\K9O=IWKW[^7N2[FL[S;L+<1V"]DKM8A]"#UVI0:Y
M ! 7^R3*QY)R&!&1#;H=$AN.9OZ^V8YR/<^V+JGD5\ZF;)^&8&>G#\6N>T;L
MMJQV^^V%6QPV3P"^_;L=PIH+@ ;]AL3MLUW[L0Y7SJAEY^/8:Q7'TX0U.'FB
MD^2@XE6?U>FUG'9#/XGA+NSN[9HX=FSU+<.DMGFI6^)4^V9>];;_B/V>MT@2
M%" 2D#!&6>AF/@&'%OE>B",KO*N<Z(;=;/K2LSK;([[\4;+S9\JPQ?=R6]R5
MQQ633V6QY2V8M!3;N7VN^1DQE_-EVI[TP$,?1U:K<E#Z%W'%)^TYAT]6FUB_
MN'-6!&<J+ZW#AD+GTC=O[]EOSNS9_VB5^]#7)XT[=F\1(1>Y4>X&'DKR*("
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M&!'D9WZ29IA2%!(_ZX!0F"50;57/(0#G2W<-)*_#Y,3U&[!NR>4[HMMYYK5
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MVE=WP^<DT>P9ZD5MHC^E5%\EC8VR:'TT[Y6:,HYDS5+$TWMT\0.DJO*ZDA?
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MB7'4I'1NN^C)JA.3.%%9 UZO**Y+*RU#?9WVL)QNS.NILDK%6A(E) SBD'#
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M*E%7U<D&P4N1)RM]>:9/]AA2KHIN'[OI2Z\Q1CA%D/H\1'%$$0*()A$+2<J
MGV9$M396[U,=5KBVUR#.=;K@,0_7BDS-"%O&;# %_[3@<PP'>N.='@^'?%\/
M;45I +(4I"FF69SY//,STK<%?19JEO0;M:$S"8SJ\SM W=6@_T>S^MZ,-QVY
M<$F8B6K<>#UC\\K'$UY>51%3'I<D)L9]>%%3QC&B'.NOJZ]DOY7_D\7GW]8[
MT69%:KH^''Z(%*/9XUBA* PQ#X%/81IG29C"<)"U.$:IGM38:=.]] A\S3&1
MC?PB/R&=.'158>M:"&N5[67,-\M]>AK2.F!,HWSK85ULY742^RKO-& 5B6Q>
M5EFD-(0,12S&+.S;2G"@Z>K-VG ^WSI87M[BTKQSTY X-5_OGC$]7]]3U0$:
MG/[DQ5?/6;E><C6"Q64HS\@^/"^O&LV(41*Q(D%*4 !)E*0^16$$?#A$$VD<
MH%5=UNN=0>KPZB=KK=H-()2GQB?Y*]ZF"X+7#;016</K1!ED"U8Y&I4ES)@:
MJ*8$RF0M0R ,L5]+ 3094 \U+AP^_3VO5V%$"4UH$+. (,((BS@>HAL.B6[$
M,:(IYX''A9/^-]X^;V[^6)^=.-^>G>J5__:7,&A^ZR_@QA--R$O BF_Y3O/I
MYG&F4(UA)K*!;BCSZ&#^XW/Y-YX -W50<YFFJ[&-!7:7H6!VNO(LTK'&C_HC
M!K48:')CHE53T=+;_69WE#NG_U66V^_%;K?B& 4A! F+*> !0M"/X2"M2:AY
MI:65)IWKW0FE47QDAU<UT9J<4#WQ.F.R#ZP$0N_-@-'K04Y\.Z@*;U?4S"KM
MRU UNUUZ]AR"=;[TTKH5#Q/">(QQB@G%28JX/TAHD!"JG\^]^I&3)'+$.(%[
MG1*=S,TJ&R8IVQR9VJLIFC(KR]  7= O)F6:?5:=Q^^*]6VQ*^JB>?V\J??Z
M6NX$(94,E>H?PSY0',+(CS,&L9_ .$8P38.^>1!EJ@L2UMIS-_#/( YI0?UC
MMHU-5<:NS!KKI"]C7MGO5NEXL!K/S:>[LB$%69@B /T@QDD8A9RF?8.48,W\
M841#DU5BG&'4+,<80Z.VJ+GDSUC&YJ_.N,R0FFR9TKHXH3+NR&5I&L>-QI6P
M\CWP_F+H?HV8@DB(GR %@C3B,(I1/#3&"%&Z[7]D$UH)@7X]=H^JO^%<^R96
M(]H4DP3WC&DF#3U9':*Y=GQ>Y.5:7C&.R&7(S-A./+]4=#PG&O)R..;;Y[*V
M(@$A+(280P32.$DQBN*N/8&"0.TKI W;<1[I=-"&0I2V"*QSW+L3X,FGTLN$
M79]-(TE>S(0:VX_G<\H*,^J/G!^*;VNY-_A2DRRE* PYQ $#!(4Q:@H^&!=?
M(QQI^>Y1#3GVX/TK=OT<TMPE'<>AFB.?C#X]=WZ"->1?/V9RZ=<8NB)%5HA=
MAAK9Z<JSQ]ZM\6.^K+$B$**,,Y*D0O0@#D5DD?3BA[,PTME&,/CX26O#5#RY
M-=Y,UR^L4C9^W6+NQ0JM10IE[I8A*V,Z\.JBA"87ZF%->ST@+>]EK-R410T.
MJGG,M+@K\NWO@H$>1TBSC$4!H$D: Q%FI9'?XTA"ENAE$?;;=YY=O"OW7WX5
MP=.]M^TOT]R<H??^]_]"81#\IW?(VXJSA_5!/U"R;A75Z&E.<^B&5!W[YV ?
M15<#WAOOA'CJ8$N3T*L1F"OC+$,_'?;O6:SFEDF# &X%20"Y^!,A#%+"(LC2
M_M  Y#'3*@#1^=Q)0K9W%D*UUQG2CM&LDF,<G,T6DZD%8\HD+4-%C)!?#K\T
M>Z]SE5A1WS?G$O="A_9UL?^2[S>RQ<R7U\ES%C-?7@W$49P-D1YA*-,\K#NB
M)?=[TB=P[2+M.3SOC7Q U<,&-Q\;4ZLF(5-QJB<I3\E\A&OZN\0N$'1%=&S0
MN@P1LM*3%RX2L\..^DO"%^MT4L1B&@8  1Z2$,.097V=#HQ@K)D%CFC(N42=
M8_OWKH1-LVYF#(]J@C01@7IZ]!)S'JGK0W%[K)OKQ.I27L@^9SF-416@!;:7
M(5,V.O+LK65+W)B]E]->[1"@F*$4LB2,,H(H1S3MSUO*6A[-HCZ3%IS+TK,'
M+__B_]7W@^9EB>8]B?_TDAO?]^4?;SW<QWWC[<OV/8G**YJ[<IM0H;3SHHXB
M^VJ:YIIV/3%[]G). VB>VZ-?8.:*6HWA<1DR-:H'5Q_$,6'#X+;HMAF( C\(
M4A^#F 51PGW.AR#-SWRLG]=I??PDR=SIB9OG>@1?%J0PN(D!O@E\?$&1O'7M
M9?DFO[_-#UX4B-\0TZ+YH2"\"4!\@Y+PNJ:]] G ^)YJ16NJIY+.S*B?/Y[N
MHYY1WYYR\DK*:$3?,I3-'/[E6Z9->% N+MQN"[E8OMY]6!?;MWNZ?BCJ]>ZL
M]14@&*<@(S$(:  @1BCIK]6"(D/EFE6&XQMT7VXX8/3D94"_%GMOT\+4K'"V
M0*Z:Z$S,JIX,G=$IT7F"S@[?C7<N41-7;[Y*V;4R3GM\+T.W;';H:6&G;:Y4
MM>V/O%X7^WS+UH>]B!DJ<KHU)LOOBDU1KY+(CS'U$YR1+$P)(SSC0PU&2&(]
M;;/0H'MM>W1U3@-JVGGW.DE7YIU%AI<Q[VQVJ'0V&L>N,J^2D"10O@X&04A]
M/_9A'/4-H2!)=?;"#3Y^DBWQEU9'YU[[U%KS5*9Q&5-G3 =>7>/4Y,+6G0(K
M/T(Q@$D0 I3Y811$"*=#E,^SV+!HQ*RQJ2M)FBQ?:QHY(EDMZ)Z47[V0^^6+
M&I9U.X-:L<HX9I>A5/:ZHWD+@R9/ZO>X;<K[O'ER5^Y>OY/TB@"?_%E4JRP&
MP(^3-($<QRA#-,R2./8#2C@77VL]V#FF'2WMTC\XU4+S!FQ>#\[[+.%=WO2T
M3ZB:6$W%I9Y.&=/HZ(ZVBQQ=$2L;S"Y#IZSTY-E%;+;8&:E.67DOTJ$51# #
M-$@  C%(0YR%*.C;A-B/+>B38DOS*50+T(Y&J=(Z2J4<,&I-IUXC<TJE:K'H
M:Y4FOXM6*]V^J.F5$4.JBO5?^3X_K'<BA"/;^V)?R/(:>>ZT>X7@MV:;<T4P
MC7B<01A"&/MQ&D51-JAEFD4ZRF6G1<<*UH%L$ICU(YAZRF6)7C4%FYY9/24[
M)_4QPO[M$N]S"W)B25,B[HJTV25^&1)GN4^ERZ&JNS=3Y>)GY:M.6?XMWY7-
MU>./6XYIF!+(?(!$JRCP.0GPT#*1-^BJ"YZ-]AS+70^QF9K;$T@]L;-"K)K4
M3<VIGM ]HO,,W\PRIT#:U?TO>Y0O0^*L]NC9#IAMMI3+:G8-K_FV>2$^75>/
MCZ9V$%812C F(8H 3RE@%*=!U#<N<N-$ZXI .TTZ%KEFC?+76XGNT2%[S<(:
M2_2JZ=P,S.I)W0#0:Q!V]#XZ1=^!G+C$1HFX:V4V=IE?AN+9[M33<AL7G"F7
M2+>GZ]LD^M/ZSZZU5$2:=T7='G$[%OLO[Q_R0P/G[*'N%$<P]$.,88(@"[,4
M01"F\G5ZZA.L>0#-(1#G)3K]C<1]H/*F0_V+YBDUE\904\Z%6$%/37OZNS4_
M ?NY)6Z\$WCOA'ZV4V_F1%]1WPFLMPQ%GJ*C3\N[I^)64[EYOI5K L\0K<1G
M<QISB$3VSS"E(6:D;Q6&"3629^/6G&MPA\Q(<,TYU%+52<@SD\X.VLO:.8LR
M7B+K=?D;3?.B-&Y\;UX6,DLL::I5LTTCLGNY2_-"VS'&400!Q@G@"4; #].L
M;SN($MWS>5;:=*Y<#3XCW1K+II9Z34BCF88U )O%PP;B@K3L.G6O*YHEZA>E
M:[;Z]+*Z667,3BZ]8A$"Q \3!N(L"$6S/(WZ1BE,?)U*X9%-.:X3OIR0V<R'
M7R?41LYKE4O[>>V2LE;CS%29XT4IV.C.:&68FASIWCYLDM?Z&0D#EB(0D-3G
MD9\%$>L1X33SS>XA=H'$>0PWW(0[=@G0J3W4]' IAM 3R\$"/],JX BJKXCM
M% 9<AA)/TM,+-Q>[9U=7P[N4_I(#H3XD01: ,( LA@CZ" ^)/>4D-9/KD8TN
M<UW0%J-Z@CLAE8;:VB\3+B<B5>-.02PMD;\L7;35J0L2:)4S7;5[E.)?@A"@
M.(-^R$ "(4<^!"A /03 J&&(:J7I):XKVN563_TF)]50 Y\N,RY/"U685%!$
MJP99EB[:[=H%=73 GZ6L?H50 $G"$ ,D2*(D]BE)^U81"4*=I<BQ;3E>B[R2
M%UK-S%_GU$KV;95.!QGVHO)G\QQ9F>9EZ=KHWNCENIHLZ9T'?MX: -1/LY F
M41K%,8I1 .*^M31"6JIEVH9CM6IO6)$SZTT'[!?O/[P.W!PG5G7FU%A.ES&7
M1O?BQ?.I8UEY;>[<WQ[^7'W<?,VWQUW^_JY[)IALZN);4?_X)._Z_Y3_6:<[
M>7M? "@.<02C+$U$1H9]%H0QR^(XR##A$50YQ6"U0:U997"&H8/IE7=>_X!R
MCU0M"+!+[_5(8#9F]<*!:Z1ZGQN8GL3I-4 5[RZPR_.VW!SE :)F%79Y?#^"
MI^XBUK?'W?K@;8MJLRNKXR'W[LJ#][TSP;K#_5=5;R&[W_B (.P\@ XA+[@#
M)WS.ZQO<=*ET./XT[S,HR^WW8B=/%K\5XW'_I1"-DJK*ZRH;AMD)!$]\DL 4
MB'8#PGU",T"21'P'Q0PCHG>Q@=VF'7N2$T2OQ:AYL8%EGM52RADIUG,I/=!F
M=>T9U=X)K/ O"I[%S:T'6F1>B98=66490;2KSCV]$,$EAR?Q/!]A[\17?_NW
M_COB/_+LYM_^[7\ 4$L#!!0    ( $-"?$S!__T9DHX  $X[!P 5    ;6)R
M>"TR,#$W,3(S,5]P<F4N>&UL[+W;EMLXLB9\/T]1?\]U=>%\V&OWS,*QQWN[
MG%ZVNWOV%9>L9*8YI12]):6KW$__ Y+(/.E $23%E/NBJZML D)\\0&(" 0"
M__Z__[B;_?0M7RR+<OZ7/\$_@S_]E,^GY74QO_W+G_[V\6?UT;QY\Z?__;_^
MQ[__?S___'_UA[<_V7)Z?Y?/5S^913Y9Y=<__5ZLOOSTC^M\^=M/-XOR[J=_
ME(O?BF^3GW_>-/II_2^S8O[;O\5_?)XL\Y_^6!;_MIQ^R>\F;\OI9+7^[2^K
MU==_^^67WW___<]_?%[,_EPN;G]! .!?ZE9[OXC_]7/UV<_QCWZ&Z&<,__S'
M\OI//P4)Y\OU;S?XD>KS/UY\_SM>?PVEE+^L_[;^=%GL^C!T"W_YO[^^_;B6
M\^=BOEQ-YM/\3__K?_STTP:.13G+/^0W/\7__]N'-T\ZN0M_-KT/G_UY6M[]
M$K_X14VGB_O\VOWQ-9\O\Z6:7U^MON2+[1^_+2:?BUFQ*O)E&-BZ_R^+_.8O
M?[K[O/@C8 (Y1!M$_N?)':V^?\W_\J=E<?=U%@#ZI7\);+Z:%+/N!'G6W^#R
M?)I\GG6HEZ?==26-GLPB03]^R?/5T;'N_+B7D;R?+,)J\R5?%=/)[*1A[6S9
MU1A->7=7K.)"&!5ERODJ+)EAZ6PP_QHT'6"4#>=8\QZZ&_,\;$BK(G#\7;G*
M@QJ_1[X?'^C!9CV/[MUDL0@;V;>\,:PG==/SZ.,>=7T_RZ]N]GR0)M6IW?<L
M;;/5N%'CKD9:&55ABKDPPU;?W\QORL7=VC0Z-M F;;L:I_OO^_ #QT;T]*MN
M?_O4B7:X5;=C>^"Y6B[O[[Y&#31=9YOWT->8/Z[*Z6\ZV,!AE;^+)LB:02V'
MWZBSCB6YO[N;++Y?W5RM85/3H.]3K,G3>NEV[,V6I%W?=C6.-\'KNPNKVQ_'
MA['CTQY&<>I$;]"TAU$^WMKNOI;S:"==W=0?;&UYG<_SFV)UNB0IW?<JK<UO
M\L4BOPY_'%:J?&T<GN[ ==!UKU*ZFYL\+@!Y_;<?)JO0Z[0,!O"L.&6![*K_
M/N2MEKR_3V;WZ]]4LUGY>W2D6@C7N+,>)&FVC.YMT-V(5I/Y;;0<-P0^/J#=
MW_<UGM.7UF;M^QKOPX1Y_C<M!6C<8?\2O5^4/EKK'_+E_2PN[E=?\\7D%,NQ
MB[Y[D[-:#=QR5=S%<+&?%(NX-.3+M8T;E_=I,&O">O]TF5_;O_EU6PPZ_MV^
M\&FZ8!UJU=78WDU6]XO &GV_+.;Y<K/M!HBN&WA\3=H.,<Z&=#FABZY&_7$5
M6'BWL=_,9/G%ATWQZ#@/-NIC9 \+Q"E#>]FJC[&M7<HOY>PZ7RR;Q2&:M1YF
MK">%L5MTU9D4]Y^7^7_?AQ]PW^( C@YUS_=]C:?A##_2K+O1;?>9C\7MO+@)
M"IFOU'1:WJ_#Y._+6='D0."T7H8=>[UO_II/EF'1O#M)"5W]PIEDOKKY1S1U
MYZO*0&BZP73].\/*?ZI_D-;KL+)U.R?/.S>;68]M^NI*CN>T/C;6?=_W-9Y3
MF=ZT?5_C33EA:--7_W)L_V8;9V^ZOK;MKR]YFLW$PZU:C>UQ%I/<C&V>WT:'
M]^WD<_[,T-S5;K98/&D6TZ=D3)^";#WF7;UU/-)W^:K;P3[OL./QOL\717GM
MYAU#O+O;7L8>_(M%QYCOZ[CC\7\*7E#>[<A?=MGUF,O59-;QF%]TV=V86Q!C
M]7*8#5GP=9$O@[V_CAZ\#7^P_3[VVWD^Y&80^1^K?'Z=7Z\3,:MAS,KI+GG7
MLMY,EI_7 M\O?[Z=3+[^$M?T7_+9:EG]R7J5_QG ;<KI_]S^<;9-&8E#6X]J
M,ENJS\O58C)=56.:193^\J?P^UF#5AEA'&AK&$*<:2JI!8)1 J5UD#$#\5-1
M9S&YMEQL >]7UJU%6:7)O-1"I9_'1WG%<CHKH\]G[A<QIO$I*$>'\?UV )YN
M?RA3AECBI0,2$ NTTUI(2A#''/@ ,6N"Z&,2J\7TIW)QG2_^\B?XIY_"WVP.
M,]]N!-F;?[QF].K%2C193%],A:<-MU_\\G4=%/IY^J6875>M8SIV#]PJ1Z20
M('ZUGORR<T$9=JG9:6Z^ZA4'.JPQ!A!#Z@6WEA@EMJS UDIXUA4GHO]Q,ILL
M O1;(@49WI7SZ>8_#B\CQUIGU#GJ(>+:2TJ)X,()4\DN%?Z!UH;&+'BY-G2,
M\L.$W\>NEWY7_)-J*"9\&>/FG_)E#'^8O40YWBBCDBMBO:>:0R:,Q921[<@)
M\KC1W-C##W39_.@<W%1:O"VF<6GW^5J^CQ]4,V+L:Y8A9Q!47AD&-!<! <=5
M-7I.J4Z@!OYQJ-$1O,?)T>F.]'Y1WN3+>*-N,HM#WT^E9@TSR3@&&!-AL!%>
M,H]-99D1H*%,(!.Y;#+U G#J6J/+R:*V)9NM,[N:9,$H1YZ'3=-"*80GV.MZ
M$AA*10(MZ&73HF-HAUI?]C@=Q]>7PPT#?,1SK+D*@D(A>%A9?25M^!N>0"1V
MV43J!>"!MZN3F+1?1L>!(8(*9#Q6/-AJX=\K&;4#*(%$_&02O0B/O@82=87M
MR&(BNTZY7G5(Q$D&J9$(2F <YMQ@)Q!5!#"OPV[1:+GL1]9'1[J[U= DP-J\
MDPQ9Q@@R2!.CK4"$,<=0<.8YI!@;GF*8OK( 26-.E .!/<PB<* ,P(!3O$Z7
MO+KQQ3P,J)C,WI?+8DVIXW.]2?-,"RN$YDY:S8D(\".M*79(:<>\E(V,[9ZV
M\4TV^W$YGWZ8A4%++;@!'@D2_![!A*DD MJJM,G;SQ3L5E7/]]\4? 8SVM:#
MK *I397^[/L,:\BL9EI+8XD%W@*K*MDX<"G&VLD+][=\\;GL>>ENJ]J=#$D#
M<RBBQ/L"L6)'^+^8-OYM,EO7\%B9R6+QO9C?KA-/#Q"G4?M,8(2D1PP8KHFE
M2'-4(TF(2(ESCIA(K1E0]H_Q4/QZO\B_3HK*_C_N.>[\/L/($XBDT09Q)[ C
MTJ%*-BIARD)T\A'*Z^-/%YB>9>-JNF%E"FHE(%>8:F $P@SP&AE-8$J,\_1S
ME-ZC"MVR(P7)X5:1\FN^6'U_/YML*MB$9?!K-/#>Y8<7D_W-,H2-,M1 XJ 2
MRBF'O:S72\]3#-L1KRG)QDV'F [%GA<7T_/5F_ET=A_+5_ZU+*]_+V:S RQJ
MTCSS4D#$&77$,!^#MX#P>MY0Y(9<@5X1FWK =MB=ZN@6E7E$E?-$2BV5D50+
M#^HY :DR@Q[+#K0W=>1"G8C=4)I_FK3X\N9M W^[:1=93&D$Q#HN >7!C.=:
MPPH!AFV*98/ZXD"OX9>>D#L#=YI'9_8WRI!A%FD1+#Q()$7!J#<UC$;)E'UG
ME)YU]^K?SZ\TK <\GWV<6-WH<'9'@\PP'# +*N%,8\\Q$:26SBEU86FL7:CY
M<(9[.UQ?YZF^@DHYQ*7G(GB)5$N!R5;&(+E*20T9I2_5#WLZ 7<H ME\47Q;
M7VH^B4.'FF7*:2-03*F"CJE@$XAU2,KY\.]")F72CS =M@<2=8CN8 <0NPLH
M'V?2X8:9@Q1(91T6V$AI/6"Z\CPX3LNZ/]GM>J5+4J<(G\_ /LFPSA3GPGJG
MJ ZK+)<H;-JTDDI:U.CN9&?ILKV[ZSVP)AG3X7:PC2H>EYZNBRZ8V62Y+&Z*
MO-D]L9/[RA0R-LP=R S5A(7=76-084*1HQ=L,O7CN/6M@C,L8,U6KHPKR'WX
M'Q:2:>4P=[HZR>.>N)0(XPA/OX:, )P([7 VT]&G878:3'M;918P3HEWQ %J
MD?*"V'J%5D[8"[:6^B%1=V /1:I6<>P#R&GAB$&0">:10I(C9V%M'G*2LL&=
M;$A=!*4ZPWK W)^-CM8C/Y9)MN/K# KBXB%!,#^M$L8+HZMLA&B67EQTNPL5
MOTS^281UR%VMG#?BRO-/,RX@@% #R8B#F'K@?;VD @M2KAB,TIKN@2B)F X6
MN+Z^7A\D3F;O)\7UF[F9?"V"R?EH](<BV$<;9TQ)J9E5A$$#@U,@!*VC&F'/
M]I>6R-$#DSI'>2AN?8AU>>;YM9LLYL%<6ZKI]/[N?A9+J07OLI@6ATRAXXTS
M&O9]:0"55ED4W GEK:_C($B12[.R>^!6YRB?S[P^R:S.*%*40^\!9\@ 0  G
MN))*P*12(2.,2_; G&1,QY)>E)!6E $L2' ^(6+" H0A%E+7>[JW*2O0Z7?X
M+RI4U 7>9[B->>"5B N[FJDX$Q)A+X3D!@%J( ^6AW(RWI1EI)&+T%LNQL,>
M%A0[K9YT^SK+UR+,K]5=N5@5_US_^=X,[,.I&YW\1.8@L-AS@0VBUDI H.05
MBM2QE&/5D7KD75+K9<['.;1RGOA/6&FN%FLXK]?^Y?M\\?%+T$'CD-"^#C+I
ML'"8*:8]Y@ #[Y"HI%>"7UB!O5X9V0OBY^';>J1+=;_Z4BZ*?^;7C7GVO&$F
M#9?2.$DH$X081QQ"-9@&IQR.C# M:4!^)2)]3EZ]62[O3^;4IE&F4/ XO!%!
MRG@0Q(!3I)X]V@QZV':!?&J%\CFY='6_6JXF\WCGZ41"/6J9>4$)CQ=Z29#;
M2LT<?Y@[U P;(+@\5K6'^@SG)RULK0:M,V$4A]IIYI6$S#+A@^Q;N8WRPT8/
M7C?%NH?[##0[P<0ZT"HSW%@L (?<,*NYAP2:K9PV1N<2:'5Z3<"+H54BS&>C
MTU'+:D^+C#E)85A^&3$2$B.B4!OY*#(&I%R5%#\ZC5I!?#8*-3.H#C7++ #,
MQ^PL!6.Y/@6\UY6DGM@4:TK^Z&1JC_,P ?(&Z96#1\@/C.GAE9P&H?*3^LD0
M)@[(X$1ICI'B5DON**5<,P4 98T\U3/BT:2.Z6D=93:04@++--=6$>$#?T&%
M"!?XPFJ9]L26YKFRZ2HX^Y)Q[L>>SK-R,.4$A($!T@.CA<%AUUBOZY)C9U4C
MF[ZGX_5RN7PR^G4!W4.'ZCL;9) +KS2.%;<H]88Z86 E(;;\PN[+]Z3]Y^?I
M74 ]G-EY/P_ !_SB"\]WN?JC.'S]XN7GL6AC$,<A9SF %$(/'6+<.NTD(3(I
M(VR$)$I5[XM](QG1X3(+O]XOIE\FRUS=+O*UJ?U\]+:\FQ3S@PF&#?O(H.?!
M.U-68TQ)K#*AN=Q@H(P0<-!RJT,L32DT>)%?V _(QXFVYS6@_U/>+U?E_'WP
MG.XFT_Q^G:BS?#.?_IK??<X7._C2I%EF(;90(ZX04C2Z<I+Y[9P+KKQ(B;F-
MD"(]:+7L#>S65/GU.FS- <MR?I@;S[\+X_,0"$RX\D92J1SQ06@'" 36"YZR
M"XTP@:)G,B2B.U@^\OWG9?[?]T%X]RW\XU/X\2,&S)X6F652"DXE=N$?PH8M
MV] MNXE68-!"JJ_.AND&U#.2YJC9LK=-YC 16AMDH62:L)BP#RH9'10I5VU&
MN <E:_HX<UKA>B;N[-VB#GZ?66.\9=!3X8-I)YADH/(LB6(VY5;QZ^#,J3H^
MS)I6J [F8&_NC<7#2U,N5\NKF[_-OR[*;^L7.F,F;%A]W1^Q6G!^[0-VCW-E
M]?<J6_9J$?[M_^73U3'_O/M?RS"#"%#IA%#48XXT=C6N",M+*VC6L7M_=H4,
MEQ2V'N'1)?')=QF"PEAG,+!4&VD@H1C62P!A%[9]GI4-+VO@M]9#:^\N1F##
MM-H>T[Z/_LN;XN/J_OJ[+Q?;)[ C%M?W!YC4LJ?X6(@/,@9)51B8PXQ!'3PA
MHI2$@I&4JF@CY%I+_99#8MR:1\$"N"O6KUM?W:AW^>]V<7^KOGZ=%=.U9@Y3
MIU'CZ/$2@BASEBD3+%IHA*LDD6'UORR/L .V] %K:X)\R*=Y\36P]M?)XK=\
M%<81EMG)[-15YL1N,NRI5\H:1IFWR&B%?2T=!"BEAO (;:4.2-,OP-WN4QUN
M5$=64888(20Z,YHS:6(E4EM!R:4>]KF-UT"C_D'N9*ORQ6*Y>F?5/XK5EV+^
MMWFQBNGYDU6^;+YC'>LCTX81B#D)DT(":*'CVVPTR2E&[,+N4'2\<76,;FO6
M^")\<WMU\W(?/77].;VG3$*'(+!&!20Y TXB+RH9C;<IIL\(KTATP*#>,6[-
MH_IT:$_@Z.5'&>>4.ZF!0%PJ2K%Q5%4CDS*I7MT(-Y^.XCW).*9K>.\AQJ[/
M,J6"AX8\AMKC*)/$JN:?!\TJ28S?&4Y1RT[-MD*OO6[G\\E=?EW_^N&5?O?7
MF6,." H5YP0K:@44O#ZX9Q<38DM34]DUC.WS'ZJ\W(9*W_=]!H!1&AB/()'Q
M>=QX#E?++M6@SPV_!K5W!&1KQ;^)R1NK?/I%%V5#W1]HDFDHE"-40LN8)P(#
M %@U:FWXH&]YO@;U=X?E4 <N5ZLO^>)Q2O/AH\%=GV=&4ZV]#S0FB%)AXP6$
M2K( XZ#UK5^-K=<AHN?BRM&$E]T-L@"'\<2XL"1BXJBG$.)*.FOTA5B-W2CX
M"%M:(=H^"I4OOA730'R?Y]LGD(Z$G/8U"!ZRQ<8K)IT,OT+"VDID[;E*<R'V
M9%=J*WO M+UQ6<R+N_N[8.'>3V8?RN^3V>K[$?-R;XN,Z+ A2@\=A9IHP#FN
M\VV8U'30]Q)?%P\Z W6PFQ^3L&,>L2_J;S*+(36$(JN=-P)SXU"UGS+N84HN
M[0C#AQT;%6UA')0*1Y-\'GV5><P %4[$U#ROB$(85[FAC$)S839#"_WM8D K
M[(;BP';].LJ")]]E''!@L/0V;&\0R@"*JF7AR WZ#LI /#A5BV5W^ W&A<D?
MS;CP^+M,& PQ],);)A %$'M!*EFP82D'W".T'3KA0@)^0W'AQ5;XMICG;U;Y
MW<%' /<VR@S4S //@<?8$48I@[4QA %.63%&6%.K8T.B,UQ;>QO!Q5F;RKY<
M? A*"/U\4?-KFW_+9^6ZY',=9]OG?33O(1,:,$PA0%H*Y,(D@+B6"0IZ8<F=
M72BW' +H <CS+O]C]>GW?/8M_S4@\F7O*7?['C,B)/<8:1*ODJ"X^S[(S"!*
MJ<HVPNWJ?.1*!'ZX0@B[I'!_Q"=[#Q5A.=@N4Y#1L)=;P9T66BAJU(/K[UR*
MVSRB$YL>2-8'O*W7K6VVSZ,SJ>G]7:42G^^B1Z-V&8=*(VV(-I#$HT@.@*O&
M'Z9(2MCU-:3E)*Y!'</;&3U^G13S51ZK%>8GD.-IJ\RYZ PRC*A@7!-'A:A\
M"HX02+&37\,I7L?42 (W(30_RV/]C;S:+0\_H7ZT348HYP):RI"@0#BO-:I.
MP3F@25<17D,4-I$4'4([F/>]X?'Z8N$A?_O19YD%T&#%D=0,<1CL^G5QD"VY
M!4XAR6OPL--MC@0TA^*%OE\&,:/D=Y^+^5I- 81E$;2T_H]/B\E\N='3YL&W
M=2I,8/^V8'(PI^*_'"DPV.&O9)8!(8U580>&.J@#0U8=L7,F= HK1U@$NP=6
MGD\99R3UAWQ:WL[CW>HWUP'VXJ:(XU?+9;Y:JFD0<[$6[/%SAT'&N_SZ\$[;
M\R]FB%(H!," F6!:0..(KPS/L&K(E!2L$1;I'H;L9U!,HD<0\*@-T$_YXNZP
M)_#\ZTPKS 7BU@J)N53 AO^JQNJA2PE007#1+.H.U9Y\PDV6R)OY=)%/=D:7
M3NXCHSBLVXAH(95'A'E?O5 6[=?P%REL^0&"Y3UBW4FX?)U0%,3<'A^_SQ?_
ME4_V9G@=;YD11K2FBED)I( .4U5GP'.NDDHAP!\L_MT)PJU9LCM"^L+7M?=[
MUYGF/63( 0F"JTPT$YXCCH-7Q+@)4F&HA$^Y@ (O.Z#=+])#F>@1C%A(/:R&
M5Y]GQ>WF6>#[_,V\P8G=Z9UD$@A '6(8BC @[4V\IE$=3(;)E<*WDR/D0SSK
MW(,MW1O<YR?=Q^ 3S*_W[(2G-,]BZ$\Q2H0(7H!$$D-;'Q50(Y(2&D^.MU\<
MT5H#?7Z*??I2+-HSK&Z=Q>1_Y+25##-&%84.\1I4Y)+L\Y-C]Q='L+8XGY]?
MOKQ?K+ZT)MA#\PPB"BGQU"!/@A\".3/US"+8)NV5)P?^+XYAK8$> <6*FQ2&
M5:TS'/P8BK&D&"$4?-]87*$^3O<@:0D[.89_>01KB?.Y^:5N@A^60K&G'60.
M24TT85I!3##V5M4!.N8)2"JD?7+P_,)8E@1UZPC%80?$%\OI9!;'LQ[=MJ)2
M531P7\PBI<],2PN81(X1)[WQ6CE:1V:P2JK5CGZ R/J V/? N0=?I!N^'>XO
M(P!*B(.%(!35V"- ZL(5//Q!2N4^] /$Y0?"O0>>U2Y)-S0[V%WFM0\3BE)$
MD"34*VJ!KZ4-BWP*RWZ :/XPL/=TF+B]1;8M/G#D9*A%5QEV7(?Q0$NA%D1R
MX5EU6XD[@5,>BT _0-"_?\C;GQUMZA1<A8U[]2'_EL_O\V48PC1JZG;_>='!
M5ADQVF#MD84V_"NR'KDJ L,%]"F9R^@'R&KO%-W6S'!W7V?E]_R!M<N/7_-I
M,9G%)(IM1H[.Y_E-L5J^NX_W5\N;JLW>W.:D3K-@,&+($%" 0*F5PLA411ZY
M1#S):O\!4N*'!+]#VNT87=B%OQ77^?6G\C_S[_40U6UH$W;N7-W%1Q.;<[#M
M+V0$:@^UX10K""F 1#]@HE!2$4[T Z3CGTT3#^S\]U]>*"$(]=OZKW;^S;:?
M%[C>584F_SPM[S8*"5!]BZ__A%W]7;D*:_AFAW\ZE. OY_,@WI_ZC]_9_//J
MY8OH!^)UNQMD"GO(/.3 $0DL#+8)E6%U0$H&PT2H1JQO[ESM@O!A4)\"?CIT
M]ML!?ZIA#QE0W!FFC=->.BDH%9!&N0*=%''LPAX>3E5N.03(9YVH[R:+F%C_
M+;?Y:E+,EJ]^XA+GK44*> H]<!XSH;;'5EZ$OVA43:$_"=_,PS#7US<_';F5
MLN/K#$O&+$:<$$Y\\+P-EKJ236)W894B4A5<=@WH4&=0'[^4BW4:=QQRDY>A
M=WV?F;#"(1UK^VE.@''(N5HVPGU28OTXR=):N\\?:>T S[-QY?B#T+M;9#86
MAM622(<55X!!Y\U6/FF$2$IZ'1]?$G5\C#&M,!WPC'N7*7"T$-K!=AESUCBG
M'.;6"TRDE<A7LH;I=VE/0Z=J_.59=F?8#E9,YJ3:JA08@0(6 EO,J4.$:EHC
MHV32$>'X^-'E?M06PT%Y<%)A514 4%+@>(V( $ #HRL;3FHL+FRM:*&_ X55
M3\-N* ZT*ZQJ,= "<NJ1U=H':*&I90$LZ<QMK#PX58L'"ZN>AM]@7&A56%5S
M%=9'+@PA5@%E37#T*EDP92G.[0CWATZXD(!?Z[.+M;VSF%P7\]MH_NQ[NV7O
MMT%:I[#6W%FA$8(,TJHJ@Y?0HPLK%M>%'= 5EDDZWQBH\:G1]<\??K)O;X,,
M8QT+!T,3UBQIF7=&\]J2U3ZE?/*(5OP.-/9<]UW F42 1RQ^$.IJ?N0QEN,M
M,PN 4@0";(PBE BH/*EDD!Q<2)7]KA3YG!>=@ML]03[]7K8D2-TR T(9JQE#
ME@M-  E&CJZQ<>I"/,=!"=(6W!X($IJU74,>M<T8Q01H$J116")#,:@R88,<
M%J:$+T=D5@Q+DM;P=D^3>#&M)4L>FF:0ZEB$7H6=%P(G$!*D7@TUL"E;S8AR
M]@8E26MT>^!(\:WM2O+0--,(^V">A<T2QT=S$?2N]L88@2D<&5'^W; <:8ON
M4!&+IR,_$M)^^7$F@TUON$5: @DH51IR5<=A,$B)78QH7>DCMIT,YGDH\FYR
M=_RD=5^3^ :.Y\'Y<Y9BJY@3WLA:0B>3[K"/G2ZGJ?@@6UHCVGKK^=M\F4_O
M [3O@Y3%<EDNOJ]/ZP[O.H=;9;'F;KQ48Y"15%N"T8,%3H&]P)2\-!66?4$[
M6,[&_>=E<5U,%M\_3F;YU<W'53G][5B.S[XV&>2("4L0,89X0KE6LMI15>(C
MA2.R5WK)\^D(T\%X\S#*.&^N;M;%D"?3]36^HVD_1QMG#F@F)6: .RF$I (;
M4$EMF+JPA:@#[3_G4]<0#T6L-^^OCA[6U=]DG&G K1)A=?8>6N=E]8*?5X"E
M5>P=(4TZ5&K9#:3G,7G?-G@1<4^+S$'*A;."Q)M56!+F:;5"*\22@G,CO$+4
MGW_4%M&.8BV;"W-7-[75M;:UW+H"__4^Z_>$+C+IM;5&>$XI]#I,(VKKF<1H
M6E6<L?.DA6[W!U^ZA+DC\CP=2C7 =>6!]Y-%?,CA6ZP/NSB83="BNPPH#S7
M4$M$%0C",E9+2[E-J0$]HN.C 4C5%^3GV<^JAT,^3%;YQZ#9X$,>J@EP>B>9
M0$(II)0DRH1-76BD;86"!C;EYNR(CJ2Z)E[O0 ]%M\W[-+_FJR_E]69J1$&N
M?I\'57PIOC9B6^,^,A^@Y$XI3PF/-BCB"E<8")+T&,OH0]#I9.L+YR&7MH>3
MG.UE@OSZ :*/7P*NVS>2X)'EK7E'F9%68V@891!C"C4U'E5H$ SL)0>?NEGB
M>@/[/-2[6A2WQ7PRBW^Z*5O0G&T[VF9& ZDEM!P8RQT$T.G:DA":I>0+CMYS
M[)I@Z?@.%I#:[O;;6U#F?A'1.Q2=VMD@HY!A9XSGR$I.%:78U(NU0B#% AOA
M(Y%=LZ<34+M/\XAUHHKRVI>S6?E[^+,W\V)53&;O[S_/BNG535!)_##TO?Q2
MSAJ&)5IWGP&C%)76XYAVCX*SHUR]*!O$4X[^1_CB8X_>Y5 JZ(&0E2N\V:[5
MMTDQBQ/F4_DQG\T>;,?J@[_-@WIGW]<RY \]GL[4;GXWTS$M6"JIJ3-.!KN"
MD]I]HD"FE+(;X3N. U'X++KI@=O;2T;;/[*3]6G9X_';(-GWOY>ST/)T!I_2
M>R8$Y(K'.1W3T1"!4-580(B2[HZ,L*#U0$3M405]T''[^MRBF,9!KB=/>6/*
MN[MROCZD:\'!8UUFAB(2YJ!S "C&@ 7&5ZDI2F*==$WUQSJ7Z!/W'C?V^ 1U
M/KV/=;(>YDF"B=FLWTS'$V6FD,8Q\QX02<6#<T99$N]^K*.+WL$?VJI4U]=%
M5.GD;/9EBQ%DBFL&*< $6N9U,&:"X_B J4BYR37&AS7'8&KVKZ8'ZI^A?N''
MZ9?\^CZFZ.RKSW@A=0TIXM1J'\ABE(@7**2--2LQ=PIX2QN]?3#$L6J;NH9&
M!(O2,RGUNA8\94B33;U,X(+4%U9Z+%7!#>H:G@;H8'6"\MGZX#;F"CS*HCM6
M06I_JTQA)7!8EY04%F%K+&>TDA-[>8$%,5MK^GE%H<Y0/3-[CB8^'VR7L3"]
MK 8:&2",XPXB4LGJ#4AS[<;'H$ZTWHQ)K? =[GQIDZET/.OYR8<9)DIA&?YI
M"::0&TM(-=N\-$DUBDYFRQ"/]G6DVQ?G2@F@MG:TJE_5AR]K/?LLTQ0BR6%<
M7H4Q %OF9#4ZKLB%%)_H1^$= )JL;M-,W=O/,L,=@  P(K& #@2GG_-J=$J[
M"\O9ZU'=[0!-5O=?FZE[^UDFF$<&<RJL"S8W"_\5*%BM/6'8EY4UUZ.ZVP'Z
M6N[W8T==,+0)MPX(::@#J(8&:G71*>1I?D8RF*_Q?K^'7 GDF?#2A7]3$FE6
M2>CD99?>/TW%3>_WGX9H^UTD9EK:^.+2_>W]<H5A^(0>V5'V-\D<(YZS^(!=
M6/DXI6[]D.9FU,1>2K'#[I17]H)K.AL^YE]7ZU\&^ 1"[&R5>2  (F%/#-:O
MAF&OA:JVAV188B]Y*^F,$UU FTZ+J^FJC&-@<0Q'*V$>:98)"DB\/>R-M<9"
M1K2M+2?BDV[?C]#SZ(D8G6";SHS_F,SO)XOO4(9O6$-:[&B34>X%#P-&'C.Z
M?B67UZ$1JW2*(3%"]Z0G3J0#.UB!CTX>?O**"R9U<+R,=))BHA_B:4S['Z#
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M7?=X313]W<PFR^6QXKL'6F74D&!**B<!0E0J @07E:S"Z0LK5M)6T<]G:6>
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M!C/E0S[+)\O]5TY.Z"(+@ &LC4-8*B$9(U:(2BI@U<55TQV"8CTKX7)V71B
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M%GI&J]%#!%)LK@-<WMJFQ 6,NQKS7(QS=]\7JY]%L;O,:#^2LUOFT39!D;C
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M=F2HK"M5/KI3Z-^1=SND/T5L=?SP7Z=,B,W>$*04VODX7D81M4AC00%Q$E$
MA%-Z9'=R7$N H]>ZM GN]3OSL3N;SK+EDN;!&&\PM%0)CQ1R%CDHJ]%01D9F
M.4JD2H?(-ECC#[\H_RBWJ__]O_X_4$L! A0#%     @ 0T)\3(^_;!G:9@$
MB@X2 !$              ( !     &UB<G@M,C Q-S$R,S$N>&UL4$L! A0#
M%     @ 0T)\3'Q&IE<K%P  3A(! !$              ( !"6<! &UB<G@M
M,C Q-S$R,S$N>'-D4$L! A0#%     @ 0T)\3+>BZ-5P&0  +AL! !4
M         ( !8WX! &UB<G@M,C Q-S$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M $-"?$QR&C@!M&   )S!!  5              "  0:8 0!M8G)X+3(P,3<Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " !#0GQ,E>2OJM3N   A] P %0
M        @ 'M^ $ ;6)R>"TR,#$W,3(S,5]L86(N>&UL4$L! A0#%     @
M0T)\3,'__1F2C@  3CL' !4              ( !].<" &UB<G@M,C Q-S$R
@,S%?<')E+GAM;%!+!08     !@ & (H!  "Y=@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
